id,permalink,username,text,date
1267606607833247750,https://twitter.com/MedpageOnco/status/1267606607833247750,MedpageOnco,"Sentinel node biopsy achieved ""oncological equivalence"" with neck dissection in patients with operable T1-T2N0 oral and #oropharyngealcancer, reported Renaud Garrel, MD, PhD, of Montpellier University Hospital Center, at virtual #ASCO20. @ASCO 
https://t.co/SFnSuYgqcd",2020-06-01
1267606495350394880,https://twitter.com/fumikochino/status/1267606495350394880,fumikochino,"With #ASCO20 finished, I have so much free time I made this succulent planter. I realize it’s just throwing dirt and some variety cacti I bought online in a decorative ceramic bowl but I feel inordinately proud of myself. ❤️ https://t.co/sdtLktWbRR",2020-06-01
1267605968118059013,https://twitter.com/ATarhiniMDPhD/status/1267605968118059013,ATarhiniMDPhD,Our in-depth analysis of immune related adverse events (irAEs) and the use of immunosuppressants and hormone replacement therapy and the association with clinical outcome @ASCO @MoffittNews @MoffittResearch https://t.co/XxWSXzg6BV,2020-06-01
1267605825994084352,https://twitter.com/VeredStearns/status/1267605825994084352,VeredStearns,Miss everyone #ASCO20 #WLO2020 https://t.co/BoUsDAk5Ni,2020-06-01
1267605812664569856,https://twitter.com/BrasilOncologia/status/1267605812664569856,BrasilOncologia,"Os oncologistas discutiram ontem em #webinar ao vivo os destaques do 3º dia da #ASCO20. Os temas abordados foram #melanoma, #sarcoma, #mutações raras, novas #drogas e potencial agnóstico, #tumores geniturinários, #biomarcadores e #medicina de precisão.  https://t.co/5pV1yw7V03 https://t.co/wNGDmage1C",2020-06-01
1267605100048105478,https://twitter.com/SuparnaWedam/status/1267605100048105478,SuparnaWedam,Miss this inspiring evening in person to celebrate #camarederie #leadership #WWCC #ASCO20 #WLO2020 @VeredStearns @ndenduluri1 @LalehAmiri @SandraSwainMD https://t.co/5tDxG1PBYh https://t.co/TLNDekQi9h,2020-06-01
1267602796599271424,https://twitter.com/PortalOnconews/status/1267602796599271424,PortalOnconews,Estudo de Fase II apresentado no #ASCO20 apresentou taxas de resposta encorajadoras com olaparibe como monoterapia em pts com câncer de mama metastático HER2 negativo com mutação germinativa ou somática BRCA1/2 - https://t.co/nvgfAMrN6K @ASCO #ONCONEWS https://t.co/uJdxRlwUKM,2020-06-01
1267602169638858754,https://twitter.com/dapattmd/status/1267602169638858754,dapattmd,"2019 Women Leaders in Oncology Event - ASCO 
Inspired by #WWCC and women in research #yia ⁦@MdBosserman⁩ ⁦@ConquerCancerFd⁩ @asco ⁦@ndenduluri1⁩ ⁦@TexasOncology⁩ ⁦@TheUSONetwork⁩  https://t.co/jNxTsyuBzK",2020-06-01
1267601281088212998,https://twitter.com/aylaubenthal/status/1267601281088212998,aylaubenthal,"As a community oncologist, I’m thrilled to see this theme. @ASCOPres @ASCO https://t.co/NQlJqQl3BP",2020-06-01
1267600848458317826,https://twitter.com/piripiribiryani/status/1267600848458317826,piripiribiryani,Just convinced my coresident Dr. Brittany Hale @BrittanyJaneHa1 to join #Medtwitter She’s interested in #hemeonc and is fab! #WomeninMedicine @asco @hemoncwomendocs @womeninmeds @prowdwomen,2020-06-01
1267600816656904192,https://twitter.com/CleClinicMD/status/1267600816656904192,CleClinicMD,Researchers are investigating a nerve-sparing approach to prevent treatment-induced erectile dysfunction in patients with early-stage prostate cancer: #ASCO20 https://t.co/LbTwqRy7fk,2020-06-01
1267600358332915712,https://twitter.com/MDedgeHemOnc/status/1267600358332915712,MDedgeHemOnc,"3 SWOG S1416 Trial: The results are a “very positive step towards expanding the role of PARP inhibitors beyond germline BRCA in breast cancer,” reported Priyanka Sharma, MD, of the University of Kansas Medical Center at #ASCO20. https://t.co/yYnbj0TJYh #ASCO2020 #OncoAlert https://t.co/JRb3R73dkg",2020-06-01
1267599884108140544,https://twitter.com/drdonsdizon/status/1267599884108140544,drdonsdizon,All I have to say to @ASCO Pres @BurrisSkip #ASCO20 Sci Prog Chair @MLJohnsonMD2 and Cancer Ed Chair @tmprowell as well as all those @ASCO: https://t.co/wxepo9XQRG,2020-06-01
1267597960575156236,https://twitter.com/byluralong/status/1267597960575156236,byluralong,"""COVID'19 disparities persist...because of the financial necessity to continue working, as well as the lack of employment opportunities that enable...work remotely. They are more likely to be... essential workers, and that increases...exposure."" @DrBlytheAdamson #ASCO20 #COVID19",2020-06-01
1267597645821984770,https://twitter.com/manjuggm/status/1267597645821984770,manjuggm,Curious to see the results after #ASCO20 https://t.co/jE5NUklyD1,2020-06-01
1267595556769103872,https://twitter.com/OncEd/status/1267595556769103872,OncEd,"In this update from #ASCO20, Dr. Hirotsugu Kenmotsu provides an overview of the JCOG1205/1206 trial, a randomized phase III study of irinotecan/cisplatin vs. etoposide/cisplatin for completely resected high-grade neuroendocrine carcinoma of the lung: https://t.co/xBUc6i5zXc https://t.co/yKEMmgQlFb",2020-06-01
1267594307084656641,https://twitter.com/PortalOnconews/status/1267594307084656641,PortalOnconews,"Apresentado no #ASCO20, o estudo multicêntrico de Fase II DESTINY-CRC01 demonstrou bons resultados do anticorpo droga-conjugado trastuzumabe deruxtecan em pts com câncer colorretal metastático HER2+ refratários à terapias padrão - https://t.co/63GX0bu7Ld @ASCO #ONCONEWS https://t.co/SPS0RhtlCS",2020-06-01
1267594025571422208,https://twitter.com/MDedgeHemOnc/status/1267594025571422208,MDedgeHemOnc,"Tucatinib improves PFS, OS in HER2+ breast cancer with brain metastases in 70% of the patients tested in a phase 2 trial released at #ASCO20. https://t.co/MecEGtyuZP #ASCO2020 @ASCO #breastcancer #medtwitter https://t.co/P8msza286N",2020-06-01
1267593529225863170,https://twitter.com/EMittendorfMD/status/1267593529225863170,EMittendorfMD,"Could there be a better @ASCO presidential theme? Equity: every patient, every day, everywhere. As a member of ASCO’s board of directors I look forward to working with @ASCOPres Lori Pierce to make this a reality https://t.co/u6kazmcKkL",2020-06-01
1267593093831725056,https://twitter.com/DrBlytheAdamson/status/1267593093831725056,DrBlytheAdamson,"Casual nerd background and choices made before understanding this @AJMC_Journal interview was for VIDEO and not written content. 

https://t.co/4tDuy3rwli

My thoughts on #COVID19 #disparities &amp; @SafeGraph mobility data #ASCO20 @flatironhealth  #womenintech @ratemyskyperoom https://t.co/CqVHRShdt7",2020-06-01
1267592512203522051,https://twitter.com/Medscape/status/1267592512203522051,Medscape,Frontline pembrolizumab doubles PFS in patients with MSI-H/dMMR Metastatic CRC in the KEYNOTE-177 study released at #ASCO20. https://t.co/vXLP6qxXcU #ASCO2020,2020-06-01
1267590959744913422,https://twitter.com/CarmenCalfa/status/1267590959744913422,CarmenCalfa,Echoing @ndenduluri1 sentiment! Look forward to connecting with you all tonight! @MdBosserman @pipcosper #ASCO20 https://t.co/EfEdNNLv5u,2020-06-01
1267588849489686528,https://twitter.com/m0370/status/1267588849489686528,m0370,JCOG0603は色々考察されてるが、この3枚目画像は大切だな。初回再発後に再切除を目指した割合がケモ群で60→53%と低く、治療もIRIベースが多い。すでにケモが入ってるとR0切除を目指さず緩和化学療法に移行する抵抗感が低いというのは想像できる。後治療の積極性の違いに影響したかもしれない。#ASCO20 https://t.co/1RAefznT5y,2020-06-01
1267586768662036481,https://twitter.com/Big4BioSF/status/1267586768662036481,Big4BioSF,"Myovant announced Phase III data for its drug relugolix for advanced prostate cancer at #ASCO20. The company has also submitted an NDA for treating uterine fibroids with relugolix. 

$MYOV 
https://t.co/QZS5HBuQOu",2020-06-01
1267586109292281856,https://twitter.com/brettcoxmd/status/1267586109292281856,brettcoxmd,The new @ASCO President is a #radonc!  Congrats @ASCOPres! https://t.co/DV4xEnVSep,2020-06-01
1267584867824472070,https://twitter.com/pashtoonkasi/status/1267584867824472070,pashtoonkasi,#ASCO20 #TwiiterPoll 🧬🩸#ctDNA #LiquidBiopsies https://t.co/dh9n0fiCeh,2020-06-01
1267583836394848262,https://twitter.com/AAFretland/status/1267583836394848262,AAFretland,"Takk, @DagensMedisin for flott live-sending! For den som er interessert har eg tvitra lenker til ""mine"" høgdepunkt for lever-og pankreaskirurgi (på engelsk) #ASCO2020 @Kreftforeningen @Oslounivsykehus @xtofero @RoesokMD @pdline @ksoreide  https://t.co/erwnJiDKiv",2020-06-01
1267583795491778560,https://twitter.com/NateraOncology/status/1267583795491778560,NateraOncology,Are you incorporating ctDNA tests for residual disease detection and surveillance in your practice? #oncoalert #ASCO20,2020-06-01
1267583602973425666,https://twitter.com/womenofteal/status/1267583602973425666,womenofteal,"The first of a number of blog posts on the #ASCO20 Virtual Annual Meeting. In this post I highlight gynecologic cancer study results. #gyncsm  https://t.co/rfSsCKV9Ja
Thanks @alwadikhaled @drdonsdizon @jamienholloway 
@DrLesterCol @subatomicdoc for their tweet contributions",2020-06-01
1267583534232858625,https://twitter.com/big4bio/status/1267583534232858625,big4bio,"Updates from #ASCO20: 
https://t.co/8jUSTn78cu",2020-06-01
1267582956375347203,https://twitter.com/gusviani/status/1267582956375347203,gusviani,"Metastatic NSCLC EGFRm treated with TKI +/- SBRT.
⬆️OS and PFS
MVA ECOG/number Mets and SBRT Significant 📌
#ASCO20 #NSCLC #sbrt #tki https://t.co/VmgSa7FoKZ",2020-06-01
1267582560709873664,https://twitter.com/BOPACommittee/status/1267582560709873664,BOPACommittee,"See the #ASCO20 virtual conference program via the link below where you can find abstracts and information from the 2020 Conference

https://t.co/tOKbqKFrfq

#ASCO20 #BOPA

@ASCO_pubs @ASCO https://t.co/ZMvOsWiBau",2020-06-01
1267582095079157763,https://twitter.com/AAFretland/status/1267582095079157763,AAFretland,"5)Final #ASCO2020 highlight for #HPB surgeons: Gemcitabine/nab-paclitaxel as good as mFOLFIRINOX as perioperative treatment of #pancreaticcancer, median OS 24 vs 22 months, more #pathologic response with gem/nab. @IHPBA @EAHPBA #pancreaskreft https://t.co/jnP3MRjvTe",2020-06-01
1267581727981142016,https://twitter.com/OME_ResidentMD/status/1267581727981142016,OME_ResidentMD,Looking forward to a year of #Equity in #CancerCare! @ASCO #ASCO20 https://t.co/TQ4t7Fl02K,2020-06-01
1267581100093771781,https://twitter.com/BrasilOncologia/status/1267581100093771781,BrasilOncologia,"No encerramento da nossa cobertura da #ASCO20, os oncologistas discutem as principais perspectivas para os próximos anos no cenário oncológico. Assista agora ao #webinar ao vivo: https://t.co/z2AuocobB6 https://t.co/9MzIZGllZa",2020-06-01
1267580163652571136,https://twitter.com/AAFretland/status/1267580163652571136,AAFretland,4)#ASCO2020 highlights for a #HBP surgeon: #ESPAC5 finds 77% 1-year OS for #neoadjuvant #chemo in #pancreaticcancer and 40% for upfront #surgery. Small numbers. Norwegian #NORPACT1 trial will provide more data @xtofero @IHPBA @EAHPBA https://t.co/ol037Zzh3u,2020-06-01
1267578922390216709,https://twitter.com/MedscapeOnc/status/1267578922390216709,MedscapeOnc,Improved rate seen in HER2+ breast cancer patients with brain mets when given combo drug + tucatinib. #ASCO20 https://t.co/eozlsKYgeY #bcsm,2020-06-01
1267577926700146689,https://twitter.com/YaleCancer/status/1267577926700146689,YaleCancer,"Congratulations to five @YaleCancer @SmilowCancer physicians awarded @ConquerCancerfd research awards during #ASCO20. @YaleMed @YNHH #cancerresearch 
https://t.co/cIQPSzeN7d https://t.co/2aHDkAzwSQ",2020-06-01
1267577657471963137,https://twitter.com/AAFretland/status/1267577657471963137,AAFretland,"3)#ASCO2020 highlights for a #HPB surgeon. Actionable targets are a fact! Treatment for #MSI-high (https://t.co/fASOnwNAZl), #BRAF (https://t.co/EqN2CPYl4e) and #HER2 (https://t.co/TrSvMxWxq5)  are working for #metastatic #colorectal #Cancer @Kreftforeningen @IHPBA @EAHPBA",2020-06-01
1267577509090033664,https://twitter.com/ShannonWestin/status/1267577509090033664,ShannonWestin,Thanks @aaronshafer99 - it was my honor to serve as an @SGO_org #ASCO20 correspondent! So much great research for our patients #gyncsm https://t.co/srCOcqjZr3,2020-06-01
1267577165572378627,https://twitter.com/MDedgeHemOnc/status/1267577165572378627,MDedgeHemOnc,"SWOG S1416 Trial: For patients with BRCA-like TNBC, adding veliparib to cisplatin chemotherapy may extend survival. #ASCO20 https://t.co/TipPKsgwSG @ASCO #oncology #breastcancer #OncoAlert https://t.co/agyKyTUaFv",2020-06-01
1267576872415768589,https://twitter.com/GuOnco/status/1267576872415768589,GuOnco,"68Ga-PSMA-11 to predict nodal metastasis prior RP. Sensitivity needs to improve, but perhaps a nomogram with other well known factors should be considered to improve prediction. #ASCO20 #prostatecancer #PSMA #oncogu @EZucca @CarcanoMD @JoaoNeif @DD_Preto https://t.co/ilmijHK5F0",2020-06-01
1267576667171667976,https://twitter.com/ASCO_pubs/status/1267576667171667976,ASCO_pubs,ADAURA Establishes Adjuvant Osimertinib as a New Standard of Care for Early-Stage EGFR-Mutated #NSCLC https://t.co/2BiZDhckjT #ASCODailyNews #LBA #ASCO20 @DrRoyHerbstYale @dave6408 https://t.co/onNA1rE6xp,2020-06-01
1267576661333159936,https://twitter.com/uk_oncologist/status/1267576661333159936,uk_oncologist,That’s impressive #CRC #TNT #ASCO20 @DrVMisra @finlaycurran @azizosurgeon @CRSelvasekar https://t.co/yrpaYSs52S,2020-06-01
1267576168120758286,https://twitter.com/GuOnco/status/1267576168120758286,GuOnco,(CONDOR Study) 18F-DCFPyL-PET/CT in BC relapsed prostate cancer. New tool but old endpoints. Keep calm and be careful with lead time-like bias. #ASCO20 #prostatecancer #oncogu @EZucca @CarcanoMD @JoaoNeif @DD_Preto https://t.co/VwFp7LBtsG,2020-06-01
1267576114781749265,https://twitter.com/AAFretland/status/1267576114781749265,AAFretland,2)#ASCO2020 highlights for a #HPB surgeon: #IDEA collaboration found that 3 months #CAPOX is similar to 6 months adjuvant after resection for #CRC. Can we reduce burden of #neuropathy for our patients now? @IHPBA @EAHPBA https://t.co/2UM6tVMCdx,2020-06-01
1267575280895512576,https://twitter.com/CVSPharmD/status/1267575280895512576,CVSPharmD,Presenting… CVS Health Data at #ASCO20 https://t.co/aDtnP3b4w7,2020-06-01
1267575212893261826,https://twitter.com/medcitynews/status/1267575212893261826,medcitynews,"ASCO data for Amgen’s acute leukemia drug disappoint, but path forward remains, experts say by @biotechvisigoth @medcitynews https://t.co/nSNNjUMuJF $AMGN  #ASCO20",2020-06-01
1267575122409463810,https://twitter.com/StephLBaum/status/1267575122409463810,StephLBaum,"ASCO data for Amgen’s acute leukemia drug disappoint, but path forward remains, experts say by @biotechvisigoth @medcitynews https://t.co/Dfkr7dKZtn $AMGN  #ASCO20",2020-06-01
1267575036816306177,https://twitter.com/AAFretland/status/1267575036816306177,AAFretland,1) #ASCO2020 highlights for a #HPB surgeon: JCOG0603 - adjuvant FOLFOX vs hepatectomy only for colorectal mets - DFS better with chemo but OS worse. Is this the end for adjuvant after #liver resection of #colorectal mets? @ihpba https://t.co/Wiywb0JrG8,2020-06-01
1267574149821730825,https://twitter.com/diariomedico/status/1267574149821730825,diariomedico,#ASCO2020 | Nueva opción en tercera línea de tratamiento del cáncer de estómago con sobreexpresión de HER2 https://t.co/UreiI4Lckq https://t.co/m345u00yrV,2020-06-01
1267573803649052672,https://twitter.com/aaronshafer99/status/1267573803649052672,aaronshafer99,Listen to ⁦@ShannonWestin⁩ go over Gyn Onc highlights from #ASCO2020 https://t.co/5KyWANC1Zu,2020-06-01
1267573227460743168,https://twitter.com/ndmd74/status/1267573227460743168,ndmd74,"Wearing my @ASTRO_org hat, I join others in the #medical community to condemn #systemicracism and #PoliceBrutality and urge citizens to #Peacefulprotest and demonstrate their solidarity with #JusticeForAll. #Vote2020! Be peacefully proactive! @ASCO #radonc @AmerMedicalAssn",2020-06-01
1267573118652100609,https://twitter.com/BridgeGap1/status/1267573118652100609,BridgeGap1,Hoping the advocates from @ASCO will join in the discussion on how we can address #racialdisparities in #breastcancer together https://t.co/l3cKuHO63A,2020-06-01
1267572949416062978,https://twitter.com/medicalnewser/status/1267572949416062978,medicalnewser,"Amgen Reports Clinical Data of AMG 510 in CodeBreaK 100 Study for Multiple Solid Tumors #ASCO20, 

Shots:

The CodeBreaK 100 development program evaluates AMG 510 (proposed INN sotorasib, qd) in heavily pretreated... ,https://t.co/Oa53PwZ7hj https://t.co/vC9OvheQir",2020-06-01
1267572918587965445,https://twitter.com/UCD_Cancer/status/1267572918587965445,UCD_Cancer,"There have been many attempts to develop an immunotherapy biomarker in renal cell carcinoma. Unfortunately, there have been many challenges, making this task more difficult than originally thought. @PrimoLaraMD https://t.co/fkvxfsW6NH #ASCO2020 https://t.co/grQ4SKjHyM",2020-06-01
1267571671311024128,https://twitter.com/CarmenCalfa/status/1267571671311024128,CarmenCalfa,"It has never felt more importantly to be an @ASCO member than now. Thank you Dr. @BurrisSkip for an amazing, most challenging, year! Congratulations Dr. Lori Pierce @ASCOPres. Love the path chosen. ""Equity: Every Patient. Every Day. Everywhere."" https://t.co/JvFQ0zdmXo",2020-06-01
1267570872291921923,https://twitter.com/komenla/status/1267570872291921923,komenla,New findings presented at #ASCO20 show no survival or quality of life benefit from local surgery/radiation tx for newly dx #metastatic #breastcancer patients. Read more: https://t.co/chMOJbkpjz,2020-06-01
1267570329074970624,https://twitter.com/radionome/status/1267570329074970624,radionome,#ASNR20 and #ASCO20 are both completely virtual this year and live right now.. virtual meetings are definitely bigger bang for the buck for providers but will they stay virtual in the future?,2020-06-01
1267569366226386946,https://twitter.com/urotoday/status/1267569366226386946,urotoday,Short-term adjuvant vs neoadjuvant hormone therapy in localized #ProstateCancer: a pooled individual patient analysis of two phase III trials. Presented by @DrSpratticus @UMRogelCancer. #ASCO20 coverage by @aloktewar @DanaFarber on UroToday &gt; https://t.co/YqSR1qatbx @ASCO https://t.co/lDhTk4yosb,2020-06-01
1267568799806623751,https://twitter.com/EisaiUS/status/1267568799806623751,EisaiUS,#ICYMI: Our virtual oral presentation on the latest results from a Phase 2 trial evaluating an investigational IO+TKI combination for #kidneycancer is now available at #ASCO20. Learn more: https://t.co/Y74vGRDNtR https://t.co/EJERdGvB61,2020-06-01
1267568458495074305,https://twitter.com/annalaucis/status/1267568458495074305,annalaucis,"Very important theme of health equity for @ASCO 2020-21 -- I'm very excited to see where the excellent leadership of Dr. Pierce @ASCOPres takes the organization and the field of oncology this year!!

@UMRogelCancer @UMichRadOnc @umichmedicine @UMich #WomenWhoCurie #RadOncRocks https://t.co/pm7abVhqnw",2020-06-01
1267568128365494272,https://twitter.com/stage4kelly/status/1267568128365494272,stage4kelly,You can still watch sessions and read abstracts you missed! #ASCO20 https://t.co/QtcyKiPNBh,2020-06-01
1267567605914537984,https://twitter.com/stage4kelly/status/1267567605914537984,stage4kelly,"Looking forward to what Dr. Pierce, the new @ASCOPres, will accomplish during her presidential yr, and grateful for what Dr @BurrisSkip did in his year. (also wondering why the terms aren't 2 years - seems like you just hit your stride and it's over??) @ASCO #HealthEquity #Equity https://t.co/1VR1CsxjGe",2020-06-01
1267567346140549121,https://twitter.com/RossFH/status/1267567346140549121,RossFH,About 90% of randomized trials of cancer treatment used performance status as exclusion criteria; ~40% of trials excluded participation for ECOG&gt;1. @RKouzyMD @asco #asco20 #goASCO20 #gyncsm https://t.co/lTD6a50DAg https://t.co/HrKniUk22Y,2020-06-01
1267566343487963149,https://twitter.com/MDedgeHemOnc/status/1267566343487963149,MDedgeHemOnc,"At #ASCO20 the KEYNOTE 355 trial showed adding pembrolizumab to #chemotherapy improved survival for patients with #TNBC, only if their tumors were enriched with high levels of PD-L1. https://t.co/KnzJ6Zx0Rk #ASCO2020 #OncoAlert https://t.co/1EqWyt4xib",2020-06-01
1267566160733777920,https://twitter.com/MoffittNews/status/1267566160733777920,MoffittNews,"As part of the #ASCO20 Virtual Scientific Program, @DrBlueBMT of @MoffittNews discusses a study on the impact of doxycycline use on outcomes in AL amyloidosis. View abstract here: https://t.co/vuI9poV9qL https://t.co/XL429Ltw2W",2020-06-01
1267565903731757056,https://twitter.com/stage4kelly/status/1267565903731757056,stage4kelly,".@GRASPtweets  #GRASP is an incredible bidirectional learning program for people with cancer, oncologists and researchers. I am so incredibly proud of @christeeny513 and @itsnot_pink for bringing this to life.  Piloted at  #SABCS19 it's now taking #ASCO20 by storm. https://t.co/ISeKbkCF7e",2020-06-01
1267565298237964294,https://twitter.com/GuOnco/status/1267565298237964294,GuOnco,"Once again, congrats @DrChoueiri and team for the great  SAVOIR trial. We and our patients were surprised when study closed. Savolitinib seems a promise drug for MET driven PRCC. Hope to see other trials in this scenario. #ASCO20 #oncogu @EZucca @CarcanoMD @JoaoNeif @DD_Preto https://t.co/Ii6CmpzGXU",2020-06-01
1267565154029514754,https://twitter.com/DrR_DUNNE/status/1267565154029514754,DrR_DUNNE,Finally catching up on #ASCO20 and first session I open is my former night float senior resident and colleague @mnoel3232 -great job Marcus! #pancreaticcancer highlight session https://t.co/isXXta42wK,2020-06-01
1267564918636793856,https://twitter.com/PortalOnconews/status/1267564918636793856,PortalOnconews,"Estratégias de tto mais custo-efetivas estiveram em evidência na sessão oral de câncer de cabeça e pescoço do #ASCO20. Quem analisa os estudos são os médicos @alinelauda, Thiago Bueno e Célia Viegas - https://t.co/nHEGmbneuq @ASCO #ONCONEWS #TV_ONCONEWS https://t.co/9AZHEgOEZK",2020-06-01
1267564237532037126,https://twitter.com/MLPOncoData/status/1267564237532037126,MLPOncoData,"Participación en estudios clínicos en cáncer de pulmón aumenta los costos para el pagador (en un centro, en Estados Unidos) #ASCO20 https://t.co/3u90ggNIld",2020-06-01
1267564085018845192,https://twitter.com/SeattleCCA/status/1267564085018845192,SeattleCCA,"#ASCO20: SCCA's President &amp; Executive Director Dr. Nancy Davidson's poster ""Gender differences in faculty rank and subspecialty choice in academic medical oncology."" Read on our SCCA at @ASCO page: https://t.co/rmbDULiKPd https://t.co/IaSCgg4DIG",2020-06-01
1267563966869303296,https://twitter.com/DrMMurphy/status/1267563966869303296,DrMMurphy,The *perfect* @ASCO theme we can all get behind! #Equity : Every Patient. Every Day. Everywhere. 🙏🏼 @ASCOPres https://t.co/9gYQa4IOco,2020-06-01
1267563283810324481,https://twitter.com/rodrocconi/status/1267563283810324481,rodrocconi,"outstanding theme @ASCOPres been years in the making to put a “punctuation” at the end of @ASCO mission statement = Conquering cancer though research, education, and promotion of the highest quality patient care “FOR ALL.” https://t.co/Lf0CVyGp1t",2020-06-01
1267563250356490241,https://twitter.com/gustavovalves/status/1267563250356490241,gustavovalves,I feel honored and blessed to be part of this project. IO changing the lives of patients with #mCRC. Keynote-177 #ASCO20 @Merck https://t.co/GmlCETmKIS,2020-06-01
1267563037155713024,https://twitter.com/Starkindler/status/1267563037155713024,Starkindler,#pfizerproud of the work being done to advance critical #cancer research during #COVID19. #ASCO20 #ScienceWillWin #PFEColleague https://t.co/cOEGivFp2i,2020-06-01
1267563031569018881,https://twitter.com/inas_md/status/1267563031569018881,inas_md,"#ASCO20 
Love this! ❤ https://t.co/stlQxghEBf",2020-06-01
1267562816258613249,https://twitter.com/Medscape/status/1267562816258613249,Medscape,Practices that embrace OCM make different care choices. https://t.co/pYNWwiMFhK #ASCO20,2020-06-01
1267561768802562050,https://twitter.com/GuOnco/status/1267561768802562050,GuOnco,(ANZUP 1603 Trial) 177Lu-PSMA in mCRPC post-Docetaxel. Exciting PSA50-RR and low-toxicity profile. Looking forward to the VISION trial results. #ASCO20 #prostatecancer #PSMA #genitourinarycancers #oncogu @EZucca  @CarcanoMD @JoaoNeif @DD_Preto https://t.co/t637Bz0kRe,2020-06-01
1267561635545300993,https://twitter.com/urotoday/status/1267561635545300993,urotoday,"Evaluation of a mainstream model of #GeneticTesting for #Men with #ProstateCancer. #ASCO20 presentation by Tahlia Scheinberg, MBBS @GarvanInstitute. Written coverage by @aloktewar @DanaFarber on UroToday &gt; https://t.co/1vfYYM5xuf @ASCO https://t.co/95vRgXVqUH",2020-06-01
1267561526606483457,https://twitter.com/JackWestMD/status/1267561526606483457,JackWestMD,"#ASCO20 was a whirlwind of data; more than anyone can take in. Get summary &amp; perspective by heading to @nexusoncology's new SOUND BITES at https://t.co/Z3iCZ0efvH. I &amp; other experts break down highlights, &amp; you can have content sent to your phone or inbox in short sound bites.",2020-06-01
1267561468146450432,https://twitter.com/SLentzsch/status/1267561468146450432,SLentzsch,#ASCO20 N=426 newly diagnosed AL pt with  ASCT between 2014-2018 were retrospectively reviewed by @CIBMTR @adsouza_md @myeloma_doc_com  Induction in ND AL prior to ASCT improved PFS at 2 yrs p&lt;0.01. Effect was seen even in patients with &lt;10% plasma cells https://t.co/xwMcg5jG2h,2020-06-01
1267560554572505091,https://twitter.com/MedpageOnco/status/1267560554572505091,MedpageOnco,"This therapy rapidly suppressed testosterone and cut the incidence of serious heart events, reported Neal Shore, MD, of the Carolina Urologic Research Center, at virtual #ASCO20. By @icingram. #prostatecancer #PCSM @ASCO 
https://t.co/6WQlzu25I8",2020-06-01
1267560349525516293,https://twitter.com/MoffittNews/status/1267560349525516293,MoffittNews,"At #ASCO20 Virtual Scientific Program, Dr. Heather Han (@HeatherHan19) presents new data on combination therapy in patients with gBRCA-associated advanced breast cancer. View abstract: https://t.co/HcSbwr9Hyu #BCSM https://t.co/lYYnH2YajG",2020-06-01
1267560234270240768,https://twitter.com/CharuAggarwalMD/status/1267560234270240768,CharuAggarwalMD,"#ASCO20 #WLO2020 

Congrats @DrDawnHershman @lillian_siu Will toast you virtually tonight! 

cc: @ndenduluri1 @DrSGraff @IshwariaMD @drjennifergao @JuliaLClose @SuzanneColeMD @CarmenCalfa @ErikaHamilton9 @MdBosserman @DrMarkham @NarjustDumaMD @SandraSwainMD @ConquerCancerFd https://t.co/GSuXGP1n7P",2020-06-01
1267560145598513152,https://twitter.com/GuOnco/status/1267560145598513152,GuOnco,With extended FUP KN-426 continue to support PEM+AXI as a SOC in first line landscape for aRCC. But the robust benefit is for IMDC Interm/Poor risk groups! Should we prioritize TKI for Favorable risk patients? #ASCO20 #kidneycancer #oncogu @EZucca @CarcanoMD  @JoaoNeif @ddpreto https://t.co/QfY9igsQhI,2020-06-01
1267559864324157440,https://twitter.com/HTGMolecular/status/1267559864324157440,HTGMolecular,"The #ASCO20 Virtual Scientific Meeting may be over, but you can still read all the #HTGMolecular customer posters that were presented.  https://t.co/9X2utZOqJD #AdvancingPrecisionMedicine https://t.co/PRlfXfD1JW",2020-06-01
1267559141679104000,https://twitter.com/brownalex275/status/1267559141679104000,brownalex275,Learn more about how we are redesigning the clinical trial experience for patients during #COVID19. #ASCO20 #ScienceWillWin #PFEColleague https://t.co/gaqtwHa1Mn,2020-06-01
1267558796185890816,https://twitter.com/marklewismd/status/1267558796185890816,marklewismd,"After #asco20 I think we should document that both we and our patients are alert &amp; oriented x 5

Person
Place
Time
Situation
Cost of care",2020-06-01
1267558741769142285,https://twitter.com/dfcidatascience/status/1267558741769142285,dfcidatascience,"Two #ASCO20 plenary presentations feature @eaonc studies w/ statistical analyses led by Susanna Jacobus, MS (#multiplemyeloma) &amp; Fengmin Zhao, PhD (#metastaticbreastcancer). Both studies highlight practice-changing results &amp; the importance of publicly-funded cooperative research. https://t.co/n4Dw1nqcjI",2020-06-01
1267558579881426944,https://twitter.com/montypal/status/1267558579881426944,montypal,I was wondering if this would be easily quantifiable. Thank you to @SWOG @DrDawnHershman et al for showing us the impact of #COVID19 on trial accrual. So impt to remember that the clinical trials of today lead to many cancer survivors of tomorrow. @neerajaiims @DrChoueiri #ASCO20 https://t.co/cLPe6i05Sp,2020-06-01
1267558247206092806,https://twitter.com/ndenduluri1/status/1267558247206092806,ndenduluri1,Look forward to connecting virtually but will miss this fantastic evening in person - not too late to register https://t.co/rnywsGAOro Congrats to @lillian_siu and @DrDawnHershman #WWCC #WLO2020 #mentorship @ConquerCancerFd #ASCO20 https://t.co/HFXgxTE69t https://t.co/FvN7LTOlPX,2020-06-01
1267557796175843328,https://twitter.com/urotoday/status/1267557796175843328,urotoday,"Abstract TPS5586 - a phase 2 randomized trial of #Radium223 Dichloride and SABR vs SABR for oligometastatic #ProstateCancers #RAVENS. Presented by Matthew Deek, MD @HopkinsMedicine. #ASCO20 coverage by @GoldbergHanan @UpstateNews on UroToday &gt; https://t.co/wLX0NU3XWc https://t.co/stEokKGWFq",2020-06-01
1267557531431264256,https://twitter.com/ASCOPost/status/1267557531431264256,ASCOPost,Ivosidenib Plus Venetoclax With or Without Azacitidine for IDH1-Mutated AML https://t.co/TIkFxBtQQm #leusm #hematology #ASCO20,2020-06-01
1267557399117926402,https://twitter.com/JeamesSailor/status/1267557399117926402,JeamesSailor,Outcomes of this could help the disproportionate enrollment of black men in clinical trials. VA scientists race to determine effectiveness of prostate cancer drug for COVID-19 patients https://t.co/he4pFUNxJZ @UsTOOHQ @MensHlthNetwork @ASCOPost @ASCO @AACR #disparities #CBPR,2020-06-01
1267556995521003520,https://twitter.com/GuOnco/status/1267556995521003520,GuOnco,"The first Phase III trial (IMvigor010) did not meet its primary endpoint of DFS when evaluating adjuvant atezolizumab in MIUC, even in higher PD-L1 status patients. Surveillance is still the best approach. #ASCO20 #bladdercancer #oncogu @EZucca @CarcanoMD @JoaoNeif @DD_Preto https://t.co/vIjDb2EbDm",2020-06-01
1267556777761128448,https://twitter.com/VivekSubbiah/status/1267556777761128448,VivekSubbiah,"Congratulations  @ASCOPres !!! Right time, right place, &amp; Right presidential theme --&gt; Equity: Every Patient ✅. Every Day✅. Everywhere.✅👉@ASCO #ASCO20 --&gt; #ASCO21 https://t.co/L7inuF4EXV",2020-06-01
1267556480116498433,https://twitter.com/oulkhouir/status/1267556480116498433,oulkhouir,"l’#ASCO2020 qui réunit des milliers d’oncologues du monde devait se tenir à Chicago, cette année il est virtuel! Autre rassemblement qui a lieu contre un autre cancer de ce monde, le racisme malheureusement lui bien réel! #JusticeForGeorgeFloyd https://t.co/7AAyG0K6lI",2020-06-01
1267556049185357824,https://twitter.com/clarissamathias/status/1267556049185357824,clarissamathias,"A cobertura que a SBOC faz do #ASCO2020 traz agora os destaques em tumores do sistema nervoso central, entre eles novidades em biomarcadores moleculares e de imagem, terapia alvo, imunoterapia e linfomas primários… https://t.co/EXVlOiOwAF",2020-06-01
1267555732523753477,https://twitter.com/draandreanutro1/status/1267555732523753477,draandreanutro1,"Nesse podcast discutimos vários temas apresentados na ASCO 2020. Mntenha-se atualizado!
https://t.co/yhb9gwu3u7
#ASCO2020 #ONCOLOGIA #OBESIDADEBRASIL #NUTRICAO #NUTROLOGIA #ONCOLOGIAEINSTEIN https://t.co/3Jh8S04sKb",2020-06-01
1267555367308808192,https://twitter.com/marklewismd/status/1267555367308808192,marklewismd,"Remember my #asco20 recommendation to not underestimate patients’ savvy in navigating the medical literature?

My patient, unprompted to comment on my publications: “I enjoyed reading your article in the New England Journal of Medicine!” 👀",2020-06-01
1267554374009655296,https://twitter.com/OncologyTimes/status/1267554374009655296,OncologyTimes,In Case You Missed It: Watch this interview with study author Dr. Paulo Ghia of @MyUniSR.  #ASCO20 #leusm https://t.co/gW04wrzvnr,2020-06-01
1267554253054279680,https://twitter.com/SBOC_Oncologia/status/1267554253054279680,SBOC_Oncologia,"O Comitê de Tumores Ginecológicos da SBOC também está no #ASCO2020 e comenta os destaques da área. Assista ao vídeo com Dra. Angélica Nogueira, Dra. Carla Rameri, Dra. Daniela de Freitas, Dra. Karime Kalil e Dr. Paulo Mora, em https://t.co/TFbMleFyNv. #ASCOvirtual #SBOCnaASCO https://t.co/EG8lbOB4MC",2020-06-01
1267553451246080000,https://twitter.com/OncLive/status/1267553451246080000,OncLive,Infigratinib Demonstrates Clinical Activity Across Settings in Urothelial Cancer @YungLyou @cityofhope @ASCO #ASCO20 https://t.co/C2R68t09Ag,2020-06-01
1267553323382603787,https://twitter.com/CR_Curran/status/1267553323382603787,CR_Curran,Excited and honored to have had our poster included in #ASCO20. We focused on outcomes of patients with metastatic urothelial carcinoma post-treatment with Enfortumab vedotin. Definitely an area of unmet need for #bladdercancer. Thanks for your help and guidance @sonpavde @ASCO https://t.co/4UNZQlVv0M,2020-06-01
1267552995841015808,https://twitter.com/tmprowell/status/1267552995841015808,tmprowell,".@adamfeuerstein of @statnews gave the #ASCO20 Virtual Scientific Program a 👍 despite challenges posed by #COVID19. We’re all coming up with some new approaches  worth keeping (about scientific  confs &amp; everything else) during this #pandemic.  

https://t.co/f9gGtufOPJ",2020-06-01
1267552216543567872,https://twitter.com/Karyopharm/status/1267552216543567872,Karyopharm,Karyopharm in the News – We're proud to see the BOSTON Phase 3 data featured in the @ASCO Daily News: https://t.co/q5VbfN38uX (For XPOVIO full prescribing information please visit: https://t.co/di3iCQtd7Z.) https://t.co/zoKKIWLlD7,2020-06-01
1267551592238190592,https://twitter.com/AndreGoyMD/status/1267551592238190592,AndreGoyMD,"With #COVID19 pandemic-related restrictions beginning to ease, @ASCO is providing timely information on how oncology practices can start safely resuming routine operations. Check out this article detailing their helpful recent guidance: https://t.co/HPyfjKT4NF #cancer https://t.co/jAcq5RP3Tm",2020-06-01
1267551540828606466,https://twitter.com/MoffittNews/status/1267551540828606466,MoffittNews,#ASCO20 Virtual Scientific Program: @atarhinimdphd of @MoffittNews discusses a study investigating immune adverse events and the use of immunosuppressants and hormone replacement in #melanoma. View abstract here: https://t.co/dDpfarbgEy https://t.co/t8MCtEW4Fh,2020-06-01
1267551124447531013,https://twitter.com/VivekSubbiah/status/1267551124447531013,VivekSubbiah,"How are the virtual exhibits coming out for industry or non-profits or journals @ASCO #ASCO20 ? Missing the Hershey kisses, free coffee or frozen yoghurt ? @chadinabhan @DrChoueiri @marklewismd @montypal @neerajaiims @mtmdphd @JackWestMD @StephenVLiu @NarjustDumaMD @DrSGraff",2020-06-01
1267550992087814149,https://twitter.com/MDedgeHemOnc/status/1267550992087814149,MDedgeHemOnc,"Did you miss #ASCO20? Click here for all of the news articles, https://t.co/G8mACcdrL5. #ASCO2020 #OncoAlert #medtwitter https://t.co/IRw9Y8bOPe",2020-06-01
1267550929844404224,https://twitter.com/CR_Curran/status/1267550929844404224,CR_Curran,Fantastic recap of the fantastic bladder cancer research progress at @ASCO #ASCO20 https://t.co/NACXKaqp6y,2020-06-01
1267550907362762754,https://twitter.com/fireflyann/status/1267550907362762754,fireflyann,"perhaps this can be one of the take aways from #ASCO20

well said, well said. https://t.co/yHWEG8I7Wr",2020-06-01
1267550718761807873,https://twitter.com/PennMDForum/status/1267550718761807873,PennMDForum,Quick overview from @DavidFajgenbaum about his @ASCO opening address #ASCO2020 https://t.co/vIbJezKSTD,2020-06-01
1267549015249387521,https://twitter.com/SCIDirector/status/1267549015249387521,SCIDirector,SCI member @JoelNealMD and colleagues found that cabozantinib combined with atezolizumab showed encouraging clinical activity in patients with advanced #NSCLC who had progressed after prior immune checkpoint inhibitor therapy https://t.co/4O0lzEXkvJ #ASCO2020 #lcsm #lungcancer https://t.co/IUz0kxeY8K,2020-06-01
1267548647002124288,https://twitter.com/mtmdphd/status/1267548647002124288,mtmdphd,"1/ [THREAD] Timeline @ASCO Social Media &amp; Analyses [Updated: May 27, 2020] #socialoncology #socpharm #ASCO20
https://t.co/N9lGzuGCqe",2020-06-01
1267548533319663627,https://twitter.com/mtmdphd/status/1267548533319663627,mtmdphd,"Twitter During @ASCO 2011-16: Advanced Metrics &amp; User Trends [May 17, 2017] @doctorpemm @mtmdphd @mpdrc @nephondemand @JOP_ASCO https://t.co/uioLBfZHnr https://t.co/sDGd8R6s2a",2020-06-01
1267547726566260736,https://twitter.com/MoffittNews/status/1267547726566260736,MoffittNews,"Available now, @abarata3105 (@MoffittNews) shares new data on neurotoxicity associated with CAR T therapy at #ASCO20 Virtual Scientific Program. View here: https://t.co/4fwLrPKODA https://t.co/FOBRL7rDF9",2020-06-01
1267547717359861761,https://twitter.com/MedscapeOnc/status/1267547717359861761,MedscapeOnc,Practices that embrace OCM may see modest cost savings. https://t.co/cr2sra37aa #ASCO20,2020-06-01
1267547465722494977,https://twitter.com/Medscape/status/1267547465722494977,Medscape,Patients with COVID-19 and cancer that is progressing cancer had a fivefold increased risk of 30-day mortality. https://t.co/j5sjZKF6Ts #ASCO20,2020-06-01
1267547130429874177,https://twitter.com/KoontzCenter/status/1267547130429874177,KoontzCenter,"#ASCO20 Update!
Phase 3 data supports adding PDL-1 inhibitors to chemotherapy as first-line treatment for patients with locally recurrent, inoperable, or #mTNBC whose tumors expressed PD-L1. https://t.co/tsnSIuFUhd https://t.co/cvbGnMbBFO",2020-06-01
1267546899311181826,https://twitter.com/CharuAggarwalMD/status/1267546899311181826,CharuAggarwalMD,Was a lively discussion today! Thanks @JohnCendpts for having me on the panel with @JackWestMD @DanChenMDPhD and @OzAzamTmunity1. Thoroughly enjoyed the discussion around new and emerging + (some) practice changing data from #ASCO20 @ASCO https://t.co/UcfcuVU7yL,2020-06-01
1267546459651653638,https://twitter.com/ASCOPost/status/1267546459651653638,ASCOPost,Durvalumab Added to Standard Chemotherapy Improved Overall Survival in Patients With Malignant Pleural Mesothelioma https://t.co/w9bj7nzIpZ #LCSM #cancer #oncology #ASCO20,2020-06-01
1267546310661545986,https://twitter.com/BioCanRx/status/1267546310661545986,BioCanRx,"Allogene, Servier’s ‘off-the-shelf’ CAR-T shows high response rate in Phase I lymphoma data at #ASCO20  https://t.co/FbIvogBtfn #CancerResearch #Immunotherapy",2020-06-01
1267546283268616192,https://twitter.com/SandraSwainMD/status/1267546283268616192,SandraSwainMD,"Women Who Conquer Cancer #WWCC raised nearly $5M in 7 yrs, funding 30 research grants, 9 Mentorship Awards #ASCO20 @ConquerCancer #WLO2020! Please donate-text WLO to 41444 https://t.co/3sUSC69HHp",2020-06-01
1267546271344197640,https://twitter.com/MM_Oncology/status/1267546271344197640,MM_Oncology,"#ASCO20 video: @TomBeer (@OHSUKnight) highlights the key messages &amp; caveats of the OS data from the #PROSPER, #SPARTAN &amp; #ARAMIS trials of enzalutamide, apalutamide, and darolutamide in nonmetastatic #CRPC #ProstateCancer @uroupdate https://t.co/Ofb7pKH2qB",2020-06-01
1267545224588464128,https://twitter.com/OncologyTimes/status/1267545224588464128,OncologyTimes,More from our #ASCO20 coverage on #LungCancer: First-Line Tiragolumab + Atezolizumab Improves Survival Among NSCLC Patients https://t.co/T1bVrHG5vl #cancer #cancertreatment #medtwitter via @SarahCannonDocs https://t.co/LSrNxseZ0s,2020-06-01
1267545205403680770,https://twitter.com/DFBC_PedCare/status/1267545205403680770,DFBC_PedCare,"Congratulations to David Shulman, MD, who has earned a Career Development Award from @ASCO's @ConquerCancerFd. Learn more about the award: https://t.co/y6KevKflfc https://t.co/HmPh1yx9UO",2020-06-01
1267545129025327104,https://twitter.com/Pachecutek/status/1267545129025327104,Pachecutek,"Prospective agnostic germline testing in pediatric cancer patients. ""...Broad germline testing should be considered for all children with cancer..."" #ASCO2020 #GeneticCounseling https://t.co/Eze126mttx",2020-06-01
1267544932228698112,https://twitter.com/_SEOM/status/1267544932228698112,_SEOM,"📡#ASCO20 | El Dr. Alfonso Gómez de Liaño analiza las novedades sobre cáncer genitourinario (no próstata). 

🎞️ Sus vídeo-píldoras ya están disponibles en nuestra plataforma de formación #OncoNexion. 

 🔗https://t.co/wCdmkxtv0q https://t.co/5avhygkOEr",2020-06-01
1267544675180781569,https://twitter.com/mtmdphd/status/1267544675180781569,mtmdphd,Top Influencers of #ASCO20 👉 @ASCO @OncoAlert @tmprowell @VivekSubbiah @marklewismd @GlopesMd https://t.co/hcGtsIEu8D via @symplur Post Plenary tail. Good business meeting today.,2020-06-01
1267544669510144003,https://twitter.com/IBCResearch/status/1267544669510144003,IBCResearch,"Virtual #ASCO20 is a big win for #patientadvocates as well. Few of us have the $$$ resources for hotel, travel &amp; registration. TY @ASCO for leveling the playing field. https://t.co/YHZfcZrrnA",2020-06-01
1267544241900683265,https://twitter.com/ELNEC1/status/1267544241900683265,ELNEC1,"Congratulations Dr. Betty Ferrell, #ELNEC Director, on the #ASCO20 award for your contributions to palliative and supportive care in #oncology from @ASCO! In this video, she reflects on her career, #palliativecare, and quality of life. @cityofhope

https://t.co/eke8kyAwKB https://t.co/GNGwzBAuIb",2020-06-01
1267544064708280329,https://twitter.com/tsemiglazovaMD/status/1267544064708280329,tsemiglazovaMD,"#ASCO20 👏👏👏🙏 @ASCO presidential theme, Equity: Every Patient. Every Day. Everywhere. Lori J. Pierce #OncoAlert #niioncologii https://t.co/9qaoTLYxF1",2020-06-01
1267543867626270721,https://twitter.com/holly7holly/status/1267543867626270721,holly7holly,"When should we treat #cancer patients during a #pandemic? Read about how we tried to answer that question with our new #oncCOVID app! @DrSpratticus @MatthewSchippe4 @umichsph @ASCO 
https://t.co/pehyeDu1GE",2020-06-01
1267543694619615234,https://twitter.com/MedscapeOnc/status/1267543694619615234,MedscapeOnc,"Virtual #ASCO20 Is underway. What you need to know:
https://t.co/GDx779EbMN https://t.co/CLu3h10PxI",2020-06-01
1267543097724076039,https://twitter.com/_SEOM/status/1267543097724076039,_SEOM,"📡#ASCO20 | El Dr. Antonio Rueda comenta las novedades sobre linfomas.

🎞️ Sus vídeo-píldoras ya están disponibles en nuestra plataforma de formación #OncoNexion. 

🔗 https://t.co/wCdmkxtv0q https://t.co/hW6yvhGjnR",2020-06-01
1267542573792534529,https://twitter.com/mtmdphd/status/1267542573792534529,mtmdphd,#CCC19 #ASCO20 Happy Hour @COVID19nCCC https://t.co/bjf3xKm2Vt,2020-06-01
1267542475306082304,https://twitter.com/_SEOM/status/1267542475306082304,_SEOM,"📡#ASCO20 | La Dra. Auxiliadora Gómez España, oncóloga médico del @HUReinaSofia, analiza las novedades en cáncer gastrointestinal (colorrectal).

🎞️ Sus vídeo-píldoras ya están disponibles en nuestra plataforma de formación #OncoNexion. 

🔗 https://t.co/wCdmkxtv0q https://t.co/rQwcoQ4RlM",2020-06-01
1267541685610917889,https://twitter.com/LLSusa/status/1267541685610917889,LLSusa,"Learn more about cancer in the time of COVID-19, and progress in myeloma and lymphoma in our recap from the American Society of Clinical Oncology virtual conference this past weekend &gt;&gt; https://t.co/cZWd8nN3Jk  #ASCO2020 @ASCO https://t.co/C2kOkcsPXd",2020-06-01
1267541438365122561,https://twitter.com/renalandurology/status/1267541438365122561,renalandurology,Pembrolizumab-axitinib continued to offer durable benefits in advanced RCC https://t.co/m8hLxkGqzs #ASCO20 #kcsm,2020-06-01
1267539875525509123,https://twitter.com/milosicevic/status/1267539875525509123,milosicevic,"Welcome to new @ASCOPres and aspirational theme on equity for every patient, every day, everywhere 💙🌍 #ASCO20 #HealthForAll https://t.co/pzoLoss1SU",2020-06-01
1267539788007178240,https://twitter.com/BrasilOncologia/status/1267539788007178240,BrasilOncologia,"Dra. Ana Gelatti, oncologista clínica e membro do GBOT e Dra. Clarissa Mathias, oncologista clínica e diretora do GBOT destacaram três estudos da #ASCO20 sobre o uso de #imunoterapia de 1ª linha em #câncer de #pulmão não-pequenas células: https://t.co/hrME25ASk2 https://t.co/mdzjRr3WG1",2020-06-01
1267539546058547200,https://twitter.com/gastromom/status/1267539546058547200,gastromom,"Scouring tweets from  #ASCO20 and trying to find an institution or researcher who might be focused on primary prevention and environmental causes of malignancy 

anyone?",2020-06-01
1267539255435419649,https://twitter.com/PortalOnconews/status/1267539255435419649,PortalOnconews,Estudo de Fase II de braço único selecionado para sessão oral na #ASCO20 mostrou que a associação do anti-PD-L1 durvalumabe à quimio com cisplatina e pemetrexede pode ampliar a sobrevida de pts com mesotelioma pleural maligno irressecável - https://t.co/HyDAby5WFO @ASCO #ONCONEWS https://t.co/JIdmOHxlbZ,2020-06-01
1267538817407430662,https://twitter.com/amyakirkham/status/1267538817407430662,amyakirkham,"#ASCO2020 
Use of antioxidant &amp; vitamin B12 supplements before/during chemotherapy associated with worse cancer outcomes.
https://t.co/SvQobEmUpM

A possible alternative, fasting/caloric restriction shows 'selective (oxidative) stress resistance' for healthy but not cancer cells.",2020-06-01
1267538757013643269,https://twitter.com/tanyawildes/status/1267538757013643269,tanyawildes,"Disappointed to hear a lot of #ASCO2020 presenters who have not incorporated respectful language as beautifully described by @tmprowell (link below).  

Shoutout to @szusmani - exemplary language in his oral abstract - well done, Saad! 

https://t.co/3OLDw97zaS",2020-06-01
1267538506953474049,https://twitter.com/ASCOPres/status/1267538506953474049,ASCOPres,"I’ve been interested throughout my whole career in how to best create #equity in cancer care for all patients. So, I'm excited to introduce my @ASCO presidential theme, Equity: Every Patient. Every Day. Everywhere. https://t.co/X8W3Qn8R9R",2020-06-01
1267538498069819394,https://twitter.com/sttrcancer/status/1267538498069819394,sttrcancer,"American Society of Clinical Oncology’s (@ASCO) annual meeting went virtual this year! Here are the latest findings by @FredHutch experts on #bladdercancer, pediatric cancer, gender disparities and financial toxicity: https://t.co/jge77RGYRY",2020-06-01
1267537677324189696,https://twitter.com/oncologytube/status/1267537677324189696,oncologytube,"Charles Rudin, MD on KEYNOTE-604: How Does This Compare to Other Trials? #ASCO2020 @charlesrudin #ASCO @sloan_kettering https://t.co/Bdy36cZo1s https://t.co/syE3tIiAtN",2020-06-01
1267537672081338368,https://twitter.com/oncologytube/status/1267537672081338368,oncologytube,"Charles Rudin, MD on KEYNOTE-604: Pembrolizumab or Placebo Plus Etoposide as Therapy in SCLC #ASCO2020 @charlesrudin #ASCO @sloan_kettering https://t.co/KuglpFc0Fu https://t.co/T1lMnnTZJI",2020-06-01
1267536535391358976,https://twitter.com/Sara55251834/status/1267536535391358976,Sara55251834,Learn more about how we are redesigning the clinical trial experience for patients during #COVID19. #ASCO20 #ScienceWillWin #PFEColleague https://t.co/Vl6OmHbTRN,2020-06-01
1267536526780411906,https://twitter.com/Sara55251834/status/1267536526780411906,Sara55251834,Learn more about how we are redesigning the clinical trial experience for patients during #COVID19. #ASCO20 #ScienceWillWin #PFEColleague https://t.co/O70PboTT3N,2020-06-01
1267536139033985030,https://twitter.com/deeplens_ai/status/1267536139033985030,deeplens_ai,"#ASCO20 Abstract Accepted -- 3 months of retrospective data triaged in 3 weeks... 
Discover more here. https://t.co/4AK5O6xHkF

#ASCO20 #clinicaltrials  #clinicalresearch #precisiononcology #moleculardiagnostics #patientrecruitment #clinicalstudies https://t.co/OUJ2TCzhBu",2020-06-01
1267535905696313345,https://twitter.com/jayistobe/status/1267535905696313345,jayistobe,"At #ASCO20, our data reflects our commitment and relentless pursuit of science, innovation and collaboration to improve patients’ lives. https://t.co/lvF9A9GEol https://t.co/I2fqVkfIEM",2020-06-01
1267535446709547011,https://twitter.com/LucaDezzani/status/1267535446709547011,LucaDezzani,Looks like quite a few people enjoyed #ASCO20 being virtual to the extent they would join #ASCO21 from remote! https://t.co/Rg4PMLo4JQ,2020-06-01
1267534611753598977,https://twitter.com/COVID19nCCC/status/1267534611753598977,COVID19nCCC,"[THREAD] COVID-19 and Cancer Consortium (CCC19) - LBA110 #ASCO20 #COVID19nCancer @COVID19nCCC #CCC19 #NCT04354701 https://t.co/xqZPC8wTjd
https://t.co/437KNNCKqh",2020-06-01
1267533912806494210,https://twitter.com/pharm2market/status/1267533912806494210,pharm2market,Asco 2020 – J&amp;J sees multiple myeloma responses deepen | @johnsonandjohnson #JNJ @ASCO #ASCO @JNJNews https://t.co/h7K2f1WoDp,2020-06-01
1267533891906174976,https://twitter.com/aspenbio/status/1267533891906174976,aspenbio,Asco 2020 – J&amp;J sees multiple myeloma responses deepen | @johnsonandjohnson #JNJ @ASCO #ASCO @JNJNews https://t.co/PLTN3Qy5ra,2020-06-01
1267533880237711362,https://twitter.com/MedpageOnco/status/1267533880237711362,MedpageOnco,"In patients with MET-driven papillary #renalcellcarcinoma, treatment with an investigational MET inhibitor yielded positive results, reported @DrChoueiri, MD, of @DanaFarber, at virtual #ASCO20. By @icingram. #kcsm
https://t.co/jiu3gEzV7r",2020-06-01
1267533667720728583,https://twitter.com/IFCTlung/status/1267533667720728583,IFCTlung,Quelles nouvelles options pour l’immunothérapie en première ligne dans les NSCLC sans addiction oncogénique ? En direct sur @FrequenceMedica avec @GerardZalcman et @nicogirardcurie : https://t.co/ViQ6fmS4ww #ASCO20 @IFCTlung https://t.co/uSx9ToezTM,2020-06-01
1267533638708588544,https://twitter.com/oncologytube/status/1267533638708588544,oncologytube,"John Kuruvilla, MD on A New Standard in Phase II Study of Pembrolizumab vs. Brentuximab #ASCO2020 @ClevelandClinic #ASCO https://t.co/odIdpe1JXR https://t.co/oiejfaJh2M",2020-06-01
1267533379907526657,https://twitter.com/SeattleCCA/status/1267533379907526657,SeattleCCA,"#ASCO20: @PGrivasMDPhD  symposium ""Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19)."" Read on our SCCA at @ASCO page: https://t.co/q5qOEm9P8w #COVID19 https://t.co/5RGADBHWVq",2020-06-01
1267532284036550656,https://twitter.com/tmprowell/status/1267532284036550656,tmprowell,"We might need to begin with healthcare is a right, not a privilege. 😞

#ASCO20 #HealthInequity https://t.co/8nOiVsUaFP",2020-06-01
1267531873808338944,https://twitter.com/oncologytube/status/1267531873808338944,oncologytube,"John Kuruvilla, MD on the Specific of the Phase II Study of Pembrolizumab vs. Brentuximab #ASCO2020 @ClevelandClinic #ASCO https://t.co/Ez0Q9axmIG https://t.co/tW7IgN35eP",2020-06-01
1267531679343706113,https://twitter.com/theMMRF/status/1267531679343706113,theMMRF,"We are thrilled to bring you highlights from #ASCO20! Read our blog for a summary of the latest presentations, including Saturday and Sunday abstracts from Dr. Saad Usmani (@szusmani) and Dr. Shaji Kumar (@myelomaMD). https://t.co/6CWNwOwmWB #mmsm",2020-06-01
1267531672561598464,https://twitter.com/Breastcancerorg/status/1267531672561598464,Breastcancerorg,Study: Chemo before surgery for early-stage HER2+ #breastcancer doesn't have to include anthracycline #ASCO20 https://t.co/170R2My2Sc https://t.co/QfhP94Aog6,2020-06-01
1267531458236895240,https://twitter.com/MoffittNews/status/1267531458236895240,MoffittNews,"At the #ASCO20 Virtual Scientific Program, Dr. Veronica Mariotti of @MoffittNews shares the results of a study analyzing the effect of ARID1a mutations on survival in metastatic breast cancer patients. View here: https://t.co/2up9JJ5eOa #BCSM https://t.co/msG5nbvWLp",2020-06-01
1267531450620039168,https://twitter.com/ThePCCTC/status/1267531450620039168,ThePCCTC,"While held virtually this year, our Scientific Oversight Committee had another inspiriting meeting at #ASCO20, unified in our mission to translate scientific discoveries to improved standards of care for men with prostate cancer! https://t.co/ySzmQcNQYF https://t.co/yuLiIdzVfK",2020-06-01
1267531371439775746,https://twitter.com/Nuc69Girl/status/1267531371439775746,Nuc69Girl,"Cardinal Health Specialty Solutions VP/Senior Medical Director, Ajeet Gajra, MD,  and experts have published findings on the use of augmented intelligence in oncology released at #ASCO20. Listen or read  abstract here. https://t.co/qlR1uoaRGV",2020-06-01
1267531360865927168,https://twitter.com/AmgenOncology/status/1267531360865927168,AmgenOncology,"Christophe Bourdon, @Amgen’s VP and General Manager of Oncology wraps our AMGEN #ATHOME series and shares why we were proud to be part of this year’s #ASCO20 and equally proud of Amgen’s commitment to research and patients. https://t.co/jFICfC1V8T",2020-06-01
1267531357326135298,https://twitter.com/sema4/status/1267531357326135298,sema4,"Is there a more efficient way to tap into #EHR data to assess real-world cancer outcomes? At Sema4, we use #NLP &amp; #AI to abstract outcomes. Read our #ASCO20 abstract to learn how we applied this approach for #LungCancer: https://t.co/wujqP0Gw8b https://t.co/hHsvufEEk0",2020-06-01
1267530980279177223,https://twitter.com/slcphd/status/1267530980279177223,slcphd,"Needed to dial-down the brain a bit @ASCO, 
No better spot than in the field with my Madison. Beautiful day, gorgeous horse.
#rescuedpetsarethebestpets https://t.co/QDsbOIZVvA",2020-06-01
1267529647174156289,https://twitter.com/ARosen380/status/1267529647174156289,ARosen380,"Proud to be a @FightCRC #researchadvocate. We spent this morning discussing #colorectalcancer #research from @ASCO on patient communication, therapeutics, and early-age onset CRC.  #strongarmselfie #EAOCRC #crcsm @EarlyOnsetCRC #ASCO20 https://t.co/MKEoIXiu42",2020-06-01
1267528130454974464,https://twitter.com/rameshv27/status/1267528130454974464,rameshv27,Learn more about how we are redesigning the clinical trial experience for patients during #COVID19. #ASCO20 #ScienceWillWin #PFEColleague https://t.co/PoWeF75Q0J,2020-06-01
1267527516811603971,https://twitter.com/TamaraSN2/status/1267527516811603971,TamaraSN2,Promissing data in Asian patients #ASCO20 #DS8201 #Gastric We probably need to wait this results in western patients #DestinyGC02trial #NCT04014075 ongoing participation @TamaraSN2 @hospitalclinic https://t.co/umqUorpxJp,2020-06-01
1267527301001908224,https://twitter.com/AutumnKilker/status/1267527301001908224,AutumnKilker,#pfizerproud of the work being done to advance critical #cancer research during #COVID19. #ASCO20 #ScienceWillWin #PFEColleague https://t.co/vDdsoQtZsU,2020-06-01
1267527045468295178,https://twitter.com/EMessean/status/1267527045468295178,EMessean,"#ASCO2020 Dernier jour pour l’#OncologyPressRoom de 
@AgenceLJCom
 💪👏
#proudagency #communication #RelationsPresse https://t.co/GNPR5CQxTp",2020-06-01
1267526815943397376,https://twitter.com/CanUrolAssoc/status/1267526815943397376,CanUrolAssoc,"Tonight ▶️ Join us for Canadian Highlights from #ASCO2020! Tune in: https://t.co/6gIkD9EcDV 
#UroSoMe #bladdercancer #kidneycancer #prostatecancer
@lalaniMD @sebastienhotte https://t.co/qETRYUm5CA",2020-06-01
1267526674658312198,https://twitter.com/DavidP4AD/status/1267526674658312198,DavidP4AD,Study presented at @ASCO concludes US needs direct Medicare negotiations w/drug corps. We are paying launch prices double that of European countries &amp; after introduction their prices go down while ours go up. It's time to fix what was done wrong in 2003. https://t.co/d35SLCBXVf,2020-06-01
1267526337063014402,https://twitter.com/renalandurology/status/1267526337063014402,renalandurology,Savolitinib shows “encouraging efficacy” in MET-driven papillary RCC https://t.co/OkzCpejt8G #ASCO20 #kcsm,2020-06-01
1267524354973278208,https://twitter.com/DaneJDicksonMD/status/1267524354973278208,DaneJDicksonMD,"Opening remarks for #ASCO2020 general session may have been virtual, but the message is for us all: Unite and Conquer: Accelerating Progress Together https://t.co/GJk2of1psY #cancer #realworlddata https://t.co/AUOXMpOtSQ",2020-06-01
1267523965464875008,https://twitter.com/Dr_Ivanoncologo/status/1267523965464875008,Dr_Ivanoncologo,#ASCO20 les comparto el Top 5 de los abstracts presentados #oncoalert  https://t.co/KsTFLMJbV4,2020-06-01
1267523875417452546,https://twitter.com/Dr_Ivanoncologo/status/1267523875417452546,Dr_Ivanoncologo,#ASCO20 les comparto el Top 5 de los abstracts presentados #oncoalert  https://t.co/gpA7Y4xSiA,2020-06-01
1267523864185233414,https://twitter.com/TenBridge/status/1267523864185233414,TenBridge,"Great roundup by @MMarchioneAP of new cancer drugs in development -- including an important advance in prostate cancer from #TBCPartner @Myovant, as announced at #ASCO20 and in @NEJM last week: https://t.co/TnJcD0XDYL",2020-06-01
1267523418141765632,https://twitter.com/ReeseFCRC/status/1267523418141765632,ReeseFCRC,".@FightCRC #researchadvocates spent this morning diving into the #research from #ASCO20! Abstracts covered patient communication, therapeutics, and early-age onset #colorectalcancer. Great discussions and lots of insight from this group.  #strongarmselfie #EAOCRC @EarlyOnsetCRC https://t.co/tXxL7lJoQq",2020-06-01
1267523247920369664,https://twitter.com/HemOncToday/status/1267523247920369664,HemOncToday,"From @ASCO @ASCO20 - Off-the-shelf CAR-T #CellTherapy regimen safe for advanced lymphoma, from Sattva S. Neelapu, MD @MDAndersonNews https://t.co/7a3X8eJfV3 @AllogeneTx @Servier https://t.co/EHsbGVbuql",2020-06-01
1267523192169443328,https://twitter.com/Dr_Ivanoncologo/status/1267523192169443328,Dr_Ivanoncologo,#ASCO20 les comparto el Top 5 de los abstracts presentados. #oncoalert  https://t.co/UUn8UgMsuM,2020-06-01
1267523070161416194,https://twitter.com/oncologytube/status/1267523070161416194,oncologytube,"John Kuruvilla, MD on KEYNOTE-204: Phase II Study of Pembrolizumab vs. Brentuximab #ASCO2020 @ClevelandClinic #ASCO https://t.co/qUSWhMAltn https://t.co/RQozGBntiO",2020-06-01
1267522802531266564,https://twitter.com/RossFH/status/1267522802531266564,RossFH,"In large cohort of #ovariancancer patients receiving NACT, incidence of DVT/PE during treatment was ~15% -- opportunity to improve care with VTE prophylaxis during treatment? @ASCO #asco20 #goASCO20 #gyncsm @ggardnermd @zivanovicmd @KaraLongRoche @dchimd https://t.co/iugz0STihD",2020-06-01
1267522694917926913,https://twitter.com/DrPaulyDeSantis/status/1267522694917926913,DrPaulyDeSantis,"Provocative NDMM question, if one were to design a new Ph3 should it have a Quad (DVRd) or Triplet (VRd) control arm given ph3 Quads will readout prior to the hypothetical trial completing. interesting b/c SVd (BOSTON) results not too relevant given triplet are SOC #MMSM #ASCO20",2020-06-01
1267521480319021056,https://twitter.com/HemOncToday/status/1267521480319021056,HemOncToday,"🆕 randomized phase 3 study results @ASCO #ASCO20 - Early local therapy did not prolong survival among women with de novo metastatic breast cancer https://t.co/aOBkgLyY8k Seema Ahsan Khan, MD @LurieCancer @NUFeinbergMed https://t.co/gFNKDasawJ",2020-06-01
1267521234524270594,https://twitter.com/UWashOBGYN/status/1267521234524270594,UWashOBGYN,"Gyn Onc division chief @SwisherLiz is the lead author of the MAGENTA (Making Genetic Tests Available) study, a three-year study recently published in @ASCO. #breastcancer #ovariancancer #genetictesting https://t.co/kREps1qOJ7",2020-06-01
1267521053640716288,https://twitter.com/oncologytube/status/1267521053640716288,oncologytube,"Suneel Kamath, MD on Starting Therapies for Rural Patients with Breast Cancer @SKamath_MD #ASCO2020 @ClevelandClinic #ASCO https://t.co/Fh2UMkGgWQ https://t.co/uuI64uVZrk",2020-06-01
1267520708755820544,https://twitter.com/LennyVSt/status/1267520708755820544,LennyVSt,"#ASCO20 top 3 according to Brad:
$JNJ's BCMA CART data
$ROG Roche's TIGIT data on top of PD-L1
$AZN AstraZeneca Tagrisso data in EGFR lung cancer and Enhertu data in non-breast cancer HER2 positive tumors. https://t.co/F9SlM6cG8l",2020-06-01
1267520289560244226,https://twitter.com/MDedgeHemOnc/status/1267520289560244226,MDedgeHemOnc,Active cancer increases death risk in patients with COVID-19. #ASCO20 @ASCO https://t.co/X3EAFV0NyG #Oncoalert #ListenUpMBC #COVID19 #ASCO2020 https://t.co/WXX6giXLfR,2020-06-01
1267519738982400001,https://twitter.com/DrDHodgson/status/1267519738982400001,DrDHodgson,"My highly telegenic colleague Dr. Kuruvilla on results of KEYNOTE-204 Trial in relapsed/refractory HL! Spoiler:  PFS 13.2 mo. w pembro vs 8.3 mo. w Brentuximab. Great to see new agents so effective for this problem. 
https://t.co/MkeIEfVM5x
#lymphoma  @pmcancercentre #ASCO2020",2020-06-01
1267519631218151424,https://twitter.com/DrKarineTawagi/status/1267519631218151424,DrKarineTawagi,"Many exciting updates from #ASCO20 &amp; honored to have served as a Featured Voice - reminder that all content is available @ASCO for the next 180 days. Still have a few sessions to catch up on - for any faculty out there, please share must watch / practice changing for H/O Fellows! https://t.co/dfbAB3XlR5",2020-06-01
1267519516029915136,https://twitter.com/CAudigierValett/status/1267519516029915136,CAudigierValett,"Here we are!
#ASCO20 virtual e-journal with real friends 

🗓DAY 2  in virtual Chicago :1 juin 2020

🗣➡️ https://t.co/HP8RbKADlY

👨🏽‍💻@CadranelJ 
👨🏽‍💻@nicogirardcurie 
👨🏽‍💻@DMSLung 
👩🏽‍💻@CAudigierValett 

#LaLettreDuCancerologue @Edimark_Onco @Edimark_Sante #LCSM #OncoAlert #lungcancer https://t.co/bOhj5jn3Xz",2020-06-01
1267519370881835009,https://twitter.com/Paula_1701Alba/status/1267519370881835009,Paula_1701Alba,"#ASCO20 
#IreneMonteroDimision 
#Incompetente
#EresUnFraude
..en todos los sentidos https://t.co/t46fxPXZMw https://t.co/uMaLyw3xjs",2020-06-01
1267519287301935105,https://twitter.com/MoffittNews/status/1267519287301935105,MoffittNews,At the #ASCO20 Virtual Scientific Program @PoorviDesaiMD (@MoffittNews) shares new insights of Anaplastic Large Cell Lymphoma. View abstract: https://t.co/AuYqJYQLFU #LymSM https://t.co/s8bZU9WJiF,2020-06-01
1267518919188680704,https://twitter.com/oncologytube/status/1267518919188680704,oncologytube,"Suneel Kamath, MD on How Rural Patients are Doing with Treatment in Breast Cancer @SKamath_MD #ASCO2020 @ClevelandClinic #ASCO https://t.co/vjptnY6BxD https://t.co/b6Bc9JBj1d",2020-06-01
1267518913765490689,https://twitter.com/oncologytube/status/1267518913765490689,oncologytube,"Suneel Kamath, MD on Treatment for Rural Patients @SKamath_MD #ASCO2020 @ClevelandClinic #ASCO https://t.co/h8TFBFTMBS https://t.co/gDav0KG093",2020-06-01
1267518715962277889,https://twitter.com/JTrentMDPhD/status/1267518715962277889,JTrentMDPhD,Congratulations @ASCO for an incredible scientific program #ASCO20 ! https://t.co/t9dWBjAltr,2020-06-01
1267518652867215360,https://twitter.com/schedule1movie/status/1267518652867215360,schedule1movie,"How unjust &amp; absurd would it be if a promising cancer treatment was banned from science?  Why can't we study the Endocannabinoid system?  I shrank my terminal cancer on Cannabis.  We should be celebrating, instead the DEA thinks I'm a felon?  https://t.co/F87EUP6A4Q #asco #ASCO20 https://t.co/mdIjbDOINh",2020-06-01
1267518643593711616,https://twitter.com/FrequenceMedica/status/1267518643593711616,FrequenceMedica,l'#ASCO2020 on line en et Live sur #frequence medicale https://t.co/9mC0eDpM8i https://t.co/3edTGMHn44,2020-06-01
1267518195751161858,https://twitter.com/MLJohnsonMD2/status/1267518195751161858,MLJohnsonMD2,"Love it! Thanks to you all at @ASCO for such an amazing partnership. Excited for Virtual Ed coming soon 
@tmprowell @BurrisSkip https://t.co/LYLAu6Gldi",2020-06-01
1267518055283855362,https://twitter.com/random_mommy/status/1267518055283855362,random_mommy,Anyone else having more problems with @ASCO #ASCO20 prerecorded videos? I haven’t had any luck today and playing catch up. #informationoverload,2020-06-01
1267517536859537420,https://twitter.com/cure_magazine/status/1267517536859537420,cure_magazine,"#ASCO2020 News: When compared with Nexavar, Fotivda showed improved progression-free survival, and a more manageable safety profile for patients with relapsed or refractory metastatic renal cell carcinoma.
https://t.co/s7mdTJjwsG",2020-06-01
1267517128892125184,https://twitter.com/cancerassassin1/status/1267517128892125184,cancerassassin1,"#ASCO20: The GI Oncology Aftermath

aka Quarterbacking literally on a Monday AM 😆 from my @ASCO Instagram Live partner. https://t.co/TwDNvoGbq3 https://t.co/f11MDaOxHE",2020-06-01
1267517112416903169,https://twitter.com/AiroLung/status/1267517112416903169,AiroLung,"https://t.co/2UuGVCfNBn
Risultati importanti sul piano della DFS , 
basteranno per l'approvazione del farmaco in Italia o serviranno dati più consistenti sulla OS ?
#ASCO20 #lungcancer @AIOMtweet",2020-06-01
1267516584400228356,https://twitter.com/CancerResrch/status/1267516584400228356,CancerResrch,"We recommend the #ASCO20 session: ""The assoc. of tTMB using the @FoundationATCG genomic platform..."" which may be found here: https://t.co/Uyi2ne4gYU. To learn more about tumor mutational burden and why it needs to be standardized, be sure to visit: https://t.co/DdboNsSRIo",2020-06-01
1267516455844708359,https://twitter.com/OncLive/status/1267516455844708359,OncLive,"AMG 510, a novel KRAS G12C inhibitor, demonstrated early evidence of a consistent safety profile and anticancer activity across a range of advanced KRAS G12C-mutant solid tumors other than NSCLC and CRC. @DavidHongMD @MDAndersonNews @ASCO #ASCO20 https://t.co/KeMHvfsJ91",2020-06-01
1267516397602566155,https://twitter.com/oncologytube/status/1267516397602566155,oncologytube,"Moshe Ornstein, MD on Phase 1B Trial of Neoadjuvant/adjuvant Durvalumab: Why are the rates of Toxicity Higher than Expected? #ASCO2020 @MosheOrnsteinMD #ASCO @ClevelandClinic https://t.co/7BuakmwDxK https://t.co/qbISaaT3Uw",2020-06-01
1267516380791943169,https://twitter.com/urotoday/status/1267516380791943169,urotoday,#IMvigor010 primary analysis from a phase III randomized study of adjuvant Atezolizumab vs observation in high-risk muscle-invasive #UrothelialCarcinoma. @tompowles1 and @MattGalsky join @CaPsurvivorship to discuss data released at #ASCO20 &gt; https://t.co/ah7tvtpYIT @ASCO https://t.co/RfeJN6DL6S,2020-06-01
1267516288483516416,https://twitter.com/cancerGRACE/status/1267516288483516416,cancerGRACE,"https://t.co/ZtJZeem2z3
Interesting article from #ASCO20 Daily News.

Have you experienced this?  https://t.co/RbyGuvNW7n
#cancerGRACE #cancerpatients",2020-06-01
1267516287988772866,https://twitter.com/CCR_AACR/status/1267516287988772866,CCR_AACR,#ClinicalTrial: Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312). https://t.co/vEa45zyeHD #ASCO20 https://t.co/x9DepyDcPr,2020-06-01
1267516259614294017,https://twitter.com/sema4/status/1267516259614294017,sema4,"DYK only 8% of US cancer patients participate in #ClinicalTrials? To increase enrollment, Sema4 harnesses #AI to better match patients to trials in NSCLC, SCLC, &amp; prostate cancer. Read our #ASCO20 abstract: https://t.co/iEkg7AAhyc https://t.co/2v938pfiSM",2020-06-01
1267516175279370240,https://twitter.com/TargetedOnc/status/1267516175279370240,TargetedOnc,"Pralsetinib demonstrated significant efficacy across various advanced solid tumor types harboring RET alterations, including in patients with difficult-to-treat cancers, according to findings from a subgroup of the ongoing phase 1/2 ARROW trial #ASCO20
https://t.co/EWhRjzGSNd",2020-06-01
1267515972296019968,https://twitter.com/tmprowell/status/1267515972296019968,tmprowell,"I want this picture in hard copy! 😍

BUT NOT TODAY @tonsterps!!  I promised no texts or requests of any kind until tomorrow morning, &amp; I am a woman of my word! 🤣

#ASCO20 #LoveThem 
cc @ASCO @BurrisSkip @MLJohnsonMD2 https://t.co/6MfkVd5iEq",2020-06-01
1267514666869239808,https://twitter.com/_SEOM/status/1267514666869239808,_SEOM,"📡#ASCO20 | La Dra. Teresa Morán, oncóloga médico del @ICOnoticies, analiza las novedades en cáncer de pulmón regional-local de célula no pequeña, célula pequeña y otros tumores torácicos.

🎞️ Sus vídeo-píldoras ya están disponibles en #OncoNexion. 

🔗 https://t.co/wCdmkxtv0q https://t.co/QsnuyrCb2G",2020-06-01
1267514512329957376,https://twitter.com/oncologytube/status/1267514512329957376,oncologytube,"Moshe Ornstein, MD on Phase 1B Trial of Neoadjuvant/adjuvant Durvalumab in RCC #ASCO2020 @MosheOrnsteinMD #ASCO @ClevelandClinic https://t.co/cYiElyidE0 https://t.co/84A6XPkcuk",2020-06-01
1267513394120347649,https://twitter.com/PortalOnconews/status/1267513394120347649,PortalOnconews,Os oncologistas @AlexandrePallad e @BiachiTiago discutem alguns dos destaques do Panorama Gastrointestinal – Não Colorretal - apresentados no #ASCO20 - https://t.co/Kpkj0e5uTk @ASCO @Inca_rj @Icesp_ @hsiriolibanes #TV_ONCONEWS #ONCONEWS #ONCONEWSnoASCO20 https://t.co/44j18dbPOz,2020-06-01
1267512841675902977,https://twitter.com/PChavee/status/1267512841675902977,PChavee,"GSK: Thanks to the #oncology community for a productive, insightful and thoroughly unique #ASCO20. What did you learn at ASCO this year? https://t.co/OyXLcP56y9",2020-06-01
1267512830716268550,https://twitter.com/SandraSwainMD/status/1267512830716268550,SandraSwainMD,Done! @ndenduluri1. I am so excited about the success of Women Who Conquer Cancer #WWCC @Conquercancer #ASCO20  and all the support that has been raised for women researchers. https://t.co/uwQ6TVw75u,2020-06-01
1267512800869593093,https://twitter.com/tmprowell/status/1267512800869593093,tmprowell,"Congrats to Dr. Lori Pierce, new @ASCOPres, leading @ASCO during historic times! 

#WomenInMedicine #pandemic https://t.co/DqKWEDqevy",2020-06-01
1267512721752326145,https://twitter.com/shrivastava_sam/status/1267512721752326145,shrivastava_sam,"One of the best talk #ASCO20 for me was Stick it to cancer by Dr. Stephanie Goff. 

Ironically all 3 sessions I liked the best had 2 things in common, great science, data. 
AND

All women 👍🏽

. #WomenInSTEM",2020-06-01
1267512495817789443,https://twitter.com/CancerResearch/status/1267512495817789443,CancerResearch,"Dr. Joshua Lang discusses #biomarkers in general as well as emerging biomarkers of these combination therapies in urothelial carcinoma. #ASCO20

https://t.co/O7anibC3TK",2020-06-01
1267512412502097920,https://twitter.com/tonsterps/status/1267512412502097920,tonsterps,"Virtual cheers from the AM Education team to a successful #ASCO20, and a special thanks to @asco faculty and volunteers, particularly @BurrisSkip, @MLJohnsonMD2, and @tmprowell for their leadership! Next up, Virtual Education Program, coming Aug 8-10. https://t.co/sAJYaKb6e1",2020-06-01
1267511953200746497,https://twitter.com/DagensMedisin/status/1267511953200746497,DagensMedisin,– Norske sykehus med på de viktigste studiene på #ASCO20 https://t.co/CGCkiuSb3B,2020-06-01
1267510997943832580,https://twitter.com/ShaalanBeg/status/1267510997943832580,ShaalanBeg,"⚡️ “ASCO20 Virtual Meeting” ⚡️
Here is my list of  major GI oncology updates from #ASCO20 

https://t.co/m2tsxSDopI https://t.co/PpewNhTP5I",2020-06-01
1267510809258835969,https://twitter.com/drdgoldstein/status/1267510809258835969,drdgoldstein,"#ASCO20 is over!

Time for the next conference …..….. methods to reduce drug costs. 

The First International Summit on Interventional Pharmacoeconomics

Zoom - June 29-July 1st

Registration now open

Great speaker lineup…..

More details: https://t.co/Ied4ImnwPH",2020-06-01
1267510768133685255,https://twitter.com/onkolojidernegi/status/1267510768133685255,onkolojidernegi,"#ASCO2020 TTOD Oturumları 
1 Haziran Program Detay↗️

📲 https://t.co/jl1H8lzbwe web sitesi üzerinden online olarak programı takip edebilirsiniz.

#asco @ascocancer
#ascocancer #kanser
#kansertedavisindeyenilikler
#kansergüncelbilgi
#türktıbbionkolojiderneği
#TTOD https://t.co/VHoDyqI4kQ",2020-06-01
1267510111913852929,https://twitter.com/PDRennert/status/1267510111913852929,PDRennert,RIGHT NOW YOU SHOULD BE WATCHING @JohnCendpts and his awesome #ASCO20 panel @OzAzamTmunity1 @DanChenMDPhD @JackWestMD @CharuAggarwalMD,2020-06-01
1267509938919600128,https://twitter.com/bem09/status/1267509938919600128,bem09,"As #ASCO20 approaches, Levi Garraway, Chief Medical Officer and Head of Global Product Development at Genentech and Roche, shares his outlook on cancer research. Watch the video below: https://t.co/9v5Y0eldUs https://t.co/nzNQwXPU08",2020-06-01
1267509934293475328,https://twitter.com/MM_Oncology/status/1267509934293475328,MM_Oncology,#ASCO20 news: Here now is the accompanying report - click through for the details of the #HER2CLIMB data on intracranial efficacy of #tucatinib in patients with metastatic #BreastCancer 👉 https://t.co/w9Zxy7czs4 👈 @DanaFarberNews @nlinmd https://t.co/6HJ3W3k4e9,2020-06-01
1267509779355877377,https://twitter.com/FabioGomes_Go/status/1267509779355877377,FabioGomes_Go,Not 1...not 2...not 3...but 4 randomised controlled trials on the value of geriatric assessments for cancer patients! Impressive!! Congratulations to all investigators @ASCO #ASCO20 @rochgerionc @DanengLi @KhengSoo1 @SIOGorg @YoungSIOG https://t.co/oxV0MtE9pF,2020-06-01
1267509574954696705,https://twitter.com/audvin/status/1267509574954696705,audvin,"ASCO 2020 takeaways: AstraZeneca does a star turn, KRAS fizzles, and cell therapy shows progress - by @adamfeuerstein https://t.co/qiqge40PDy #ASCO20 

With stats from @symplur",2020-06-01
1267509418763202570,https://twitter.com/Dr_Ivanoncologo/status/1267509418763202570,Dr_Ivanoncologo,#Cáncer l #ASCO20 Actualización: Beneficio de supervivencia de #nivolumab + #ipilimumab en #Cáncerdepulmón de células no pequeñas https://t.co/VJGaats1Fa,2020-06-01
1267509217776283650,https://twitter.com/MDedgeHemOnc/status/1267509217776283650,MDedgeHemOnc,"Adjuvant osimertinib extends DFS in localized #NSCLC with Roy S. Herbst, MD, Ph.D., chief medical oncology at the @YaleCancer and @SmilowCancer at @Yale. #ASCO20 https://t.co/c5WlgCrU1z #OncoAlert #Cancer #ASCO2020 https://t.co/Z7Nw33jOue",2020-06-01
1267508714120118275,https://twitter.com/ASCO_pubs/status/1267508714120118275,ASCO_pubs,Practice-Changing KEYNOTE-177 Results Support First-Line Pembrolizumab Monotherapy for MSI-H mCRC https://t.co/uFGmRdFINe #ASCODailyNews #ASCO20 #LBA,2020-06-01
1267508709741084686,https://twitter.com/Oncoinfo_it/status/1267508709741084686,Oncoinfo_it,"#ASCO20 | La #PrecisionMedicine ha un ruolo da protagonista al congresso, con la presentazione di centinaia di ricerche su questo tema. Qui la selezione dei 10 studi più rilevanti della terza giornata, a cura di Chiara Cremolini e Sara Lonardi.

https://t.co/tTPCmSx6t9",2020-06-01
1267508688392278016,https://twitter.com/salutedomani/status/1267508688392278016,salutedomani,"Leiomiosarcoma, i risultati del trattamento in prima linea per trabectedina con doxorubicina #ASCO20 https://t.co/4Xp1suDP3E",2020-06-01
1267508468094648321,https://twitter.com/KPCancerRsrch/status/1267508468094648321,KPCancerRsrch,Over the weekend in a #ASCO20 Virtual Scientific Program @KPDOR's Dr. Caan was quoted in this @ASCO Daily News story (https://t.co/4qWZlhvFCx) about the importance of muscle abnormalities in patients with cancer. Check it out. #CancerResearch,2020-06-01
1267508179031687174,https://twitter.com/OncologyTimes/status/1267508179031687174,OncologyTimes,#ASCO20 Update: Survival Benefit of Nivolumab + Ipilimumab in Non-small Cell #LungCancer https://t.co/RMyDAauG7B #mondaythoughts #cancer https://t.co/3FWtBP38PV,2020-06-01
1267507500988993548,https://twitter.com/DrSGraff/status/1267507500988993548,DrSGraff,Dr. @BurrisSkip passes the torch to a new @ASCOPres Dr. Lori Pierce. Congrats &amp; best wishes to both of you as you move into new leadership roles for @ASCO #ASCO20 https://t.co/jiNL8VSQ2O,2020-06-01
1267506479738863619,https://twitter.com/_SEOM/status/1267506479738863619,_SEOM,"📡#ASCO20 | La Dra. Miren Taberna, oncóloga médico del @ICOnoticies, comenta las novedades sobre tumores de cabeza y cuello.

🎞️ Sus vídeo-píldoras ya están disponibles en nuestra plataforma de formación #OncoNexion. 

🔗 https://t.co/wCdmkxtv0q https://t.co/skZPiFj858",2020-06-01
1267506243733725185,https://twitter.com/CAPCpalliative/status/1267506243733725185,CAPCpalliative,'Oncologists seek more palliative care education' via @medical_xpress &gt;&gt; https://t.co/Jk4RW57jlw #palliative #oncology #hpm #hapc @ASCO,2020-06-01
1267505827050590212,https://twitter.com/caPeTTenaTi/status/1267505827050590212,caPeTTenaTi,#ASCO20: Biomarker Analysis and Updated Clinical Follow-Up Of Preoperative Ipilimumab Plus Nivolumab in Stage III Urothelial Cancer (NABUCCO) https://t.co/SH0a19FgOp,2020-06-01
1267505733802885122,https://twitter.com/GBOT_Alerta/status/1267505733802885122,GBOT_Alerta,"O abstract 9012 identificou mutações que previram recorrência local após a radioterapia, mas não após cirurgia. Os achados sugerem que as mutações do KEAP1 / NFE2L2 são um biomarcador preditivo de radiorresistência clínica. Por Tercia Reis #ASCO20 #GBOT_Alerta https://t.co/PI82PRGjZc",2020-06-01
1267505719236009987,https://twitter.com/_SEOM/status/1267505719236009987,_SEOM,"📡#ASCO20 | La Dra. Marga Majem (@margamajem), oncóloga médico de @HospitalSantPau, analiza las novedades sobre melanoma. 

🎞️ Sus vídeo-píldoras ya están disponibles en nuestra plataforma de formación #OncoNexion. 

🔗 https://t.co/wCdmkxtv0q https://t.co/o6xIc52fBc",2020-06-01
1267505161976643587,https://twitter.com/Slabodkin/status/1267505161976643587,Slabodkin,"Tests to detect #cancer, guide treatment heat up with barrage of data at #ASCO2020 https://t.co/Ropcl2ec7u #asco20 #cancertreatment #cancerdiagnostics #liquidbiopsy #liquidbiopsies #liquidassay #cancerdiagnosis #genetics #genetictests #genetictesting #breastcancer",2020-06-01
1267505002324668421,https://twitter.com/caPeTTenaTi/status/1267505002324668421,caPeTTenaTi,"#ASCO20 : Pembrolizumab (Pembro) for the Treatment of Patients with Bacillus Calmette-Guérin (BCG) Unresponsive, High-Risk (HR) Non–Muscle-Invasive Bladder Cancer (NMIBC): Over Two Years Follow-Up of KEYNOTE-057 https://t.co/5Ta1NlySwx",2020-06-01
1267504704608768006,https://twitter.com/CharuAggarwalMD/status/1267504704608768006,CharuAggarwalMD,Congratulations! @ASCO @ASCOPres https://t.co/51TVRSHqmn,2020-06-01
1267504694387245057,https://twitter.com/ASGCTherapy/status/1267504694387245057,ASGCTherapy,Study results presented at #ASCO20 showed that 93% of evaluable patients achieved objective responses (including 80% achieving complete responses) from a #CART #CellTherapy treatment for relapsed/refractory indolent non-Hodgkin #lymphoma. https://t.co/4eByfr0tBN,2020-06-01
1267504674535399425,https://twitter.com/cellmaxlife/status/1267504674535399425,cellmaxlife,"Additional details around the FirstSight blood test in detecting precancerous colorectal adenomas were released at 2020 Virtual @ASCO, highlighting a significant association between blood test scores and polyps found in enrolled subjects by colonoscopy. https://t.co/W9MYTJg5cC",2020-06-01
1267504599872811009,https://twitter.com/Maimah/status/1267504599872811009,Maimah,"We must all tackle the racism that affects every aspect of disparities for people of color.  @tigerlilycares is asking that you sign the #inclusionpledge, to ensuring women of color have a seat at every table-Sign the Petition! https://t.co/rOdQm9HLSd #listenupmbc #asco2020",2020-06-01
1267504238101438464,https://twitter.com/GBOT_Alerta/status/1267504238101438464,GBOT_Alerta,"Savolitinib em PSC/oCPCNP METexon14+:  PH2, braço único, asiático: ORR 49.2%, DCR 93%; eficácia mantida indep sub-hist e tto; PFS PSC 5.5m, oNSCLC 9.7m; SAE 26%: fc hepática 4.3% edema 7%. Eficácia promissora, necessário + dados SAE. Por Aline Fares #GBOT_Alerta #ASCO20 https://t.co/GWJuNvWFD2",2020-06-01
1267503717231800322,https://twitter.com/sbarnettARK/status/1267503717231800322,sbarnettARK,"Here's what seems clear from the #ASCO2020 abstracts on tumor-normal (#germline) sequencing of #cancer patients:

(1) A significant minority of cancer patients (5-15%) harbor clinically-actionable variants, such as those indicating PARP inhibition or immunotherapy use.",2020-06-01
1267503512881180677,https://twitter.com/HematologyAdv/status/1267503512881180677,HematologyAdv,Approximately one fifth of hematopoietic stem cell transplant recipients may experience clinically significant #PTSD symptoms after transplant. #ASCO2020 @ASCO https://t.co/GqofprFyoV,2020-06-01
1267503483575508997,https://twitter.com/GSK/status/1267503483575508997,GSK,"Thanks to the #oncology community for a productive, insightful and thoroughly unique #ASCO20. What did you learn at ASCO this year? https://t.co/cBS9eqtRqA",2020-06-01
1267503446233677830,https://twitter.com/GBOT_Alerta/status/1267503446233677830,GBOT_Alerta,"PrE0505: Durvalumabe com doublet de platina para mesotelioma metastático. PhII de braço único com SG de 20,6 meses e TRG de 56,4%. Notícias animadoras e SG esperada de cerca de 12 meses. PhIII  (PrE0506/DREAM3R) esperado. @MarceloCorassa #ASCO20 #GBOT_Alerta https://t.co/OROr86FnJf",2020-06-01
1267503189189935104,https://twitter.com/draandreanutro1/status/1267503189189935104,draandreanutro1,"Assistam essa discussão sobre 2 possibilidades de avaliar sarcopenia.  https://t.co/iTOTDccdnc
#ASCO2020 #oncologia #nutrologia #obesidadebrasil #nutricao https://t.co/vVPOK1KhkQ",2020-06-01
1267503018561462274,https://twitter.com/TiansterZhang/status/1267503018561462274,TiansterZhang,"Wonderful to see our @ASCO leadership, elected board and new president! They will do great things this year and into 2021! https://t.co/llZ9kwuTO1",2020-06-01
1267502684615184386,https://twitter.com/HematologyAdv/status/1267502684615184386,HematologyAdv,"Presented at #ASCO2020 -- Researchers outlined a validated p-DRI for #AML and #ALL that successfully stratifies children undergoing allogeneic hematopoietic cell transplantation for prognostication. 
https://t.co/TNti5KAHni @ASCO",2020-06-01
1267502473645821956,https://twitter.com/MoffittNews/status/1267502473645821956,MoffittNews,"At the #ASCO20 Virtual Scientific Program, @Ramikomrokji of @MoffittNews presents new data on the use of luspatercept in patients with lower-risk MDS. View abstract: https://t.co/0mizaAG1MT #ASCO20 https://t.co/gRIYul56dV",2020-06-01
1267502125271007234,https://twitter.com/acmoorephd/status/1267502125271007234,acmoorephd,"The latest #lungcancer advocacy groups' #COVID19 briefing, including #ASCO20 updates, @IASLC ""Lung Cancer Considered"" podcast, and a brief survey opportunity. #lcsm https://t.co/SZavPoWjPH",2020-06-01
1267501915534835712,https://twitter.com/MedscapeOnc/status/1267501915534835712,MedscapeOnc,"Some women with gestational trophoblastic tumors respond to immunotherapy when they are resistant to single chemotherapy, results from TROPHIMMUN phase 2 trial show. https://t.co/VxSXc4mrCq #ASCO20",2020-06-01
1267501670713495554,https://twitter.com/SeattleCCA/status/1267501670713495554,SeattleCCA,"#ASCO20: Dr. Heather Greenlee's poster ""Phase I/II study of SAR439859, an oral selective estrogen receptor degrader (SERD), in estrogen receptor-positive (ER+)/human epidermal growth factor receptor..."" Read on our SCCA at @ASCO page: https://t.co/aKeZVXT2d8 #BreastCancer https://t.co/Yi8QZUn7su",2020-06-01
1267501585388748803,https://twitter.com/tsemiglazovaMD/status/1267501585388748803,tsemiglazovaMD,#ASCO20 #e16041 #rehabilitatioin of Geriatric mCRC pts with #geriatricexamination: Cumulative Illness Rating Scale for Geriatrics; Activities of Daily Living; Daily instrumental activity scale; Mini nutritional assessment; Clock Drawing Test; Geriatric depression scale #OncoAlert,2020-06-01
1267501550462816261,https://twitter.com/drumutdemirci/status/1267501550462816261,drumutdemirci,"ASCO 2020; Onkoloji pratiğimizi yenileyen ve güçlendiren çalışmalar üç oturumla sizlerle !

 @ASCO  #asco2020virtual #kanser #onkoloji #cancer #oncology #ascodanbildiriyorum webtarged https://t.co/kOe6oBmCZF",2020-06-01
1267501537560981504,https://twitter.com/kuraoncology/status/1267501537560981504,kuraoncology,We were honored to share the virtual stage with industry experts this past week at #ASCO20. https://t.co/wcG8EqM7dg,2020-06-01
1267501501603348484,https://twitter.com/draandreanutro1/status/1267501501603348484,draandreanutro1,"Não percam a discussão sobre 2 trabalhos muito interessantes aprovados na ASCO 2020. 
https://t.co/Gvgvw6riGn
#oncologia #ASCO2020 #obesidade #obesidadebrasil #nutrologia #nutrologia https://t.co/PWroQFcFzF",2020-06-01
1267501310527578116,https://twitter.com/OncLive/status/1267501310527578116,OncLive,Pralsetinib Active Across RET+ Tumor Types and Gains FDA Review @VivekSubbiah @MDAndersonNews @ASCO #ASCO20 https://t.co/VoqQ3XgiHm,2020-06-01
1267501202939564037,https://twitter.com/sema4/status/1267501202939564037,sema4,"How can we predict response to immunotherapy in advanced #NSCLC? Sema4 researchers, led by @RongChenBioinfo, used #RWD to show that complete blood counts are a promising predictive biomarker. Read our #ASCO20 abstract: https://t.co/njVHgrGIJE https://t.co/cco7EnavFK",2020-06-01
1267501190096588807,https://twitter.com/IQVIA_global/status/1267501190096588807,IQVIA_global,"IQVIA experts used #AI and #ML to identify patients diagnosed with #CLL who were likely to progress to next line of treatment in the near future, enabling better #oncology care. Read the abstract in our #ASCO20 Virtual Scientific Program: https://t.co/PGrm5WSYmh https://t.co/wC88CczCIT",2020-06-01
1267500808016400389,https://twitter.com/ScienceAtBMS/status/1267500808016400389,ScienceAtBMS,#ASCO20 looked different this year but we are signing off more hopeful for the future of cancer care than ever. We continue to be grateful for the advancements made by the healthcare community to address patient needs. Thank you for all you do. https://t.co/O4FRtkhIqf,2020-06-01
1267500486891986944,https://twitter.com/OBRtweets/status/1267500486891986944,OBRtweets,"Alan Venook, MD, of @UCSF discusses the Keynote-177 study investigating MSI High/mismatch repair deficient metastatic colorectal cancer #ASCO20 https://t.co/2X6PdZdXqE",2020-06-01
1267500480030097408,https://twitter.com/NCICareDelivRes/status/1267500480030097408,NCICareDelivRes,"Early results from the first completed #NCORP #CCDR study being reported @ASCO #ASCO202 – almost 75% of patients with advanced colorectal #cancer experience major financial hardship within a year of starting chemotherapy. More here: https://t.co/CSFl05YgLn
@ShankaranVeena @SWOG",2020-06-01
1267500133647876099,https://twitter.com/BehrouzZand/status/1267500133647876099,BehrouzZand,"Three RCT trials of secondary cytoreductive surgery in recurrent ovarian cancer but only DESKTOP III has shown OS benefit. Who?  Patients with AGO score ( PS of zero, complete resection during primary treatment, and ascites &lt;500 mL).  #ASCO20 #gyncsm #SGOatASCO https://t.co/MjJN0UMQqg",2020-06-01
1267499785453359104,https://twitter.com/ERPlimackMD/status/1267499785453359104,ERPlimackMD,"This is a really important slide 👇@MattGalsky #ASCO20 suggesting a detriment to combination gem+platinum chemo + atezolizumab in #bladdercancer for PDL1+ TMB high patients in IMvigor130. Until we know more, the data suggest we should sequence and not combine these up front. https://t.co/aaJbzKFU9p",2020-06-01
1267499496709271554,https://twitter.com/ourbrainbank/status/1267499496709271554,ourbrainbank,"Kudos to everyone involved with #ASCO2020, let's hope we can meet in person next time. #GBM researchers: consider incorporating the OurBrainBank app into a clinical trial, or check out the #data we've collected from hundreds of #glioblastoma patients https://t.co/QMBETBxs5r",2020-06-01
1267499146690191360,https://twitter.com/ASCOPost/status/1267499146690191360,ASCOPost,"Jeffrey A. Meyerhardt, MD, MPH, on Colon Cancer: Celecoxib and FOLFOX for Stage III Disease https://t.co/8G76LtNieN #crcsm #oncology #cancer #ASCO20 @DanaFarber https://t.co/jtybAh4G5f",2020-06-01
1267498655310704640,https://twitter.com/awolff/status/1267498655310704640,awolff,"""Equity: Every Patient. Every Day. Everywhere.""  Congratulations to Dr. Lori Pierce as she starts her term as @ASCOPres @ASCO!  A more timely &amp; acute issue than ever before! Specially in our own USA. #HealthPolicyIsEconomicPolicy #ASCO20 #ASCO21 #LeadershipMatters! https://t.co/Sgc8DDkvh7",2020-06-01
1267498512461119490,https://twitter.com/ERPlimackMD/status/1267498512461119490,ERPlimackMD,"Thank you @BurrisSkip for your leadership during this challenging year. I'm grateful for the opportunity to serve  as a member of the @ASCO board with @ASCOPres Dr. Lori Pierce. What an acutely appropriate theme for this year ""Equity: Every Patient. Every Day. Everywhere"" #ASCO20 https://t.co/cCDkHoT38N",2020-06-01
1267498172961697792,https://twitter.com/SOG_Galicia/status/1267498172961697792,SOG_Galicia,"Vídeo-píldoras de #ASCO20 en  #OncoNexion,  la plataforma de formación de @_SEOM

La Dra. García Campelo (@charocampelo) comenta las novedades sobre cáncer de pulmón metastásico de célula no pequeña. 

Acceso 👇🏼👇🏼👇🏼
🔗 https://t.co/snBlvIqm4Q",2020-06-01
1267498122521051137,https://twitter.com/JTrentMDPhD/status/1267498122521051137,JTrentMDPhD,Super simple to support #Cancer research @ConquerCancerFd . I am forever indebted for my @ASCO #Sarcoma YIA. Please donate: https://t.co/hnwpRPMf7z  or text ASCO to 41444 @Sarcoma_QB @DrSarcoma @immunosarc @GinaDAmatoMD1 @JuliaLClose @WTapMD https://t.co/OradmyNMnV,2020-06-01
1267497831083855873,https://twitter.com/SeattleCCA/status/1267497831083855873,SeattleCCA,"#ASCO20: Dr. Jing Zeng's poster ""Prognostic role of mid-treatment PET/CT and plasma cytokines in patients undergoing chemoradiation for locally advanced non-small cell lung cancer (LA-NSCLC)."" Read on our SCCA at @ASCO page: https://t.co/vSXEILc35r https://t.co/28bMRgOo9z",2020-06-01
1267497423150161920,https://twitter.com/cure_magazine/status/1267497423150161920,cure_magazine,"“The improvement in disease-free survival following surgery that was seen in the ADAURA study supports the use of this targeted therapy in an earlier stage of disease.” #ASCO2020
https://t.co/5BxOqI5w6P",2020-06-01
1267497385107701772,https://twitter.com/Drug_Topics/status/1267497385107701772,Drug_Topics,A study presented at #ASCO20 evaluated recent evidence for #cannabis and cannabinoids as adjuvant therapy in palliative and supportive oncology care https://t.co/mAoLwn7JMy https://t.co/1P8lWAcPDH,2020-06-01
1267497084355317760,https://twitter.com/ASCOPres/status/1267497084355317760,ASCOPres,Honored to virtually accept the gavel from @BurrisSkip &amp; take the role of @ASCO President! #ASCO20,2020-06-01
1267496871225933824,https://twitter.com/dhovekamp42/status/1267496871225933824,dhovekamp42,$ADAP #ASCO20 #COVID19 https://t.co/y2rBjTNHvF,2020-06-01
1267496777021894656,https://twitter.com/VUMC_Cancer/status/1267496777021894656,VUMC_Cancer,"At #ASCO20, @VUMC_Cancer senior authors, @hemoncwarner and @brian_rini reported from an ongoing international initiative by #CCC19 to track outcomes within a vulnerable population of cancer patients with COVID-19. @VUMC_MD @VUMChealth 
https://t.co/mzyOwOshbm",2020-06-01
1267496753647009794,https://twitter.com/oncology_bg/status/1267496753647009794,oncology_bg,Just recorded my #ASCO20 round up video with @ecancer summarizing the key take aways from the meeting. Stay tuned!,2020-06-01
1267496721715613697,https://twitter.com/Pharmashot/status/1267496721715613697,Pharmashot,"Insights+ Exclusive: Key Events of ASCO 2020 Virtual Annual Meeting #ASCO20 #Cancer #oncology #ASCO20VR @ASCO 
https://t.co/Bof92XnKmH https://t.co/zjkC7scUag",2020-06-01
1267496536126230530,https://twitter.com/mtmdphd/status/1267496536126230530,mtmdphd,"Equity: Every Patient. Every Day. Everywhere - #ASCO20 - #ASCO21 Theme of Lori J. Pierce, MD, FASTRO, FASCO - 2020-2021 @ASCO President https://t.co/Tk0BrJCyoj",2020-06-01
1267496524847689729,https://twitter.com/DavidKahnMD/status/1267496524847689729,DavidKahnMD,Watching virtual ASCO sessions. I can speed up the presentations  x 1.5 to watch slow presenters. This is great. #ASCO2020,2020-06-01
1267496511056855041,https://twitter.com/dhovekamp42/status/1267496511056855041,dhovekamp42,$ADAP data from Synovial #Sarcoma at #ASCO20 https://t.co/Zv1ePaDMcP,2020-06-01
1267496329309282304,https://twitter.com/tomleblancMD/status/1267496329309282304,tomleblancMD,"Important findings show impact of integrated #palliative care in phase 1 trials. Palliative care enhances even cutting edge personalized #cancer care on a #clinicaltrial! Thank you @BettyFerrellPhD and @tsmit136 for doing this work #ASCO20 #hapc #pallonc
https://t.co/psywufIldc",2020-06-01
1267495575756423169,https://twitter.com/MHExecutive/status/1267495575756423169,MHExecutive,"Women who get genetic testing for hereditary breast &amp; ovarian cancer are often advised to talk to a genetic counselor before &amp; after they take the test, even if the result is negative for a mutation that would indicate a risk. #GeneticTesting #ASCO20
https://t.co/iR6nHYcwF4",2020-06-01
1267495256410542086,https://twitter.com/statnews/status/1267495256410542086,statnews,"Opinion: Key takeaways from this year's virtual #ASCO20 conference: AstraZeneca does a star turn, KRAS fizzles, and cell therapy shows progress. https://t.co/9OQyz2hTHC",2020-06-01
1267495212731052033,https://twitter.com/avalerehealth/status/1267495212731052033,avalerehealth,"Episode 2 of our, ""Start Your Day with Avalere,"" is now up! Join Samantha Ferguson, Megan Olsen, and Michael Kearney as they discuss durable therapies in #oncology.  #ASCO20

https://t.co/WaCSSZED6k",2020-06-01
1267495032686292994,https://twitter.com/MSKCC_Library/status/1267495032686292994,MSKCC_Library,Full #ASCO2020 abstract here: https://t.co/j6Oijzk71W https://t.co/HHhTHHSMCK,2020-06-01
1267494780432498688,https://twitter.com/ActionRTherapy/status/1267494780432498688,ActionRTherapy,"Clinical Trial News 📄

New form of optimised radiotherapy for head and neck cancer shown to spare swallowing structures and improve long-term side effects after treatment.
 
#ASCO20 #LivingWithAndBeyondCancer @swallowsgroup @JulieMcCrossin @ICR_London 
 
https://t.co/MyA79Wr233",2020-06-01
1267494665844068352,https://twitter.com/pashtoonkasi/status/1267494665844068352,pashtoonkasi,#ASCO20 🧬👇🏼 https://t.co/jjBT1NTl1d,2020-06-01
1267494565344239616,https://twitter.com/scooperpr/status/1267494565344239616,scooperpr,"ASCO 2020 takeaways: AstraZeneca does a star turn, KRAS fizzles, and cell therapy shows progress https://t.co/yGfPgoO3O0 via @statnews $AZN (client) #ASCO20",2020-06-01
1267494467566788608,https://twitter.com/pashtoonkasi/status/1267494467566788608,pashtoonkasi,#ASCO20 #CRCSM Important @NRGonc #clinicaltrials to accrue to. 👇🏼 https://t.co/TPcUfAwwVl,2020-06-01
1267493812408025090,https://twitter.com/ecancer/status/1267493812408025090,ecancer,"#ASCO20: Early data show cancer progression associated with increased risk of death in patients with COVID-19.
Read more here: https://t.co/BtuwtLjYHQ
#COVID19 #Coronavirus #CancerResearch #Oncology https://t.co/hX3AMUgdWn",2020-06-01
1267493674159673353,https://twitter.com/medicalnewser/status/1267493674159673353,medicalnewser,"Insights+ Exclusive: Key Events of ASCO 2020 Virtual Annual Meeting #ASCO20, 

The American Society of Clinical Oncology (ASCO) is a platform for cancer experts to share views on the latest advancements and new... ,https://t.co/Dg1Rqk5obJ",2020-06-01
1267493661027295232,https://twitter.com/urotoday/status/1267493661027295232,urotoday,#TALAPRO2 Placebo-controlled phase III study of Talazoparib + Enzalutamide for patients with first-line #mCRPC. Presented by @neerajaiims @huntsmancancer. #ASCO20 written coverage by @WallisCJD @VUMChealth on UroToday &gt; https://t.co/9Dzn1FeVqX @ASCO https://t.co/C8X4SHK0N5,2020-06-01
1267493655599865857,https://twitter.com/MoffittNews/status/1267493655599865857,MoffittNews,"Available now, @jacobadashek of @MoffittNews explores the efficacy of checkpoint blockade therapies among different ethnicities as part of the #ASCO20 Virtual Scientific Program. View abstract here: https://t.co/4g3jHyqwGZ https://t.co/lA7Ll0gcXI",2020-06-01
1267493574356152320,https://twitter.com/gmboland/status/1267493574356152320,gmboland,Amazing accomplishment by @landau_lab! A novel approach to ultra-sensitive cfDNA detection. Ideal for MRD applications. Glad we could contribute to this awesome project #LiquidBiopsy @Boland_Lab @ASCO @SocSurgOnc https://t.co/1R1csUMXJ6,2020-06-01
1267493045219528704,https://twitter.com/Carolynxmorris/status/1267493045219528704,Carolynxmorris,"Great threat on eHealth trial just presented at @ASCO , great team to work with, great value to patients https://t.co/SnrHpMfwn4",2020-06-01
1267492838020874240,https://twitter.com/BioShoock/status/1267492838020874240,BioShoock,"#ASCO20 takeaways: AstraZeneca does a star turn, KRAS fizzles, and cell therapy shows progress 

https://t.co/lOOL3ns2Nc",2020-06-01
1267492722618904578,https://twitter.com/VaughtPhD/status/1267492722618904578,VaughtPhD,"The perk of virtual #ASCO20, I finally finished viewing the on demand content this AM...however I missed meeting colleagues and friends. As a research grants manager these conferences were sometimes the only chance to meet our grantees in person and build beyond emails &amp; calls.",2020-06-01
1267492620688908288,https://twitter.com/Immunopole/status/1267492620688908288,Immunopole,"#ASCO2020 #KidneyCancer (#ccRCC) breaks the IO rules: @DrChoueiri @LabSignoretti et al. @DanaFarber showed that immunologically #HotTumors do not respond better to #PD1blockade than #ColdTumors 
Potential answers to the enigma here @NatureMedicine https://t.co/WQUfOmmpNw https://t.co/eqlOO4NqjT",2020-06-01
1267492485863018496,https://twitter.com/LaurenYoung/status/1267492485863018496,LaurenYoung,ICYMI: ⚡️ “Experts discuss cancer care in the time of COVID-19” by @Reuters_Health https://t.co/dbGOvuaYbK #AskReuters #ASCO20 https://t.co/XuVNMKZ9ll,2020-06-01
1267492406687076352,https://twitter.com/IshwariaMD/status/1267492406687076352,IshwariaMD,"The @ASCO oncology community is over 44,000 strong! Watching the #ASCO20 Annual Business Meetings. #InThisTogether
Meeting link👇
https://t.co/V19HAHLCL0 https://t.co/n9IyUXAiIM",2020-06-01
1267492353188782085,https://twitter.com/dzusack/status/1267492353188782085,dzusack,#ASCO20  I’d love to connect virtually with physicians interested in learning about our open opportunities across the country. Private message me to learn more! ♥️ @SarahCannonDocs  @PracticeWithUs https://t.co/xhDOrT8ELx,2020-06-01
1267492180756582400,https://twitter.com/SGreenbergGC/status/1267492180756582400,SGreenbergGC,"I love how #ASCO20 transcends all SM platforms. Here, an overview of gyn cancer takeaways from this weekend. I might be biased, but #2 (all pts with OvCa need GT) is SO important! #GCchat #gyncsm https://t.co/2UoTchhLEY",2020-06-01
1267492174238814210,https://twitter.com/CloverResearch/status/1267492174238814210,CloverResearch,"Who comes away the biggest ""winner"" of #ASCO20 from the following biotechs?",2020-06-01
1267491611153498115,https://twitter.com/adamfeuerstein/status/1267491611153498115,adamfeuerstein,"#ASCO20 takeaways: AstraZeneca does a star turn, KRAS fizzles, and cell therapy shows progress https://t.co/RAhkZed741 $AZN $JNJ $MRK $AMGN $ALLO $ADAP $RHHBY $BLUE $BMY",2020-06-01
1267491320014110720,https://twitter.com/DrPaulyDeSantis/status/1267491320014110720,DrPaulyDeSantis,"#ASCO20: Locke et al @moffitt show that Axi-cel re-treatment mostly only benefits patients with prior CR, lesser extent prior PR, and limited/no benefit prior SD/PD with only limited DOR. 
How does this impact your treatment plan for CAR-T relapses? https://t.co/0soBfjGOcm",2020-06-01
1267491258534158338,https://twitter.com/MDedgeHemOnc/status/1267491258534158338,MDedgeHemOnc,KEYNOTE 33 Trial: Adding pembrolizumab to #chemotherapy improved survival for patients with metastatic triple-negative #breastcancer.  https://t.co/MfTXXQlqVq #ASCO20 #ASCO2020 #bcsm #immunotherapy #ChasingMyCure https://t.co/eAF0Kx8s1J,2020-06-01
1267491076753014785,https://twitter.com/temkins/status/1267491076753014785,temkins,"Great Trial and Good New As Palliative Care Improves Well-Being and QoL in Phase I Cancer Trial Participants #ASCO20 

https://t.co/IvU0epk4FD",2020-06-01
1267489234392436737,https://twitter.com/BenjaminBesseMD/status/1267489234392436737,BenjaminBesseMD,"Smart chemos (=ADCs): a new way to merge target &amp; chemo.
2 main settings for future trials: 
- 1st line when very high ORR &amp; highly selected pts (ex. HER2mut)
- 2nd line post CT-IO (vs. docetaxel) for targets frequently expressed by IHC (ex. CAECAM5, TROP2...).
#ASCO20 https://t.co/V8d8OKAFhd",2020-06-01
1267488872063090688,https://twitter.com/marklewismd/status/1267488872063090688,marklewismd,"We have the best job, as @tmprowell often reminds me

This is turning hope into action, just as @DavidFajgenbaum inspired us to do!

#asco20
#MondayMotivation https://t.co/zKl6lkt9GP",2020-06-01
1267488772880506885,https://twitter.com/SBOC_Oncologia/status/1267488772880506885,SBOC_Oncologia,"A cobertura SBOC do #ASCO2020 traz agora os destaques em tumores do SNC, com comentários de Dr. Sandro Cavallero, Dra. Clarissa  Baldotto, Dr. Daniel Marques, Dra. Fabiana Viola e Dr. Olavo Feher. Acesse em https://t.co/TFbMleFyNv e faça login. #ASCOvirtual #SBOCnaASCO https://t.co/ohHTsnncVZ",2020-06-01
1267488596229001217,https://twitter.com/aspenbio/status/1267488596229001217,aspenbio,ASCO 2020: Discussant: Advanced Prostate Cancer: Putting Survival Into Perspective |@ASCO @cancer #ASCO #cancer https://t.co/oaXEquI2EO,2020-06-01
1267488517480841216,https://twitter.com/ChristySocal93/status/1267488517480841216,ChristySocal93,Learn more about how we are redesigning the clinical trial experience for patients during #COVID19. #ASCO20 #ScienceWillWin #PFEColleague https://t.co/aKdoPsJUhD,2020-06-01
1267488297716256769,https://twitter.com/MKnoll_MD/status/1267488297716256769,MKnoll_MD,"No adequate words to express our gratitude to you, Dr Skip Burris for your leadership as @ASCO President!!
👏🙏👏🙏👏🙏 
#ASCO20 https://t.co/N8JnTZ3BCw",2020-06-01
1267488097182285826,https://twitter.com/_SEOM/status/1267488097182285826,_SEOM,"📡#ASCO20 | La Dra. Sonia Pernas comenta los highlights sobre cáncer de mama local / regional / adyuvante.  

🎞️ Sus vídeo-píldoras ya están disponibles en nuestra plataforma de formación #OncoNexion. 

🔗 https://t.co/wCdmkxtv0q https://t.co/t66rliZws1",2020-06-01
1267487922598498305,https://twitter.com/DrPaulyDeSantis/status/1267487922598498305,DrPaulyDeSantis,#ASCO20: My Hem/Onc CAR-T Tweeps: Strati et al showed that EARLY and PROLONGED STEROID use is stat sign. associated with inferior PFS/OS. WILL THESE DATA IMPACT YOUR PLANNED USE OF STEROIDS WITH CAR-T? https://t.co/ABZlC9OngP,2020-06-01
1267487853669466112,https://twitter.com/tmprowell/status/1267487853669466112,tmprowell,"Such an honor to serve @ASCO &amp; the global #oncology community this yr as your Annual Meeting Education Chair, @BurrisSkip.

(PS, we still have an #ASCO20 Virtual Ed Program to do 8/8-8/10, so no sailing off into the wild blue yonder for you quite yet, Immediate Past @ASCOPres 😉) https://t.co/5MewbeaIJR",2020-06-01
1267486550956429312,https://twitter.com/OncEd/status/1267486550956429312,OncEd,Join chairs @GillSharlene and Dr. Jose Monzon #virtually for the Best of @ASCO Vancouver. This digital meeting will summarize the most significant treatment advances presented at #ASCO20. Registration is complimentary for healthcare professionals: https://t.co/c5LFuvjvjd https://t.co/xzSM5BH7oO,2020-06-01
1267486521675972608,https://twitter.com/Hayburysearch/status/1267486521675972608,Hayburysearch,"ASCO: AstraZeneca's Tagrisso, headed for big sales boost, cuts lung cancer recurrence by 83% https://t.co/Vm4CX4FssA #AstraZeneca #Tagrisso #ASCO2020 #ClinicalData #LungCancer #Tumor",2020-06-01
1267486434258288641,https://twitter.com/CancerDotNet/status/1267486434258288641,CancerDotNet,#ICYMI #ASCO20 #COVIDnCancer #mondaythoughts #LunchTime https://t.co/ckriUcIKK8,2020-06-01
1267486206071275521,https://twitter.com/OncLive/status/1267486206071275521,OncLive,MGD013 Demonstrates Encouraging Activity Across Tumor Types @jasonlukemd @UPMCHillmanCC @ASCO #ASCO20 https://t.co/c3KXfedfxg,2020-06-01
1267486061799911432,https://twitter.com/BostonChildrens/status/1267486061799911432,BostonChildrens,"“Allocation decision processes should not unconditionally deny patients with cancer consideration for access to scarce resources,” says @ASCO guidelines for oncologists during the #COVID19 pandemic: https://t.co/Z10PAt7JNg @DFBC_PedCare",2020-06-01
1267486060780695552,https://twitter.com/BMS_Myeloma_US/status/1267486060780695552,BMS_Myeloma_US,Did you participate in #ASCO20?  What was your favorite part of the virtual format this year? #HopeIsInOurBlood #myeloma @ASCO,2020-06-01
1267485923899404293,https://twitter.com/marklewismd/status/1267485923899404293,marklewismd,"There is no better feeling the Monday after the @asco annual meeting than to tell a patient with cancer they have a promising new treatment option today!
🙏 
#asco20
#MedTwitter",2020-06-01
1267485735986348044,https://twitter.com/WashURadOnc/status/1267485735986348044,WashURadOnc,"The @aadel_chaudhuri Lab had their #ASCO20 abstract selected for the poster session! 

""AR enhancer and locus genomic alterations as cell-free DNA biomarkers of primary resistance to AR-directed treatment of metastatic prostate cancer"" https://t.co/QD1EqZdHa6",2020-06-01
1267485444951900164,https://twitter.com/caPeTTenaTi/status/1267485444951900164,caPeTTenaTi,A must read ! #ASCO20 JAVELIN Bladder 100 Phase III Results: Maintenance Avelumab + Best Supportive Case vs BSC Alone After Platinum-Based First-Line Chemotherapy in Advanced Urothelial Carcinoma. -&gt; Improved OS!  https://t.co/mbDb7SiB8D,2020-06-01
1267484630610894848,https://twitter.com/HopkinsThoracic/status/1267484630610894848,HopkinsThoracic,Discussion of the PrE0505 study and forthcoming DREAM3R study presented by @FordePatrick at #ASCO20 @curemeso https://t.co/BpvOpAMytI,2020-06-01
1267484347835301890,https://twitter.com/Immunopole/status/1267484347835301890,Immunopole,#ASCO2020 #ALPHAtrial #Abstract8002: #ALLO501 (off-the-self allogeneic #CARTcell therapy) appeared safe and showed clinical activity in a small group of patients with relapsed or refractory #DLBCL or #FollicularLymphoma #SattvaNeelapu @MDAndersonNews https://t.co/bdQqJZ2wyg,2020-06-01
1267484307783856130,https://twitter.com/MedpageOnco/status/1267484307783856130,MedpageOnco,"Pretreated gastric cancer patients with HER2-positive disease had significantly improved rates of response and survival with this therapy, reported Kohei Shitara, MD, at virtual #ASCO20. By @icingram. @ASCO @Dr_M_Tejani  
https://t.co/NtPzonk8HX",2020-06-01
1267484018045521922,https://twitter.com/MaxCyte_info/status/1267484018045521922,MaxCyte_info,Scientists at @DanaFarber analyzed tumors from patients treated with #immunotherapy for advanced kidney #cancer to identify tumor features that influence response to immune checkpoint inhibitor drugs: https://t.co/GPJRlkDGKl. @NatureMedicine #ASCO20,2020-06-01
1267483911401005058,https://twitter.com/patilmd3/status/1267483911401005058,patilmd3,"Really exciting developments targeting the MET pathway @ASCO this year. There are promising MET combinations for acquired #ALK #EGFR #ROS1 resistance in the future.  https://t.co/HJyifgknwD
@METCrusaders @ALKLungCancer",2020-06-01
1267483804744196097,https://twitter.com/chadinabhan/status/1267483804744196097,chadinabhan,"because most days appear the same, I find it a duty to inform you that it is Monday 6/1/2020 in the #COVID19 era and it's one day after the first ever @ASCO virtual meeting #ASCO20.",2020-06-01
1267483496152535042,https://twitter.com/JohnCendpts/status/1267483496152535042,JohnCendpts,"Coming up at 1 pm ET, the first of two panel conversations with @DanChenMDPhD @CharuAggarwalMD @OzAzamTmunity1 and @JackWestMD covering the highlights at #ASCO20 -- join us! Free to attend, and come with questions
https://t.co/gAQAC8PKRO",2020-06-01
1267483458936483840,https://twitter.com/manjuggm/status/1267483458936483840,manjuggm,"In @COLONTOWN1, as new members are onboarded, their MMR status is the first thing to be asked. From the patient side, we are doing our best. More education needed on  provider &amp; pt side to make sure MMR testing is more widespread  
@FightCRC @CCAlliance #ASCO20 @TotalHealthConf https://t.co/gWJiwH2ey9",2020-06-01
1267482622806110208,https://twitter.com/PChavee/status/1267482622806110208,PChavee,"GSK: Tania Small, VP of Global Medical Oncology, GSK, has been working with colleagues and partners to bring GSK’s #ASCO20 presence to life in our new virtual world by making clinical data accessible. https://t.co/VC0A6WoDUY",2020-06-01
1267482600832204801,https://twitter.com/BrasilOncologia/status/1267482600832204801,BrasilOncologia,"No último #webinar de cobertura da #ASCO20, os oncologistas discutem ""o que muda amanhã?"". A transmissão será ao vivo, hoje, às 19h. Não perca! https://t.co/LIqRFp5qbi https://t.co/7yofNVaU9m",2020-06-01
1267482572659048449,https://twitter.com/BiosimCenter/status/1267482572659048449,BiosimCenter,"Rituximab #Biosimilar Demonstrates Similarity in @ASCO Study

Check out our #ASCO20 conference coverage here: https://t.co/PdO6MBoJuF https://t.co/m4KptjTV8J",2020-06-01
1267482374792716288,https://twitter.com/cornellGUcancer/status/1267482374792716288,cornellGUcancer,.@DrScottTagawa shares encouraging preliminary data from a study of antibody-drug conjugate sacituzumab govitecan in pts w/ pre-treated metastatic #urothelialcarcinoma. #ASCO20 https://t.co/rQxkjxKiAP #bladdercancer #blcsm https://t.co/Ih9DFcGKDF,2020-06-01
1267482312452845570,https://twitter.com/renalandurology/status/1267482312452845570,renalandurology,Metastatic RCC subtypes differ in sites of metastases https://t.co/i4pFj1svzd #ASCO20 #kcsm,2020-06-01
1267482309743296514,https://twitter.com/MoffittNews/status/1267482309743296514,MoffittNews,#ASCO20 Virtual Scientific program: @kedar_kirtane of @MoffittNews presents on a new phase I trial using TCR-engineered T cell therapy in patients with relapsed/refractory HPV16-positive cancers. View here: https://t.co/Pv3DCJnlUR https://t.co/a2yJZedVFX,2020-06-01
1267482289409327105,https://twitter.com/ASCOPres/status/1267482289409327105,ASCOPres,"It's been the privilege of my life to serve as your @ASCO President. I'm deeply humbled &amp; filled w gratitude. Thank you for your engagement, your commitment, and your trust in me. We will forever be united! -@BurrisSkip",2020-06-01
1267482281033302017,https://twitter.com/MM_Oncology/status/1267482281033302017,MM_Oncology,#ASCO20 video: WATCH PrE0505 presenter Patrick Forde @FordePatrick (@HopkinsKimmel) discuss the potential benefit of #durvalumab plus chemotherapy for patients with malignant pleural #mesothelioma #MPM https://t.co/iDCClrxX4U,2020-06-01
1267482150594473991,https://twitter.com/JNCI_Now/status/1267482150594473991,JNCI_Now,"Retrospective review finds that patients with stage III &amp; IV melanoma exposed to   antibiotics prior to immune checkpoint inhibition had worse survival than   unexposed patients.   #ASCO20 #melsm #immunoonc @JahanMohiuddin @pennmedicine 
https://t.co/jlygd9XNPN https://t.co/S6BsRsYyLo",2020-06-01
1267482140175773696,https://twitter.com/montypal/status/1267482140175773696,montypal,Fun @practiceupdate interview this morning with my stellar colleagues @NickSalgia &amp; @NazliDizman who are making waves in #kidneycancer research at a very young age! We discussed their #ASCO20 posters &amp; more - stay tuned for the link! https://t.co/dxbDRsfd6I,2020-06-01
1267482062178656256,https://twitter.com/WilliamOhMD/status/1267482062178656256,WilliamOhMD,I agree.  An outstanding discussion that both critically evaluates the data and puts it in context for clinical care.   Well done @ERPlimackMD!  #ASCO20 https://t.co/Kb06rUHzNW,2020-06-01
1267481530772881408,https://twitter.com/ASCOPost/status/1267481530772881408,ASCOPost,"Richard L. Schilsky, MD, on This Year’s Practice-Changing Findings https://t.co/I6DEZs4lW7 @rschilsky #ASCO20 #oncology #cancer https://t.co/lOXCDzE2mL",2020-06-01
1267481182679101440,https://twitter.com/fireflyann/status/1267481182679101440,fireflyann,"May I respectfully submit that 
oncologists, patient advocates  and #colorectalcancer nonprofits subscribe to (or create) a list of oncologists.

It was an amazing way to go through #ASCO2020 (goes well with a TweetDeck)

My list w/ 75 #CRCSM Oncologistss
https://t.co/zytk0fqbNA https://t.co/cHxkqLiqXi",2020-06-01
1267481057466748934,https://twitter.com/lustgartenfdn/status/1267481057466748934,lustgartenfdn,"According to results from a recent Phase II trial presented at the #ASCO20 Virtual Scientific Program, researchers noted that neoadjuvant treatment of borderline resectable #PancreaticCancer could lead to improved overall survival outcomes. https://t.co/7eLowqOved",2020-06-01
1267480736564604931,https://twitter.com/TGeorgeMD/status/1267480736564604931,TGeorgeMD,No signal assessed. Just discussions around simplifying the protocol &amp; reducing the total # of volunteers needed to answer the primary question: What is the clinical benefit of adding IO + chemo + targeted therapy in dMMR mCRC. #ASCO2020 #CRCSM https://t.co/rcHps8YeI2,2020-06-01
1267480664628097026,https://twitter.com/silverbacktx/status/1267480664628097026,silverbacktx,"#ASCO20: Silverback™ CSO Valerie Odegard reveals encouraging data from lead ImmunoTAC candidate, #SBT6050, designed to elicit a broad spectrum of anti-tumor immune responses through localized &amp; potent activation of myeloid cells.

Full @ASCO overview: https://t.co/RiznwwEIcu https://t.co/dhzgc0uXFf",2020-06-01
1267480362034139138,https://twitter.com/survivorship_JP/status/1267480362034139138,survivorship_JP,"明日子から帰国しました。#ASCO20 
https://t.co/4nC1QuQBVd",2020-06-01
1267479855806861312,https://twitter.com/survivorship_JP/status/1267479855806861312,survivorship_JP,明日子へ行く気にしてみる。#ASCO2020 https://t.co/KuzNuJJEBc,2020-06-01
1267479621601280000,https://twitter.com/evaluatevantage/status/1267479621601280000,evaluatevantage,"#ASCO20 Tigit yields more remissions, mostly in high PD-L1 patients (Via @JacobPlieth, @evaluatepharma) #tiragolumab https://t.co/0eWr4CeGoh",2020-06-01
1267479374464462848,https://twitter.com/PortalOnconews/status/1267479374464462848,PortalOnconews,"O cirurgião oncológico @DrGarciaAguilar, do @sloan_kettering, é convidado do Diálogo de Experts com a participação de @R_Perez_MD, @RenataDAlpino e @rodrigo_hanriot para discutir os destaques do #ASCO20 em câncer de reto -  https://t.co/yCJENiutQS @ASCO #ONCONEWS #TV_ONCONEWS https://t.co/PaBt1o8aBK",2020-06-01
1267479365857808384,https://twitter.com/ChyMaciej/status/1267479365857808384,ChyMaciej,"#ASCO20 Drugi duży kongres z rzędu, na którym ozymertnib pokazuje dane, które mają szansę zmieniać codzienną praktykę lekarską. https://t.co/iw2Se6FDdO Czy będzie to ""SoC""  w leczeniu uzupełniającym NDRP EGFR+ we wczesnych stopniach zaawansowania? @MenedzerZdrowia @TermediaPL https://t.co/mfY4TTULz6",2020-06-01
1267479344353427456,https://twitter.com/mrgunn/status/1267479344353427456,mrgunn,Also good #asco20 news about immunotherapy for solid tumors https://t.co/zkJm7hCmfM,2020-06-01
1267479251252465664,https://twitter.com/scooperpr/status/1267479251252465664,scooperpr,ASCO: Has AstraZeneca (client) finally found a place for long-plagued I-O candidate tremelimumab? #ASCO20 https://t.co/2faQOk1spY,2020-06-01
1267478913942294528,https://twitter.com/mrgunn/status/1267478913942294528,mrgunn,A little progress in renal cancer from #ASCO20 https://t.co/PekQMJSEDS,2020-06-01
1267478559838347268,https://twitter.com/urotoday/status/1267478559838347268,urotoday,Late toxicities &amp; recurrences in patients with clinical stage I nonseminomatous germ cell tumor after one cycle of adjuvant BEP vs primary retroperitoneal lymph node dissection &gt; https://t.co/ohd025yRLj @HHU_de @aloktewar @DanaFarber #ASCO20 @ASCO https://t.co/nEJXThZh7e,2020-06-01
1267478542327132160,https://twitter.com/JanssenEMEA/status/1267478542327132160,JanssenEMEA,"During the pandemic, it is important to remember that over 310,000 adults will still be diagnosed with #LungCancer in Europe this year🌍

There are two main types of lung cancer: 
👉Non-small-cell lung cancer (NSCLC)
👉Small-cell lung cancer (SCLC)

#ASCO20 https://t.co/dzzTHIpwhw",2020-06-01
1267478515101958146,https://twitter.com/MayoCancerCare/status/1267478515101958146,MayoCancerCare,#Carfilzomib is not superior to #Bortezomib in delaying #MultipleMyeloma progression after initial treatment: https://t.co/CaeFFjD14k #ASCO20 #mmsm @MayoMyeloma @MayoClinic,2020-06-01
1267478281584082947,https://twitter.com/CDNCancerTrials/status/1267478281584082947,CDNCancerTrials,"CCTG @ASCO #ASCO2020.  Award recipients and presentations/poster 
https://t.co/kBoilmxNND",2020-06-01
1267478237464100869,https://twitter.com/NRGonc/status/1267478237464100869,NRGonc,NRG Oncology Research at the #ASCO20 American Society of Clinical Oncology @ASCO Virtual Meeting https://t.co/fAGzZRDAkE,2020-06-01
1267477819321249798,https://twitter.com/Keniji/status/1267477819321249798,Keniji,Catching up on #ASCO20 important highlights @ASCO #BreastCancer #kNOwCancer https://t.co/RwRBInXbiI,2020-06-01
1267477597727981569,https://twitter.com/MSD_Slovenia/status/1267477597727981569,MSD_Slovenia,"Vsak pozna nekoga, ki se ga je rak dotaknil. Zato se borimo z vsemi svojimi močmi, da storimo čim več, čim prej. #ASCO20 https://t.co/BEV9eeZWTX",2020-06-01
1267477511442534400,https://twitter.com/Melanie_McQ/status/1267477511442534400,Melanie_McQ,Learn more about how we are redesigning the clinical trial experience for patients during #COVID19. #ASCO20 #ScienceWillWin #PFEColleague https://t.co/Peeg8Zr9dJ,2020-06-01
1267477455930941440,https://twitter.com/paulettedray/status/1267477455930941440,paulettedray,Learn more about how we are redesigning the clinical trial experience for patients during #COVID19. #ASCO20 #ScienceWillWin #PFEColleague https://t.co/FuCUIlh41q,2020-06-01
1267477318425075712,https://twitter.com/CDNCancerTrials/status/1267477318425075712,CDNCancerTrials,Dr Scott Bratman presented the ongoing CCTG HN10 trial as a virtual poster @ASCO #ASCO20 https://t.co/VlB2r3XXwP,2020-06-01
1267477261885870081,https://twitter.com/WebTarged/status/1267477261885870081,WebTarged,"ASCO2020'nin üçüncü gününü 2 Haziran'da Saat: 12.30 - 13.00 arasında #canlıyayında konuşacağız. 
Canlı yayına ulaşmak için https://t.co/T32dMWIwTX
@WebTarged
 
#ASCO #ASCO2020 https://t.co/zGUqke9Q11",2020-06-01
1267477064292143105,https://twitter.com/delve_insight/status/1267477064292143105,delve_insight,#GracellBiotechnologies has announced the results of two presentations including Gracell's #TruUCAR™ GC027 in relapsed or refractory T-cell acute #LymphoblasticLeukemia (r/r T-ALL) patients at the 2020 @ASCO Virtual Scientific Program. https://t.co/GaQNKOVhWq,2020-06-01
1267476864181952512,https://twitter.com/_SEOM/status/1267476864181952512,_SEOM,"📡#ASCO20 | La Dra. Ana Fernández analiza las novedades en cáncer gastrointestinal (no colorrectal). 

🎞️ Sus vídeo-píldoras ya están disponibles en nuestra plataforma de formación #OncoNexion. 

🔗 https://t.co/wCdmkxtv0q https://t.co/0crN34qXiz",2020-06-01
1267476630823469057,https://twitter.com/OncologyTimes/status/1267476630823469057,OncologyTimes,Updates from #ASCO20: Don't miss these #OvarianCancer Abstracts https://t.co/nvTTuqgEpg #cancer #medtwitter https://t.co/oXuDzs64Fj,2020-06-01
1267476187733020673,https://twitter.com/BrasilOncologia/status/1267476187733020673,BrasilOncologia,"Dr. Gilberto Castro, oncologista clínico do ICESP e do @hsiriolibanes , e Dra. Clarissa Baldotto, oncologista clínica do @rededor membro do GBOT, comentam os principais estudos sobre imunoterapia em câncer de pulmão de pequenas células da #ASCO20.  https://t.co/S5Vudis9je https://t.co/gvkOmei93R",2020-06-01
1267475275249573888,https://twitter.com/inas_md/status/1267475275249573888,inas_md,"Loving all the #ADAURA trial discussions! Looking forward to the @HOJournalClub with @JackWestMD later this week!
#LCSM #ASCO20 https://t.co/ke9GBQvzsJ",2020-06-01
1267475246094913542,https://twitter.com/manjuggm/status/1267475246094913542,manjuggm,"So important for all you experts to revise NCCN guidelines promptly when anything new comes along! Patients don’t have any time to waste!
@agrothey @cancerassassin1 @ShaalanBeg 
#ASCO20 @TotalHealthConf https://t.co/9sopu2hwbf",2020-06-01
1267474903592325123,https://twitter.com/ME_Fleury/status/1267474903592325123,ME_Fleury,Never too late to benefit from quitting smoking. New data from #ASCO20 https://t.co/Qh4HQZdiN1,2020-06-01
1267474627963555842,https://twitter.com/HemOncToday/status/1267474627963555842,HemOncToday,".@ASCO #ASCO20 - Randomized phase 3 IMvigor010 study shows atezolizumab @genentech fails to extend disease-free survival in high-risk urothelial carcinoma https://t.co/7MBUFeXWId led by Maha Hussain, MD @LurieCancer @NUFeinbergMed https://t.co/qQcZh6Zxvc",2020-06-01
1267474433943285763,https://twitter.com/NoopurRajeMD/status/1267474433943285763,NoopurRajeMD,STaMINA trial presented @ASCO by @Docmyeloma . Long term data shows no difference for eiter PFS or OS with either RVD consolidation or tandem transplant except on as treated analysis for  second transplant in high risk #mmsm. Rev until progression also validated here. https://t.co/jjxc06XM8r,2020-06-01
1267474240762232837,https://twitter.com/ABaileyDC/status/1267474240762232837,ABaileyDC,"With so much new data at @ASCO ... it seems that complete #biomarker testing with #NGS becomes the preferred method in #lungcancer, but when/who should you order the testing? Tune in this Wednesday June 3 7PM EST to find out what we think. #timematters https://t.co/xtNO7xAID6 https://t.co/DYF1tcYi9k",2020-06-01
1267474239478796288,https://twitter.com/MedscapeOnc/status/1267474239478796288,MedscapeOnc,"Virtual #ASCO20 is a big win for resource-strapped oncologists, writes @oncology_bg. 
https://t.co/vMDfyRp1EV https://t.co/fGbUeaXZyd",2020-06-01
1267474128635858944,https://twitter.com/ThisIsSeanB/status/1267474128635858944,ThisIsSeanB,"Impressive results from the OPRA trial at #ASCO20

1⃣~50% of patients can avoid TME with pre-op CRT + chemo!
2⃣Higher rates of organ preservation if CRT given first
3⃣Equal survival compared to traditional CRT + TME 
🔑is close surveillance (scope, DRE, MRI) https://t.co/YJuUHG0saE",2020-06-01
1267473630734233600,https://twitter.com/DukeCancer/status/1267473630734233600,DukeCancer,"#ASCO20 News: Thirty Percent of Patients With NSCLC Who Had Actionable Variants Were Not Prescribed Targeted Therapies. Our Vishal Vashistha, MD, spoke with @CancerTherAdvsr: https://t.co/rRtGXlRH4n",2020-06-01
1267473599021154307,https://twitter.com/AtlantaIp2/status/1267473599021154307,AtlantaIp2,Thanks @urotoday for covering the IP2-ATLANTA Trial presentation in #ASCO20 Conference Highlights -https://t.co/7Hf1P7YSlH - @IP_London @ImperialSandC @wellcometrust @NCRI_partners @NIHRCRN_nthames @LondonProstate1 @Connor_Urol @TaimurShah @UHSFT @timdudderidge @PelvicERAS https://t.co/UVWihcgYjD,2020-06-01
1267473411498000385,https://twitter.com/medcitynews/status/1267473411498000385,medcitynews,"Gilead CAR-T’s indolent lymphoma data impresses at ASCO. How to position it is another question, writes @biotechvisigoth @medcitynews  https://t.co/tJmG7xe0fG @GileadSciences $GILD #lymphoma #ASCO20",2020-06-01
1267473281235509248,https://twitter.com/StephLBaum/status/1267473281235509248,StephLBaum,"Gilead CAR-T’s indolent lymphoma data impresses at ASCO. How to position it is another question, writes @biotechvisigoth @medcitynews  https://t.co/bSuaqTSR0z @GileadSciences $GILD #lymphoma #ASCO20",2020-06-01
1267473247194484737,https://twitter.com/ACCCBuzz/status/1267473247194484737,ACCCBuzz,Conflicting testing terminology may lead to #biomarkertesting underusage in #cancer. See NEW recommendations for patient-centric testing terminology in #ASCO20 abstract from a @LUNGevity-led working group: #UnitedLanguage #PrecisionMedicine https://t.co/oND9IyveDK https://t.co/sXbv9I2IZQ,2020-06-01
1267473204387479552,https://twitter.com/LeukemiaMDA/status/1267473204387479552,LeukemiaMDA,"#ASCO20 : Emerging approaches to improve immunotherapy for cancer treatment | Studies led by @Daver_Leukemia, @fravandi1, Blumenschein, Yap of @MDAndersonNews | 
https://t.co/NcC24wDXhL | #endcancer  #leusm #AML",2020-06-01
1267473154160553984,https://twitter.com/JackWestMD/status/1267473154160553984,JackWestMD,"Y-day, in #ADAURA trial, we saw DFS HR of 0.17 for adjuvant osimertinib in pts w/stage II-IIIA, and 0.50 for pts w/st IB #EGFR mut'n+ #NSCLC.

It's now post #ASCO20 Monday Morning.

What do you think about trial design of #ADAURA to change practice for treatment costing $200K/yr?",2020-06-01
1267473133482754049,https://twitter.com/MaverickNY/status/1267473133482754049,MaverickNY,"Our second in-depth post from #ASCO20 this am explores an early target garnering a lot of noise of late.  

Is the roaring hype justified on TIGIT? What can we learn about the tiragolumab data, and what does a company exec think?  https://t.co/roUldtNYDH https://t.co/7hDBNvaBKa",2020-06-01
1267473042831269892,https://twitter.com/ImmunomedicsInc/status/1267473042831269892,ImmunomedicsInc,"Thank you, @ASCO, for a wonderful virtual #ASCO2020 Annual Meeting. We are especially grateful to all the individuals participating in our ongoing clinical trials. The continued progress in cancer therapies would not be possible without you. https://t.co/5OAHHVSBAD",2020-06-01
1267472605369556992,https://twitter.com/ByAmyBrown/status/1267472605369556992,ByAmyBrown,"Daiichi and Astra's Her2 ADC Enhertu impresses at #ASCO20, but can it live up to blockbuster hopes? I took a look at the data presented: https://t.co/hWBLk0RSve   $AZN $DSNKY",2020-06-01
1267472475463524352,https://twitter.com/GSK/status/1267472475463524352,GSK,"Tania Small, VP of Global Medical Oncology, GSK, has been working with colleagues and partners to bring GSK’s #ASCO20 presence to life in our new virtual world by making clinical data accessible. https://t.co/7kSSMuXT4u",2020-06-01
1267472219833278464,https://twitter.com/RossFH/status/1267472219833278464,RossFH,Adding pembrolizumab to standard carboplatin-paclitaxel chemotherapy seemed to lead to response rates higher than historical results for patients with advanced/recurrent #endometrialcancer. @ASCO #ASCO20 #goASCO20 #gyncsm #immunotherapy https://t.co/wL6JY8RrBo,2020-06-01
1267472121774649344,https://twitter.com/SoVzlaUro/status/1267472121774649344,SoVzlaUro,"Morbilidad asociada con #cancer detección y tratamiento: 

#Urologist perspectiva presentada por Timur Mitin, MD, PhD @OHSUKnight . #ASCO20 cobertura escrita por 
@GoldbergHanan @UpstateNews 

En &gt;https://t.co/KnwRkADh7T https://t.co/NGxYf5wvQc",2020-06-01
1267471800230969345,https://twitter.com/lymphomahub/status/1267471800230969345,lymphomahub,Should pembrolizumab be considered the new standard for patients with R/R classic Hodgkin lymphoma? Watch Dr John Kuruvilla from @UofT to find out the progression-free survival &amp; toxicity results from the KEYNOTE-204 trial presented at #ASCO2020 ⚡️https://t.co/D6BP8shrEl #Lymsm https://t.co/iuAuW52gWO,2020-06-01
1267471735131078656,https://twitter.com/chemobrainfog/status/1267471735131078656,chemobrainfog,Kudos/&amp; big personal thank you @DrDawnHershman on receiving @ASCO Women Who Conquer Cancer Mentorship Award. She has been instrumental in helping me. Her mentorship goes far beyond what she speaks about. #swogonc https://t.co/4Fz1NG6FOZ,2020-06-01
1267471637525352448,https://twitter.com/TGeorgeMD/status/1267471637525352448,TGeorgeMD,🔥Atezo alone arm is under consideration for closure (pre-KEY177) to simplify the study (leaving 2-arms: FOLFOX + bev +/- Atezo in 1L dMMR mCRC).  For now - study remains open with ALL 3 arms #ASCO20 #crcsm @NRGonc @SWOG https://t.co/l6ge0PSyvb,2020-06-01
1267471149371449345,https://twitter.com/GenoceaBio/status/1267471149371449345,GenoceaBio,"#ICYMI - Last week, @GenoceaBio shared initial clinical data at #ASCO20 that demonstrated GEN-009’s ability to generate broad sustained immunity against immunogenic tumor mutations. Learn more here: https://t.co/WnGAqIEYTo #targetsmatter #AcademicTwitter https://t.co/eDBG7U4oqB",2020-06-01
1267471099199131650,https://twitter.com/HemOncToday/status/1267471099199131650,HemOncToday,News from @ASCO #ASCO20 - Randomized phase 2 research from  @love_snuh shows Axitinib @pfizer significantly extended progression-free survival among patients with recurred or metastatic adenoid cystic carcinoma https://t.co/yUkuycb95a,2020-06-01
1267470964322861063,https://twitter.com/MedscapeFrance/status/1267470964322861063,MedscapeFrance,"Premières preuves de l’efficacité d’une immunothérapie dans les tumeurs trophoblastiques #ASCO2020 #TROPHIMMUN
https://t.co/petMMho5z3",2020-06-01
1267470957729533955,https://twitter.com/teckroofficial/status/1267470957729533955,teckroofficial,"Teckro remains committed to aiding #Cancer #ClinicalTrials, because even during a #pandemic patients are still waiting for solutions. https://t.co/anMapVroMi @ASCO #ASCO20",2020-06-01
1267470734827442177,https://twitter.com/BergHealth/status/1267470734827442177,BergHealth,"Recently at @ASCO's annual meeting, our team shared findings from a #Phase1 #clinicalstudy, co-led by @StanfordMed, where we applied our #AI-guided #drug #BPM31510 to fight #glioblastoma. #fightingcancer. Read it here: https://t.co/rchRhiq4X3",2020-06-01
1267470417993883648,https://twitter.com/BioAscend/status/1267470417993883648,BioAscend,"Join experts Neal Shore, @SagarLonialMD , @RamalingamMD, @ShannonWestin along with a panel of experts as they share insights on caring for your cancer patients during #COVID  REGISTER for upcoming webinars and view past episodes at https://t.co/906SzzHvDT  #ASCO20 #oncology https://t.co/xffNy5HQfS",2020-06-01
1267470365271511043,https://twitter.com/manjuggm/status/1267470365271511043,manjuggm,"Wow! That’s too many cases  missed that may benefit from IO.

A micro satellite PCR test should be simple and relatively easy to do with every IHC? 
#ASCO2020 #ASCOTotalHealth #crcsm
#MMRTesting https://t.co/csMA4GCJ1u",2020-06-01
1267469451961741314,https://twitter.com/MedscapeFrance/status/1267469451961741314,MedscapeFrance,"Cancer de la vessie avancé: une immunothérapie en traitement d’entretien améliore la survie, dans l'essai de phase 3 JAVELIN Bladder 100
#ASCO2020 #avelumab
https://t.co/y0PS3jIO5D",2020-06-01
1267469391257645057,https://twitter.com/AgenceLJCom/status/1267469391257645057,AgenceLJCom,"[#ASCO20]
🗓️RDV demain à 9h30 sur l'#OncologyPressRoom pour une dernière journée de session live avec @GroupeUNICANCER et les experts Pr Frédérique Penault Llorca, @jeanyvesblay, @PrDelord qui reviendront sur les grandes actus du congrès !
En savoir plus : https://t.co/EDgtSvALuM https://t.co/HHIzdlTzDo",2020-06-01
1267469143953100805,https://twitter.com/jillfeldman4/status/1267469143953100805,jillfeldman4,TONIGHT! You don't want to miss this discussion on myths in #EGFR lung cancer with @LeciaSequist @Jbauml @JSabari @RamalingamMD @HelenaYu923 &amp; @ivybelkins with live Q &amp; A. You can register at https://t.co/mhQWtxT82v #LCSM #ASCO20 #OncoAlert @EGFRResisters @CEC_Onc @AstraZeneca https://t.co/zSVL0ycV3k,2020-06-01
1267468800032673793,https://twitter.com/SyneosHealth/status/1267468800032673793,SyneosHealth,"If we missed you at #ASCO20, tune into our new Insights Hub Live series. Watch our first episode, focused on #oncology where we discuss everything from new entrants and access to trial design and unique HCP experiences. Watch here: https://t.co/kD4JCBGC9m. https://t.co/wzTpiaMJy0",2020-06-01
1267468473841614853,https://twitter.com/OncLive/status/1267468473841614853,OncLive,Clinical outcomes in patients with recurrent ovarian cancer who were treated with niraparib plus bevacizumab were significantly improved when compared with niraparib alone. @Rigshospitalet @ASCO #ASCO20 #gyncsm https://t.co/uosHAFcrRb,2020-06-01
1267468458700177409,https://twitter.com/diariomedico/status/1267468458700177409,diariomedico,La sesión plenaria del congreso americano de oncología #ASCO2020 ha traído nuevos datos que consolidan la medicina personalizada en estadios precoces del cáncer de pulmón https://t.co/D9zx6CIA6N https://t.co/2waUpsQOkV,2020-06-01
1267468033276157954,https://twitter.com/AbbVieUS/status/1267468033276157954,AbbVieUS,"We're proud to be a part of #ASCO20 with the top oncologists, researchers, patients and advocates. https://t.co/mq7rLQ7nin",2020-06-01
1267467963097141248,https://twitter.com/OWise_uk/status/1267467963097141248,OWise_uk,"Promising results from the PHOEBE clinical trial have recently been published in @ASCO!

The experimental anti-HER2 drug Pyrotinib + Xeloda showed better progression-free survival than Tykerb + Xeloda in HER2+ metastatic #breastcancer.

Read more:
https://t.co/nHhCqU5T1I https://t.co/WRJxgbPC8n",2020-06-01
1267467863079747589,https://twitter.com/d2merino/status/1267467863079747589,d2merino,"This is an insightful study that highlights #AML patient preferences on treatment, which focuses on quality of life, and what outcomes matter to them! #partnersincare #ASCO20 https://t.co/Z74oq6tW5e",2020-06-01
1267467808998404101,https://twitter.com/LeCancerFr/status/1267467808998404101,LeCancerFr,#ASCO20 ASCO® 2020 : cap vers une médecine encore plus personnalisée - https://t.co/owDYEHDPCm https://t.co/isRxi4px3U,2020-06-01
1267467806876065797,https://twitter.com/LeCancerFr/status/1267467806876065797,LeCancerFr,#ASCO20 ASCO® 2020 : cap vers une médecine encore plus personnalisée - https://t.co/owDYEHDPCm https://t.co/Cc1220MLhv,2020-06-01
1267467524297445376,https://twitter.com/FoxChaseCancer/status/1267467524297445376,FoxChaseCancer,"At #ASCO20, Fox Chase's Dr. Martin Edelman presented the design of an ongoing study focused on determining the safety &amp; efficacy of using enhanced marrow infiltrating lymphocytes for the treatment of #NSCLC. More information on this research here: https://t.co/T6BrinfoQZ.",2020-06-01
1267467274379825154,https://twitter.com/LeCancerFr/status/1267467274379825154,LeCancerFr,#ASCO20 De nouveaux médicaments prometteurs dans le cancer du sein RH+ métastatique. - https://t.co/6bBg88Rzcr,2020-06-01
1267467224173940736,https://twitter.com/BiosimCenter/status/1267467224173940736,BiosimCenter,"Filgrastim Agent Is Cost-Effective in #NSCLC, According to @ASCO Study

Check out our #ASCO20 conference coverage here: https://t.co/K3R7qiWCeH https://t.co/a5EPBPTs3y",2020-06-01
1267466978157084677,https://twitter.com/LeCancerFr/status/1267466978157084677,LeCancerFr,#ASCO20 Deux équipes de biomarqueurs pour jouer la sensibilité ou la résistance au ribociclib. - https://t.co/3LKJ0r8rEi https://t.co/HMFZxOoGtQ,2020-06-01
1267466976827527168,https://twitter.com/LeCancerFr/status/1267466976827527168,LeCancerFr,#ASCO20 Deux équipes de biomarqueurs pour jouer la sensibilité ou la résistance au ribociclib. - https://t.co/3LKJ0r8rEi https://t.co/fZVsQSr8VY,2020-06-01
1267466462995890177,https://twitter.com/rokenforpeace/status/1267466462995890177,rokenforpeace,"AIO, CELIM2-Study
PFS 15months with  FFX+CET (KrasWT) and FFX+BEv (KRasmut); 17mo with FFX (KrasMut) alone.
CR+PR more than 70% (higher with Cetuxi-FFX, 86%) 
Median number of mets were more than 5. No MS status data
#ASCO2020  #ASCO20 #Cancer #clinicaltrials",2020-06-01
1267466451763552257,https://twitter.com/SamPayabvash/status/1267466451763552257,SamPayabvash,Dr. Chang Ho on optimal MRI protocol for #epilepsy in children #ASCO20 @TheASNR https://t.co/XFKh13DZbY,2020-06-01
1267466179691655175,https://twitter.com/ASCOPost/status/1267466179691655175,ASCOPost,"David R. Wise, MD, PhD, on Novel Biomarkers in Prostate Cancer: Is Tissue the Issue? https://t.co/WbjK7MIvIJ #pcsm #oncology #biomarkers #ASCO20 @nyulangone https://t.co/AeLGIIQ4BC",2020-06-01
1267465688907755520,https://twitter.com/OncologistTom/status/1267465688907755520,OncologistTom,‼️#DESKTOPIII The discussion about cytoreductive surgery in recurrent ovarian cancer will never end #ASCO20 #ASCO https://t.co/po1l9KpjoH,2020-06-01
1267465638815117312,https://twitter.com/LeCancerFr/status/1267465638815117312,LeCancerFr,#ASCO20 Mutants ESR1 présents d’emblée dans l’étude PADA-1 : rares mais de mauvais pronostic. - https://t.co/1Pib90jnrW https://t.co/NGqPsRyxGL,2020-06-01
1267465635266793472,https://twitter.com/LeCancerFr/status/1267465635266793472,LeCancerFr,#ASCO20 Mutants ESR1 présents d’emblée dans l’étude PADA-1 : rares mais de mauvais pronostic. - https://t.co/1Pib90jnrW https://t.co/pyrpUC7dcg,2020-06-01
1267465494375866369,https://twitter.com/fwhealthtech/status/1267465494375866369,fwhealthtech,"ASCO20: Genetic screening for prostate cancer effective
https://t.co/AnRPKmNFpv #ASCO2020 #medtech @ICR_London",2020-06-01
1267465018729168899,https://twitter.com/LeCancerFr/status/1267465018729168899,LeCancerFr,"#ASCO20 Un ASCO® de transition : des confirmations, encore des interrogations… - https://t.co/W3h9ySPl8s https://t.co/ku5Pl7thvK",2020-06-01
1267465016212631553,https://twitter.com/LeCancerFr/status/1267465016212631553,LeCancerFr,"#ASCO20 Un ASCO® de transition : des confirmations, encore des interrogations… - https://t.co/W3h9ySPl8s https://t.co/vE4K1iZ0z3",2020-06-01
1267464865964310539,https://twitter.com/deeplens_ai/status/1267464865964310539,deeplens_ai,"We are excited to be at #ASCO20 with an accepted abstract on how VIPER efficiently and effectively improved oncology fulfillment.
Discover more here. https://t.co/0N7wlU5gq8
 #clinicaltrials  #clinicalresearch #precisiononcology #patientrecruitment #clinicalstudies https://t.co/qUMdUGIH71",2020-06-01
1267464713165832197,https://twitter.com/LeCancerFr/status/1267464713165832197,LeCancerFr,"#ASCO20 Mes coups de cœur de ce congrès virtuel : Ribociclib, Tucatinib et Bicalutamide - https://t.co/5VqSr1LUcP https://t.co/p1Ik2ujOWC",2020-06-01
1267464684468342788,https://twitter.com/renalandurology/status/1267464684468342788,renalandurology,Tivozanib offers survival benefit similar to sorafenib in refractory mRCC https://t.co/157zOksM2m #ASCO20 #kcsm,2020-06-01
1267464242128662528,https://twitter.com/JordiRemon/status/1267464242128662528,JordiRemon,"ADAURA: is a trial of discord? The trial is positive for primary endpoint. ADAURA has strengths, however, some caveats exist for discussion. Biopsy at the time of osimertinib PD is relevant. MET amp the mech of AR? Exist a link between MET ampl and Brain mets risk #ASCO20 #LCSM https://t.co/0GYNY4FHn5",2020-06-01
1267464225812865031,https://twitter.com/LeCancerFr/status/1267464225812865031,LeCancerFr,#ASCO20 Cancer du sein triple positif : et maintenant la désescalade en néo-adjuvant ! - https://t.co/nBIBTYkauP https://t.co/N45Gwf0Usc,2020-06-01
1267463641487548417,https://twitter.com/n8pennell/status/1267463641487548417,n8pennell,Also not too shabby results of DESTINY-Lung trial in HER2 mutated NSCLC #ASCO20 #LCSM Think we may be adding HER2 to the must-test list soon https://t.co/zSfYawEV3L,2020-06-01
1267463556271951874,https://twitter.com/carisls/status/1267463556271951874,carisls,We were delighted to have participated and presented virtually alongside some of the greatest minds in clinical cancer care at #ASCO20. https://t.co/fFTwCx1EOS,2020-06-01
1267463532674719746,https://twitter.com/ecancer/status/1267463532674719746,ecancer,"#ASCO20: Dr Cornelis van Tilburg speaks to us about the clinical outcome and benefit for molecular subgroups seen in the paediatric precision oncology study #INFORM.
Watch here: https://t.co/4JCN2ISK4a
@ASCO #PaediatricOncology #CancerResearch #PrecisionMedicine https://t.co/kCX02aylR7",2020-06-01
1267463095431110658,https://twitter.com/LeCancerFr/status/1267463095431110658,LeCancerFr,#ASCO20 Mieux utiliser l’immunothérapie dans le cancer du sein avancé triple négatif. - https://t.co/UVdV9dEPQ8 https://t.co/ws4ke97mB7,2020-06-01
1267463091446583296,https://twitter.com/LeCancerFr/status/1267463091446583296,LeCancerFr,#ASCO20 Mieux utiliser l’immunothérapie dans le cancer du sein avancé triple négatif. - https://t.co/UVdV9dEPQ8 https://t.co/0aQWJJZJkc,2020-06-01
1267462966930280454,https://twitter.com/wangyub/status/1267462966930280454,wangyub,Is this change your practice about folfirinox for pan ca? #ASCO20VR #PancreaticCancer @ASCO https://t.co/q3VlyjIQcf,2020-06-01
1267462552830775301,https://twitter.com/LeCancerFr/status/1267462552830775301,LeCancerFr,#ASCO20 Mon ASCO ® 2020 - https://t.co/It9qHVWbL9 https://t.co/w8iG85mL0F,2020-06-01
1267462550582681601,https://twitter.com/LeCancerFr/status/1267462550582681601,LeCancerFr,#ASCO20 Mon ASCO ® 2020 - https://t.co/It9qHVWbL9 https://t.co/eV9BJmCHmt,2020-06-01
1267462149494001666,https://twitter.com/LeCancerFr/status/1267462149494001666,LeCancerFr,#ASCO20 Brèves … discussions sur des posters. - https://t.co/y4kXN5PATb https://t.co/3zeEIofa0S,2020-06-01
1267462148659314689,https://twitter.com/LeCancerFr/status/1267462148659314689,LeCancerFr,#ASCO20 Brèves … discussions sur des posters. - https://t.co/y4kXN5PATb https://t.co/ngHcf2qN4K,2020-06-01
1267462144578256896,https://twitter.com/LeCancerFr/status/1267462144578256896,LeCancerFr,#ASCO20 Brèves … discussions sur des posters. - https://t.co/y4kXN5PATb https://t.co/LKFgiKrSNT,2020-06-01
1267462051926024192,https://twitter.com/psico_onco/status/1267462051926024192,psico_onco,"#ASCO20
Dal mio punto di vista, trovo importanti anche i dati relativi alla qualità di vita: riduzione dei sintomi cognitivi e ritardo nella comporsa del dolore... 👇 https://t.co/QbVoXSwNDC",2020-06-01
1267461873290616834,https://twitter.com/LeCancerFr/status/1267461873290616834,LeCancerFr,#ASCO20 L’abstention thérapeutique dans le Carcinome Canalaire In Situ est-elle une option raisonnable ? - https://t.co/fYmfZBop90,2020-06-01
1267461398319292417,https://twitter.com/MedscapeOnc/status/1267461398319292417,MedscapeOnc,"#ASCO20: When added to standard chemo, a generic PPI demonstrated a higher-than-expected rate of pathologic complete response in TNBC.  https://t.co/ojI7aJ75sM #bcsm",2020-06-01
1267460895556472837,https://twitter.com/mdlhenning/status/1267460895556472837,mdlhenning,Very good surogate-discussion in lung-cancer during #ASCO20 . SOLO-1 with Olaparib 1st-line in ovarian cancer had a HR = 0.30 for PFS. While waiting for OS-results the coming 2 years should we gyn-oncs not have a similar discussion abt validation of our surogate endpoints? https://t.co/DgW6OZtxiY,2020-06-01
1267459774779666437,https://twitter.com/Oncoinfo_it/status/1267459774779666437,Oncoinfo_it,"[1/5] #ASCO20 #PrecisionMedicine | The prevalence of KRASG12C mutations utilizing circulating tumor DNA (ctDNA) in 80,911 patients with cancer",2020-06-01
1267459669280403456,https://twitter.com/WCMLymphoma/status/1267459669280403456,WCMLymphoma,Dr. Sarah Rutherford (@drsarahruth) shares encouraging findings from a phase I #clinicaltrial of venetoclax + DA-EPOCH-R as initial therapy for aggressive B-cell #lymphoma. https://t.co/x3DbBeUsIf #ASCO20 #lymsm https://t.co/OJeTg7OHpy,2020-06-01
1267459658832392194,https://twitter.com/MoffittNews/status/1267459658832392194,MoffittNews,"During the #ASCO20 Virtual Scientific Program, @jlanc66 of @MoffittNews presents five-year final results on a study comparing CPX-351 versus 7+3 in older patients with newly diagnosed high-risk/secondary AML. View abstract: https://t.co/J0HdVrCbUY #LeuSM https://t.co/ZaNlB6Vfp2",2020-06-01
1267459571880165377,https://twitter.com/StephLBaum/status/1267459571880165377,StephLBaum,Blueprint gets #FDA priority review for competitor to newly approved Lilly cancer drug by @biotechvisigoth @medcitynews https://t.co/g4Hv4EoA2g @BlueprintMeds $BPMC $LLY #ASCO20,2020-06-01
1267459570424840192,https://twitter.com/Oncoinfo_it/status/1267459570424840192,Oncoinfo_it,"#ASCO20 | Dallo studio #COMBIAD arrivano dati di grandissima importanza per i pazienti con #melanoma BRAF mutato. A illustrarceli è Paola Queirolo, che sottolinea il grande impatto della combinazione dabrafenib + trametinib.

https://t.co/t4pX3MmgBM",2020-06-01
1267459364283207680,https://twitter.com/medcitynews/status/1267459364283207680,medcitynews,Blueprint gets #FDA priority review for competitor to newly approved Lilly cancer drug by @biotechvisigoth @medcitynews https://t.co/jxNjWpTQRu @BlueprintMeds $BPMC $LLY #ASCO20,2020-06-01
1267459337766592512,https://twitter.com/marklewismd/status/1267459337766592512,marklewismd,Time hop just reminded me of another casualty of no in-person #ASCO20: family time in Chicago 😔 https://t.co/011XpjmbAH,2020-06-01
1267459327616520197,https://twitter.com/SempriniJason/status/1267459327616520197,SempriniJason,4) W predict that DBT within a breast notification law has a &gt;50% chance of being more costly and less effective than the standard of care without notification and a 9% chance of being more effective and less costly. #ASCO2020 #breastcancer,2020-06-01
1267459284788367361,https://twitter.com/DrAttai/status/1267459284788367361,DrAttai,NO #BCSM chat this evening - we'll be back Monday 6/8 with highlights form #ASCO20 cc @stales,2020-06-01
1267459140378669058,https://twitter.com/JazzPharma/status/1267459140378669058,JazzPharma,"Thank you @ASCO, our partners and to everyone who contributed to this year’s #ASCO20 Virtual Scientific Program. We are inspired by the data presented at this year’s meeting. https://t.co/RTB2Pi2H9I",2020-06-01
1267458946136190983,https://twitter.com/SempriniJason/status/1267458946136190983,SempriniJason,"3) this benefit carries a high cost compared to mammography. We estimate that each additional quality-adjusted life year costs $155,00 to $330,000. We acknowledge that some accepted breast cancer treatments have higher cost effectiveness thresholds. #asco2020 #breastcancer",2020-06-01
1267458597086265347,https://twitter.com/AldoLADETTINO/status/1267458597086265347,AldoLADETTINO,Urothelial cancer and maintenance #ASCO20 2020: Immunotherapy following chemotherapy offers extended survival to patients with advanced urothelial cancer - ecancer. https://t.co/dtF7nBVaKS,2020-06-01
1267458381708759040,https://twitter.com/LurieCancer/status/1267458381708759040,LurieCancer,"John Peipert, PhD, will be presenting his research on the prognostic value of PROs in patients with #hematologic #malignancies during this year’s @ASCO Annual Meeting. Read more about his research, here: https://t.co/XHmbWXvh5M. https://t.co/9o6TUFxDTu",2020-06-01
1267458298799960065,https://twitter.com/radiotherapiefr/status/1267458298799960065,radiotherapiefr,#Asco2020 : une molécule contre certains #cancers ovariens #CancerOvaire #Hcsmeufr | @scoopit https://t.co/jPZM18WWQo,2020-06-01
1267457833479671809,https://twitter.com/BioAscend/status/1267457833479671809,BioAscend,Live Streaming Satellite Symposium June 11 7pm EDT. Experts @szusmani @PLMcCarthyMD  &amp; Krina Patel will discuss expanding role of immunotherapy for treatment of multiple myeloma including updates from #ASCO20  Register NOW at https://t.co/7ybJNNLQK6 #mmsm #CME #medicaleducation https://t.co/ReYqDtlg0P,2020-06-01
1267457763975798792,https://twitter.com/SempriniJason/status/1267457763975798792,SempriniJason,1) DBT is a sophisticated screening technique and may be more accurate than a mammogram for women with dense breasts. 2) we found that earlier detection from DBT would reduce the number of deaths and late stage diagnoses. #ASCO2020 #breastcancer,2020-06-01
1267457676847570945,https://twitter.com/realdrgabriel/status/1267457676847570945,realdrgabriel,"Mindact trial after 8y. Clinical high risk and low genetic risk probably need more treatment, either by OFS or chemo. #bcsm #ASCO20 https://t.co/9B4QtHF06m",2020-06-01
1267457480776392710,https://twitter.com/catalystcrnc/status/1267457480776392710,catalystcrnc,"Thank you @ASCO for an informative #virtual scientific program and engaging lineup of scientific content, as well as a beautiful virtual booth. We are already looking forward to #ASCO21! Until then, #CatchCatalyst at our next event--&gt; @DrugInfoAssn https://t.co/h0sApNrycC https://t.co/1HzYpxowJJ",2020-06-01
1267457335435329536,https://twitter.com/MDRoeland/status/1267457335435329536,MDRoeland,More data from #ASCO2020 showing dietary supplement use during chemo increases risk of recurrence. Patients need to know that supplements are not necessarily safe. #cancerdiet https://t.co/cheh4Fb0oW,2020-06-01
1267457120217096193,https://twitter.com/BioWorld/status/1267457120217096193,BioWorld,"Astrazeneca Tagrisso seems poised to become standard of care in the adjuvant setting for early stage (IB, II and IIIA) EGFR-mutated NSCLC, thanks to phase III data from the study called Adaura, made public at #ASCO20 https://t.co/8oqsJfCuh7",2020-06-01
1267456862301102081,https://twitter.com/NeoGenomics/status/1267456862301102081,NeoGenomics,"Accurately identify mutations in NSCLC from circulating tumor DNA (ctDNA) to better understand the tumor profile in 7 calendar days. 
Learn more https://t.co/YvKLJPCoXr
#precisionmedicine #liquidbiosy #lungcancer #ASCO20 https://t.co/c9DVLsXFFT",2020-06-01
1267456781434961928,https://twitter.com/Oncoinfo_it/status/1267456781434961928,Oncoinfo_it,[1/5] #ASCO20 #PrecisionMedicine | Characterization of patients with multiple primary tumors.,2020-06-01
1267456668448808962,https://twitter.com/SempriniJason/status/1267456668448808962,SempriniJason,Proud and humbled to be included in the @ASCO 2020 meeting. Here is my research estimating the cost-effectiveness of Adjunctive DBT for young women with dense breasts. #ASCO2020 #breastcancer  https://t.co/V7T9KZTlpv,2020-06-01
1267456664002859009,https://twitter.com/ASTRO_org/status/1267456664002859009,ASTRO_org,Congratulations to #RadOnc Dr. Anthony D’Amico for receiving the Excellence in Teaching Award at #ASCO20! https://t.co/29AfYOVm2n @ASCO,2020-06-01
1267456617068367874,https://twitter.com/UoBAccelerate/status/1267456617068367874,UoBAccelerate,"New technique to identify glycans associated with cancer with unprecedented accuracy developed by University of Birmingham, UK. 

#prostatecancer #ASCO2020

https://t.co/xxTAv5jc3a https://t.co/GKkjImVUtT",2020-06-01
1267456513083346944,https://twitter.com/Oncoinfo_it/status/1267456513083346944,Oncoinfo_it,"#ASCO20 | Risultati di grande impatto per lo studio #ADAURA, dati che modificheranno la pratica clinica nella terapia adiuvante dei pazienti con NSCLC. Il commento di Filippo de Marinis, @OncoPolmoneIEO.

https://t.co/OqfZljvmn1",2020-06-01
1267456487598800896,https://twitter.com/CancerResrch/status/1267456487598800896,CancerResrch,"Our VP of Public Affairs, Ryan Hohman &amp; our Dir. of Research Partnerships @d2merino are authors on this important abstract that highlights the need for patient input in treatment decisions - https://t.co/P4mDtmNPqX #ASCO20 @pfizer https://t.co/jeHJrwHCCX",2020-06-01
1267456293981138944,https://twitter.com/marklewismd/status/1267456293981138944,marklewismd,"Post-#ASCO20 Monday is the ultimate case of gen Mondays but for some reason I’m still feeling fired up for clinic today 🤷🏼‍♂️ 
#MondayMotivation https://t.co/i9aZ5NbqdJ",2020-06-01
1267456079409152000,https://twitter.com/Oncoinfo_it/status/1267456079409152000,Oncoinfo_it,"#ASCO20 | Presentati due poster interessanti che fanno luce sul rapporto tra biopsia liquida e tissutale: quali le implicazioni cliniche di questi dati, in un’ottica di #PrecisionMedicine? Lo abbiamo chiesto a Fortunato Ciardiello e Nicola Normanno.

https://t.co/ONoYDsNDFP",2020-06-01
1267456058290733067,https://twitter.com/VHIO/status/1267456058290733067,VHIO,"""És la primera vegada que un fàrmac immunoterapèutic administrat en monoteràpia es mostra eficaç com a primera línia en el tractament del #CàncerColorectal""

🗨️Explica @elena_elez del #VHIO-@vallhebron, qui ha participat a l'estudi #KEYNOTE177 

#ASCO20

https://t.co/o2g6LMMMLP https://t.co/daEgKgfVp0",2020-06-01
1267455982315220995,https://twitter.com/urotoday/status/1267455982315220995,urotoday,#JAVELIN Bladder100: Avelumab for previously untreated locally adv or metastatic #UrothelialCarcinoma. @tompowles1 @QMBCI and  @MattGalsky @TischCancer join @CaPsurvivorship @NUFeinbergMed to discuss results released at #ASCO20 virtual scientific program &gt; https://t.co/wQ6RgsQhn9 https://t.co/av2lzCyrDQ,2020-06-01
1267455943178096642,https://twitter.com/AgiosPharma/status/1267455943178096642,AgiosPharma,So inspiring to be part of the #ASCO20 community and continue to find creative ways to advance research even during a global pandemic. https://t.co/GqnK2UnSXm,2020-06-01
1267455890812211201,https://twitter.com/Accuray_Fr/status/1267455890812211201,Accuray_Fr,#Asco2020 : une molécule contre certains #cancers ovariens #CancerOvaire #Hcsmeufr | @scoopit https://t.co/L3Nc7A2Tam,2020-06-01
1267455865491251200,https://twitter.com/EMDOncologyUS/status/1267455865491251200,EMDOncologyUS,"While this year’s #ASCO20 was virtual, it was a reminder to all of us of how vital it is to ensure the #oncology community has access to the most cutting edge scientific results so it can continue to deliver the most up-to-date care to patients around the world. https://t.co/34JQ7ePDMI",2020-06-01
1267455862815285249,https://twitter.com/TakedaOncology/status/1267455862815285249,TakedaOncology,ICYMI: We are invigorated by events where the #cancer community comes together to share how they are working to improve the lives of people with cancer. To learn more about the data we presented at #ASCO20 visit: https://t.co/V073zgLkbj,2020-06-01
1267455623274401794,https://twitter.com/CureMelanoma/status/1267455623274401794,CureMelanoma,Therapeutic agent presented good data when options are limited. A clinical trial at @ASCO (abstract 10006) in patients w/prior treatment w/checkpoint inhibitors &amp; targeted therapy shows a tumor infiltrating lymphocyte(TIL) therapy(lifileucel) holds promise https://t.co/LloSzSVXNE https://t.co/T0mDcBY8Fe,2020-06-01
1267455289621504001,https://twitter.com/Pharmashot/status/1267455289621504001,Pharmashot,"Amgen Reports Clinical Data of AMG 510 in CodeBreaK 100 Study for Multiple Solid Tumors #ASCO20 @AmgenOncology @ASCO 
https://t.co/UV3g2nJVVS https://t.co/UsYjhaXpSn",2020-06-01
1267455169538777096,https://twitter.com/JTrentMDPhD/status/1267455169538777096,JTrentMDPhD,Check out this study by @SylvesterCancer 1st yr fellow @AndreaEspejoMD. Molecular drivers of #sarcoma in 143 #angiosarcoma patients. #immunotherapy #HemOncWomeDocs #WomenInMedicine @OncoAlert #ASCO20 @ASCO @atperez_md @CarmenCalfa @NGoelMD @MKnoll_MD @DrSGraff @ErikaHamilton9 https://t.co/6qX18qWcHh,2020-06-01
1267454636635627527,https://twitter.com/eduhor82/status/1267454636635627527,eduhor82,"#TNT (total neoadjuvant therapy): way forward in #CRCSM 
💫3 RCTs:
1️⃣ #OPRA (phase2): ⬆️OP in RCT+consolidation chemo consolidation vs RCT+Induction chemo

2️⃣ #RAPIDO (phase3):
Lower DrTF and DM &amp; ⬆️ pCR.
💥Practice changing e@rly?

3️⃣ #PRODIGE23 (phase3):⬆️ypCR,DFS&amp;MFS

#ASCO20 https://t.co/LdGdcB2Mc9 https://t.co/EFzgADsQgi",2020-06-01
1267454551709360128,https://twitter.com/realdrgabriel/status/1267454551709360128,realdrgabriel,"SYSUCC-001 trial. Maintanance capecitabine after adjuvant treatment for TNBC. Without OS benefit, there is no place to changing practice. #bcsm #ASCO20",2020-06-01
1267454429449650176,https://twitter.com/n8pennell/status/1267454429449650176,n8pennell,"Very interesting slide on PFS of atezolizumab plus anti-TIGIT Ab tiragolumab in PDL1 &gt;=50%, didn't see much Twitter discussion on this, any thoughts? Obviously larger trial needed but still pretty interesting #ASCO20 #LCSM https://t.co/tNxbZnA5Fm",2020-06-01
1267454165485334529,https://twitter.com/tmprowell/status/1267454165485334529,tmprowell,"As a recipient of an @ASCO Young Investigator Award &gt;15y ago, I’m still paying it back &amp; paying it forward to the next generation of young investigators by donating to @ConquerCancerFd. 

#ASCO20 #MedTwitter #MedStudentTwitter

cc @ASCOPres https://t.co/zWHi7R4ycv",2020-06-01
1267454042927742977,https://twitter.com/Oncoinfo_it/status/1267454042927742977,Oncoinfo_it,"#ASCO20 | Presentati dati importanti su darolutamide nel carcinoma prostatico resistente alla castrazione non metastatico, sia in termini di Metastasis Free Survival che di OS che di safety e QoL. A commentarceli Roberto Iacovelli.

https://t.co/stbvxSz0N4",2020-06-01
1267453990343790594,https://twitter.com/mickgrant/status/1267453990343790594,mickgrant,Excited to see the initial findings from our radiomic classifier of primary #renaltumours; didn't think an idea I dreamt up at the back of the @RoyalFreeLondon sMDT would go to @ASCO conference @tompowles1  https://t.co/3CkF7fd9mT https://t.co/ajiJZyCJIm,2020-06-01
1267453762534285312,https://twitter.com/BentheFidler/status/1267453762534285312,BentheFidler,"#COVID19 could slow progress in reducing #cancer death, NCI head warns https://t.co/mnqJMJEaLS by @NedPagliarulo #ASCO20 @NCIDirector  @theNCI",2020-06-01
1267453568581320705,https://twitter.com/Oncoinfo_it/status/1267453568581320705,Oncoinfo_it,"#ASCO20 | #KEYNOTE189: dati incoraggianti per la lungosopravvivenza dei pazienti trattati in prima linea con #pembrolizumab + chemioterapia. Interessanti soprattutto i dati sui pazienti PD_L1 negativi, perché? Lo abbiamo chiesto a Diego Luigi Cortinovis.

https://t.co/3VqeMdxgod",2020-06-01
1267453382412972033,https://twitter.com/OncLive/status/1267453382412972033,OncLive,"WATCH: @szusmani, of @LevineCancer @AtriumHealth, discusses research with teclistamab (JNJ-64007957) in relapsed/refractory multiple myeloma. @ASCO #ASCO20 #mmsm https://t.co/ENsMcRsXRp",2020-06-01
1267453351656071174,https://twitter.com/GBOT_Alerta/status/1267453351656071174,GBOT_Alerta,"Estudo fase 1 com SAR408701 em CPNPC não escamoso com expressão de CEACAM5 (abstract 9505).
SAR408701 mostrou TR 20,3% nos casos com alta expressão de CEACAM5. 
Estudo de fase 3 de SAR408701 versus docetaxel foi iniciado. @helanofreitas #ASCO20 #GBOT_Alerta https://t.co/RSyBoR7PuR",2020-06-01
1267452967264743436,https://twitter.com/sarojniraula/status/1267452967264743436,sarojniraula,"Recurring dilemma. MA.17 #BCSM was terminated early after interim results. Pts. offered letrozole. Now 17 years later, still unclear if that made women (mostly already cured) live longer/better. Early access important but NEVER at the cost of evidence.#LCSM #ASCO20 @ASCO https://t.co/R6UrqG8e77",2020-06-01
1267452958393982976,https://twitter.com/OncoBiz/status/1267452958393982976,OncoBiz,Filgrastim biosimilar demonstrates cost value in @ASCO ASCO study: https://t.co/SJyjZE5R2V,2020-06-01
1267452921672806411,https://twitter.com/n8pennell/status/1267452921672806411,n8pennell,Don't forget to download the slides of presentations from the #ASCO20 Virtual Meeting! Getting this done now for ASCO reviews. https://t.co/7FHnkKlOTf,2020-06-01
1267452861606232065,https://twitter.com/PortalOnconews/status/1267452861606232065,PortalOnconews,Os resultados de duas coortes do estudo TAPUR fornecem evidências de mundo real para apoiar dados recentes de ensaios clínicos que demonstram o papel do olaparibe no tto de câncer de próstata e pâncreas avançado com mutações BRCA1/2 - https://t.co/LzsPNChz5a @ASCO #ASCO20 https://t.co/zJ2gFkhTuV,2020-06-01
1267452845550428160,https://twitter.com/CRcomment/status/1267452845550428160,CRcomment,Register for @PeerView's #ProstateCancer CME/MOC web broadcast on 6/23 at 7 PM EDT featuring @WilliamOhMD #ASCO20  https://t.co/12ss0On1RE,2020-06-01
1267452134351679488,https://twitter.com/ExactSciences/status/1267452134351679488,ExactSciences,"We relentlessly pursue solutions for detecting the deadliest cancers earlier, including #livercancer. New data at #ASCO20 highlight a robust algorithm based on novel blood-based biomarkers for early-stage #HCC detection. Abstract 4577. Learn more: https://t.co/qvAMGZVbdl https://t.co/EW38whkK91",2020-06-01
1267452075627229185,https://twitter.com/n8pennell/status/1267452075627229185,n8pennell,"Does anyone know what % of pts enrolled on ADAURA had AJCC version 8 stage IB (size 3-4cm?), as opposed to &gt;4cm IB from version 7? Did those have any benefit? If not we can dismiss IB and focus only on treating current v8 stage 2 and 3. @DrRoyHerbstYale #ASCO20 #LCSM https://t.co/2qSf0vM7pb",2020-06-01
1267451873369317376,https://twitter.com/BioWorld/status/1267451873369317376,BioWorld,#ASCO20: Allogene CAR T ‘shelf life’ mulled as early phase I results rival autologous  https://t.co/It5T94mugK,2020-06-01
1267451835121577985,https://twitter.com/ASCOPost/status/1267451835121577985,ASCOPost,"Merry-Jennifer Markham, MD: Perspectives on Three Abstracts From the ASCO Cancer Communications Chair https://t.co/BRHhmocZnY #ASCO20 @DrMarkham #oncology #gyncsm #COVID19 https://t.co/euQO1TqiVI",2020-06-01
1267451815412379649,https://twitter.com/drsomedeb/status/1267451815412379649,drsomedeb,"Thank you @n8pennell for putting forward this important perspective! Any waste is unwelcome, but generalization won’t help us move forward. Excellent thread. #ASCO2020 #osimertinib @kyawzinthein86 @ADesaiMD @SneghaAnanth @ShoMidha https://t.co/7lLGdQ4CeZ",2020-06-01
1267451810555604993,https://twitter.com/phio_pharma/status/1267451810555604993,phio_pharma,At #ASCO2020 Phio presented data that demonstrated that INTASYL compounds are able to overcome the immunosuppressive TME by reprogramming T cells in order to inhibit tumor growth. A poster further detailing the data is available on our website: https://t.co/AXpcbtskym,2020-06-01
1267451625762938880,https://twitter.com/jsromanc/status/1267451625762938880,jsromanc,"yo leyendo los post de los latinos que apoyan a Trump, es más diciendo ""QUE LO AMAN"" WTF.. #ParaguayDoesntSupportTrump #ASCO2020 https://t.co/CESzu4rkRU",2020-06-01
1267451293259489283,https://twitter.com/lymphomahub/status/1267451293259489283,lymphomahub,"Pleased to be recognized as a top influencer during #ASCO20! If you weren’t able to join the ASCO 2020 virtual meeting, visit https://t.co/K9TTapzTnx over the coming days to view our summary articles and virtual expert interviews! #lymsm https://t.co/LVukUDMFdQ",2020-06-01
1267450328577904642,https://twitter.com/MedpageOnco/status/1267450328577904642,MedpageOnco,"Patients with untreated heavily mutated metastatic #colorectalcancer lived twice as long without disease progression when they were treated this way, reported Thierry Andre, MD, of Sorbonne University, at virtual #ASCO20. @ASCO #CRCSM
https://t.co/Hd6STMmGik",2020-06-01
1267449857901391873,https://twitter.com/Pharmashot/status/1267449857901391873,Pharmashot,"AstraZeneca and Daiichi Sankyo Provide Updates of Enhertu (fam-trastuzumab deruxtecan-nxki) in HER2-Positive Metastatic Colorectal Cancer and HER2-Mutant Non-Small Cell Lung Cancer #ASCO20 @AstraZeneca @ASCO 
https://t.co/ukMWYKFZfo https://t.co/SjMNX4tMH6",2020-06-01
1267449844597231619,https://twitter.com/jamienholloway/status/1267449844597231619,jamienholloway,Monday morning quarterbacking continues on ADAURA: this is a great slide from @BenjaminBesseMD of another adjuvant study. OPTIMAL also had compelling DFS (HR 0.19) but OS didn't follow. Wonder if we'll ever get to see the OS for ADAURA... #ASCO20 https://t.co/5XTtVF983c,2020-06-01
1267449824242253825,https://twitter.com/LucenceHealth/status/1267449824242253825,LucenceHealth,THIS WEEK: Join a webinar on #COVID19 &amp; #LungCancer presented by the Singapore Society of Oncology on 6/4 at 5 PM Pacific featuring speakers from @COVID19nCCC and across the globe.  Learn more &amp; register: https://t.co/DnRWExeqfZ #ASCO20 #oncology,2020-06-01
1267449601944162310,https://twitter.com/medtalksgermany/status/1267449601944162310,medtalksgermany,"Zum letzten Mal das #ascodirect Highlight für Sie! Ab 16 Uhr diskutieren internationale Experten mit den Autoren der #asco2020 #practicechanging studies deren Ergebnisse in Hinblick auf Europa.
Auf keinen Fall verpassen! 👉 https://t.co/cO7TV6p60R
#oncology #digitalhealth https://t.co/63neu4zlAK",2020-06-01
1267449328093859840,https://twitter.com/OncologyCentral/status/1267449328093859840,OncologyCentral,Watch our Editors' highlights from #ASCO20 on @OncologyCentral now:,2020-06-01
1267449320267223040,https://twitter.com/trials4now/status/1267449320267223040,trials4now,Helpful place to start: Cancer types in children via @CancerDotNet @ASCO https://t.co/1yrrGPg7iT,2020-06-01
1267448385205948416,https://twitter.com/EBOncology/status/1267448385205948416,EBOncology,"UDPATES w. comment from Dr. Michael Overman of @MDAndersonNews: ""These results should change clinical practice."" #ASCO20 @Merck https://t.co/nPdBDJaqEo",2020-06-01
1267448312619286529,https://twitter.com/PfizerCongress/status/1267448312619286529,PfizerCongress,"While we weren’t able to be together for #ASCO20, we’re proud to continue driving scientific innovation to help people that are living with #cancer. Learn more:",2020-06-01
1267448142255009792,https://twitter.com/Oncoinfo_it/status/1267448142255009792,Oncoinfo_it,[1/4] #ASCO20 #PrecisionMedicine | Plasma-derived cfDNA to reveal potential biomarkers of response prediction and monitoring in non-small cell lung cancer (NSCLC) patients on immunotherapy.,2020-06-01
1267447918300221441,https://twitter.com/BosBizAllison/status/1267447918300221441,BosBizAllison,"... Well, this is a new version of my name. #ASCO20 https://t.co/So611g7pea",2020-06-01
1267447913095081986,https://twitter.com/OncologistTom/status/1267447913095081986,OncologistTom,#ADAURA OS curves are not impressive🤔🤔 #ASCO20 #ASCO https://t.co/BmpukHQ68G,2020-06-01
1267446810689376258,https://twitter.com/bioinformer/status/1267446810689376258,bioinformer,"Incredible paper from @ASCO &gt; ""Clinical evaluation and performance of @QIAGENbiox #Clinical Insight Interpret (QCI-I) as a reporting tool for a comprehensive #cancer panel (#TSO500)."" https://t.co/wnplKUpePl  #oncology #genomics #bioinformatics #diagnostics Snapshot of QCI-I 👇 https://t.co/bchNaEPhIL",2020-06-01
1267446737435795456,https://twitter.com/DagensMedisin/status/1267446737435795456,DagensMedisin,Se livestream kl 17: Kreftleger oppsummerer årets høydepunkter på #ASCO20 https://t.co/tWWTDa64pT,2020-06-01
1267446405595095040,https://twitter.com/subatomicdoc/status/1267446405595095040,subatomicdoc,"Now that #ASCO20 is over and I still haven't seen any answers to my question - I have a breast cancer research idea for a medical oncologist who works well with pathology and surgery. #bcsm
@tmprowell @DrSGraff @NicoleKuderer",2020-06-01
1267446305091129344,https://twitter.com/MoffittNews/status/1267446305091129344,MoffittNews,Dr. Heather Han (@HeatherHan19) presents new data @ASCO Virtual Scientific Program on  a combination therapy in patients with gBRCA-associated advanced breast cancer. View abstract: https://t.co/HcSbwr9Hyu #ASCO20 #BCSM https://t.co/DHT7Gobz8n,2020-06-01
1267445130602176512,https://twitter.com/MedscapeFrance/status/1267445130602176512,MedscapeFrance,"Cancer de la vessie avancé: une immunothérapie en traitement d’entretien améliore la survie, dans l'essai de phase 3 JAVELIN Bladder 100
#ASCO2020 #avelumab
https://t.co/kEBv2AjxlZ",2020-06-01
1267445040273448960,https://twitter.com/ASCOPost/status/1267445040273448960,ASCOPost,HIF2A Inhibitor for von Hippel-Lindau Disease–Associated Renal Cell Carcinoma https://t.co/21g5Bf3clZ #kcsm #oncology #ASCO20,2020-06-01
1267444958958673924,https://twitter.com/MaverickNY/status/1267444958958673924,MaverickNY,"A false dawn or a big win in adjuvant lung cancer for the ADAURA trial at #ASCO20?  
We discussed the controversy with a lung cancer KOL who had some hard hitting and thoughtful comments to share: https://t.co/0HB0p2aa6p https://t.co/9EeUSTBKGh",2020-06-01
1267444171691999232,https://twitter.com/inas_md/status/1267444171691999232,inas_md,Love this discussion by @n8pennell #ASCO20 #LCSM https://t.co/OjMDXJzvhE,2020-06-01
1267444107493937157,https://twitter.com/DrKateAbsolom/status/1267444107493937157,DrKateAbsolom,Very pleased to share the results of our eRAPID eHealth chemotherapy RCT presented by PI Prof Galina Velikova at @ASCO #ASCO20 last week. See abstract: https://t.co/ZOZFoN4tjz video and summary below @LeedsMedHealth @POGWeb @LeedsCTRU @LeedsHospitals https://t.co/6AqLqTsfMB,2020-06-01
1267444003454230531,https://twitter.com/ASCOPost/status/1267444003454230531,ASCOPost,"Michael S. Hofman, MBBS, on Prostate Cancer: LuPSMA vs Cabazitaxel in Metastatic Castration-Resistant Disease https://t.co/dvtJxp42Gj… #pcsm #ASCO20 #oncology @DrMHofman https://t.co/7DtH4BcpV4",2020-06-01
1267443782334722049,https://twitter.com/MedscapePharm/status/1267443782334722049,MedscapePharm,"#ASCO20: When added to standard chemo, a generic PPI demonstrated a higher-than-expected rate of pathologic complete response in TNBC.  https://t.co/CxX7usOuY3",2020-06-01
1267443578449477634,https://twitter.com/dr_jonathant/status/1267443578449477634,dr_jonathant,Enjoyable multidisciplinary deep dive into #rectalcancer trials featured at #ASCO20 https://t.co/NDTDRSpeAS,2020-06-01
1267443530265497600,https://twitter.com/ASCOPost/status/1267443530265497600,ASCOPost,"Michael S. Hofman, MBBS, on Prostate Cancer: LuPSMA vs Cabazitaxel in Metastatic Castration-Resistant Disease https://t.co/vyisMP3i5s #pcsm #ASCO20 #oncology https://t.co/MCRgibVxzx",2020-06-01
1267443379354447872,https://twitter.com/prat_aleix/status/1267443379354447872,prat_aleix,"#ASCO20 DUTRENEO phase II trial led by @drenriquegrande and Paco Real in bladder cancer. Prospective selection of patients in the neoadj. setting using gene signatures is feasible. In this study, mean time from sample receipt until result at our Lab @idibaps: 4.5 working days! https://t.co/ANu8go2gL7",2020-06-01
1267443029973053441,https://twitter.com/MedscapeOnc/status/1267443029973053441,MedscapeOnc,#ASCO20: Improval rate seen in HER2+ breast #cancer patients with brain metastases when given combo drug with tucatinib. https://t.co/8fYAh2kDoc https://t.co/pJ53JK9qhK,2020-06-01
1267442938881114112,https://twitter.com/mydocwire/status/1267442938881114112,mydocwire,#ASCO20: Blood test predicts response to prostate cancer treatment https://t.co/9tNaCAQKoJ,2020-06-01
1267442586471596032,https://twitter.com/_SEOM/status/1267442586471596032,_SEOM,"📡#ASCO20 | La Dra. Claudia Valverde, oncóloga médico del hospital @vallhebron y presidenta del @GrupoGeis, comenta las novedades en sarcomas. 

🎞️ Sus vídeo-píldoras ya están disponibles en nuestra plataforma de formación #OncoNexion. 

🔗 https://t.co/wCdmkxtv0q https://t.co/iHxHcvM8si",2020-06-01
1267441881534865409,https://twitter.com/bradloncar/status/1267441881534865409,bradloncar,Here’s a short video blog about #ASCO20 data that interested me. https://t.co/PNOwQKV2sl,2020-06-01
1267441298325360640,https://twitter.com/outcomes4me/status/1267441298325360640,outcomes4me,"#ASCO2020 Alpelisib Plus Fulvestrant Demonstrates Efficacy in PIK3CA-Mutated, HR+, HER2- Breast Cancer After CDK4/6 Inhibitor https://t.co/ak4H23CyS9",2020-06-01
1267441268868747264,https://twitter.com/Oncoinfo_it/status/1267441268868747264,Oncoinfo_it,[1/4] #ASCO20 #PrecisionMedicine | Characterization of KRAS mutations (mt) in non-small cell lung cancer (NSCLC).,2020-06-01
1267441154368438274,https://twitter.com/outcomes4me/status/1267441154368438274,outcomes4me,"#ASCO2020 new Kisqali analysis in breast cancer
https://t.co/Ov1PBIulx7",2020-06-01
1267441075523895296,https://twitter.com/n8pennell/status/1267441075523895296,n8pennell,"The IB in ADAURA I think is from AJCC version 7, so in practice now we would really only be talking about stage 2 and 3 (former &gt;4cm IBs now are all stage 2). #ASCO20 #LCSM https://t.co/2qSf0vM7pb",2020-06-01
1267441045668847618,https://twitter.com/healthhashtags/status/1267441045668847618,healthhashtags,Today's Health Conferences: #ASCO20 #ATC2020Virtual #ASNR20 #EAS2020 https://t.co/YnZewsLKhm #hcsm,2020-06-01
1267441013783552002,https://twitter.com/ASCOPost/status/1267441013783552002,ASCOPost,Tepotinib Shows Activity in Patients With NSCLC and MET Exon 14–Skipping Mutation https://t.co/rwFuq8SQIh #oncology #LCSM #ASCO20,2020-06-01
1267440936805699585,https://twitter.com/urotoday/status/1267440936805699585,urotoday,#TERAVOLT – Thoracic Cancers International #COVID19 Collaboration: impact of #cancer therapy and COVID-19 therapy on survival. Presented by @HornLeora @VUMChealth. #ASCO20 coverage by @GoldbergHanan @UpstateNews on UroToday &gt; https://t.co/FYSOmidCNc @ASCO https://t.co/KpkOX8Bodf,2020-06-01
1267440855939534854,https://twitter.com/ASCO_pubs/status/1267440855939534854,ASCO_pubs,"Carfilzomib, Bortezomib Combinations Yield Equivalent PFS in Newly Diagnosed Myeloma: The ENDURANCE Trial https://t.co/CCTnB0AnpX #ASCODailyNews #MMSM #ASCO20 #LBA https://t.co/r9NJta355O",2020-06-01
1267440814663311362,https://twitter.com/LillyMedical/status/1267440814663311362,LillyMedical,"Hey #ASCO20, thanks for the great virtual conversations. Don’t forget that the Lilly Medical team is available to continue answering your questions and engaging with you! https://t.co/lrGWgajAXO #WeAreLilly https://t.co/fHZ9sc5z9V",2020-06-01
1267440807297966081,https://twitter.com/Roche/status/1267440807297966081,Roche,"At #ASCO20 participants discuss the latest #science to achieve progress for patients under the motto “Unite and Conquer; Accelerating Progress Together”. Listen to why Levi Garraway, Chief Medical Officer &amp; Head of Global Product Development, is committed to conquering #cancer. https://t.co/ceamlVDXV9",2020-06-01
1267440765799501831,https://twitter.com/VHIO/status/1267440765799501831,VHIO,"#VHIO's @judithbalmana presented the progress of the phase IIIB study #LUCY at #ASCO20 @ASCO 

The results confirm that #olaparib is safe and effective as a monotherapy in patients with metastatic #BreastCancer

Read more here 👇
https://t.co/jTkDoRIEPW https://t.co/TCH4czmS2L",2020-06-01
1267440637034606593,https://twitter.com/Adaptimmune/status/1267440637034606593,Adaptimmune,Thank you @ASCO for a successful virtual #ASCO20 meeting during these challenging times. Our team enjoyed connecting with everyone and we look forward to seeing everyone in person next year! https://t.co/OhAu3uAgEC,2020-06-01
1267440028365586432,https://twitter.com/n8pennell/status/1267440028365586432,n8pennell,"THREAD: I have heard a lot of self-righteous indignation about how we would be bankrupting the system with adjuvant targeted treatment for EGFR mutation+ NSCLC pts, so let's take a quick look at how many pts we're talking about here to put this in perspective. #ASCO20 #LCSM 1/8",2020-06-01
1267439624504344576,https://twitter.com/Charbel_matar1/status/1267439624504344576,Charbel_matar1,Nice summary of yesterday's breast plenary session! #ASCO20 https://t.co/h3UySaH2By,2020-06-01
1267439603272880129,https://twitter.com/Oncoinfo_it/status/1267439603272880129,Oncoinfo_it,"#ASCO20 #PrecisionMedicine | A multi-stakeholder platform to prospectively link longitudinal real-world clinico-genomic, imaging, and outcomes data for patients with metastatic lung cancer. https://t.co/WRmH9fuxA0",2020-06-01
1267439537002774528,https://twitter.com/OncologyTimes/status/1267439537002774528,OncologyTimes,ASCO NEWS: Read the Latest on Metastatic #Colorectal Cancer from #ASCO20 https://t.co/capXBGcnbj #medtwitter #chemotherapy #mondaythoughts https://t.co/r1rxpaC8tO,2020-06-01
1267439536373665792,https://twitter.com/OncEd/status/1267439536373665792,OncEd,"In this video update during #ASCO20, Dr. Nirav Shah provides the results of autologous transplantation in relapsed diffuse large B-cell #lymphoma in patients achieving only a PET/CT positive partial remission in the CAR-T cell era: https://t.co/Xlo7ktsp2s https://t.co/nePyLjSCcG",2020-06-01
1267439450113654791,https://twitter.com/cellectis/status/1267439450113654791,cellectis,"Positive initial results from the Phase 1 ALPHA trial in R/R NHL for Cellectis’ first licensed allogeneic product candidate, ALLO-501(UCART19), presented at @ASCO #ASCO2020. Congratulations to our partners @AllogeneTx &amp; @Servier $CLLS https://t.co/JyiDjjh0zu",2020-06-01
1267439317154246658,https://twitter.com/Oncoinfo_it/status/1267439317154246658,Oncoinfo_it,"#ASCO20 | @OmidHamidMD, Director of Immunotherapy and Translational Research at The Angeles Clinic and Research Institute, Los Angeles, give us an overview of the most interesting astracts on immunotherapy and #melanoma presented at @ASCO.

https://t.co/q8qnF22uCh",2020-06-01
1267438918284333057,https://twitter.com/EuroImmunoOnc/status/1267438918284333057,EuroImmunoOnc,Impact of previous nephrectomy on clinical outcome of metastatic renal carcinoma treated with #ImmunoOncology (IO): A real-world study on behalf of Meet-URO group (MeetUro-7b): https://t.co/KD9CiWkCS6 @JCO_ASCO @ASCO #oncology,2020-06-01
1267438832598867974,https://twitter.com/Oncoinfo_it/status/1267438832598867974,Oncoinfo_it,[1/5] #ASCO20 #PrecisionMedicine | Primary adult retroperitoneal sarcoma (RS): Comprehensive genomic profiling (CGP) study.,2020-06-01
1267438599701762048,https://twitter.com/KidneyCancer/status/1267438599701762048,KidneyCancer,"We gathered a few #kidneycancer research highlights from @ASCO #ASCO20 in this blog post: https://t.co/WXSwfNGddS 

Let us know what your highlights were too and what they mean for people heading to their in-person or virtual appointments. #UnstoppableTogether https://t.co/i8TsJVKvbl",2020-06-01
1267438289054830592,https://twitter.com/OncLive/status/1267438289054830592,OncLive,"Relugolix demonstrated superiority over leuprolide in sustained testosterone-suppression through 48 weeks, fast T-recovery after discontinuation, and a 50% reduction in MACE in patients with advanced prostate cancer. @ASCO #ASCO20 #pcsm https://t.co/bwFkrgbbLh",2020-06-01
1267438245664583680,https://twitter.com/ASCOPost/status/1267438245664583680,ASCOPost,"Fatima Cardoso, MD, on Breast Cancer: MammaPrint as Guidance for Adjuvant Chemotherapy https://t.co/UJIzoHwgL1 #ASCO20 #bcsm #oncology https://t.co/n3r97PNyge",2020-06-01
1267437375082369024,https://twitter.com/Oncoinfo_it/status/1267437375082369024,Oncoinfo_it,[1/5] #ASCO20 #PrecisionMedicine | Utility of circulating cell-free DNA (cfDNA) analysis in patients with carcinoma of unknown primary (CUP) in identifying alterations with strong evidence for response or resistance to targeted therapy.,2020-06-01
1267437288440696834,https://twitter.com/ASCO/status/1267437288440696834,ASCO,📌Save the date for #ASCO20 Virtual Ed Program: August 8-10 https://t.co/EvbgU72ZSF,2020-06-01
1267436336933474312,https://twitter.com/ebrsonline/status/1267436336933474312,ebrsonline,"RAPIDO: improvements in pCR and composite outcome of disease-related treatment failure

But, at what cost? @DrGarciaAguilar stresses need to consider similar OS, increase 3+ AEs, and quality of TME specimen

@ahmerkarimuddin @amirbastawrous @drcarl_vancouvr @_CSSO #ASCO20 https://t.co/05OA79ivml",2020-06-01
1267436001020055552,https://twitter.com/Oncoinfo_it/status/1267436001020055552,Oncoinfo_it,[1/5] #ASCO20 #PrecisionMedicine | Clinically advanced renal cell carcinoma (RCC) and renal sarcoma (RSC) in young patients: A comprehensive genomic profiling (CGP) study.,2020-06-01
1267435717552152578,https://twitter.com/ASCOPost/status/1267435717552152578,ASCOPost,Geriatric Assessment–Driven Intervention Benefits Older Adults With Cancer https://t.co/aPzw3jjV9t #ASCO20 #gerionc #oncology,2020-06-01
1267435683121070082,https://twitter.com/FernandoOnco/status/1267435683121070082,FernandoOnco,"1/2 #ASCO20 some studies with complex statistical designs to prove a benefit with little clinical significance, others with a primary outcome perhaps not as appropriate but with impressive HR... @OncoAlert",2020-06-01
1267435276026155009,https://twitter.com/CharuAggarwalMD/status/1267435276026155009,CharuAggarwalMD,"Yesterday, we saw impressive DFS HR of 0.17 for adjuvant osimertinib in pts with Stage II-IIIA, and 0.21 including IB #NSCLC #ADAURA

It's now post #ASCO20 Monday Morning, would you prescribe osi for:

@JackWestMD @n8pennell @StephenVLiu @LeciaSequist @Jbauml @HosseinBorghaei",2020-06-01
1267434780691439617,https://twitter.com/Martha__Carlson/status/1267434780691439617,Martha__Carlson,If you benefited from all the people sharing important cancer info from the virtual #ASCO20 take a minute to donate $5 (or more) for their @ConquerCancerFd https://t.co/GdIuRa0vLa,2020-06-01
1267434647644000256,https://twitter.com/Oncoinfo_it/status/1267434647644000256,Oncoinfo_it,[1/5] #ASCO20 #PrecisionMedicine | Clinically aggressive malignancies associated with STK11 germline mutations (STK11GCa): A comprehensive genomic profiling (CGP) study.,2020-06-01
1267434434388770821,https://twitter.com/MM_Oncology/status/1267434434388770821,MM_Oncology,#ASCO20 video: We spoke to Seema Khan (@NorthwesternMed) about their phase 3 study of locoregional therapy for stage IV #BreastCancer – click through to WATCH the interview #bcsm @eaonc https://t.co/lQQq8HD1Hu,2020-06-01
1267434081500884992,https://twitter.com/marklewismd/status/1267434081500884992,marklewismd,"Now our challenge is to make sure our MSS patients don’t become the girl in blue

Eyes on the prize, which is helping ALL those affected by colorectal cancer

#crcsm
#ASCO20 https://t.co/vh7MzbRT1X",2020-06-01
1267433902026764292,https://twitter.com/pashtoonkasi/status/1267433902026764292,pashtoonkasi,#ASCO20 Top #NeuroendocrineTumor 📝 #Carcinoid https://t.co/IfksdQMKLS,2020-06-01
1267433897488527365,https://twitter.com/Oncoinfo_it/status/1267433897488527365,Oncoinfo_it,"#ASCO20 | Importanti novità sul trattamento del carcinoma renale, in particolare sull’impiego di #pembrolizumab in diverse combinazioni per diversi setting di malattia. Abbiamo chiesto un commento a Giuseppe Procopio, @IstTumori.

https://t.co/2Chogq2E75",2020-06-01
1267433792484098048,https://twitter.com/360DxNews/status/1267433792484098048,360DxNews,"A study presented at @ASCO showed that the test could benefit the decision-making process for younger patients in need of neoadjuvant therapy, which could lead to an expanded use of the test @ExactSciences 
https://t.co/nHzP3NxmKQ",2020-06-01
1267433739845500929,https://twitter.com/esragbilir/status/1267433739845500929,esragbilir,"Thank you all for supporting 💜#goASCO20 

🟣during #ASCO20 @ASCO Promote &amp; Raise Awareness #GynecologicOncology study

Congrats to our team of GynecologicOncologists
@Bhandoria 🇮🇳 
@ChristinaUwins 🇬🇧 
@ilkerselcukmd🇹🇷 https://t.co/gdfPtd4Bci",2020-06-01
1267433683386073088,https://twitter.com/Oncoinfo_it/status/1267433683386073088,Oncoinfo_it,[1/5] #ASCO20 #PrecisionMedicine | Early plasma circulating tumor DNA (ctDNA) changes to predict response to first-line pembrolizumab +/- chemotherapy in non-small cell lung cancer (#NSCLC).,2020-06-01
1267433218363572224,https://twitter.com/_SEOM/status/1267433218363572224,_SEOM,"📡#ASCO20 | La Dra. Elena Castro analiza los highlights en cáncer genitourinario (próstata). 

🎞️ Sus vídeo-píldoras ya están disponibles en nuestra plataforma de formación #OncoNexion. 

🔗 https://t.co/wCdmkxtv0q https://t.co/jPsBAn9N0a",2020-06-01
1267432802712158219,https://twitter.com/EBOncology/status/1267432802712158219,EBOncology,UPDATES #ADAURA results w. discussant saying he'd give #Tagrisso to his family #ASCO20 https://t.co/nfqTonLZZM,2020-06-01
1267432793174241280,https://twitter.com/saluteh24com/status/1267432793174241280,saluteh24com,"Leiomiosarcoma, i risultati del trattamento in prima linea per trabectedina con doxorubicina #ASCO20 https://t.co/bBYnPzyqXZ",2020-06-01
1267432792461205504,https://twitter.com/salutedomani/status/1267432792461205504,salutedomani,"Leiomiosarcoma, i risultati del trattamento in prima linea per trabectedina con doxorubicina #ASCO20 https://t.co/AYteHHJyOu",2020-06-01
1267432790871531520,https://twitter.com/antoniocaperna/status/1267432790871531520,antoniocaperna,"Leiomiosarcoma, i risultati del trattamento in prima linea per trabectedina con doxorubicina #ASCO20 https://t.co/7mwiTpfoxV",2020-06-01
1267432788745019392,https://twitter.com/dermanewsok/status/1267432788745019392,dermanewsok,"Leiomiosarcoma, i risultati del trattamento in prima linea per trabectedina con doxorubicina #ASCO20 https://t.co/07DA0IeWcL",2020-06-01
1267432487040548864,https://twitter.com/davisa20/status/1267432487040548864,davisa20,"No broadcast sessions today but #asco20 isn’t over.  All that great content is still available for you to view anytime at https://t.co/wfKE7dIBaZ. And we aren’t done yet,  there is even more great content planned for the virtual education program Aug. 8-10. https://t.co/604WR7OPtw",2020-06-01
1267432453607735296,https://twitter.com/_SEOM/status/1267432453607735296,_SEOM,"📡#ASCO20 | El Dr. Mariano Ponz, de la @ClinicaNavarra,  comenta el desarrollo terapéutico de terapias dirigidas y biología tumoral (no inmuno). 

🎞️ Sus vídeo-píldoras ya están disponibles en nuestra plataforma de formación #OncoNexion. 

🔗 https://t.co/wCdmkxtv0q https://t.co/Epocv8uLHr",2020-06-01
1267432443092623363,https://twitter.com/hopkinskimmel/status/1267432443092623363,hopkinskimmel,".@ValsamoA reviews her presentation of 'Integrated Tumor and Immune Cell Multiomic Analyses Predict ICB Response in Advanced #Melanoma' from #ASCO2020.

Click here to learn more: https://t.co/NUxTxMrhxT

https://t.co/YwVcCCzgBU",2020-06-01
1267432420179087360,https://twitter.com/DrGarciaAguilar/status/1267432420179087360,DrGarciaAguilar,"The RÁPIDO trial; not so fast. Similar overall survival, inferior local tumor control, more 3+ AEs, less intact TME specimens, longer hospital stay, more medication. What do patients have to gain? What about WW?#ASCO20 #ASCOTotalHealth https://t.co/TFwJOmxXdL",2020-06-01
1267432372527661056,https://twitter.com/Oncoinfo_it/status/1267432372527661056,Oncoinfo_it,[1/5] #ASCO20 #PrecisionMedicine | Association of BRCA alteration (alt) type with real-world (RW) outcomes to PARP inhibitors (PARPi) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).,2020-06-01
1267432359537848321,https://twitter.com/tolomeocaramia/status/1267432359537848321,tolomeocaramia,#GI #oncologists #mcrc #ASCO20 https://t.co/lna4wF8lCK,2020-06-01
1267431645805764609,https://twitter.com/EmilyMackler/status/1267431645805764609,EmilyMackler,"Congratulations @shannonmhough and the @UMRogelCancer oncology pharmacy team regarding this incredible work on utilizing PROs for targeted management of CINV! 
#oncopharm #oncologyquality #ASCO20 https://t.co/lUWL2Qctsb",2020-06-01
1267431459075371008,https://twitter.com/VivekSubbiah/status/1267431459075371008,VivekSubbiah,Dr. @OncHahn is a 1st year Hem/Onc Fellow at @CancerMedMDA @MDAndersonNews. He presented --&gt; Phase I clinical trials as a therapeutic option for pts w metastatic #renal cell #Cancer @ASCO #ASCO20. Fantastic work &amp; bright future ahead w @oalhalabimd. 👏   https://t.co/IsHWuFnxQU https://t.co/fYHdRN0u3C,2020-06-01
1267431174609285120,https://twitter.com/VPwnd_fan/status/1267431174609285120,VPwnd_fan,INTRODUCING: my new podcast “Poster Sesh”!! every week on the pod I will gleefully tear apart trainee research with a particular focus on masters’ thesises and medical school summer projects  #ASCO20,2020-06-01
1267430837110308869,https://twitter.com/Oncoinfo_it/status/1267430837110308869,Oncoinfo_it,"[1/4] #ASCO20 #PrecisionMedicine | Contrasting genomic profiles in post-systemic treatment metastatic sites (MET), pretreatment primary tumors (PT), and liquid biopsies (LB) of clinically advanced prostate cancer (PC).",2020-06-01
1267430625201414145,https://twitter.com/SUTOUHA/status/1267430625201414145,SUTOUHA,#ASCO20 を眺めてて、遺伝子検査はどう対応するかなぁと考えていた,2020-06-01
1267430553399070722,https://twitter.com/gulleyj1/status/1267430553399070722,gulleyj1,Looking forward to opening this #COVID-19 in #Cancer patient study in the @NCIResearchCtr and @NIHClinicalCntr https://t.co/EgSFZD8oJk Our own @FatimaKarzai will be the site PI. #ASCO20 https://t.co/EqYjAzmOLn,2020-06-01
1267430028872163328,https://twitter.com/salutedomani/status/1267430028872163328,salutedomani,"Leiomiosarcoma, i risultati del trattamento in prima linea per trabectedina con doxorubicina #ASCO20 https://t.co/iYOuDxBNBM",2020-06-01
1267429802505637889,https://twitter.com/IllinoisBiotech/status/1267429802505637889,IllinoisBiotech,The latest Daily News Brief - iBIO! https://t.co/7PZN43EVWd Thanks to @IAmBiotech @NorthwesternEng #asco20 #pandemic,2020-06-01
1267429747136610306,https://twitter.com/rteston/status/1267429747136610306,rteston,#ASCO20 Capri : un dispositif de télémédecine pour le cancer https://t.co/CtDEeF73gW #hcsmeufr #esante https://t.co/gnAnWX3Vrb,2020-06-01
1267429692568670210,https://twitter.com/MDedgeHemOnc/status/1267429692568670210,MDedgeHemOnc,"“Neoadjuvant therapy downstages the tumor and improves the rate of breast conserving surgery,” Dr. Cynthia X. Ma said at @ASCO's virtual scientific program. https://t.co/fxfFmL1WiJ https://t.co/7PmdIlMfkn",2020-06-01
1267429689154433026,https://twitter.com/JCOG_official/status/1267429689154433026,JCOG_official,"#ASCO20 - JCOG1711「漿膜下浸潤及び漿膜浸潤を伴う進行胃癌を対象とした大網切除に対する大網温存の非劣性を検証するランダム化比較第III相試験」現在登録中です。

#JCOG 抄録はこちらからご覧ください
https://t.co/TwadpK7E6z",2020-06-01
1267429437810905094,https://twitter.com/JCOG_official/status/1267429437810905094,JCOG_official,"Check out this #ASCO20 abstract: “Randomized phase III trial to evaluate omentum preserving gastrectomy for patients with resectable advanced gastric cancer: JCOG1711 (ROAD-GC)” was activated in March 2019.
View #JCOG Abstract: https://t.co/TwadpJQ3f1",2020-06-01
1267428908082835458,https://twitter.com/LecointreRomain/status/1267428908082835458,LecointreRomain,How are you preparing for #ASCO2020 ? Les collaborateurs de @GSK répondent dans cette série de vidéo #cancer #congres https://t.co/F5rixPgNyp,2020-06-01
1267428838062952449,https://twitter.com/oncologician/status/1267428838062952449,oncologician,"Attending #ASCO20 meeting is like visiting a Zara store .You go in ,like something, ask the cost and come out without buying anything (Courtesy - @venkymd ) https://t.co/20afyEyJYE https://t.co/BtfcrBwF3K",2020-06-01
1267428704021630976,https://twitter.com/VincentRK/status/1267428704021630976,VincentRK,#ASCO20 Top Myeloma abstracts. https://t.co/OgWyMQo1EY,2020-06-01
1267428224419627008,https://twitter.com/TheCancerLetter/status/1267428224419627008,TheCancerLetter,.@OtisBrawley: #ASCO20 #CCC19 data suggests that that elective surgery does not put patients at increased risk of adverse outcomes if infected with #COVID19 postoperatively. —https://t.co/jtOy4DEEXr https://t.co/OM0MMw2WQm,2020-06-01
1267428198016528384,https://twitter.com/FundacionECO/status/1267428198016528384,FundacionECO,"👉 Accede ya al programa de ONCOFIR Best of ASCO
Un repaso de las novedades terapéuticas que se presentarán en el #ASCO20 y el conocimiento médico más actualizado en Oncología
📅 Curso virtual disponible a partir del 15 de junio 
https://t.co/gMg0vgf8qb 
@oncofir @sefh_",2020-06-01
1267427795967324160,https://twitter.com/FarmaciaHums/status/1267427795967324160,FarmaciaHums,Interesantes resultados en #SesionPlenaria #ASCO2020 https://t.co/A3LqDW4VQM,2020-06-01
1267427675754450945,https://twitter.com/JCOG_official/status/1267427675754450945,JCOG_official,"#ASCO20 - JCOG0912：臨床病期I期胃癌に対する術後QoLは再建法に依存しないが、患者報告による下痢、便秘、逆流は再建法によって異なる可能性あり

#JCOG 抄録はこちらからご覧ください
https://t.co/rmw5qIMNtZ",2020-06-01
1267427424125550594,https://twitter.com/JCOG_official/status/1267427424125550594,JCOG_official,"In #ASCO20, HRQoL assessment in JCOG0912, a phase III noninferiority trial of open vs. laparoscopic distal gastrectomies for stage I gastric cancer, concluded global health status scores were similar regardless of the reconstruction procedure.
#JCOG https://t.co/rmw5qIMNtZ",2020-06-01
1267426942539595776,https://twitter.com/CancerNetwrk/status/1267426942539595776,CancerNetwrk,"Data from the COVID-19 and Cancer Consortium registry, presented at @ASCO, reported how the COVID-19 pandemic has impacted patients with cancer thus far.
https://t.co/4veHt5jwfk https://t.co/kvcK1fGzRx",2020-06-01
1267426178232512512,https://twitter.com/Pharmashot/status/1267426178232512512,Pharmashot,"AstraZeneca Reports Results of Tagrisso (osimertinib) in P-III ADAURA Study for EGFR-Mutated Lung Cancer #ASCO20
@AstraZeneca @ASCO 
https://t.co/BtyYCv2hUw https://t.co/0y37DYd2Bp",2020-06-01
1267425914402586625,https://twitter.com/JCOG_official/status/1267425914402586625,JCOG_official,"#ASCO20 - JCOG0502副次的解析：ヨード不染帯のある臨床病期Ⅰ期食道癌患者は二次がん発症リスクが高い傾向を示す

#JCOG 抄録はこちらからご覧ください
https://t.co/lyHW0sZbCy",2020-06-01
1267425733124796416,https://twitter.com/salutedomani/status/1267425733124796416,salutedomani,TUMORE DEL POLMONE NON A PICCOLE CELLULE: OK OSIMERTINIB N PAZIENTI IN STADIO IB-IIIA POSITIVI ALLA MUTAZIONE DI EGFR #ASCO20 https://t.co/7r2ysRJQTr,2020-06-01
1267425663742509058,https://twitter.com/JCOG_official/status/1267425663742509058,JCOG_official,"In #ASCO20, supplementary analysis of JCOG0502 concluded the presence of lugol-voiding lesions in esophagus was identified as an independent predictive factor for second primary malignancies and may be useful for surveillance.
View #JCOG Abstract: https://t.co/lyHW0sZbCy",2020-06-01
1267424656086032384,https://twitter.com/JCOG_official/status/1267424656086032384,JCOG_official,"#ASCO20 - JCOG0909最終解析：臨床病期II/III（T4を除く）食道癌に対する根治的化学放射線療法 +/- 救済治療は許容範囲の毒性と良好な5年生存割合を示す

#JCOG 抄録はこちらからご覧ください
ttps://meetinglibrary.asco.org/record/186429/abstract",2020-06-01
1267424404184526849,https://twitter.com/JCOG_official/status/1267424404184526849,JCOG_official,"In #ASCO20, JCOG0909 concluded the combined modality of definitive chemoradiotherapy with salvage treatment showed acceptable toxicities, favorable 5-yr survival, and promising esophageal preservation for clinical stage II/III esophageal carcinoma.
#JCOG https://t.co/ag1ou3Mk8t",2020-06-01
1267424222806265856,https://twitter.com/pashtoonkasi/status/1267424222806265856,pashtoonkasi,#ASCO20 👇🏼Important topic for advocacy for today 🗓 🧬 https://t.co/GiL3ztbQzT,2020-06-01
1267423166919557123,https://twitter.com/OncLive/status/1267423166919557123,OncLive,Treatment with pembrolizumab induced a 4.9-month progression-free survival benefit over brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma. @pmcancercentre @ASCO #ASCO20 #lymsm https://t.co/kRsanYPTnD,2020-06-01
1267423153351020545,https://twitter.com/diariomedico/status/1267423153351020545,diariomedico,¿Cuál es el impacto de la #COVID19 en los pacientes con #cancer? Dos estudios presentados en #ASCO20 lo analizan Lo cuenta @Isagponce aquí  https://t.co/UtwX3Tkb82 https://t.co/w4E9w1dCXm,2020-06-01
1267422561459212292,https://twitter.com/jamienholloway/status/1267422561459212292,jamienholloway,Important thoughts from a lung cancer patient as we continue to consider what #ADAURA means for patients. #ASCO20 #LCSM https://t.co/2tyHBizuFU,2020-06-01
1267422268734550019,https://twitter.com/mrsphjohnson/status/1267422268734550019,mrsphjohnson,"Thanks for summarizing main points under the headlines about this study. For us lay people LRT, local regional therapy, is surgery and/or radiation. The study was just on de novo MBC, prople whose breast cancer had already spread at diagnosis. #MBC #ASCO2020 https://t.co/AqR4Tpo9ue",2020-06-01
1267422139574968320,https://twitter.com/JCOG_official/status/1267422139574968320,JCOG_official,"#ASCO20 - JCOG1311：IVB期および再発・増悪・残存子宮頸癌に対するdose-dense パクリタキセル + カルボプラチン ± ベバシズマブ 併用療法は通常のパクリタキセル + カルボプラチン ± ベバシズマブ 併用療法に対して有効性示せず

#JCOG 抄録はこちらからご覧ください
https://t.co/jbPjPCVMX1",2020-06-01
1267421887543599104,https://twitter.com/JCOG_official/status/1267421887543599104,JCOG_official,"In #ASCO20 presentation, JCOG1311 concluded the study did not meet the primary endpoint (response rate) of phase II, and dose-dense weekly paclitaxel plus carboplatin is not promising for metastatic or recurrent cervical carcinoma. 
View #JCOG Abstract: https://t.co/jbPjPCEc5t",2020-06-01
1267421407581024261,https://twitter.com/AtlantaIp2/status/1267421407581024261,AtlantaIp2,Exciting times -&gt; IP2-ATLANTA Trial Research Fellow @Connor_Urol is presenting our initial experiences at #ASCO20 #ASCO2020 - Great work from all our collaborators @wellcometrust @LondonProstate1 @timdudderidge @KamalThippu @ImperialSandC @RDsouthampton @ImperialNHS @IP_London https://t.co/JfClilH1a6,2020-06-01
1267421093431840769,https://twitter.com/Pharmafocus/status/1267421093431840769,Pharmafocus,Gilead's magrolimab shows promising responses in untreated myelodysplastic syndrome and acute myeloid leukaemia at #ASCO2020 https://t.co/mzwcSTZiII #pharma https://t.co/aVFMEmsFG0,2020-06-01
1267420669588930560,https://twitter.com/Elmedicoint/status/1267420669588930560,Elmedicoint,"#Industria |  #Janssen presenta datos prometedores en cáncer de próstata y mieloma múltiple durante #ASCO 2020 #cáncerdepróstata #mielomemúltiple #ASCO2020 @ASCO @JanssenESP 
https://t.co/MNm3jOvI4w",2020-06-01
1267420524285755395,https://twitter.com/VivekSubbiah/status/1267420524285755395,VivekSubbiah,"Anaplastic #thyroidcancer, #glioblastoma or leptomeningeal disease have few effective treatment options : https://t.co/cbuLN3T8IF @GlitzaMDPhD @CrisyRoland @DrMCabanillas have designed trials for these tough cancers #ASCO20 @asco",2020-06-01
1267419773899550725,https://twitter.com/ipreeshagul/status/1267419773899550725,ipreeshagul,"While #ASCO2020 was very different this year, I still left the plenary with that same motivation to improve, hope for our patients and desire to contribute to science. 
I joined many others and donated to @ConquerCancerFd . 
Come join me @kaushalpar @NagashreeSeeth1 @Rajvi_P https://t.co/UVs2hVUI65",2020-06-01
1267419732174688257,https://twitter.com/pashtoonkasi/status/1267419732174688257,pashtoonkasi,#ASCO20 #CRCSM #Immunotherapy https://t.co/QBLO3RmAtT,2020-06-01
1267419622699159552,https://twitter.com/JCOG_official/status/1267419622699159552,JCOG_official,"#ASCO20 口演発表 – JCOG1205/1206：高悪性度神経内分泌肺癌完全切除例に対するイリノテカン+シスプラチン療法はエトポシド+シスプラチン療法と比較して無再発生存期間改善せず

#JCOG 抄録はこちらからご覧ください
https://t.co/DV35UewVOz",2020-06-01
1267419506231607297,https://twitter.com/VivekSubbiah/status/1267419506231607297,VivekSubbiah,Palliative &amp; supportive care interventions increase comfort in advanced cancer patients @CancerMedMDA @IshwariaMD @ASCO #ASCO20 https://t.co/hZPL7OmUqe,2020-06-01
1267419389822939136,https://twitter.com/ESMO_Open/status/1267419389822939136,ESMO_Open,"How we treat patients with #lungcancer during the #SARS-CoV-2 pandemic: primum non nocere #ASCO20 ESMO - European Society for Medical Oncology 

https://t.co/Vuv6wZaw6V",2020-06-01
1267419371208663040,https://twitter.com/JCOG_official/status/1267419371208663040,JCOG_official,"In #ASCO20 oral presentation, JCOG1205/1206 concluded the study failed to show the superiority of IP to EP in RFS for pts with completely resected HGNEC, and EP is still a standard treatment for this population.
View #JCOG Abstract: https://t.co/DV35UewVOz",2020-06-01
1267419296969490432,https://twitter.com/Tres_Prima/status/1267419296969490432,Tres_Prima,"Este fin de semana ha tenido lugar el congreso @ASCO; por primera vez, se celebró en formato virtual a causa de la pandemia del #COVID19 . Los asistentes pudieron disfrutar de las diferentes conferencias, así como  de un entorno virtual generado. #ASCO20 . Próximamente @_SEOM https://t.co/kxD646bVq2",2020-06-01
1267419053431443456,https://twitter.com/VivekSubbiah/status/1267419053431443456,VivekSubbiah,Updated targeted therapy clinical trials results continue to show improved outcomes for advanced colorectal and bladder cancers  @asco #ASCO20 https://t.co/TtpQPOJfzY,2020-06-01
1267418563284877317,https://twitter.com/Pharmashot/status/1267418563284877317,Pharmashot,"Seattle Genetics Report Updated Results of Tukysa (tucatinib) in HER2CLIMB Study for Patients With HER2-Positive Breast Cancer with Stable or Active Brain Metastases #ASCO20 @SeattleGenetics @ASCO 
https://t.co/e12I9BRLS0 https://t.co/TT9GdXv2Er",2020-06-01
1267418239266684934,https://twitter.com/ecancer/status/1267418239266684934,ecancer,"#ASCO20: Special report provides guidance to oncology practices on resuming cancer care during COVID-19 pandemic.
Read more here: https://t.co/M51w6B0dMm
#COVID19 #CancerCare #Oncology #Coronavirus https://t.co/BYtHMog0RV",2020-06-01
1267418184279302144,https://twitter.com/CanUrolAssoc/status/1267418184279302144,CanUrolAssoc,"Tonight ▶️ Join us for Canadian Highlights from #ASCO2020! Tune in: https://t.co/6gIkD9EcDV 
#UroSoMe #bladdercancer #kidneycancer #prostatecancer https://t.co/VL6BK2Jd0t",2020-06-01
1267418177715277824,https://twitter.com/CatalentPharma/status/1267418177715277824,CatalentPharma,Join Catalent as we provide opening remarks and sponsor a panel discussion for the @ASCO Postview where industry experts will break down the biggest data that came out from ASCO’s virtual conference. Register here: https://t.co/R67QN8XYUl,2020-06-01
1267418149441409024,https://twitter.com/onmedicanews/status/1267418149441409024,onmedicanews,The first ever pilot in the UK by @ICR_London suggests genetic screening for #prostatecancer in #GP surgeries could be possible: https://t.co/eDktzA0mdW #ASCO2020 #doctors #joinonmedica,2020-06-01
1267417106028658691,https://twitter.com/JCOG_official/status/1267417106028658691,JCOG_official,"#ASCO20 口演発表 - JCOG1306：高悪性度非円形細胞肉腫に対するゲムシタビン+ドセタキセル療法による術前・術後補助化学療法は、アドリアマイシン+イホスファミド療法と比較して全生存期間劣る

#JCOG 抄録はこちらからご覧ください
https://t.co/zBoTTLOsUh",2020-06-01
1267416854408069120,https://twitter.com/JCOG_official/status/1267416854408069120,JCOG_official,"In #ASCO20 oral presentation, JCOG1306 concluded AI remains the standard regimen in the perioperative Cx for high-grade STS in the extremities and trunk, because non-inferiority of GD to AI was not confirmed although the toxicities were modest in GD. #JCOG
https://t.co/zBoTTLOsUh",2020-06-01
1267416800683327488,https://twitter.com/CharuAggarwalMD/status/1267416800683327488,CharuAggarwalMD,"A small group of us got together @ASCO to ride together @onepeloton virtually. Next year, let’s make it bigger and make it a way to support @ConquerCancerFd #ASCO20 

Who’s in? 

cc: @Rfonsi1 @ggreen1986 @NarjustDumaMD @DrChoueiri @AngieDemichele https://t.co/9aX0zJG7jR",2020-06-01
1267415387576156160,https://twitter.com/KickBrainTumors/status/1267415387576156160,KickBrainTumors,🙌🏽2️⃣0️⃣2️⃣0️⃣ #ASCO2020 https://t.co/3RVivLLp6I,2020-06-01
1267415055458537472,https://twitter.com/MOCBrasil/status/1267415055458537472,MOCBrasil,"ASCO 2020 - Live sobre Pulmão e Medicina de Precisão - 1º/06 às 18:30

#MOCnaASCO #ASCO2020 #ASCO #LCSM #lungcancer @CarolinaKHaddad @camillayamada @FabioSchutz78 @rcarvalhoonco @thiagoonco 
https://t.co/HozNy1jrp6",2020-06-01
1267414589458825218,https://twitter.com/JCOG_official/status/1267414589458825218,JCOG_official,"#ASCO20 口演発表 – JCOG1114C：初発中枢神経系原発悪性リンパ腫に対する照射前大量MTX療法後のTMZ併用放射線療法＋維持TMZ療法は、照射前大量MTX療法＋放射線治療に対して全生存期間改善せず

#JCOG 抄録はこちらからご覧ください
https://t.co/PAEqYCZjws",2020-06-01
1267414533745901569,https://twitter.com/ecancer_espanol/status/1267414533745901569,ecancer_espanol,"El Dr. Javier Cortés habla con ecancer sobre el estudio KEYNOTE-355 que presentó en la reunión virtual ASCO 2020.
#ASCO20 #ecancer #VirtualConference 
https://t.co/UYzhGAQEuQ",2020-06-01
1267414405706285057,https://twitter.com/medicalnewser/status/1267414405706285057,medicalnewser,"Merck KGaA and Pfizer's Bavencio (avelumab) Demonstrates the Potential in Gestational Trophoblastic Tumors #ASCO20, 

Shots:

The P-II study involves assessing of Bavencio in 15 women (median age 34yrs.) with GTT that are resistant to... ,https://t.co/sSzAgnqYzo https://t.co/vhLmO2kFs3",2020-06-01
1267414351201394689,https://twitter.com/msdsalute/status/1267414351201394689,msdsalute,"MSD è da sempre accanto alle persone affette da melanoma.
Grazie alla ricerca, sono stati fatti enormi progressi nella cura del #melanoma #ASCO20 #VinciamoControilCancro",2020-06-01
1267414338073059328,https://twitter.com/JCOG_official/status/1267414338073059328,JCOG_official,"In #ASCO20 oral presentation, JCOG1114C concluded the study failed to demonstrate the benefit of the addition of TMZ to WBRT and adjuvant TMZ in newly diagnosed primary central nervous system lymphoma.
View #JCOG Abstract: https://t.co/PAEqYCHI7S",2020-06-01
1267413079651803137,https://twitter.com/NEJM/status/1267413079651803137,NEJM,Read new research studies published in NEJM and presented at the ASCO Annual Meeting. #ASCO20,2020-06-01
1267412776105934848,https://twitter.com/pastanaga/status/1267412776105934848,pastanaga,"Aunque no es lo mismo que estar Chicago, siempre es un reto emocionante cubrir el congreso de la ASCO. Os dejo mi último artículo, recién publicado, por si fuera de vuestro interés #ASCO2020 #Cancer #Oncología https://t.co/2cvAdQzZRf",2020-06-01
1267412540545478658,https://twitter.com/tompowles1/status/1267412540545478658,tompowles1,All you wanted to know about FGFR in bladder cancer but were afraid to ask. Jonathan Rosenberg @DrRosenbergMSK gives a fantastic overview. #ASCO2020 https://t.co/Pe3xFbyph8,2020-06-01
1267412384483860482,https://twitter.com/StephenVLiu/status/1267412384483860482,StephenVLiu,"Powerful figure from @BenjaminBesseMD provides balance to #ADAURA post #ASCO20 - even a profound improvement in DFS/PFS does not guarantee OS benefit, particularly if relapse/progression can be successfully treated with effective agents in later lines. #OncoAlert #LCSM https://t.co/0SSvAlIu87",2020-06-01
1267412073048420352,https://twitter.com/JCOG_official/status/1267412073048420352,JCOG_official,"#ASCO20 口演発表 - JCOG0603：大腸癌肝転移切除後患者を対象としたmFOLFOX6は無病生存期間改善するも全生存期間は劣る傾向

#JCOG 抄録はこちらから
https://t.co/nhYiMcLiBy",2020-06-01
1267411873667796993,https://twitter.com/dermanewsok/status/1267411873667796993,dermanewsok,LINFOMA DI HODGKIN CLASSICO: SUPERIORITA' DI PEMBROLIZUMAB SULLO STANDARD DI CURA BRENTUXIMAB VEDOTIN #ASCO20 https://t.co/ljnJEeoJPa,2020-06-01
1267411872174665731,https://twitter.com/saluteh24com/status/1267411872174665731,saluteh24com,LINFOMA DI HODGKIN CLASSICO: SUPERIORITA' DI PEMBROLIZUMAB SULLO STANDARD DI CURA BRENTUXIMAB VEDOTIN #ASCO20 https://t.co/EsNKHq7AwL,2020-06-01
1267411870413058050,https://twitter.com/salutedomani/status/1267411870413058050,salutedomani,LINFOMA DI HODGKIN CLASSICO: SUPERIORITA' DI PEMBROLIZUMAB SULLO STANDARD DI CURA BRENTUXIMAB VEDOTIN #ASCO20 https://t.co/YgrRCa6prq,2020-06-01
1267411868030603268,https://twitter.com/antoniocaperna/status/1267411868030603268,antoniocaperna,LINFOMA DI HODGKIN CLASSICO: SUPERIORITA' DI PEMBROLIZUMAB SULLO STANDARD DI CURA BRENTUXIMAB VEDOTIN #ASCO20 https://t.co/o10bMwaw9H,2020-06-01
1267411821712957440,https://twitter.com/JCOG_official/status/1267411821712957440,JCOG_official,"In #ASCO20 oral presentation, JCOG0603 concluded adjuvant mFOLFOX is not beneficial to pts after hepatectomy for liver only mets from colorectal cancer, based on the result of adjuvant mFOLFOX improving DFS but worsening OS over surgery alone.
#JCOG https://t.co/nhYiMctHcY",2020-06-01
1267411094118830082,https://twitter.com/salutedomani/status/1267411094118830082,salutedomani,LINFOMA DI HODGKIN CLASSICO: SUPERIORITA' DI PEMBROLIZUMAB SULLO STANDARD DI CURA BRENTUXIMAB VEDOTIN #ASCO20 https://t.co/7FSYe5iqPr,2020-06-01
1267410969862553601,https://twitter.com/salutedomani/status/1267410969862553601,salutedomani,"CORONAVIRUS, “COOPERAZIONE FRA ONCOLOGI DI TUTTO IL MONDO SUI FATTORI DI RISCHIO PIÙ DECESSI NEI PAZIENTI CON CANCRO DEL POLMONE, SOLO L’8% IN RIANIMAZIONE” #ASCO20 https://t.co/JHM7CzVFf4",2020-06-01
1267410800588869632,https://twitter.com/institut_curie/status/1267410800588869632,institut_curie,"#ASCO20 ⚗️ Depuis le 29 mai, les plus grands experts de la #cancérologie participent à la conférence virtuelle de l'@ASCO. Les projets innovants portés par nos médecins et chercheurs 👨‍⚕️👩‍🔬 y sont présentés à cette occasion.

➕ d'informations ➡️ https://t.co/kR1YOv63su https://t.co/8s6LzsEeoQ",2020-06-01
1267410785069871106,https://twitter.com/MM_Oncology/status/1267410785069871106,MM_Oncology,#ASCO20: IMvigor010 trial did not show improved disease-free survival with adjuvant #atezolizumab versus observation for muscle-invasive #UrothelialCarcinoma says Maha Hussain (@LurieCancer) @uroupdate @ASCO https://t.co/Fm9aRSVD1C,2020-06-01
1267410621156528128,https://twitter.com/MerckHealthcare/status/1267410621156528128,MerckHealthcare,"While this year’s #ASCO20 was virtual, it was a reminder to all of us of how vital it is to ensure the #oncology community has access to the most cutting edge scientific results so it can continue to deliver the most up-to-date care to patients around the world. https://t.co/XjaazIxxXa",2020-06-01
1267409877128880128,https://twitter.com/n8pennell/status/1267409877128880128,n8pennell,Already missing #ASCO20? There is still plenty of time to donate to @ConquerCancerFd! https://t.co/Otn8tSf1u7,2020-06-01
1267409109139156992,https://twitter.com/JCOG_official/status/1267409109139156992,JCOG_official,"#ASCO20 口演発表 – JCOG1008：局所進行頭頸部扁平上皮癌術後の再発ハイリスク患者に対する術後補助化学放射線療法はweeklyシスプラチンが3-weeklyシスプラチンに対して利便性があり全生存期間も劣らない

#JCOG 抄録はこちらからご覧ください
https://t.co/WGis8iIMfe",2020-06-01
1267408530136608769,https://twitter.com/GBOT_Alerta/status/1267408530136608769,GBOT_Alerta,JCOG1205/06: cisp/irinotecano (IP) x Cisp/etoposídeo (EP) em carcinomas neuroendócrinos (SCLC e LCNEC) adjuvante. Com seguimento de 24.1 meses SLD 3 a 65.4% (EP) vs 69.0% (IP)  (HR -1.07) e SG 3 a de 84.1% (EP) vs 79.0% (IP) - (HR 1.54) #ASCO20 #GBOT_Alerta por Carlos Teixeira https://t.co/KjPnwxdlG1,2020-06-01
1267408063981641730,https://twitter.com/OncLive/status/1267408063981641730,OncLive,Mirvetuximab soravtansine in combination with bevacizumab to treat patients with platinum-agnostic ovarian cancer demonstrated encouraging ORRs regardless of platinum status with a favorable tolerability profile. @ASCO #ASCO20 #gyncsm https://t.co/RBPNyfmzqN,2020-06-01
1267408063683792896,https://twitter.com/NCRI_partners/status/1267408063683792896,NCRI_partners,"The NCRI #HeadNeck_Group supported the development of this research idea and the trial was developed by #NCRI_CTRad. Result were presented by @DrChrisNutting at #ASCO20. 
https://t.co/dLkRPBNTfi",2020-06-01
1267407904870551552,https://twitter.com/dr_jonathant/status/1267407904870551552,dr_jonathant,"A #RadBio conundrum for #radonc in the wake of #ASCO20:

Preop 5 x 5Gy = 50Gy chemoRT 
for stage II/III #rectalcancer 🤔

(equiv local control in 4 RCTs: Polish I/II, TROG, RAPIDO)

This is best explained by:",2020-06-01
1267407262747951104,https://twitter.com/FedericaIacono5/status/1267407262747951104,FedericaIacono5,"Clinical activity of Pralsetinib in Ret fusion positive solid tumors 
#OncoAlert
#ASCO2020 https://t.co/XtLWDrgp9t",2020-06-01
1267407125384437760,https://twitter.com/salutedomani/status/1267407125384437760,salutedomani,"Chemo Within 3 Months of coronavirus COVID-19 Diagnosis Associated With an Increased Risk of Death in Patients With Thoracic Cancer #ASCO20
https://t.co/btxCecnl2X",2020-06-01
1267406911143661574,https://twitter.com/salutedomani/status/1267406911143661574,salutedomani,Early Data Show Cancer Progression Associated With Increased Risk of Death in Patients With coronavirus COVID-19 #ASCO20 https://t.co/MX3WIXmXu0,2020-06-01
1267406429176033280,https://twitter.com/AnthonyMJoshua/status/1267406429176033280,AnthonyMJoshua,"Very proud to say I am only now catching up on the plenary- maybe next year we can do plenary at 10pm EST so its 1pm here.
#ASCO20 #15hrsaheadofCST #iwasntupat4am #aussiescatchingup",2020-06-01
1267404491420295168,https://twitter.com/salutedomani/status/1267404491420295168,salutedomani,"Report, proteggere medici e pazienti in tempo di coronavirus Covid-19 #ASCO20 https://t.co/gRuq2r5T2J",2020-06-01
1267404282682359809,https://twitter.com/ESMO_Open/status/1267404282682359809,ESMO_Open,"How we treat patients with #lungcancer during the #SARS-CoV-2 pandemic ESMO - European Society for Medical Oncology #ASCO20

https://t.co/eqrkxJ2sSB",2020-06-01
1267404121683853312,https://twitter.com/Pharmashot/status/1267404121683853312,Pharmashot,"Merck KGaA and Pfizer’s Bavencio (avelumab) Demonstrate the Potential in Gestational Trophoblastic Tumors #ASCO20 @merckgroup @pfizer @ASCO 
https://t.co/OJWdPh7ZMW https://t.co/DzVlT0fGoq",2020-06-01
1267403935947673600,https://twitter.com/sergio_crispino/status/1267403935947673600,sergio_crispino,"Everett E. Vokes, MD, FASCO, Elected ASCO President for 2021-2022 Term | ASCO I’m really happy! @esmo @aiom @asco ⁦@eupatientsforum⁩ ⁦⁦@Europarl_EN⁩ ⁦@EUScienceInnov⁩ ⁦@EU_Health⁩ ⁦⁩ ⁦@cipomo⁩ ⁦⁦@ESTRO_RT⁩  https://t.co/FzcBdrrasW",2020-06-01
1267403779374268416,https://twitter.com/_SEOM/status/1267403779374268416,_SEOM,"📡#ASCO20 | La Dra. Charo García Campelo (@charocampelo) comenta las novedades sobre cáncer de pulmón metastásico de célula no pequeña. 

🎞️ Sus vídeo-píldoras ya están disponibles en nuestra plataforma de formación #OncoNexion. 

🔗 https://t.co/wCdmkxtv0q https://t.co/mtjavUBkp6",2020-06-01
1267403717231419392,https://twitter.com/GBOT_Alerta/status/1267403717231419392,GBOT_Alerta,"ECOG-ACRIN 5162: osimertinibe 160mg/d em EGFR ins20 (n=21),  taxa de resposta de 24% (objetivo=30%). SLP de 9,6meses, controle de doença de 82% e boa tolerância. @dramilenamak #ASCO20 #GBOT_Alerta https://t.co/rGrOCGBHdr",2020-06-01
1267403577078710278,https://twitter.com/BTOGORG/status/1267403577078710278,BTOGORG,If you didn't catch the #ASCO20 virtual meeting don't worry - we're bringing you all the #thoraciconcology highlights in our webinar Asco in an Hour. Register to join us on Thursday 4 June https://t.co/KK0k0DeRwG #BTOGASCO20 https://t.co/sX5lAM8N3O,2020-06-01
1267403057513496576,https://twitter.com/msdsalute/status/1267403057513496576,msdsalute,In Italia i tumori del colon retto rappresentano la 3° neoplasia negli uomini (14%) e la seconda nelle donne (12%) per incidenza #ASCO20 #VinciamoControilCancro,2020-06-01
1267402756253458432,https://twitter.com/PharmaLeader1/status/1267402756253458432,PharmaLeader1,#ASCO2020 #ASCO20 #oncology https://t.co/fuN8sNPS6t,2020-06-01
1267402590641369088,https://twitter.com/PharmaLeader1/status/1267402590641369088,PharmaLeader1,#ASCO2020 #oncology #asco20 https://t.co/8PmbVf5kd5,2020-06-01
1267402427965288448,https://twitter.com/SalemGIOncDoc/status/1267402427965288448,SalemGIOncDoc,#ASCO20 virtual meeting is over. I found it to be an excellent meeting with many practice changing #clinicaltrials particularly in #GI #Cancers #colorectalcancer. Thanks to everyone who made it possible and made it happen during #COVID19 &amp; big thanks to the #ASCO team and staff!! https://t.co/xZXdUOEYs8,2020-06-01
1267402396411494400,https://twitter.com/PharmaLeader1/status/1267402396411494400,PharmaLeader1,#ASCO2020 #ASCO20 #oncology https://t.co/iJAEbTeSC5,2020-06-01
1267401775998545920,https://twitter.com/medtalksgermany/status/1267401775998545920,medtalksgermany,"Ein letztes Mal präsentieren Ihnen unsere Faculties ab 13 Uhr die Highlights des #asco2020 und diskutieren diese in einer anschließenden Expertenrunde. Alle 14 Tracks parallel, live und kostenfrei!
Für Sie bei #ascodirect 👉 https://t.co/0NpJwhHzVm
#oncology #digitalhealth https://t.co/dJEPf63jy5",2020-06-01
1267401640455405568,https://twitter.com/ActaSanitaria/status/1267401640455405568,ActaSanitaria,Nuevos datos de @PhrmMar sobre trabectedina y doxorubicina en #leiomiosarcomas #ASCO20 - https://t.co/HQ0HwV091U https://t.co/g1ugRZ8tag,2020-06-01
1267401312091725824,https://twitter.com/MM_Oncology/status/1267401312091725824,MM_Oncology,#ASCO20 video: WATCH @DrChoueiri (@DanaFarber) discuss the initial FRACTION-RCC findings for #nivolumab plus #ipilimumab in treatment-refractory patients with advanced #RCC @uroupdate @DanaFarberNews https://t.co/42NqxPNAjt,2020-06-01
1267401089068007426,https://twitter.com/FunchainMD/status/1267401089068007426,FunchainMD,"Important patient-centered points here on the 52% 5 yr RFS with adjuvant dabrafenib + trametinib in #melanoma presented at #ASCO20

-increased cure
-only 1 yr of treatment 
-the chance to have children https://t.co/TiWsr7pL7Q",2020-06-01
1267398612239122433,https://twitter.com/_SEOM/status/1267398612239122433,_SEOM,"📡#ASCO20 | El Dr. Ignacio Romero analiza los highlights sobre cáncer ginecológico.

🎞️Sus vídeo-píldoras ya están disponibles en nuestra plataforma de formación #OncoNexion. 

🔗https://t.co/wCdmkxtv0q https://t.co/YUmLpMiQrF",2020-06-01
1267397204307857408,https://twitter.com/VHIO/status/1267397204307857408,VHIO,"Imnunoterapia en solitario contra el #CáncerColorrectal 

El estudio #KEYNOTE177, en el que ha participado @elena_elez del #VHIO-@vallhebron, se encuentra entre los estudios más relevantes del #ASCO20

Por @anasoti vía @efesalud
https://t.co/Lu6699JdQh",2020-06-01
1267397157864144896,https://twitter.com/ForgioneAu/status/1267397157864144896,ForgioneAu,I’m pleased to see that the role of #advocates in clinical trial design is finally taking the stage at #ASCO20. Many patients suffer immensely from “tolerable” TRAEs. https://t.co/Qym5uTcoRD,2020-06-01
1267395465802330112,https://twitter.com/INCa_veillePro/status/1267395465802330112,INCa_veillePro,#OncoActu les news du jour en oncologie dans le monde anglophone - Spécial #ASCO20 https://t.co/ACl7WT9Isw https://t.co/csj4c0GIfW,2020-06-01
1267395279319437312,https://twitter.com/royalmarsdenNHS/status/1267395279319437312,royalmarsdenNHS,"A combination of two immunotherapy drugs, ipilimumab and nivolumab, has stopped or reversed the progression of advanced #melanoma in some patients with mucosal melanoma for five years, according to a study co-led by @royalmarsdenNHS : https://t.co/ZSY55993P1 #ASCO20 https://t.co/ngPe9lsgED",2020-06-01
1267394631278395392,https://twitter.com/subatomicdoc/status/1267394631278395392,subatomicdoc,"That feeling just before #ASCO20 got started?
@VivekSubbiah @tmprowell @DrChoueiri https://t.co/mr7F8TNDfJ",2020-06-01
1267394033464336384,https://twitter.com/sanofi/status/1267394033464336384,sanofi,"As #ASCO20 comes to a close, we feel inspired by the impactful data presented at the meeting. Our ambition is to contribute meaningful solutions for people battling cancer, and we work every day to achieve this goal. https://t.co/ev0swF9pNt",2020-06-01
1267394004414369793,https://twitter.com/1stOncology/status/1267394004414369793,1stOncology,#NRGOncology reported Combined #Cediranib and #Olaparib Presents Similar Activity to Standard of Care Treatment for Platinum-Sensitive #OvarianCancer #ASCO20 https://t.co/9FkrVW2eNI,2020-06-01
1267393892971839494,https://twitter.com/Marzia_Del_Re/status/1267393892971839494,Marzia_Del_Re,"Impressive data from #KEYNOTE177 - 1st line #IO is #SOC in #MSI-H #mCRC.
Intriguing data in the #KRASmut subgroup. Is #KRAS the new #biomarker for #immunotherapy #resistance?? 😩 #ASCO20 🎯 https://t.co/EVVTzAfFsN",2020-06-01
1267393791058677760,https://twitter.com/AstraZenecaFR/status/1267393791058677760,AstraZenecaFR,"L'ambition d'@AstraZeneca en tant qu'acteur en #oncologie est de contribuer à redéfinir le traitement et la prise en charge des patients atteints de cancer. Nos 98 abstracts acceptés lors de cet #ASCO20, dont une session plénière aujourd'hui, témoignent de cet engagement. https://t.co/dAegStZqvF",2020-06-01
1267393717473701888,https://twitter.com/1stOncology/status/1267393717473701888,1stOncology,#CarisLifeSciences Showcases Data on #KRASMutations in Patients With #NonSmallCellLung and #PancreaticCancer at #ASCO20 Virtual Scientific Program https://t.co/HfFYnG64ly,2020-06-01
1267393510090567683,https://twitter.com/1stOncology/status/1267393510090567683,1stOncology,#Gracell Announces Two Presentations at the Annual Meeting of #ASCO20 https://t.co/7KVrF1Xq75,2020-06-01
1267393401948745728,https://twitter.com/1stOncology/status/1267393401948745728,1stOncology,"#COTA, Inc. Announces Participation in #ASCO20 and #DIA20 Virtual Global Annual Meeting https://t.co/d2qRgtWsCz",2020-06-01
1267393391865794563,https://twitter.com/ilpensiero/status/1267393391865794563,ilpensiero,"Su @Oncoinfo_it continuano gli aggiornamenti con news, interviste, commenti degli esperti, webinar in diretta da #ASCO20.

Clicca qui per accedere allo speciale 👇🏽
https://t.co/L49uxRbllh",2020-06-01
1267393216363458561,https://twitter.com/1stOncology/status/1267393216363458561,1stOncology,#ToleroPharmaceuticals Presents Findings from First Clinical Studies Evaluating Investigational Agents #TP1287 and #TP3654 in Patients with Advanced #SolidTumors at #ASCO20 https://t.co/0PaepJZO63,2020-06-01
1267392998230261760,https://twitter.com/1stOncology/status/1267392998230261760,1stOncology,#Agendia Announces Data Presented at #ASCO20 Demonstrating Importance of Further Classification of #BreastCancers to Enable Precise Prognosis and Treatment https://t.co/CHsluIQ76Q,2020-06-01
1267392965665849344,https://twitter.com/OncLive/status/1267392965665849344,OncLive,"The allogeneic CAR T-cell therapy ALLO-501, paired with the monoclonal antibody ALLO-647, has clinical activity and a manageable safety profile in patients with relapsed/refractory large B-cell or follicular lymphoma. @MDAndersonNews @ASCO #ASCO20 #lymsm https://t.co/VJ9bV9gDvL",2020-06-01
1267392818856640513,https://twitter.com/1stOncology/status/1267392818856640513,1stOncology,#Amgen Presents New #AMG510 Clinical Data Across Multiple #SolidTumors During #ASCO20 Virtual Scientific Program $AMGN https://t.co/RApKgDFSeM,2020-06-01
1267392808593260544,https://twitter.com/Oncoinfo_it/status/1267392808593260544,Oncoinfo_it,"#ASCO20 | Il modello di cure palliative e oncologiche integrate per i pazienti con #LMA sottoposti a chemioterapia intensiva ha portato a miglioramenti sostanziali nella qualità di vita, nei disagi psicologici e nelle cure per il fine vita.

https://t.co/PVbWJhHfyc",2020-06-01
1267392626161926144,https://twitter.com/1stOncology/status/1267392626161926144,1stOncology,#Libtayo® (#Cemiplimab-rwlc) Longer-term Results in Advanced #CutaneousSquamousCellCarcinoma Presented at #ASCO20 Show Durable Responses that Deepen Over Time $REGN https://t.co/z1iw1IbuTx,2020-06-01
1267392360456941568,https://twitter.com/1stOncology/status/1267392360456941568,1stOncology,#Medicenna Updates Efficacy Results from Phase 2b Recurrent #GBM Trial at #ASCO20 $MDNA https://t.co/gOU01nQ0it,2020-06-01
1267392170287263744,https://twitter.com/1stOncology/status/1267392170287263744,1stOncology,"#Medicenna Presents Data on #MDNA11, an #IL2Superkine at #ASCO20 $MDNA https://t.co/DQHteYK7uY",2020-06-01
1267391960714670080,https://twitter.com/1stOncology/status/1267391960714670080,1stOncology,"#Janssen Highlights Innovative #Oncology Portfolio and Pipeline of Oral, Biologic and Cell Therapies Through #ASCO20 Virtual Scientific Program $JNJ https://t.co/yjelBhK0Uv",2020-06-01
1267391788001619969,https://twitter.com/1stOncology/status/1267391788001619969,1stOncology,Data Affirming #Biocept's Target #Selector™ Platform Identifies #Cancer Mutations in Cerebrospinal Fluid Presented at #ASCO20 Virtual Scientific Program $BIOC https://t.co/2YZ4lUyoVW,2020-06-01
1267391630887223296,https://twitter.com/Oncoinfo_it/status/1267391630887223296,Oncoinfo_it,"#ASCO20 | Si è rilevata la tendenza a offrire le cure palliative a chi usufruisce di un’assicurazione privata o di Medicaid, rispetto a chi è assicurato da Medicare. Ancora, si è notata una differenza raziale nel ricorso ai servizi di cure palliative.

https://t.co/vobrT3X6Tm",2020-06-01
1267391600176447488,https://twitter.com/1stOncology/status/1267391600176447488,1stOncology,#CardiffOncology Data Continues to Demonstrate Efficacy of #Onvansertib in Patients with #KRASMutated Metastatic #ColorectalCancer Presented at #ASCO20 $CRDF https://t.co/kanXbruhA3,2020-06-01
1267391430500118529,https://twitter.com/Urooologist/status/1267391430500118529,Urooologist,"#ASCO20
泌尿器領域のplenary session
転移性尿路上皮癌に対して1st line治療が効いた後、経過観察→増悪してから治療介入するよりアベルマブのメンテナンス治療したほうがOS、PFSともに延長した
増悪後2nd lineでI-Oが入った症例も43%含まれる

GC後はすぐにI-Odrug入れるべきなのか… https://t.co/fgzrxXCKLR",2020-06-01
1267391247368380416,https://twitter.com/1stOncology/status/1267391247368380416,1stOncology,"#Eisai Announces Updated Results of #ENHANCE1, a Phase 1b/2 Trial Investigating #HALAVEN® (#EribulinMesylate) plus #KEYTRUDA® (#Pembrolizumab) in Patients with Metastatic Triple-Negative #BreastCancer at #ASCO20 https://t.co/ouMUvEo9UY",2020-06-01
1267391079374041088,https://twitter.com/Oncoinfo_it/status/1267391079374041088,Oncoinfo_it,"#ASCO20 | Meno della metà dei pazienti oncologici riceve cure che seguono le linee guida concordate dal @NCCN e la mortalità specifica della malattia cresce a motivo di questa mancanza.

https://t.co/u3tT3fuyNM",2020-06-01
1267390972725350401,https://twitter.com/1stOncology/status/1267390972725350401,1stOncology,#Amphivena Presents Data from First-in-Human Study of #AMV564 in #SolidTumor Patients at the #ASCO20 https://t.co/KAqp71Kqqt,2020-06-01
1267390405386973185,https://twitter.com/1stOncology/status/1267390405386973185,1stOncology,"(#ASCO20) #AscentagePharma Presents Latest Clinical Data of #Apoptosis Targeting Drug Candidates, Showing Promising Clinical Effects with Combination Therapies https://t.co/vFp1BsMLGp",2020-06-01
1267390208078561280,https://twitter.com/1stOncology/status/1267390208078561280,1stOncology,#TaihoOncology Announces Presentation of Data for Futibatinib in Advanced #Intrahepatic #Cholangiocarcinoma at #ASCO20 https://t.co/IEW2MC1VUN,2020-06-01
1267389637921816576,https://twitter.com/Oncoinfo_it/status/1267389637921816576,Oncoinfo_it,"#ASCO20 | Secondo l’analisi delle app sul mercato correlate all’oncologia sono poche quelle aggiornate e di alta qualità; l’analisi ha anche rimarcato la considerevole assenza di stakeholder-chiave in oncologia nello sviluppo delle app.

https://t.co/iwyKEQQSR4",2020-06-01
1267389241027211264,https://twitter.com/1stOncology/status/1267389241027211264,1stOncology,#CityOfHope Physicians Present Innovative #Cancer Research at #ASCO20 Virtual Session https://t.co/xnMTgGuwli,2020-06-01
1267389086039339008,https://twitter.com/Pharmashot/status/1267389086039339008,Pharmashot,"Takeda to Present Results of Iclusig (ponatinib) in P-II OPTIC Study for Chronic Myeloid Leukemia in the Chronic Phase at ASCO and EHA #ASCO20 @TakedaPharma @ASCO 
https://t.co/4vDae1GsoG https://t.co/2d4VRll1yC",2020-06-01
1267388529442557953,https://twitter.com/1stOncology/status/1267388529442557953,1stOncology,Results from #LENVIMA® (#Lenvatinib) plus #KEYTRUDA® (#Pembrolizumab) Trials in Unresectable #HepatocellularCarcinoma and Advanced #RenalCellCarcinoma to be Presented at #ASCO20 https://t.co/t0E93AO7Nf,2020-06-01
1267387914276810752,https://twitter.com/VHIO/status/1267387914276810752,VHIO,"Les investigadores del #VHIO @EnriquetaFelip @evamuco i @elena_elez anuncien en #ASCO20 els avanços de les seves investigacions sobre
 
🔹Immunoteràpia en el càncer de pulmó
🔹Personalització del tractament del melanoma
🔹Prevenció del burnout
 
Més info👇
https://t.co/xKrNfAbAzm https://t.co/nz4WyPssXh",2020-06-01
1267387424851791872,https://twitter.com/WebTarged/status/1267387424851791872,WebTarged,#ASCO2020 'nin İkinci Günü için Canlı Yayındayız! https://t.co/T32dMWIwTX https://t.co/n3GzU4Q4g1,2020-06-01
1267387185046511616,https://twitter.com/1stOncology/status/1267387185046511616,1stOncology,#ChiMed to Discuss Select Global Clinical Trial Data Presented at #ASCO20 $HCM https://t.co/RUt6wGicIj,2020-06-01
1267387038426267649,https://twitter.com/1stOncology/status/1267387038426267649,1stOncology,#MarkerTherapeutics Reports Interim Results of its #MultiTAASpecific #TCellTherapy in Patients with #PancreaticAdenocarcinoma at #ASCO20 $MRKR https://t.co/qZ9TfSrIkg,2020-06-01
1267386748931203074,https://twitter.com/1stOncology/status/1267386748931203074,1stOncology,#TGTherapeutics Announces Final Results of the #GENUINE Phase 3 Study Evaluating #Ublituximab plus #Ibrutinib in Previously Treated High-Risk #ChronicLymphocyticLeukemia at #ASCO20 https://t.co/bwwv7F1hrg,2020-06-01
1267386701925752833,https://twitter.com/Oncoinfo_it/status/1267386701925752833,Oncoinfo_it,"#ASCO20 | Presentati i dati aggiornati dello studio registrativo di Fase III #ALEX: aumenta la percentuale di sopravvivenza a 5 anni con #alectinib rispetto a #crizotinib, in pazienti affetti da carcinoma polmonare non a piccole cellule (#NSCLC) ALK+.

https://t.co/p71ARPh1w0",2020-06-01
1267386356554256384,https://twitter.com/MM_Hub/status/1267386356554256384,MM_Hub,"Delighted to be recognized as a top influencer! Thank you 
@ASCO for delivering an excellent meeting yet again! If you were not able to join the #ASCO20 Annual Meeting online, visit https://t.co/SACgsPLy5p over the coming days for a full, comprehensive coverage! #mmsm https://t.co/NTv712uW9T",2020-06-01
1267386216493834240,https://twitter.com/pharma_jonpi/status/1267386216493834240,pharma_jonpi,PharmaMar Presents Promising Trabectedin and Doxorubicin Data at ASCO . #ASCO20 #yondelis #pharmamar https://t.co/mEpiugjzk2,2020-06-01
1267384819442487296,https://twitter.com/Oncoinfo_it/status/1267384819442487296,Oncoinfo_it,#ASCO20 | The @OmidHamidMD's key message from @ASCO 2020. https://t.co/pndRNCKfXU,2020-06-01
1267384201210400768,https://twitter.com/msdsalute/status/1267384201210400768,msdsalute,MSD è impegnata a fianco delle persone con tumore del rene #KidneyCancer #ASCO20 #VinciamoControilCancro https://t.co/4hN37Dxr6M,2020-06-01
1267383094446866432,https://twitter.com/dr_turk/status/1267383094446866432,dr_turk,"Great to see our work on the DEBIOC trial samples presented @ASCO

We performed bioinformatic analysis using @AlmacGroup claraT assay to discover effects of @AstraZeneca drug AZD8931 (Sapitinib) in #oesophageal #cancer

Much more work to do on this! 

https://t.co/8S46mDomy3",2020-06-01
1267382899852050433,https://twitter.com/NCRI_partners/status/1267382899852050433,NCRI_partners,"Look back at some of the NCRI Group research that was selected for presentation at #ASCO20 https://t.co/Jn9VpjkCrZ 
https://t.co/J7CAVCXUf8",2020-06-01
1267382880608501760,https://twitter.com/EvaluateJP/status/1267382880608501760,EvaluateJP,"2026年に405億ドルを超えると予測されるNSCLCは、固形がんの2大適応症の1つであり、#ASCO2020 の主要な話題の1つだ。2026年にこの領域でAZは115億ドルを占め、その大部分がTagrissoとImfinziによる貢献である。

詳細はこちら：https://t.co/EHgx9ae523

#エバリュエート #Evaluate #NSCLC #oncology",2020-06-01
1267377254675480576,https://twitter.com/AML_Hub/status/1267377254675480576,AML_Hub,"If you missed our coverage of the #ASCO20 virtual meeting, visit our Twitter moment for the latest developments in the field❗️ #leusm
⚡️ “American Society of Clinical Oncology virtual meeting - ASCO20” by @AML_Hub https://t.co/m6XL8mfsJj",2020-06-01
1267376817381367808,https://twitter.com/Prof_IanD/status/1267376817381367808,Prof_IanD,#INTEGERATE #ASCO20 #gerionc https://t.co/COmsRy9Gqb,2020-06-01
1267376033755475968,https://twitter.com/fransvanworkum/status/1267376033755475968,fransvanworkum,Fantastic job by @VerstegenMoniek presenting results of the ICAN randomized controlled trial this weekend at @ASCO: Intrathoracic versus Cervical ANastomosis after MIE. Better outcome for intrathoracic. Check it out: https://t.co/0YNEHUJIGv https://t.co/qKKXnPsAr7,2020-06-01
1267375424616742912,https://twitter.com/Biotech2050/status/1267375424616742912,Biotech2050,$HALO Subcutaneous Dara #mmsm #myeloma #ASCO20 https://t.co/hdspQU9wht,2020-06-01
1267375381146935308,https://twitter.com/DagensMedisin/status/1267375381146935308,DagensMedisin,Bergensforskere la frem resultater fra forskning på ny form for immunterapi #ASCO20 https://t.co/WOCBWUX6Uy,2020-06-01
1267374091742437376,https://twitter.com/ESMO_Open/status/1267374091742437376,ESMO_Open,"How we treat patients with #braintumour during the #COVID-19 pandemic #ASCO20 ESMO - European Society for Medical Oncology 

https://t.co/TiFwUeAknv",2020-06-01
1267374088399568896,https://twitter.com/medtalksgermany/status/1267374088399568896,medtalksgermany,"Ebenfalls ab 11 Uhr veranstalten @bmsnews ein Satellitensymposium über therapeutische Fortschritte in der #Hämatologie.
Schalten Sie bei #ascodirect ein!
👉 https://t.co/ohtVe555l1
@bms_germany #hematology #asco2020 #oncology #ascodirect",2020-06-01
1267373756311355393,https://twitter.com/HealthTalkNorge/status/1267373756311355393,HealthTalkNorge,"En kombinasjon av Erleada og ADT forlenget livet til prostatapasienter med 14 måneder og ga en økt metastasefri overlevelse på 24 måneder viser studie som ble presentert på #ASCO20  

https://t.co/sMmLSLJd4d",2020-06-01
1267373358787760130,https://twitter.com/aftimosp/status/1267373358787760130,aftimosp,#ASCO20 #OncoAlert @OncoAlert https://t.co/aNWGjZGPhS,2020-06-01
1267373139832516610,https://twitter.com/Annals_Oncology/status/1267373139832516610,Annals_Oncology,Updated OS and final PFS data of the ALEX trial of Alectinib vs Crizotinib in ALK+ NSCLC were presented in a poster discussion session at #ASCO20 by @peters_solange . The paper is now available #openaccess in Annals of Oncology https://t.co/ilPXVrVenM #LCSM @TonyMok9 https://t.co/cN1VQ5hGK0,2020-06-01
1267372791403347969,https://twitter.com/eduhor82/status/1267372791403347969,eduhor82,"#PancreaticCancer Neoadjuvant
 2 PHASE II TRIALS:

1️⃣ #ESPAC - 5F: BORDERLINE
Folfirinox&gt;Gemcap&gt;CRT in 1yr-OS

2️⃣ #SWOG 1505: Resectable
Similar 2yr-OS than historical data

#ASCO20 https://t.co/8dbIGFUW4H",2020-06-01
1267372317560078339,https://twitter.com/colon_survivor/status/1267372317560078339,colon_survivor,"Access to genetic testing and counseling should go hand in hand with a cancer diagnosis for everyone. #IHaveLynchSyndrome #ASCO20 #genetic_testing #genetic_counseling
@AJMC_Journal https://t.co/qbfwCoD75v",2020-06-01
1267371994527477761,https://twitter.com/DrABiondo/status/1267371994527477761,DrABiondo,Great team effort by the Drug Development Unit at @ICR_London @royalmarsdenNHS. A privilige to be a co-author of a phase I trial of a FR alpha targeted thymidylate synthase inhibitor CT900 presented at #ASCO2020. https://t.co/IEri7tovJt,2020-06-01
1267371577202671623,https://twitter.com/medtalksgermany/status/1267371577202671623,medtalksgermany,"Unser letzter Tag des #ascodirect startet ab 11 Uhr mit einem Satellitensymposium von @AstraZeneca zum Thema #Lungenkarzinom weiter denken.
Schauen Sie vorbei 👉 https://t.co/UxDZWRS48R
@AstraZenecaDE #oncology #asco2020 #lungcancer",2020-06-01
1267369839531712512,https://twitter.com/Pharmashot/status/1267369839531712512,Pharmashot,"Merck’s Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-177 for Patients with MSI-H Colorectal Cancer #ASCO2020 #ASCO20 @Merck @ASCO 
https://t.co/StNSwHPAKr https://t.co/S1wdp0XwzX",2020-06-01
1267369683986112512,https://twitter.com/pharma_jonpi/status/1267369683986112512,pharma_jonpi,"Yondelis® en Combinación con Doxo Es un Tratamiento Efectivo en Primera Línea para Pacientes con LeiomioSarcoma .
El Estudio Alcanzó los Objetivos Primario y Secundarios . By Dra. Patricia Pautier ( Instituto Gustave Roussy ). #pharmamar #ASCO20 #yondelis
 https://t.co/gwLCraeFHl https://t.co/82csDPgV3r",2020-06-01
1267369383363518466,https://twitter.com/MorphoSys/status/1267369383363518466,MorphoSys,#ASCO20 Virtual is a wrap. We look forward to connecting at #EHA25Virtual. https://t.co/hOynUxV2nU,2020-06-01
1267368097188544513,https://twitter.com/VHIO/status/1267368097188544513,VHIO,"🆕Un fármaco inmunoterápico administrado en monoterapia demuestra ser eficaz como primera línea en el tratamiento del #CáncerColorrectalMetastásico

📽️@elena_elez, del #VHIO-@vallhebron, explica los resultados del estudio #KEYNOTE177 anunciados en la sesión plenaria de #ASCO20 https://t.co/mwFtmYIuJx",2020-06-01
1267367776903147526,https://twitter.com/tcellsrus/status/1267367776903147526,tcellsrus,This is just shoddy #ASCO2020    reporting. Can you imagine Ford introducing an exciting new car that is reported as being  better than anything on the road yet we know nothing more than it has 4 doors and a name ?  https://t.co/LYpcqC6IQc,2020-06-01
1267367505527558144,https://twitter.com/AML_Hub/status/1267367505527558144,AML_Hub,"We are proud to be recognized as a top influencer during #ASCO20! If you missed the virtual meeting, we will be publishing 📰 our ASCO coverage over the coming days at https://t.co/rkJONeh8EB. #Leusm https://t.co/SCOlEqK3sF",2020-06-01
1267366107662467081,https://twitter.com/BenedettaGuani/status/1267366107662467081,BenedettaGuani,ASCO2020 présentation on https://t.co/qxgPIlO1gd. https://t.co/0kE22sXWqC.    #ASCO2020 #cancerointerview #chuv #Senticolgroup https://t.co/HmXnU3EUfE,2020-06-01
1267365615821623297,https://twitter.com/TheLancetOncol/status/1267365615821623297,TheLancetOncol,The full article with results from the first 200 patients from TERAVOLT will be published in @TheLancetOncol very soon. #ASCO20 https://t.co/cB7QrIeeqx,2020-06-01
1267364353453379590,https://twitter.com/nickymitchell/status/1267364353453379590,nickymitchell,Excellent thread interpreting the updated results of adjuvant BEP x1 vs RPLND for Stage 1 NSGCT #ASCO20 https://t.co/Z31IJqMf1m,2020-06-01
1267363680532008960,https://twitter.com/CelyadSA/status/1267363680532008960,CelyadSA,"Celyad Provides Update on Allogeneic CAR-T Franchise including CYAD-101 and shRNA Platform at the 2020 ASCO Virtual Scientific Program. #allogeneic #ASCO2020  $CYAD
https://t.co/eVKapzKyix",2020-06-01
1267362261217263617,https://twitter.com/VHIO/status/1267362261217263617,VHIO,"📢Prevención del #Burnout en jóvenes oncólogos

La Dra. @elena_elez del #VHIO es la primera autora de un estudio realizado por la sección +MIR de la @_SEOM, cuyos resultados fueron presentados durante esta edición de #ASCO20

Más info👇
https://t.co/reL1zYYH3q https://t.co/uPcPXkJaXP",2020-06-01
1267361467768156160,https://twitter.com/Tony_Calles/status/1267361467768156160,Tony_Calles,"📚 I am glad to see the warm welcome to our chapter published in the American Society of Clinical Oncology (@ASCO) Educational Book. 📈 It is climbing among the most read articles! Wow, thank you to all the readers!!! #ASCO20 #LCSM  @OncoAlert 
https://t.co/rUHETSGocY https://t.co/RnEv9ALeHp",2020-06-01
1267360185082949632,https://twitter.com/ICR_London/status/1267360185082949632,ICR_London,"NEWS: A new pilot study,  presented at the #ASCO20 virtual meeting, shows that genetic screening for #ProstateCancer in GP surgeries could be effective at picking up otherwise undiagnosed cases of the disease. 

https://t.co/fgYcGuvi6s",2020-06-01
1267357111958138883,https://twitter.com/MilitaZaheed/status/1267357111958138883,MilitaZaheed,"Tumour/normal NGS identified Germline pathogenic variants in 16%; 92% previously undetected. High rates in #sarcoma, cholangio, CUP. We also found PGVs with therapeutic targets in sarcoma. Changing the way Familial Cancer Services approach rare cancers.  #ASCO20, @ArulChinnaiyan https://t.co/ZheeXuJxiw",2020-06-01
1267356470682824707,https://twitter.com/Ancora_AI/status/1267356470682824707,Ancora_AI,Interesting trial evaluating gut diversity as a significant predictor of survival in #cervicalcancer patients. Gut microbiome needs to be further researched as part of treatment strategy. #ASCO20 https://t.co/gdk7jBLkr1,2020-06-01
1267355985347149824,https://twitter.com/cancer_ref/status/1267355985347149824,cancer_ref,"https://t.co/OD9BneawdA
#ASCO20",2020-06-01
1267355024000258049,https://twitter.com/joaomaiadias/status/1267355024000258049,joaomaiadias,"Hey @ASCO, thanks for #ASCO2020.

A question that would be interesting and easy to answer, given the data you have:

- How many tonnes of CO2 were averted this year by the virtual format?",2020-06-01
1267354676812328961,https://twitter.com/PamelaKunzMD/status/1267354676812328961,PamelaKunzMD,"Finally making my way through the #NeuroendocrineTumor abstracts from #ASCO20. My top 5 ⬇️:

@marklewismd @helops79 @DianeReidyLagun @OncoThor @ShikhaJainMD @XKeutgen @AGangiMD @SukiPaddaMD @NANETS1 @CureNETs 🦓",2020-06-01
1267354310058311681,https://twitter.com/MSuppli/status/1267354310058311681,MSuppli,28% with DFS at 3 years in stage II-III lung cancer seems low? Inferior control arm? #nsclc  #ASCO20 https://t.co/H1jA8UtfHF,2020-06-01
1267353939961405440,https://twitter.com/AstraZenecaES/status/1267353939961405440,AstraZenecaES,"Gracias por habernos acompañado este fin de semana en #ASCO20, dejarnos compartir nuestras innovaciones y mostraros cómo #AstraZeneca trabaja día a día para cambiar el paradigma del cáncer a nivel mundial. https://t.co/9UKVNtbKqU",2020-06-01
1267353471390547969,https://twitter.com/Ancora_AI/status/1267353471390547969,Ancora_AI,"Great news for #bladdercancer. Avelumab maintenance after chemo shows improvement in overall survival.
Thank you to all the Javelin 100 #clinicaltrial participants!
#Cancerresearch #ASCO20 https://t.co/3RqrFT02JZ",2020-06-01
1267352943260508163,https://twitter.com/Biotech2050/status/1267352943260508163,Biotech2050,$BMY #ASCO20 #mmsm https://t.co/oLtedi1gj2,2020-06-01
1267352294221365255,https://twitter.com/fpizart/status/1267352294221365255,fpizart,"Medscape: Some women with gestational trophoblastic tumors respond to immunotherapy when they are resistant to single chemotherapy, say results from TROPHIMMUN phase 2 trial. https://t.co/qDw3s84GQj #ASCO20 https://t.co/qXmWcIraSB",2020-06-01
1267352292552040452,https://twitter.com/fpizart/status/1267352292552040452,fpizart,"Medscape: Impartiality of medical society leadership called into question. 
https://t.co/cASWPcy4U3 #ASCO20 https://t.co/9NUzAFBfe3",2020-06-01
1267352290723323904,https://twitter.com/fpizart/status/1267352290723323904,fpizart,"Medscape: #ASCO20: When added to standard chemo, a generic PPI demonstrated a higher-than-expected rate of pathologic complete response in TNBC.  https://t.co/Hw8gw8mlbP https://t.co/cRoweIkjaM",2020-06-01
1267352288529612803,https://twitter.com/fpizart/status/1267352288529612803,fpizart,Medscape: #ASCO20: Improval rate seen in HER2+ breast #cancer patients with brain metastases when given combo drug with tucatinib. https://t.co/mnyp8iawuu https://t.co/BKPwG0CtPU https://t.co/tAxHUOya3J,2020-06-01
1267352285182595072,https://twitter.com/fpizart/status/1267352285182595072,fpizart,Medscape: Frontline pembrolizumab doubles PFS in patients with MSI-H/dMMR Metastatic CRC in the KEYNOTE-177 study released at #ASCO20. https://t.co/wBi0dpxkB5 #ASCO2020 https://t.co/b3Ll2s2NOU https://t.co/6LjN03cr32,2020-06-01
1267350474954551296,https://twitter.com/KiadisPharma/status/1267350474954551296,KiadisPharma,"Reflecting on #ASCO20. At Kiadis we're driven by our ambition to deliver cell-based immunotherapy treatments to every patient who needs it, and it's exciting to see that this ambition is shared by so many across the world. We're looking forward to 2021! https://t.co/w0jzcxOiP1. https://t.co/3YMISY2POS",2020-06-01
1267350262445899776,https://twitter.com/MSD_Switzerland/status/1267350262445899776,MSD_Switzerland,"Our commitment to patients is unwavering. We believe in doing all we can to extend and improve the lives of people with #cancer. Learn more about our engagement to help people impacted by this disease: https://t.co/XXnmqI4oEb
#ASCO20 #inventingforlive #fightcancer https://t.co/5PZoOML7oY",2020-06-01
1267350135434067968,https://twitter.com/OncoSantPau/status/1267350135434067968,OncoSantPau,La Dra.@margamajem entre els coautors d’aquest estudi presentat en sessió plenària a #ASCO20. Enhorabona a tot l’equip!! #orgullsantpau @HospitalSantPau https://t.co/B4VbyB1mNg,2020-06-01
1267347762133241857,https://twitter.com/LecointreRomain/status/1267347762133241857,LecointreRomain,#ASCO20 #cancer #Immunotherapy #immunotherapie @MSDFrOncologie https://t.co/29TLYufYMM,2020-06-01
1267347659129487361,https://twitter.com/OncLive/status/1267347659129487361,OncLive,The BCMA-targeting CAR T-cell therapy idecabtagene vicleucel induced a response in nearly three-fourths of patients with heavily pretreated relapsed/refractory multiple myeloma. @DanaFarber @ASCO #ASCO20 #mmsm https://t.co/y6t5ljArQ3,2020-06-01
1267347648463417344,https://twitter.com/VHIO/status/1267347648463417344,VHIO,"📢New treatment for HER2-positive #BreastCancer patients with brain metastases

@MOliveira000 is one of the #VHIO researchers who participated in the #HER2CLIMB study, the results of which were presented at #ASCO20 @ASCO 

More info👇
https://t.co/jTkDoS0gew https://t.co/tzGawEzPR0",2020-06-01
1267345689345839104,https://twitter.com/FogCityMidge/status/1267345689345839104,FogCityMidge,"As looters and rioters destroy our cities and businesses with the police unable to protect us, it’s clear gun stores are essential! We must protect ourselves when no one else can! @dare2bewell @asco #openourgunstores #opencalifornia",2020-06-01
1267345451206021122,https://twitter.com/caseofdees/status/1267345451206021122,caseofdees,Welke Nederlandse of Belgische (gynaecoloog-)oncoloog doet op deze wijze verslag van #ASCO20. I ❤ @drdonsdizon https://t.co/b5bILX7lV4,2020-06-01
1267344497018634240,https://twitter.com/s_couraud/status/1267344497018634240,s_couraud,"Given recent results at #ASCO20, which of the following would you prescribe now to a 57yo never smoker woman, with a del19 EGFR mt, who underwent lobectomy + lymphadectomy and  adjuvant platin-based chemo?
@OncoAlert",2020-06-01
1267340796744925184,https://twitter.com/cordekroon/status/1267340796744925184,cordekroon,Gezien @caseofdees #niksnieuws #ASCO20 #gyncsm https://t.co/kzMl9hZ7d2,2020-06-01
1267340525658673152,https://twitter.com/TDTM2V/status/1267340525658673152,TDTM2V,#Erytech annonce la présentation de posters lors de la conférence annuelle #ASCO2020 https://t.co/vRbMIi9Wi6,2020-06-01
1267339756104347650,https://twitter.com/ScripIanHaydock/status/1267339756104347650,ScripIanHaydock,"#ASCO2020 #prostatecancer 

ASCO 2020: Can Xtandi PROSPER In Prostate OS Data Battle? https://t.co/prKa1feREk",2020-06-01
1267339368060125186,https://twitter.com/SPGMIHealthcare/status/1267339368060125186,SPGMIHealthcare,"Find out what Gilead said at the ASCO conference about #Yescarta's performance in treating a certain type of blood #cancer in a mid-stage study. #ASCO20  @GileadSciences 
https://t.co/45K8AkSkMH https://t.co/XcxopR3I1J",2020-06-01
1267337421131309056,https://twitter.com/SPGMIHealthcare/status/1267337421131309056,SPGMIHealthcare,"More coverage from the ASCO conference: Takeda blood #cancer drug unable to notably improve survival #ASCO20 
@TakedaPharma
https://t.co/U4J7XeMdA6 https://t.co/g2SVwbWhwK",2020-06-01
1267336471129751552,https://twitter.com/els_dewulf/status/1267336471129751552,els_dewulf,No pictures like this at #asco20 https://t.co/XPbgHiJhii,2020-06-01
1267336463399768065,https://twitter.com/SPGMIHealthcare/status/1267336463399768065,SPGMIHealthcare,"ICYMI: ASCO conference: Kura's tipifarnib shrinks neck, head tumors in mid-stage study #ASCO20 @kuraoncology  #cancer @MichaelHGibney has the details 
https://t.co/GAOVdD9wx8 https://t.co/cHeoypGf39",2020-06-01
1267334392113815554,https://twitter.com/m0370/status/1267334392113815554,m0370,KEYNOTE-177の結果を見るとMSI-H大腸癌のケモコンボはどうなのかとかイピニボ（CHECKMATE-8HW待ち）も気になるけど、MSI-H大腸癌の術後ICIもどうなるんだろうな。もともとMSI-Hは再発が少なく術後療法は省略されることもあるけど、手術時にMSI-Hが測れるようになると治療が変わるだろうか。#ASCO20,2020-06-01
1267334269019361280,https://twitter.com/m0370/status/1267334269019361280,m0370,"MSI-H大腸癌の一次治療ペムブロリズマブ（KEYNOTE-177）に関するASCOデイリーニュース解説記事。ICIは確かに有望な選択肢ではあるが、早期にPDとなる3割の患者をレスキューするためにさらに研究が必要、と（バイオマーカーを探すとか併用療法を考えるとか…）。
#ASCO20
https://t.co/8MrUwSqDiQ https://t.co/YpgnhVJRlp",2020-06-01
1267332561442873345,https://twitter.com/OncLive/status/1267332561442873345,OncLive,"Pembrolizumab in combination w/ several chemo partners led to a statistically significant improvement in PFS versus chemo alone as a first-line treatment for patients w/ locally recurrent, inoperable, or metastatic TNBC whose tumors expressed PD-L1 #ASCO20 https://t.co/wp8pI8XtVJ",2020-06-01
1267331209182371841,https://twitter.com/ProjectBreath/status/1267331209182371841,ProjectBreath,"This is what true #patient empowerment and patient-centric #healthcare looks like!

Thank you @marklewismd for your advocacy as an oncologist and a #rarecancer patient.
#ASCO20 #ASCO2020 #ASCO20VR #cancercare https://t.co/EgbyCKQLPg",2020-06-01
1267325836102979584,https://twitter.com/Latinamd/status/1267325836102979584,Latinamd,#ASCO20 Plenary session: KEYNOTE-177: Pembrolizumab in #MSI-H CRC. I just wished this will apply to more patients. ( only 15% of pts) https://t.co/YGVICBzAif,2020-06-01
1267324684862963713,https://twitter.com/FuenteApolo/status/1267324684862963713,FuenteApolo,#ASCO20 #hncsm #radonc https://t.co/9614hEbjqs,2020-06-01
1267322482253586433,https://twitter.com/Latinamd/status/1267322482253586433,Latinamd,Reminder of how far we have come in treatment of #EGFR #lungcancer #lcsm #ASCO20 https://t.co/8pZHgttbhd,2020-06-01
1267322095245176832,https://twitter.com/IvyLorena_Md/status/1267322095245176832,IvyLorena_Md,"Donate today to support cancer research #ConquerCancer 

Dona hoy para apoyar la investigación del cáncer #ConquistarElCancer 

#WeCan #NosotrosPodemos #CancerFree #CancerAwareness #ASCO20 @ASCO @ConquerCancerFd https://t.co/jUIk01sV3L",2020-06-01
1267320575170674689,https://twitter.com/Biotech2050/status/1267320575170674689,Biotech2050,$BMY #ASCO20 https://t.co/7x4mdppBS2,2020-06-01
1267319934297747458,https://twitter.com/Biotech2050/status/1267319934297747458,Biotech2050,$KPTI #selinexor #mmsm #ASCO20 https://t.co/PK1gGHjI4p,2020-06-01
1267319708098985984,https://twitter.com/DrHMahmudMD/status/1267319708098985984,DrHMahmudMD,#ASCO20 #EGFR https://t.co/KhgPxW925Y,2020-06-01
1267319329126842368,https://twitter.com/Biotech2050/status/1267319329126842368,Biotech2050,"$KPTI #selinexor #mmsm #ASCO20 
https://t.co/GmoYi2DkCL",2020-06-01
1267318324351787009,https://twitter.com/lisamforce/status/1267318324351787009,lisamforce,"Attended my 1st @ASCO virtually this wkend &amp; while I’ve never seen the wonder in person, I loved watching in pjs w/ my dog! Hope conferences cont to offer virtual option post-COVID - ⬆️ access if tight finances, inability to travel d/t work coverage, etc. Thanks #ASCO20!",2020-06-01
1267317813288435717,https://twitter.com/SiwenONC/status/1267317813288435717,SiwenONC,"Check out Abstracts 10004 and 10005, addressing the efficacy and safety of ipi + nivo in melanoma patients who have already progressed on anti-PD1. Look forward to results from the ongoing S1616. @ASCO @ProfGLongMIA",2020-06-01
1267317571453431808,https://twitter.com/fedelosco/status/1267317571453431808,fedelosco,"#Atezolizumab in BCG unresponsive CIS #bladdercancer a new option of treatment presented in #ASCO20 , what It will be the best option?. What do you think? @GustavoVillold4 @Martin_AngelMD @jpsade2 @CAU_URO @aaoncoclinica @pekijammer @SoaresAndrey https://t.co/zoSmAF4HKq",2020-06-01
1267317460736315392,https://twitter.com/OncLive/status/1267317460736315392,OncLive,Patients with previously treated HER2-positive metastatic breast cancer and brain metastases achieved significant intracranial responses with a combination of tucatinib plus trastuzumab and capecitabine. @DanaFarber @ASCO #ASCO20 #bcsm https://t.co/dgBEBzxOVh,2020-06-01
1267316180475240448,https://twitter.com/LizCancerHealth/status/1267316180475240448,LizCancerHealth,Didn't get into the #ASCO20 tweet scrum this year -- too distracted by current events! -- but @cancerhealthmag will be covering highlights from the virtual meeting in the coming days. https://t.co/jH8djAGd3X,2020-06-01
1267316024061370369,https://twitter.com/Latinamd/status/1267316024061370369,Latinamd,"Great work @anavmanana on your #ASCO20 abstract on lack of diversity in H/O fellowship programs. #DiversityIsStrength  now more than ever. @LatinasInMed 
@NarjustDumaMD https://t.co/mDxAM8pFnn",2020-06-01
1267312302002442241,https://twitter.com/Latinamd/status/1267312302002442241,Latinamd,One thing that was missing at virtual #ASCO20 was our annual Columbia reunion. Missed you @ninashah33 @ThomasUldrick @dr_aphillips https://t.co/sKgwdJVbob,2020-06-01
1267311283440889857,https://twitter.com/VivekSubbiah/status/1267311283440889857,VivekSubbiah,"Just watched  @marklewismd &amp; Dr. Steven Lemery's talk again for the 3rd time @ASCO #ASCO20 ! So inspiring ! These 2 talks + @DavidFajgenbaum 's talk are a must watch for everyone in Oncology (academia, community, industry, FDA, patient &amp; family) @ASCOPres @tmprowell @MLJohnsonMD2 https://t.co/IK7y71pgL8",2020-06-01
1267310587114975232,https://twitter.com/acmoorephd/status/1267310587114975232,acmoorephd,"While we gathered this weekend to discuss advances in oncology research and care, we cannot overlook recent events. Thank you @ASCOPres. #ASCO20 https://t.co/CHKbXFWEiv",2020-06-01
1267308303375192064,https://twitter.com/rannetu/status/1267308303375192064,rannetu,"しゅごい。
#ADAURA
#ASCO20",2020-06-01
1267306771116257283,https://twitter.com/tkdmHawkeye/status/1267306771116257283,tkdmHawkeye,"KN177
奏効率はペムブロのほうがいいし一度効果があればdurable responseがあるのも納得、でもPFSのKM曲線が逆転するからPD率が29% vs 12%でペムブロのほうが多いの、なにか予測する方法とかあるのだろうか。
#ASCO20 https://t.co/KttMHIgpfT",2020-06-01
1267305930850476032,https://twitter.com/SBRInvestor/status/1267305930850476032,SBRInvestor,"""Repositioning PARP inhibitors for SARS-CoV-2 infection” https://t.co/KVLkjjHbb8 @asco @oncoalert @tmprowell @viveksubbiah @marklewismd @glopesMD @Drchoueiri @narjustDumaMD @DrSgraff @ascopres @katsuakimaehara @crisbergerot @PauloBergerot @nazlidizman @renohemonc @jamienholloway",2020-06-01
1267305916698935297,https://twitter.com/khushboor14/status/1267305916698935297,khushboor14,Tumor agnostic therapies are rapidly evolving to modify treatment paradigm for various solid tumors #ASCO2020 https://t.co/A1S1rE1iFu,2020-06-01
1267305910961147907,https://twitter.com/AshleySumrallMD/status/1267305910961147907,AshleySumrallMD,This is a huge job &amp; wonderful achievement for @KMilehamMD 😊 I know she is up for the challenge &amp; will excel. Congrats! #asco20 https://t.co/Fw9M9GJKha,2020-06-01
1267305489701974017,https://twitter.com/SBRInvestor/status/1267305489701974017,SBRInvestor,https://t.co/purXzZAEwN WHICH PARPi will prevail with least SAEs like MDS? @asco @oncoalert @tmprowell @viveksubbiah @marklewismd @glopesMD @Drchoueiri @narjustDumaMD @DrSgraff @ascopres @katsuakimaehara @crisbergerot @PauloBergerot @nazlidizman $clvs @renohemonc @jamienholloway https://t.co/6QQFkGHgNi,2020-06-01
1267305365672284160,https://twitter.com/bradloncar/status/1267305365672284160,bradloncar,"Innovent +10% to an all-time high. 

I think you can call this an #ASCO20 winner because they presented multiple studies of their PD-1 Tyvyt, which is the only PD1 on the NRDL. And it's one of the few companies with TIGIT in the clinic today...first patient dosed last week.",2020-06-01
1267304710798823427,https://twitter.com/parpinellivo/status/1267304710798823427,parpinellivo,"#ASCO2020: risultati positivi per un protocollo di trattamento del sarcoma di Ewing metastatico. Lo studio, coordinato da @IstTumori (Chair #RobertoLuksch), ha coinvolto 14 centri italiani che hanno trattato oltre 150 pazienti dell’età media di 15 anni https://t.co/9BrYbWhmWX",2020-06-01
1267304551746600962,https://twitter.com/Latinamd/status/1267304551746600962,Latinamd,"#foodforthought: Abs: 9005: Updated analysis of CTONG1104: gefitinib vs chemo in adjuvant +EGFR #lungcancer- a negative study where DFS did not translate into OS  #ASCO20 #lcsm 

How does this compare to #ADAURA- 1st gen TKI, 2 yr vs 3yrs, HR 0.56, crossover?
@n8pennell https://t.co/GcA46MAQQe",2020-06-01
1267304069225426951,https://twitter.com/emadshash/status/1267304069225426951,emadshash,"https://t.co/Sw9wtvWjKj Strange observation #ASCO20 and @Medscape commentary, majority of oncologists use already PPIs as a routine bed side treatment for patients receiving chemotherapy, but we don't see that high pCR!! A deeper look on our retrospective data warranted https://t.co/6ozqqC5LOT",2020-06-01
1267304035788263426,https://twitter.com/SChellapuram/status/1267304035788263426,SChellapuram,"#ASCO2020
ADURA:Adjuvant Osimertinib in Stage IB,II,IIIA
VISION:Tepotinib in MET Exon14 Skip mutation
JAVELIN100:Avelumab maintainance post paltinum in met UB
ARROW:Pralsetinib in RET fusion tumour
KN117:Pembrolizumab in upfront MSI-H mCRC
ENDURANCE:KRD=VRD in NDMM
@ASCO",2020-06-01
1267302932430508032,https://twitter.com/fireflyann/status/1267302932430508032,fireflyann,"so happy to hear your expert opinion re #MSI #colorectalcancer patients 1st Line option!

#ASCO20 #ASCO2020 #CRCSM #Keynote-177 https://t.co/d2bdWahT11",2020-06-01
1267302362101755904,https://twitter.com/OncLive/status/1267302362101755904,OncLive,Results from CheckMate 9LA suggested that frontline treatment w/ nivolumab plus ipilimumab combined w/ platinum-doublet chemotherapy in patients w/ metastatic or recurrent NSCLC should be considered a new option for this population. #ASCO20 #lcsm https://t.co/r4ZSYqdfv2,2020-06-01
1267302170581491712,https://twitter.com/parpinellivo/status/1267302170581491712,parpinellivo,"#ASCO2020: presentati i dati raccolti dal Registro TERAVOLT, che cerca di valutare l’impatto del #COVID19  sulla popolazione dei pazienti con tumore toracico. Ne parla @marinagarassino, oncologa @IstTumori #Milano https://t.co/e3ZDQxxfkD",2020-06-01
1267301406358171649,https://twitter.com/COSAoncology/status/1267301406358171649,COSAoncology,"A little different but another thought provoking #ASCO2020. Plenty of inspiration for #COSA2020. If you missed it, don’t worry. Over the next few weeks COSA members across disciplines will be sharing their #ASCO2020 highlights. https://t.co/EQ17crEH3E",2020-06-01
1267300081998454784,https://twitter.com/CarlosHTonco/status/1267300081998454784,CarlosHTonco,Very interesting polls!!! #asco20 https://t.co/06zM6fBZKv,2020-06-01
1267299476777005056,https://twitter.com/bigbird_vn/status/1267299476777005056,bigbird_vn,ADAURA試験がASCOのプレナリーセッションに選ばれてるから、発表と同時にNEJMあたりに論文が出るだろうと思っていたら、待ちぼうけを食らっている。超遅いLate-Breaking Abstract #ASCO20 https://t.co/7anQ9ec6Qr,2020-06-01
1267298451416637440,https://twitter.com/Latinamd/status/1267298451416637440,Latinamd,Thank you @ASCO @ASCOPres for joining the voice of many other medical associations who have come up w a statement to address #healthequity during these difficult times #ThisisOurLane https://t.co/mkuXTim8k4,2020-06-01
1267297992031297538,https://twitter.com/inas_md/status/1267297992031297538,inas_md,"#ASCO20 
Thanks @SurbhiSidanaMD for this excellent summary of the Endurance trail.
#MultipleMyeloma https://t.co/u69ZPwEaLN",2020-06-01
1267297916059860992,https://twitter.com/fedelosco/status/1267297916059860992,fedelosco,Great results of #JAVELIN100 in #ASCO2020 showing significant longer OS with #avelumab 1st line maintenance vs control in #bladdercancer @Martin_AngelMD @GustavoVillold4 @OncoAlert @aaoncoclinica @CAU_URO @SoaresAndrey #UroOncoIAF https://t.co/c6m3HIS85g,2020-06-01
1267295537855901696,https://twitter.com/Latinamd/status/1267295537855901696,Latinamd,"Congratulations to my former co-fellow Jared Weiss @UNC_Lineberger for an excellent highlight of the day for locally advanced #lungcancer, #mesothelioma #ASCO20 https://t.co/rK0X0Gthwf",2020-06-01
1267295277502914562,https://twitter.com/smitha42/status/1267295277502914562,smitha42,Totally agree! Kudos to all involved with #ASCO20! Moving #cancer care and #CancerResearch forward despite the pandemic. https://t.co/wNpFL6y3x5,2020-06-01
1267294988167024645,https://twitter.com/double_whammied/status/1267294988167024645,double_whammied,Always so happy to see any study that looks at the sexual side effects of cancer treatment. #ASCO20 https://t.co/3Yi6oUZEVK,2020-06-01
1267294950435303426,https://twitter.com/manjuggm/status/1267294950435303426,manjuggm,"If you need pt materials (pts discussing how CIPN has ruined their life), the @Colontown1 Live Wire neighborhood (focused on oxaliplatin induced peripheral neuropathy) offers many horror stories. #Icingduringoxaliplatin⬇️acute cold sensitivity, pl see abstract e16140 
#ASCO2020 https://t.co/3iHAKI24rv",2020-06-01
1267294300385284097,https://twitter.com/SeattleCCA/status/1267294300385284097,SeattleCCA,"#ASCO20: Dr. David Maloney's publication ""Characterization of cytokine release syndrome (CRS) and neurological events (NEs) in the phase I TRANSCEND NHL 001 trial of lisocabtagene maraleucel (liso-cel)..."" Read on our SCCA at @ASCO page: https://t.co/gELR1blisv #Hematology https://t.co/kpKMi5HKrC",2020-06-01
1267294196697726976,https://twitter.com/fireflyann/status/1267294196697726976,fireflyann,"now that #ASCO20 is over (but the tweets continue)
any more ideas to share  for the ultimate Poster Discussant Guide? https://t.co/HhiYvmtVxr",2020-06-01
1267294046189469697,https://twitter.com/DrAyeshaSheikh/status/1267294046189469697,DrAyeshaSheikh,#ASCO20 Great discussion of #JAVELIN100 and summary of the best management of locally advanced/metastatic urothelial cancer by @ERPlimackMD. Longest OS achieved by first line platinum chemo x 4-6 cycles followed (in responders) by #avelumab maintenance or #pembrolizumab https://t.co/5Zz7aErgtD,2020-06-01
1267292343046111237,https://twitter.com/RicardoTixi/status/1267292343046111237,RicardoTixi,"Este proyecto sigue y lo mantenemos por el beneficio de nuestros pacientes Latinoamericanos https://t.co/E8TTKGOjs5 jamás desmayaremos en cumplir nuestros objetivos, docencia e investigación @school_latin @OrgSlacom @ASCO @ESMO_Open @lacentralec @SLAGO2019",2020-06-01
1267291588679647232,https://twitter.com/DrAyeshaSheikh/status/1267291588679647232,DrAyeshaSheikh,#ASCO20 Practice changing in #bladdercancer: #JAVELIN100 shoes significantly longer OS with #avelumab 1st-line maintenance vs best supportive care both in overall population &amp; PD-L1+ (mOS 21.4 vs 14.3m) after initial platinum based chemo https://t.co/xkLql7c4cl,2020-06-01
1267290137165168640,https://twitter.com/inas_md/status/1267290137165168640,inas_md,"9 days to get NGS results!! Wouldn't that be nice? 😆
#ASCO20 https://t.co/NaGqsOdAJB",2020-06-01
1267288472076894208,https://twitter.com/DrAyeshaSheikh/status/1267288472076894208,DrAyeshaSheikh,Practice changing in #NSCLC : #ADAURA Phase III study shows adjuvant #osimertinib in Stage IB/II/IIIA lung cancer with #EGFR  mutation associated with 79% reduction in the risk of disease recurrence or death (DFS HR 0.21). Marked separation of curves right from the start #ASCO20 https://t.co/81e6j5itxA,2020-06-01
1267287596289458183,https://twitter.com/TaylorJ_MD/status/1267287596289458183,TaylorJ_MD,Just watched since didn’t have time earlier - disappointing results. No difference in PFS even though deeper responses with KRd. More peripheral neuropathy with VRd but more cardiopulmonary/renal with KRd. #mmsm #ASCO20 https://t.co/Ly0wvzvR2d,2020-06-01
1267287260711485440,https://twitter.com/OncLive/status/1267287260711485440,OncLive,Modest survival benefits were observed in patients with ES-SCLC who received the combination of pembrolizumab and etoposide plus platinum compared with patients who received EP and placebo. @charlesrudin @sloan_kettering #ASCO20 #lcsm https://t.co/sUfZ4PXTFQ,2020-06-01
1267286917172932610,https://twitter.com/manjuggm/status/1267286917172932610,manjuggm,"Amazing tweet thread! Thank you for sharing!

#ASCO20 #ASCOTotalHealth #CRCSM https://t.co/U77GSWjxb6",2020-06-01
1267286869508714498,https://twitter.com/Viriwana/status/1267286869508714498,Viriwana,"Impresionantes resultados, sin embargo hay preguntas en el aire: Tratamiento a la recurrencia? Se podría tomar como estándar en adyuvancia en la población mexicana, considerando los ingresos? #ASCO20 #RealLifeData https://t.co/t9CGPKlhjy",2020-06-01
1267286314644393985,https://twitter.com/shannonmhough/status/1267286314644393985,shannonmhough,So thankful to @ASCO for the opportunity to present @UMRogelCancer work w/PharmD care + SMS PROs for CINV to ⬇️ ED and urgent care use after treatment #ASCO20 #oncopharm https://t.co/Xd66r5JTsU https://t.co/MwQ3JCWcux,2020-06-01
1267286259728297986,https://twitter.com/MarkYarchoan/status/1267286259728297986,MarkYarchoan,"Every time there's a targeted agent basket study, the cholangios are among the best responders. Time to add RET to the list of potentially actionable cholangio mutations... (FGFR2, IDH1, HER2, BRAF, etc.) #hpbcsm #ASCO2020 https://t.co/f1gYVSP0pb",2020-06-01
1267286158368804864,https://twitter.com/VincentRK/status/1267286158368804864,VincentRK,"I just donated. Please donate to #ConquerCancer #ASCO20 
Every bit helps. https://t.co/hWUWTzz9SO https://t.co/4rEBW8Eorm",2020-06-01
1267286139867746306,https://twitter.com/IBCResearch/status/1267286139867746306,IBCResearch,"Hey, most advocates are volunteers...giving our time &amp; money to a cause we believe in. Do you believe in the mission of @ASCO, if so, open your wallet &amp; give back for 2 days of amazing presentations, plus access to volumes of other abstracts &amp; discussion. #ASCO20 #JustDoIt https://t.co/AmELAJDj6v",2020-06-01
1267286098138497024,https://twitter.com/inas_md/status/1267286098138497024,inas_md,"#ASCO20 
Studying this thread before my next GU clinic with @ShuchiGulati 😂 https://t.co/gocultGVgU",2020-06-01
1267285829954809856,https://twitter.com/DrAyeshaSheikh/status/1267285829954809856,DrAyeshaSheikh,"#ASCO20 Practice changing in MSI-H mCRC: #Pembrolizumab in first line is superior to chemo with median PFS of 16.5 vs 8.2m, ORR of 43.8% vs 33.1% with better tolerance including older patients #KEYNOTE177 @BUHemeOncFellow https://t.co/Wfl21iSMUQ",2020-06-01
1267285159226859521,https://twitter.com/Latinamd/status/1267285159226859521,Latinamd,"Just Donated to @ConquerCancerFd ....please text ASCO to 41444 to support cancer research, young investigators #ASCO20 https://t.co/6qhNkRq25L",2020-06-01
1267284296064270341,https://twitter.com/LucyModahlMD/status/1267284296064270341,LucyModahlMD,"Thank you @ASCOPres 
@ASCO https://t.co/KivbmvEtFy",2020-06-01
1267283335811825664,https://twitter.com/Latinamd/status/1267283335811825664,Latinamd,"I have been thinking about this DFS vs OS conundrum for #osimertinib in the adjuvant NSCLC . #valuebasedcare means no only that we get more cures (OS) for the💲💰but that we prevent illness (i.e. early mets). 
So I will seriously discuss this option w pts #ASCO20 #ADAURA #lcsm https://t.co/MgiHPl4tXF",2020-06-01
1267283200361091077,https://twitter.com/DrErin_DO/status/1267283200361091077,DrErin_DO,My twitter feed is either #ASCO2020 slide pics or #BlackLivesMatters supporters. Looks like I’m following all the right people 😊 🤗,2020-06-01
1267282187662966785,https://twitter.com/liangc_science/status/1267282187662966785,liangc_science,Reflections on #ASCO2020 $ARVN Ph1 data: (1) low ORR esp. 280mg group is disappointing but n=12 is too early for conclusion. Low ORR might be due to the drug itself or patient selection. Need to see more AR IHCs in tumor biopsies to see how well 280mg degrades AR. (1/2) https://t.co/5GIdMhjwAw,2020-06-01
1267282172303589380,https://twitter.com/SoaresAndrey/status/1267282172303589380,SoaresAndrey,LACOG 0415 is the first prospective trial from #LACOG-GU and was presented in the oral session during #ASCO20. Here I discuss with the presenter of this trial @hosp_einstein https://t.co/bNg7Q1oms1 https://t.co/1DUgHNtCxa,2020-06-01
1267282118188523520,https://twitter.com/DrVikasAsati/status/1267282118188523520,DrVikasAsati,Anyone dared to remain wake up in India till ADAURA presentation started?😊 I couldn’t. #ASCO20,2020-06-01
1267281702155624448,https://twitter.com/drdonsdizon/status/1267281702155624448,drdonsdizon,Incredible science presented at #ASCO20 but I missed so many. Here are just a few. Prayers we are able to meet F2F at #ASCO21. https://t.co/8dX07sXzKV,2020-06-01
1267281405106688002,https://twitter.com/amarkelkar/status/1267281405106688002,amarkelkar,"Pain management is another way implicit bias and racism get institutionalized, especially in cancer care and though implicit bias training is gaining a foothold in #MedEd, we have a long way to go to right this wrong. #MedTwitter #ASCO20 #opioid https://t.co/S8kXRV5Xux",2020-06-01
1267280944400158720,https://twitter.com/LguzzardiM/status/1267280944400158720,LguzzardiM,"#GeneticTesting Can Guide Treatment, but Access AND #GeneticCounseling Are Essential, Multiple Studies Confirm at ⁦#ASCO20

 #hereditarycancer #gcchat #genetics #patientsafety 

Via ⁦@AJMC_Journal⁩  https://t.co/VXUE6IIRjc",2020-06-01
1267280322951024646,https://twitter.com/Benyam_Muluneh/status/1267280322951024646,Benyam_Muluneh,"Interim analysis of OPTIC: A dose-ranging study of three ponatinib starting doses. Still many unanswered questions. Ultimately, dosing should be individualized based on risk and disease burden and increase/decrease as appropriate. #ASCO20 #PrecisionDosing https://t.co/mWPwUBsCsM",2020-06-01
1267279763388891139,https://twitter.com/yzafar/status/1267279763388891139,yzafar,"Very nice discussion by @DevikaDasMD of Care Delivery orals: ""It's All About Access: How Resources Affect Who Lives and Dies""

It's true - ""A bad system will beat a good person every time""

https://t.co/PmAltaagjZ #ASCO20 https://t.co/YbL79Vp7nC",2020-06-01
1267279174936465413,https://twitter.com/armstde/status/1267279174936465413,armstde,"It was a different way of learning from #ASCO20 this year, and I miss seeing my colleagues, but it works! https://t.co/GmF7CKiC70",2020-06-01
1267279067922882560,https://twitter.com/NicoleKuderer/status/1267279067922882560,NicoleKuderer,✨🌟💫 Thanks to so many for your generous messages - I am in awe of your names✨🌟💫! #ASCOMagic💫 @ASCO @ConquerCancerFd #ASCO20,2020-06-01
1267278190701150214,https://twitter.com/Latinamd/status/1267278190701150214,Latinamd,Its all about global reach! #ASCO20 Pretty amazing 6.5M views @GlopesMd  @SylvesterCancer https://t.co/r3ayu2vLE7,2020-06-01
1267278027484004352,https://twitter.com/DrLizSamander/status/1267278027484004352,DrLizSamander,#ASCO20 genetic screening of prostate https://t.co/9rnEOE3XMn,2020-06-01
1267277517926195200,https://twitter.com/arkhaki/status/1267277517926195200,arkhaki,"Great nuanced discussion/reflection from @ArjunBalarMD about Javelin100 and broader implications for urothelial carcinoma 

#ASCO20 
#bladdercancer #blcsm https://t.co/T2aeWUJRLb",2020-06-01
1267276198561878020,https://twitter.com/BernabeCarolina/status/1267276198561878020,BernabeCarolina,Great opportunity to discuss the plenary session #ADAURA #ASCO20 https://t.co/CUf9gHVxsx,2020-06-01
1267276174314668032,https://twitter.com/hsaadati20/status/1267276174314668032,hsaadati20,Avelumab Maintenance Therapy Improves Survival in Advanced Urothelial Cancer https://t.co/zggKjmuyq8 #ASCO2020,2020-06-01
1267276154026803200,https://twitter.com/shrivastava_sam/status/1267276154026803200,shrivastava_sam,"I remember how excited a senior scientist at $CTMX was about CD71 a couple of years back. 

Hard target to hit due to on target tox. 

Mixed data. Some activity. #ASCO20",2020-06-01
1267276052684066816,https://twitter.com/hsaadati20/status/1267276052684066816,hsaadati20,Practice-Changing KEYNOTE-177 Results Support First-Line Pembrolizumab Monotherapy for MSI-H mCRC https://t.co/ef7B8B4ibg #ASCO2020,2020-06-01
1267276026654138368,https://twitter.com/TalhaBadarMD/status/1267276026654138368,TalhaBadarMD,"KEYNOTE-204: Pembro Superior to BV in Relapsed/Refractory Classic Hodgkin Lymphoma 
The ORRs were 65.6% for Pembro and 54.2% for BV. The CR rates were 24.5% for Pembro and 24.2% for BV. A longer median DOR was observed for Pembro 20.7 mo  versus BV 13.8 mo #ASCO2020 #cHL",2020-06-01
1267275845279846400,https://twitter.com/hsaadati20/status/1267275845279846400,hsaadati20,ADAURA Establishes Adjuvant Osimertinib as a New Standard of Care for Early-Stage EGFR-Mutated NSCLC https://t.co/3npg5Q0IEE #ASCO2020,2020-06-01
1267275543101267969,https://twitter.com/TiansterZhang/status/1267275543101267969,TiansterZhang,An insightful juxtaposition of Javelin 100 with the ImVigor and Keynote trials. Always on point from @ArjunBalarMD! @asco #ASCO20 #blcsm https://t.co/X4SRYVFyyT,2020-06-01
1267273887395479556,https://twitter.com/NabbsCreekGnome/status/1267273887395479556,NabbsCreekGnome,Forgot the hashtag #ASCO20 https://t.co/aMLeEb1j83,2020-06-01
1267273734429294594,https://twitter.com/hsaadati20/status/1267273734429294594,hsaadati20,Richard Schilsky on This Year’s Practice-Changing Findings - The ASCO Post.  #ASCO2020 #oncology https://t.co/MJo8A0O3ol,2020-06-01
1267273709363974144,https://twitter.com/ajumathew_/status/1267273709363974144,ajumathew_,#ASCO20 #ADAURA #Osimertinib https://t.co/DX8F9mVq8f,2020-06-01
1267273624110673920,https://twitter.com/tekincumhur/status/1267273624110673920,tekincumhur,#ASCO20 what an unusual annual meeting. Hope to participate in person next year🤞 https://t.co/AKcLEUY4Yr,2020-06-01
1267273236255059968,https://twitter.com/jasonlukemd/status/1267273236255059968,jasonlukemd,Props to #ASCO20! Definitely sad to defer fundraising for @sitcancer #immunotherapy post-docs. The gig @BuddyGuys would have been tonight &amp; miss making music w my friends the #CheckPoints. May have online release so stay tuned! Stay safe &amp; looking forward to #SITC20! @BReinfeld https://t.co/ImbY8UUkya,2020-06-01
1267273078914121729,https://twitter.com/geosullivanc/status/1267273078914121729,geosullivanc,I donated @Deirdreomahon14 ! Glad to support @ConquerCancerFd #ASCO20 and including other former onc fellows @NCIResearchCtr from around the world to keep the link going with @BurottoMauricio @robertmeehanMD and @annemnoonan https://t.co/mwjevsJeYh,2020-06-01
1267272936987205633,https://twitter.com/SoaresAndrey/status/1267272936987205633,SoaresAndrey,Nice discussion about the best kidney cancer abstracts (portuguese) #ASCO20 @OncologyBio @hosp_einstein https://t.co/zXpaXl7wvt,2020-06-01
1267272882348077057,https://twitter.com/shrivastava_sam/status/1267272882348077057,shrivastava_sam,After 2 days of solid work. The theme to me is there is still a lot to be done in many solid tumors. #ASCO20,2020-06-01
1267272721651687425,https://twitter.com/CharuAggarwalMD/status/1267272721651687425,CharuAggarwalMD,"Even though we were not all physically together, @Twitter gave us a nice platform to engage in a lively discussion about #ADAURA #ASCO20 @ASCO https://t.co/8NTrI92yee",2020-06-01
1267272652982452224,https://twitter.com/GBOT_Alerta/status/1267272652982452224,GBOT_Alerta,"ALK: A atualização de 5a do Estudo Alex mantém o ganho de SG do Alectinibe x crizotinibe (62,5% x 45,5%) no trat. de 1ªlinha CPNPC ALK+. @IvanMoreiraJun3 #ASCO20 #GBOT_Alerta https://t.co/iUGIBQuLru",2020-06-01
1267272186949185538,https://twitter.com/Farley78/status/1267272186949185538,Farley78,"#ASCO2020 Tourmaline-4 showed that ixazomib can be a good option for maintenance in non eligible NDMM (PFS 17.4 vs 9.4 - placebo controlled). It was better for patients with ISS3, VGPR or better post induction, and &gt;75y. @liga_cancer was one of the sites enrolling.",2020-06-01
1267271554880151553,https://twitter.com/MLPOncoData/status/1267271554880151553,MLPOncoData,#ASCO20 https://t.co/3X4xAJZPC3 https://t.co/3ZqqemsmGo,2020-06-01
1267271345399894018,https://twitter.com/Jamiejoyoncpgx1/status/1267271345399894018,Jamiejoyoncpgx1,This is like the cliff notes for #urothelialcarcinoma #ASCO20 👏🏻👏🏻👏🏻 https://t.co/AECEcZo6Ei,2020-06-01
1267271100372856833,https://twitter.com/GBOT_Alerta/status/1267271100372856833,GBOT_Alerta,"Amivantanab, anticorpo bi-específico contra mut EGFR e MET: result + em pcts com mut EGFRexon20. TR~40%, benefício clínico ~70%, SLP de 8,3 meses, incluindo pcts já tratados c/ qt (platina). EA manejáveis: rash 72%, reação infus 60%; EA G3/4 30%. @julianoonco #ASCO20 #GBOT_Alerta https://t.co/ElPKuctQnk",2020-06-01
1267271060862513152,https://twitter.com/shrivastava_sam/status/1267271060862513152,shrivastava_sam,"Concept of drug sequencing in IO is an interesting idea. Almost like prime and boost concept. Except it is prime and block checkpoints. #ASCO20 

Talk by Dr. Heather McArthur.",2020-06-01
1267271002943303680,https://twitter.com/MLPOncoData/status/1267271002943303680,MLPOncoData,#ASCO20 https://t.co/RozMIXV0hc https://t.co/egEczWEVJ7,2020-06-01
1267270467745964033,https://twitter.com/MLPOncoData/status/1267270467745964033,MLPOncoData,#ASCO20 https://t.co/fAWUP71bzn https://t.co/N5KXTzJeQp,2020-06-01
1267270314754441216,https://twitter.com/NarjustDumaMD/status/1267270314754441216,NarjustDumaMD,"Como decía Celia...
""My English is not very good looking""

Regarding #ASCO20 

Esta vaina se acabó! 

@EnriqueSoto8 @jesusanampa @GlopesMd @Latinamd @atperez_md @anavmanana @COlazagasti @drcoronacruz https://t.co/6eyknoMtRv",2020-06-01
1267269905277222914,https://twitter.com/TiansterZhang/status/1267269905277222914,TiansterZhang,All the take home messages in #bladdercancer from the wise @sonpavde! #blcsm #ASCO20 @ASCO https://t.co/fLzJR354Ar,2020-06-01
1267269890777296896,https://twitter.com/SomeGuyNamedDav/status/1267269890777296896,SomeGuyNamedDav,"Finished a great #ASCO20, went downstairs, at lunch, went back upstairs and had to install THREE TVs! Dad’s work is never done.",2020-06-01
1267269395635744773,https://twitter.com/OxAnalyst/status/1267269395635744773,OxAnalyst,"$KURA very nice OS data from Ph2 of Tipifarnib (n=18) #ASCO2020 

-Median OS: 15.4 mo's
-Median PFS: 5.9 mo's
-1 confirmed PR
-ORR of 50% observed in recurrent/metastatic HRAS mutant HNSCC

Approved therapies are:
-Median OS: 5-8 mo's
-Median PFS: 2-3 mo's
-ORR of 13-16%",2020-06-01
1267269314639548416,https://twitter.com/ndenduluri1/status/1267269314639548416,ndenduluri1,We can and must do better for our patients ! https://t.co/XNj3oEvdcB is where we are - let’s all engage with our respective teams and meet the @ASCOPres challenge! @ConquerCancerFd #ASCO20 https://t.co/oAGyokrZJ0,2020-06-01
1267268949017853954,https://twitter.com/neo_fonseca/status/1267268949017853954,neo_fonseca,Thx dr Burris @ASCOPres for not staying silent on racism. Our country needs greater equity &amp; not the institutionalized violence by the powerful that lead to the violent response. This was my planned virtual  #ASCO20 weekend. Instead I was pulled by our country’s woes https://t.co/7i3daoZOGy,2020-06-01
1267268538374320128,https://twitter.com/utopia15/status/1267268538374320128,utopia15,"#ASCO20 
NK Max successfully launched SNK
https://t.co/0RQT0FMmY3",2020-06-01
1267268502567583747,https://twitter.com/neerajaiims/status/1267268502567583747,neerajaiims,"Thanks @DrChoueiri I donated this morning right after @PGrivasMDPhD Thanks for the initiative. With so many @asco members, I am sure we are going to hit the finish line very soon as a wonderful culmination of #ASCO20 👍😊 https://t.co/PyR3eqmqBg",2020-06-01
1267267903092674561,https://twitter.com/LguzzardiM/status/1267267903092674561,LguzzardiM,"Polygenic Risk Score, #FamilyHistory Refine #BreastCancer Risk Assessment in #CHEK2 Mutation Carriers ⁦@MarkRobsonMD⁩ ⁦@sloan_kettering⁩ ⁦@ASCO⁩ 

#bcsm #CancerResearch #hereditarycancer #ASCO20 #genetics #gcchat

Via ⁦@PrecOncNews⁩ https://t.co/Iok2m39Cm2",2020-06-01
1267267122520109057,https://twitter.com/CancerResearch/status/1267267122520109057,CancerResearch,"In the Phase I trial discussed by Dr. Nikhil C. Munshi of @DanaFarber, patients with relapsed multiple myeloma were treated with CAR T cell therapy that targets the BCMA marker found on these cells. #ASCO20 https://t.co/ElelNcyKS2",2020-06-01
1267266791295848448,https://twitter.com/clttumordoc/status/1267266791295848448,clttumordoc,Proud of the work from our @LevineCancer #SarcomaTeam! Happy to be a role player as part of this research machine! Awesome to see this work featured as part of the #virtual @ASCO Annual Meeting. @AtriumHealth #curesarcoma https://t.co/UjyMfVtgJQ,2020-06-01
1267266665823244291,https://twitter.com/TiansterZhang/status/1267266665823244291,TiansterZhang,"So true. A toast to our common humanity and caring for everyone. With the ongoing COVID pandemic and riots across our cities, hope colleagues, friends, &amp; patients all stay safe and well. @asco @kcCURE @KidneyCancer https://t.co/1UtxT1n0mD",2020-06-01
1267266343033729024,https://twitter.com/VPrasadMDMPH/status/1267266343033729024,VPrasadMDMPH,"Some folks ask if we would interpret #ADAURA dif. if the Rx cost $5/ mo instead of ~$18k /mo

Yes, but its way more complicated...

If these drugs had reasonable prices, the entire trials landscape would be radically different

Discussed here:
https://t.co/4BCGepD2ns

#ASCO20",2020-06-01
1267266195247386624,https://twitter.com/DrErin_DO/status/1267266195247386624,DrErin_DO,Saving for later... #ASCO2020 https://t.co/1Laur5RgGU,2020-06-01
1267265754031968259,https://twitter.com/ndenduluri1/status/1267265754031968259,ndenduluri1,Thanks @FavretMD for hosting virtual #ASCO20 and contributing to https://t.co/XNj3oEvdcB and meeting the @ASCOPres challenge - now challenging @TheUSONetwork @VCSpecialists @DrCBrzezniak to donate to @ConquerCancerFd https://t.co/5iXgXOU0dW,2020-06-01
1267265627141689350,https://twitter.com/shrivastava_sam/status/1267265627141689350,shrivastava_sam,"#ASCO20 was nice to be able to listen and download so many presentations. They should make this option availble every year. 

Really liked the Cancer Prevention and Risk Reduction and Genetic Highlights session by Dr. Erin Hofstatter yesterday.",2020-06-01
1267265297704157196,https://twitter.com/m0370/status/1267265297704157196,m0370,MSI-H大腸癌のKEYNOTE-177、RASwtの方がペムブロ群で好成績なのはなぜだろね？RASによるICIの効果の違いはKEYNOTE-164ではあまり言われてなかったと思うけど。単にRASwtのほうが緩徐進行型が多くてICIに有利な患者がセレクションされていたとか？ #ASCO20 https://t.co/lhmpGioOBI,2020-06-01
1267265166539972613,https://twitter.com/NabbsCreekGnome/status/1267265166539972613,NabbsCreekGnome,"Big shout out to all the folks behind the scenes at @ASCO who were able to pivot and put on a massively huge conference online! I think I would have enjoyed it in person, but such is the time of COVID.",2020-06-01
1267265110948687877,https://twitter.com/SeattleCCA/status/1267265110948687877,SeattleCCA,"#ASCO20: Dr. Gabriela Chiorean's publication ""Phase I results from a phase 1/2 multi-center study of nab-sirolimus combined with mFOLFOX6+bevacizumab (FB) as first-line (1L) therapy in patients..."" Read on our SCCA at @ASCO page: https://t.co/HzDgN1Qpst #ColonCancer https://t.co/knIi967Jc7",2020-06-01
1267264816076464130,https://twitter.com/JohnCendpts/status/1267264816076464130,JohnCendpts,"Really interesting #ASCO20 this year, which I'll be discussing tomorrow. Great audience, join us! Will we be back in chicago next year?",2020-06-01
1267264611780304898,https://twitter.com/flatironhealth/status/1267264611780304898,flatironhealth,"Tumor-agnostic therapies continue to be a significant area of interest. With @FoundationATCG, we examine the use of pembrolizumab in a tumor-agnostic study using a real-world clinico-genomic database.

Learn more: https://t.co/7L2OzzFqZ0 

#ASCO20 #realworlddata #cancerresearch https://t.co/aE8jb94OSg",2020-06-01
1267263415044632577,https://twitter.com/sejadiMD/status/1267263415044632577,sejadiMD,#ASCO2020 Appears once an anticancer immune response takes place after a minimum time &amp; optimal neoag burden it will continue durable long term surveillance without need for ongoing anti-PD1 administration. esp. older patients! Boosters? #melanoma #cancerimmunotherapy https://t.co/25CldADLis,2020-06-01
1267263381884592128,https://twitter.com/alessi_joao/status/1267263381884592128,alessi_joao,"Our poster at #ASCO20:

Glad to share our work: Clinicopathologic characteristics and immunotherapy outcomes in SMARCA4-mutant (mut) non-small cell lung cancer (NSCLC).

https://t.co/h4LJRenxsD

Thanks again to @DrMarkAwad for your dedicated mentorship. https://t.co/s7qj92AGhv",2020-06-01
1267263304277393408,https://twitter.com/GlendaDelgadoR/status/1267263304277393408,GlendaDelgadoR,"Although not physically together @ASCO as planned, I was still able to enjoy the excellent #ASCO20 virtual platform with my role model (and mum) #DraGlendaRamos best oncologist in #Ecuador 🇪🇨 @SolcaGuayaquil @oncologiaec",2020-06-01
1267262935774216195,https://twitter.com/MLPOncoData/status/1267262935774216195,MLPOncoData,#ASCO20 CAPOX!!! https://t.co/QuBhgu54M0 https://t.co/s2Di6804Tn,2020-06-01
1267261438873047041,https://twitter.com/BreastDoctorsEx/status/1267261438873047041,BreastDoctorsEx,"米国では約6％の乳がんが見つかった時にはstage 4といわれている。
そのうち薬物治療が効いている方256名を対象に、乳房の手術をするかしないかの米国の臨床試験報告。
HER2やER陽性では違いはなく、TNではしない方が良いかもしれないと。
まだまだ検証が必要
https://t.co/xbU0KxGLeJ
#乳がん #ASCO20",2020-06-01
1267261051579404289,https://twitter.com/m0370/status/1267261051579404289,m0370,"ツイートまとめを再度更新しました。
日付別で分けようかと思ったが、バーチャルスライドのせいで発表日にツイートされてるとも限らず整理しきれていません。#ASCO20 タグを中心に検索してるのでタグがないツイートは拾い切れてないかも。
／ASCO2020の日本語ツイートまとめ https://t.co/V4XY7CcNqn",2020-06-01
1267260889188753409,https://twitter.com/PoorviDesaiMD/status/1267260889188753409,PoorviDesaiMD,"Yes! Let’s keep this going 👏🏼 

@HemOncWomenDocs 🐺 
@ConquerCancerFd 🧬 
@ASCO #ASCO20 🥼 https://t.co/ayVjqOKSTK https://t.co/PAxz8wW5xV",2020-06-01
1267260417207869447,https://twitter.com/foglesong_md/status/1267260417207869447,foglesong_md,"Good news from #ASCO2020 was that @BarackObama Obamacare decreased cancer mortality &amp; narrowed some racial disparity (more to do) Good public policy can solve big problems. Access to 🏥,👩‍🏫, 👨‍🌾, 🏡, 🚝 is essential part of our recovery. Will be long difficult but needed change. https://t.co/Cok1cGDRIu",2020-06-01
1267260396332777473,https://twitter.com/KaterinaSaveli1/status/1267260396332777473,KaterinaSaveli1,Another interesting compound in development from @ASCO today is PROTAC ARV-110: interested to see what transpires when more data is available. #ASCO2020,2020-06-01
1267260330226434049,https://twitter.com/MDedgeHemOnc/status/1267260330226434049,MDedgeHemOnc,"#ASCO20: Could relugolix be a new standard for #testosterone suppression in patients with advanced #prostatecancer? Relugolix bested leuprolide in the HERO trial, with 96.7% of patients on relugolix sustaining castration through week 48. Abstract 5602, https://t.co/EqWBxNRqHX https://t.co/uCc9rvy4fZ",2020-06-01
1267259621762367491,https://twitter.com/TargetedOnc/status/1267259621762367491,TargetedOnc,"FROM #ASCO20: In the phase 1b COSMIC-021 trial, cabozantinib and atezolizumab had clinically meaningful activity in patients with metastatic castration-resistant prostate cancer, including those with high-risk clinical features.
https://t.co/SqKEFtCv8d #pcsm #prostatecancer",2020-06-01
1267259006424416257,https://twitter.com/chadinabhan/status/1267259006424416257,chadinabhan,Now why is @DrChoueiri #ASCO20 video not playing? https://t.co/aoopUBEiz5,2020-06-01
1267258569617018882,https://twitter.com/MSD_Aus/status/1267258569617018882,MSD_Aus,"We have made so many meaningful inroads to address cancer, which touches the lives of so many – we've come too far to be stopped by this pandemic.” Roy Baynes on ensuring no patient is left behind in their #cancer care during #COVID19 #ASCO2020 https://t.co/qsAJaaVS1Y https://t.co/qJs19zxmCu",2020-06-01
1267258077314781186,https://twitter.com/PamChMD/status/1267258077314781186,PamChMD,I was not able to join ASCO this year but I am very aware that every small contribution counts always. Let's join together to continue working to conquer cancer 🌠... @AndreaAnampaG  @LatinasInMed @ASCO #ASCO20  @HemOncWomenDocs https://t.co/E4w4xO8lNe,2020-06-01
1267258058947932160,https://twitter.com/SarahSewar/status/1267258058947932160,SarahSewar,"After working this weekend it's finally time to catch up on #ASCO20
Better late than never..
#WomenInMedicine 
#MedEd",2020-06-01
1267257947232534530,https://twitter.com/BrasilOncologia/status/1267257947232534530,BrasilOncologia,"Os oncologistas discutiram ontem, durante um #webinar ao vivo, os destaques do 2º dia da #ASCO20. Os temas abordados foram relacionados à #câncer de mama, tumores gastrointestinais, neuro-oncologia e câncer de cabeça e pescoço. Assista: https://t.co/C93vGtZ9f2 https://t.co/3uRkvaEDKL",2020-06-01
1267257873500786689,https://twitter.com/FightCRC/status/1267257873500786689,FightCRC,"Be sure to join our follow up webinar with Dr. Richard Goldberg on June 23rd at 1p ET as we dive into exciting research updates from #ASCO20!
#colorectalcancer

https://t.co/qCuPRdbqqJ",2020-06-01
1267257513470238722,https://twitter.com/VitorSforni/status/1267257513470238722,VitorSforni,#ASCO20 One day I hope to get NGS results this fast! https://t.co/hSQB5qAdXX,2020-06-01
1267257060930064384,https://twitter.com/OncLive/status/1267257060930064384,OncLive,"When added to bortezomib and dexamethasone in patients with multiple myeloma, selinexor, an inhibitor of XPO1-mediated nuclear export, improves PFS and ORR and reduces the incidence of peripheral neuropathy. @uoaofficial @ASCO #ASCO20 #mmsm https://t.co/Im60E3hX2V",2020-06-01
1267256746051096576,https://twitter.com/chadinabhan/status/1267256746051096576,chadinabhan,"I didn’t catch all #ASCO20 presentations live...
Sunday night to catch up.",2020-06-01
1267256548352569345,https://twitter.com/Galenia_cat/status/1267256548352569345,Galenia_cat,"Fin de semana intenso para la #Oncologia y la #InvestigacióOncológica Todos pendientes de @ASCO y de sus novedades. Uno de los centros que año tras año tiene presencia destacada es #VHIO 

Muy contentos de poder ser testigos de las novedades y compartir #GaleniaTeam 
👇👇",2020-06-01
1267256455712788480,https://twitter.com/tkdmHawkeye/status/1267256455712788480,tkdmHawkeye,"E2108
de novoのStIV BCに対する局所手術の影響について
OSにもDFSにも手術は影響を与えなかったという結果はもう出回ってますので背景を見ていきます
デザインとしては手術の前に4-8ヶ月の薬物療法を行ってからのランダマイズであること
#ASCO20 https://t.co/GPJmIGymUl",2020-06-01
1267255827179675649,https://twitter.com/MLPOncoData/status/1267255827179675649,MLPOncoData,#ASCO20 https://t.co/k2IR9rYZ6c https://t.co/adk99rTuge,2020-06-01
1267255598472708096,https://twitter.com/crisbergerot/status/1267255598472708096,crisbergerot,"‼️@ASCO Daily News #ASCO20 @ASCO_pubs ‼️

Geriatric Assessment–Driven Intervention Benefits Older Adults With Cancer @DanengLi @WilliamDale_MD @cityofhope #GeriOnc @myCARG @MySuppCareCOH 

https://t.co/DfwE1u9l2l https://t.co/YK7nQY9oRK",2020-06-01
1267255436442550276,https://twitter.com/MLPOncoData/status/1267255436442550276,MLPOncoData,#ASCO20 https://t.co/X2LXm0s9PM https://t.co/nHF3IZjtNr,2020-06-01
1267255105553936384,https://twitter.com/MLPOncoData/status/1267255105553936384,MLPOncoData,#ASCO20 https://t.co/Fk3UVvwAta https://t.co/EkstBx0Hws,2020-06-01
1267254565486895105,https://twitter.com/GBOT_Alerta/status/1267254565486895105,GBOT_Alerta,"Geometry Mono1: Capmatinib em 2L em CPNPC IIIB/IV (uso independente de jejum). METex14mut  - TRO 48,4% SLD  8,1m/ AmpMET: DE em todos. Seguro e menos tóxico que o uso em jejum. @BabiLafayette  #ASCO20 #GBOT_Alerta https://t.co/ndQFdTqgeD",2020-06-01
1267254334666018819,https://twitter.com/GeneOnlineNews/status/1267254334666018819,GeneOnlineNews,"#ASCO20
TROPHIMMUN study evaluating @MSDInvents &amp; @pfizer's Avelumab is the first trial where PD-L1 targeting #immunotherapy is attempted against Gestational trophoblastic tumors (GTT). The results were discussed in the virtual meeting

#Cancer #GeneOnline
https://t.co/hGwdkuxZk8",2020-06-01
1267253933279510529,https://twitter.com/alessi_joao/status/1267253933279510529,alessi_joao,"Our poster at #ASCO20.

Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small-cell lung cancer and a poor performance status.

Thanks to my outstanding mentor @DrMarkAwad.

https://t.co/If18BNdQVy

@BiagioMd, @GRecondoMD, @GLambertiMD, @Deepti_Venkat https://t.co/s6COo5LxWS",2020-06-01
1267253783706378246,https://twitter.com/MDedgeHemOnc/status/1267253783706378246,MDedgeHemOnc,Radiotherapy followed by consolidative chemo and surgery can reduce treatment failure for patients with advanced rectal #cancer. https://t.co/ASRtcv5EHj #ASCO20 #ASCO2020 #oncology #medtwitter https://t.co/7yD4YvoOlH,2020-06-01
1267253755852083200,https://twitter.com/SilasInman/status/1267253755852083200,SilasInman,Trastuzumab Deruxtecan Induces Durable Responses in  HER2 -Mutant NSCLC https://t.co/XKwN4FMQnp #lcsm #ASCO20,2020-06-01
1267253488171528192,https://twitter.com/AndreaAnampaG/status/1267253488171528192,AndreaAnampaG,"Let's DONATE TO @ConquerCancerFd! 🐺🐺🐺 #ASCO20  @ASCO 
@LatinasInMed @PamChMD @Shojanny @NicoleCruzMD  @PoorviDesaiMD @BernabeCarolina @NarjustDumaMD @AMarshallMD https://t.co/80JX5DnPZq",2020-06-01
1267253238593720320,https://twitter.com/tanyawildes/status/1267253238593720320,tanyawildes,"The highlight of #ASCO2020 for me: annual CARG dinner - virtual. Loved hearing your voices, my friends! 
Posters presented, nearly-naked-husband-photobombers, 65th birthdays and big awards to celebrate, and ever-present memories of Arti and her legacy. #gerionc #drhurriaslight https://t.co/aZqJ8Wstq5",2020-06-01
1267253201620828168,https://twitter.com/crisbergerot/status/1267253201620828168,crisbergerot,"‼️ @ASCO Daily News #ASCO20 

‼️ Integrated Oncogeriatric Care Improves Health-Related Quality of Life @KhengSoo1 @ANZUPtrials @Prof_IanD #INTEGRATE #GeriOnc 

https://t.co/x05nge7AhQ https://t.co/jkBcABNDUX",2020-06-01
1267253015930683392,https://twitter.com/VivekSubbiah/status/1267253015930683392,VivekSubbiah,"Amplifying Dr.  @tmprowell &amp; @DrChoueiri’s message. The Virtual @ASCO #ASCO20 Scientific Program ✅ &amp; you have 180 days to listen to them. 

Now ➡️text ASCO to 41444 b/c it takes 30 secs to donate $5 to @ConquerCancerFd &amp; you’ll feel good to check it off your list. 👍 @ASCOPres https://t.co/ZLVeyCx4Qt",2020-06-01
1267252720693661697,https://twitter.com/RyanNguyenDO/status/1267252720693661697,RyanNguyenDO,Joining the call for @ASCO to make public statement denouncing structural racism and the role it plays in the cancer community and beyond https://t.co/ZOJMGZaA4r,2020-06-01
1267252593484599296,https://twitter.com/GBOT_Alerta/status/1267252593484599296,GBOT_Alerta,"CCTG BR.34: A adição de QT a durva/tremilimumabe (DT) - 1ª linha CPCNP não melhorou SG vs DT. SLP superior no DT + QT - 7,7 vs 3,2m. TMB plasma &lt;20 mut/Mb = &lt; SG - fator prognóstico @AnaGelatti1  #ASCO20 #GBOT_Alerta https://t.co/RNVMnEHJZH",2020-06-01
1267252378044071937,https://twitter.com/abcdiagnosis/status/1267252378044071937,abcdiagnosis,This &amp; agree! 👇🏼 #oligomets @METUPUKorg #ASCO20 #bcsm https://t.co/TuS0Sv20WL,2020-06-01
1267252062733164545,https://twitter.com/GrantWilliamsMD/status/1267252062733164545,GrantWilliamsMD,So wonderful virtually seeing everyone in @myCARG! It’s been a tremendous year for #GeriOnc at #ASCO20 and hopefully that’s the case for years to come https://t.co/T6oSBRxkPh,2020-06-01
1267252053367291906,https://twitter.com/matthewherper/status/1267252053367291906,matthewherper,"There is good news in the world.
Evidence? @adamfeuerstein’s #ASCO20 newsletter.
https://t.co/9IvWc4HuGI",2020-06-01
1267252026431492099,https://twitter.com/DrChoueiri/status/1267252026431492099,DrChoueiri,"Bladder cancer in 1 slide from our @DanaFarber bladder guru, Guru @sonpavde #ASCO20 https://t.co/6aHKFGPvvB",2020-06-01
1267252023797440513,https://twitter.com/how_sustainable/status/1267252023797440513,how_sustainable,"iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (MNLO)

#Biotech #ASCO20 #ABBV #ABIO
https://t.co/fUlacqAje7 https://t.co/iNcmpZLen0",2020-06-01
1267251986384257024,https://twitter.com/miljko/status/1267251986384257024,miljko,"Fun fact: one of the seven founding members of @ASCO (back in 1964!) was Dr. Jane Cooke Wright, a woman of color. #ASCO20 

https://t.co/CvSpMK6M8c https://t.co/N853SicAvF",2020-06-01
1267251726568034304,https://twitter.com/gustavovalves/status/1267251726568034304,gustavovalves,#ASCO20 is not over for me yet !!! https://t.co/mDUMlJZsXS,2020-06-01
1267251435135217664,https://twitter.com/fumikochino/status/1267251435135217664,fumikochino,"In the very last #ASCO20 session of the day, in the last abstract discussed... appreciated Dr. Carolyn Hendricks highlighting our study in the Care Delivery &amp; Regulatory Policy section amongst other research on ways to improve how we deliver #cancer care.
https://t.co/q8NnfvD2ve https://t.co/YcsewzzjJM",2020-06-01
1267251111171248128,https://twitter.com/stage4kelly/status/1267251111171248128,stage4kelly,#advocate friends let’s show up the oncologists by stepping up to support @ConquerCancerFd by text or online at https://t.co/8MbW2sUpMN - we are the beneficiaries of the #research! I donated and I challenge you to do the same. #ASCO20 #bcsm #lcsm #crcsm #gyncsm #melsm #pcsm #mmsm https://t.co/odrrm15H6B,2020-06-01
1267250569799852033,https://twitter.com/ranjith_menon/status/1267250569799852033,ranjith_menon,"Cancer is a complex disease. Lack of access to multi-disciplinary cancer care in developing countries leads to inaccurate treatment protocol and poor outcomes.  
@rashiejain @AmitJotwani_MD @OncoDotCom  @ASCO @ChirataeVC @tranquilquill https://t.co/SdYEzaimUi",2020-06-01
1267250008706998273,https://twitter.com/OncotypeIQ/status/1267250008706998273,OncotypeIQ,What does #breastcancer management during the Covid-19 pandemic look like? #ASCO20 Dr. Christy Russell explains https://t.co/V5umFgZRTZ #oncology #chemo #Oncotype https://t.co/Gzu4b0rmtU,2020-06-01
1267249922400755713,https://twitter.com/ADesaiMD/status/1267249922400755713,ADesaiMD,Do you remember when you joined Twitter? I do! #MyTwitterAnniversary which aptly falls right on #ASCO20 day and one year since #ASCO19 when I  joined the #Twitterverse ! https://t.co/Wj6UCb3sgA,2020-06-01
1267249614610145280,https://twitter.com/RichardWJoseph/status/1267249614610145280,RichardWJoseph,Finally getting to review some @asco videos. Getting started with highlights of melanoma. Great job by @JaniceM10! https://t.co/Mf6NUrFurH,2020-06-01
1267249517293981696,https://twitter.com/OncNursingNews/status/1267249517293981696,OncNursingNews,#ASCO2020 News: Chemotherapy administered within 3 months of a diagnosis of COVID-19 increased the risk of death in patients with thoracic cancer. https://t.co/lEi2gvH5pa,2020-06-01
1267249389963079680,https://twitter.com/arkhaki/status/1267249389963079680,arkhaki,"Great summary of bladder cancee data from #ASCO20 

@urotoday @BladderCancerUS @PGrivasMDPhD @LauraGrahamMD @LDiamantMD @sokolova_md https://t.co/eiXfLGwLck",2020-06-01
1267246484002570241,https://twitter.com/MDAndersonNews/status/1267246484002570241,MDAndersonNews,The findings of a recent MD Anderson-led study suggest #AML treatments may be tailored to individual molecular profiles: https://t.co/QM77a4RiOt #ASCO20 #endcancer,2020-06-01
1267246297406484480,https://twitter.com/alessi_joao/status/1267246297406484480,alessi_joao,"Plenary session at #ASCO20: 

ADAURA trial: Ph III, double-blind, randomized study of osimertinib vs placebo in EGFRm NSCLC post tumor resection (stage IB/II/IIIA). 

&gt; Primary endpoint result: Impressive DFS improvement in pts w/ stage II/IIIA - HR 0.17 (0.12-0.23); p&lt;0.0001.",2020-06-01
1267246064777736197,https://twitter.com/grpetersen1/status/1267246064777736197,grpetersen1,Cure #COVID19 with an #ADC Antibody Warehead Conjugate - #ASCO20 @ASH @AndyBiotech @IAmBiotech @CellectarBio @thebiotechforum @_B_I_O_T_E_C_H_ @i_biotech @BiotechWorld @biogen @ScottGottliebMD @BIOConvention @Biotechnology @BioTechMagTop @BioWorld @SteveFDA @JanssenUS @AstellasUS https://t.co/cwrM8mOogN,2020-06-01
1267245391906590720,https://twitter.com/HemOncWomenDocs/status/1267245391906590720,HemOncWomenDocs,"Where are my Wolves at!?! Wolves make a difference in the world. Wolves put their wallets where their mouths are.

Donate to change the face of #COVIDnCancer #COVID19 #ASCO20 

Cc @wearewildfang @AbbyWambach https://t.co/aETDtABmx8",2020-06-01
1267245129703649281,https://twitter.com/bigbird_vn/status/1267245129703649281,bigbird_vn,"スライド画像付きのツイートを中心にまとめました。
更新終了しました。#ASCO20「ASCO 2020: NSCLC (非小細胞肺癌のまとめ)」 https://t.co/bvXdo4lH0o",2020-06-01
1267245028163936257,https://twitter.com/sloan_kettering/status/1267245028163936257,sloan_kettering,"Polygenic Risk Score, Family History Refine #BreastCancer Risk Assessment in CHEK2 Mutation Carriers #ASCO20 https://t.co/JQ1FYAd9Hv",2020-06-01
1267244495885697032,https://twitter.com/EisaiUS/status/1267244495885697032,EisaiUS,"That’s a wrap! Thank you @ASCO for hosting a fantastic Virtual Scientific Meeting this year. We are humbled by all the contributions, research and continued efforts from all to help advance cancer care. https://t.co/oCuZmC8ZNP",2020-06-01
1267244255438872576,https://twitter.com/sloan_kettering/status/1267244255438872576,sloan_kettering,ICYMI - 18F-DCFPyL–PET/CT Imaging Improves Diagnostic Capability in Relapsed #ProstateCancer. #ASCO20 https://t.co/hvOobRPRhr,2020-05-31
1267244049066602498,https://twitter.com/subatomicdoc/status/1267244049066602498,subatomicdoc,FYI @ASCO if this isn't kosher just let me know and I'll take it down - just encouraging continued access to abstracts that might interest #radonc #medonc #surgonc #survonc folks 🙂 https://t.co/Rjj3HEZ97p,2020-05-31
1267243863275700233,https://twitter.com/sloan_kettering/status/1267243863275700233,sloan_kettering,Germline Results From Tumor-Normal Sequencing Guides Precision Therapy in Advanced Cancer Patients. #ASCO20  https://t.co/O01qcyJy4H,2020-05-31
1267243021294284803,https://twitter.com/UqbaKhan/status/1267243021294284803,UqbaKhan,"KN-177

Practice changing 1st line Rx for MSI-H CRC

Crossing of PFS curves in 6m concerning
(PD 29% w Pembro)

Seen in other IO trials as well

Innovative approach of @mdmanishshah trial in gastric ca can potentially overcome this early concern  

https://t.co/5LXPRpab0z #ASCO20 https://t.co/oF6HLSLcSJ",2020-05-31
1267242417532649472,https://twitter.com/fumikochino/status/1267242417532649472,fumikochino,"As #ASCO20 wraps, the US remains in turmoil. For those unable to see the inequities at the root of this strife, I will highlight 1 graph from our study. Even as we make progress over time, FAR MORE black patients die from #cancer than white patients. 

This is not a just society. https://t.co/RBBtgeH5cL",2020-05-31
1267242111998386176,https://twitter.com/fredtingmd/status/1267242111998386176,fredtingmd,"Great summary by @rschilsky ! @ASCOPost @ASCO #ASCO20

https://t.co/ntU2IORzuq",2020-05-31
1267241963591524352,https://twitter.com/OncLive/status/1267241963591524352,OncLive,A phase 3 study using cediranib &amp; olaparib to treat recurrent platinum-sensitive ovarian cancer did not meet its primary end point of PFS but did produce comparable activity to standard of care platinum-based chemotherapy. @DanaFarber #ASCO20 #gyncsm https://t.co/n43In39xen,2020-05-31
1267241672980733953,https://twitter.com/DavidFajgenbaum/status/1267241672980733953,DavidFajgenbaum,"Thanks Chadi! Was so thrilled to be able to share some of the highlights from our work to @CureCastleman with @ASCO! Thanks for sharing the below. More details at: https://t.co/8LgqWXCtp5, https://t.co/BMQoBF5RUz, https://t.co/5xfGB6x5qy, &amp; https://t.co/Z0jeJRvoWk #ChasingMyCure https://t.co/JwbSQyEkxv",2020-05-31
1267241246327812107,https://twitter.com/temkins/status/1267241246327812107,temkins,"There is so much heterogeneity to this disease... Caring for women with #ovariancancer is part science part art. We now have so many options in our toolboxes -- each patient needs an individualized plan to maximize their outcomes.

@ShannonWestin #ASCO20 #gyncsm #goASCO20 https://t.co/pMwQxV67p7",2020-05-31
1267241128555921408,https://twitter.com/srothschild/status/1267241128555921408,srothschild,It was fun meeting everyone today! Thank you @GinaDAmatoMD1 for hosting this event! #WomeninSarcoma #ASCO20 https://t.co/h4eVq49oiP,2020-05-31
1267240958875361280,https://twitter.com/CancerResearch/status/1267240958875361280,CancerResearch,"Playing catch up from #ASCO20? Read our conference recap now 👇

https://t.co/ElelNcyKS2",2020-05-31
1267240830869352448,https://twitter.com/tmprowell/status/1267240830869352448,tmprowell,#ASCO20 #lcsm https://t.co/mPxx9yIWAa,2020-05-31
1267240703949709316,https://twitter.com/columbiacancer/status/1267240703949709316,columbiacancer,"Congratulations to our own @DrDawnHershman, honored at #ASCO20 as a #WomenWhoConquerCancer Mentorship Awardee from the @ASCO @ConquerCancerFd. 
https://t.co/vzjrfWbaW5",2020-05-31
1267240697557590024,https://twitter.com/WeillCornell/status/1267240697557590024,WeillCornell,"Closing out @ASCO news from this weekend. 

Dr. Allyson Ocean (@drallysonocean) of @WCM_MeyerCancer and @nyphospital released data at #ASCO20

Abstract #e16776: 

“Radiomic texture analysis correlates with PDAC patient outcomes on SM-88”

Read more: https://t.co/IAS5VI2hTZ",2020-05-31
1267240193507168256,https://twitter.com/MDedgeHemOnc/status/1267240193507168256,MDedgeHemOnc,"Tucatinib improves PFS, OS in HER2+ breast cancer with brain metastases in 70% of the patients tested in a phase 2 trial released at #ASCO20. https://t.co/y1AyPs2dGX #ASCO2020 @ASCO #breastcancer #medtwitter https://t.co/qKZL56SN7F",2020-05-31
1267239904766918656,https://twitter.com/ramyathota1/status/1267239904766918656,ramyathota1,Thank you @ASCO @ASCOPres and all the presenters for a fantastic virtual conference. Hope some form of this virtual conference continues even post covid especially for the benefit global community at large #ASCO20 #ASCO2020,2020-05-31
1267239649572839425,https://twitter.com/NicoleKuderer/status/1267239649572839425,NicoleKuderer,"✨TEAM SCIENCE ✨. I may be biased. Yet most would agree maybe the best large team in oncology is @myCARG developed by Arti Hurria🙏, and just has stormed #asco20 and proven the benefits of #gerionc assessment! Please share results below:
@gary_lyman @WilliamDale_MD @rochgerionc https://t.co/yYgWkM70Xr",2020-05-31
1267239385382207488,https://twitter.com/sonpavde/status/1267239385382207488,sonpavde,Key #bladdercancer #ASCO20 presentations on 1 slide with 1 line comments- expecting a huge practice changing impact of the Javelin Bladder-100 trial! https://t.co/OibugU8zlQ,2020-05-31
1267239285532459008,https://twitter.com/marklewismd/status/1267239285532459008,marklewismd,"“Us vs them” is a false dichotomy when most of us will be patients, eventually

Why wait to be empathetic?

#asco20 https://t.co/cBzGNUKNg9",2020-05-31
1267238929381515264,https://twitter.com/maartenijzerman/status/1267238929381515264,maartenijzerman,"⁦@k_degeling⁩ has identified significant heterogeneity in published health economic studies of CRC treatments, which likely will impact decisions to reimburse and for patients to access new therapies.  #ASCO20 ⁦@UMCCR⁩  https://t.co/NJ5RHemhT5",2020-05-31
1267237774735761408,https://twitter.com/bigbird_vn/status/1267237774735761408,bigbird_vn,"スライド画像付きのツイートを中心にまとめました。
更新終了しました。#ASCO20「ASCO 2020: SCLC (小細胞肺癌のまとめ)」 https://t.co/VaIwJ7FWzz",2020-05-31
1267237755597336578,https://twitter.com/subatomicdoc/status/1267237755597336578,subatomicdoc,Unfortunately I have run out of time to tweet more research from #ASCO20 - there are a lot of good studies that I couldn't share. But I'll post the ones I liked with the URLs to the original content https://t.co/N1WmP7YLjz,2020-05-31
1267237715503771649,https://twitter.com/bigbird_vn/status/1267237715503771649,bigbird_vn,"スライド画像付きのツイートを中心にまとめました。
更新終了しました。#ASCO20「ASCO 2020: MPM (悪性中皮腫のまとめ)」 https://t.co/UADg74CqMW",2020-05-31
1267237654195851264,https://twitter.com/DrMolinaCalzada/status/1267237654195851264,DrMolinaCalzada,"Estos resultados fase 2 son muy interesantes... Estudio DESTINY-Lung01. Se evalúa una nueva molécula (T-DXtd) con una nueva estrategia (mutaciones #Her-2) en CPCNP no-esc. Esperemos fase 3, promete mucho. #ASCO20  #precisioniskey https://t.co/40PRUtxXvz",2020-05-31
1267237426541531136,https://twitter.com/StrataOncology/status/1267237426541531136,StrataOncology,"StrataNGS successfully reported results in 93% of all samples even tho less than half of &gt;20,000 tumor tissue samples met tumor surface area requirements for leading hybrid-capture CGP tests. Check out the data here https://t.co/eMgxhcA2ka! #ASCO20 #StrataNGS https://t.co/uQRAlOrMdQ",2020-05-31
1267237261965434883,https://twitter.com/EnriqueSoto8/status/1267237261965434883,EnriqueSoto8,"What an honor to be on this slide with the nicest and brightest people, Dr. Muss is such an inspiration! #Gerionc #ASCO20 @myCARG @smlichtman_md @tanyawildes @HKlepinMD @DrHollyHolmes @andrewchap361 @WilliamTewMD @GrantWilliamsMD @MelissaLoh21 @GeriOncMD @ErikaRamsdale https://t.co/x0CiuYB29H",2020-05-31
1267236916921077762,https://twitter.com/Anon_Knee_Mouse/status/1267236916921077762,Anon_Knee_Mouse,#breastcancer #asco20 Tiziana Life Sciences https://t.co/Fo0eS8hsGG,2020-05-31
1267236693972848640,https://twitter.com/GeneOnlineNews/status/1267236693972848640,GeneOnlineNews,"#ASCO20 
@genentech presented promising Phase II trial results of its novel anti-TIGIT immunotherapy, #Tiragolumab in lung cancer patients at the ASCO 2020 virtual program.

#Cancer #CancerResearch #lungcancer #TIGIT #NSCLC #Immunotherapy #GeneOnline

https://t.co/UyKcorbrip",2020-05-31
1267235968635076610,https://twitter.com/Emimenna8/status/1267235968635076610,Emimenna8,"the summary of my first #ASCO ... not in the way I expected, but not for that less enriching.  I hope we can all be in Chicago for #ASCO2021.
#ASCO2020 #oncology https://t.co/pKtL4xjnAB",2020-05-31
1267235635544326145,https://twitter.com/SyedMAhmedMDPhD/status/1267235635544326145,SyedMAhmedMDPhD,"Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 study.
https://t.co/g1EqjjcbtW
#ASCO20 #crcsm https://t.co/hgCpx3nq26",2020-05-31
1267235492732514306,https://twitter.com/ndenduluri1/status/1267235492732514306,ndenduluri1,"Well said @jasonlukemd - whether participants of the @asco AACR Vail Workshop, LDP, grant recipients, relying on @asco for immeasurable other tools, it’s important to support @ConquerCancerFd #PayItForward https://t.co/pMjR55ie0f text ASCO to 41444 #ASCO20 https://t.co/1vM2vfHdhX",2020-05-31
1267235349710999553,https://twitter.com/EnriqueSoto8/status/1267235349710999553,EnriqueSoto8,"Where do we go from here? Dr. Muss, pioneer of #gerionc, talks about the future of geriatric oncology research after #ASCO20 @myCARG #cargvirtualdinner https://t.co/x5vhAJK3gu",2020-05-31
1267234914300235781,https://twitter.com/SeattleCCA/status/1267234914300235781,SeattleCCA,"#ASCO20: Dr. Benjamin Anderson's poster ""Prospective study of an AI enabled online intervention to increase delivery of guideline compliant cancer care, on the ground."" Read on our SCCA at @ASCO page: https://t.co/l2i5qfqlxX https://t.co/RM3q13abHZ",2020-05-31
1267234801586708480,https://twitter.com/GBOT_Alerta/status/1267234801586708480,GBOT_Alerta,CheckMate 227: SG em 3 anos favorável a nivo + ipilimumabe em 1ª linha para CPNPC quando comparado com QT. Pacientes PD-L1≥ 1% - Taxa SG 33 x 22%; PD-L1 &lt;1%  - Taxa de SG 34 x 15% @AnaGelatti1 #ASCO20 #GBOT_Alerta https://t.co/2VT6aq5OSF,2020-05-31
1267234728156868608,https://twitter.com/Starkindler/status/1267234728156868608,Starkindler,Learn more about how we are redesigning the clinical trial experience for patients during #COVID19. #ASCO20 #ScienceWillWin #PFEColleague https://t.co/Sdapj7F463,2020-05-31
1267234528420081664,https://twitter.com/ElementoLab/status/1267234528420081664,ElementoLab,Truly impressive 80% complete response rate for Gilead's anti-CD19 CAR-T in follicular lymphoma and marginal zone lymphoma presented at @ASCO   https://t.co/gA2SmP1ms9,2020-05-31
1267234306025500678,https://twitter.com/ja_ocejo/status/1267234306025500678,ja_ocejo,"Had a pretty cool 1st #ASCO20 experience of hopefully many more to come.

Thank you @ASCO for making this opportunity available to student members. Glad I joined #MedTwitter, it was a great way to network with the #HemOnc #URM community! 🌎",2020-05-31
1267234200018657280,https://twitter.com/andrewjohnsmd/status/1267234200018657280,andrewjohnsmd,So cool to see “what’s next” with checkpoint inhibitors! #ASCO20 @dpgoldst @MdOzga @CanerSaygin  @OhioStateIMRes https://t.co/fgoyKKuAbP,2020-05-31
1267234181433552896,https://twitter.com/EdEsplin/status/1267234181433552896,EdEsplin,"13% of #germline mutations missed by #tumor-only testing in #breastcancer #patients. #Germline #genetictesting for all #breastcancer #patients w/#somatictesting? 
Study @Invitae presented @ASCO #ASCO2020 #oncoalert @bccww #precisiontherapy #clinicaltrials https://t.co/ZJ982BgoVv",2020-05-31
1267234159916920833,https://twitter.com/CCAlliance/status/1267234159916920833,CCAlliance,"To recap #ASCO20 critical takeaway- info on your tumor mutation can change your treatment path and outcomes! Ask onc for biomarker testing. 
Use the Clinical Trial Finder @ https://t.co/wBHowLuf2M to find life-saving trials that meet your specific cancer needs.",2020-05-31
1267234134839066624,https://twitter.com/MTCOSB/status/1267234134839066624,MTCOSB,"LBA4 MSI-H/MMR 大腸がんのペンブロvsケモ、全体としてポジティブかつ後半の差がすごい。サブグループ解析でRAS変異ありではよくないのが興味深い。大腸がんではRASは徹底的に予後不良因子。
RASの細かい変異の違いで予後の違いがあったらすごい面白いんだけどな。#ASCO20 https://t.co/Ltm8yyfGI5",2020-05-31
1267234058070822912,https://twitter.com/chemobrainfog/status/1267234058070822912,chemobrainfog,"If you learned from #ASCO20, and you can spare a bit, how about helping @ConquerCancerFd reach their goal? https://t.co/fmVUJzINFr",2020-05-31
1267233735650488321,https://twitter.com/DrEstfan/status/1267233735650488321,DrEstfan,"Just got to watch @DavidFajgenbaum inspirational talk at #ASCO20 about #castleman and #chasingmycure (which will be my next book to listen to, if this long book of Collapse ever ends). 
I feel very dwarfed and hopeful. 
And I totally agree regarding the humor. Thank you David!",2020-05-31
1267233384151109634,https://twitter.com/CCAlliance/status/1267233384151109634,CCAlliance,"Big #ASCO20 takeaways (pt 2)-
• Many mutations are checked but few are an actionable mutation (there’s a drug to target it)
• Lack of drugs to target is changing, slowly, if your mutations are not actionable currently
• New CRC mutations were identified with some success",2020-05-31
1267233209458266112,https://twitter.com/HH_Oncodr/status/1267233209458266112,HH_Oncodr,"Kudos to KN-177 team &amp; investigators for this MSI-H #coloncancer study, #ASCO2020. New standard! And ⁦@michael_overman⁩ for brilliant discussion (now a statistician too!!).  But 30% early PD on Pembro: KRASm, bulky dx, symptomatic? More studies needed;⁦@RutgersCancer⁩ https://t.co/AbxJw36L3s",2020-05-31
1267232917991960577,https://twitter.com/CCAlliance/status/1267232917991960577,CCAlliance,"big #ASCO20 takeaways! (part 1)
• Personalized medicine is here
• If you are stage IV or metastatic, have Next Generation Sequencing (NGS) done on the tumor and ALL new tumors
• Get a copy of the report, for some reason this will not be included in many patient portals",2020-05-31
1267232792422858757,https://twitter.com/CettroOncologia/status/1267232792422858757,CettroOncologia,"A combinação de doxorrubicina e trabectedina em pacientes com leiomiossarcoma avançado se mostrou eficaz.

#ASCO2020 #ASCO20 #CETTROASCO20 #ASCO20PSMA",2020-05-31
1267232525249732608,https://twitter.com/Honekko_oncolo/status/1267232525249732608,Honekko_oncolo,"フランスから、cT1-T2N0の口腔癌に対するセンチネルリンパ節生検の有用性についての報告。
従来のNDとセンチネル生検が同等との結果

DOIもそうだけど、やっぱりセンチネルリンパ節生検が有用、という方向になりそう？

＃ASCO2020　＃HNC",2020-05-31
1267232421549764609,https://twitter.com/MTCOSB/status/1267232421549764609,MTCOSB,LBA1 尿路上皮がん維持療法のアベルマブがOS positive。アベルマブ、マジでここしか使いどころないから使ってあげたい...メルケル細胞がんとか数年に一人ぐらいしか見たことないし... #ASCO20 https://t.co/iSCxEqZo56,2020-05-31
1267231594135379969,https://twitter.com/alexfmaciel/status/1267231594135379969,alexfmaciel,"Encerrando um final de semana de congresso. #ASCO20 trouxe foi excelente, depois de um ano de “entre-safra” em 2019. Veio com tudo. Muita inovação e uma sessão plenária daquelas! #oncologia #ASCO2020",2020-05-31
1267231468037824517,https://twitter.com/CelsoMello15/status/1267231468037824517,CelsoMello15,"Diferenças na classificação molecular dos tumores colorretais estadio II/III foram observadas em estudo colaborativo entre 5 países de regiões geográficas distintas. 
#ASCO20  @acccancercenter @MDAndersonNews  🇧🇷 🇨🇦 🇺🇸 🇲🇽 🇹🇭 https://t.co/3JiFO6hMuE",2020-05-31
1267231279642222592,https://twitter.com/CettroOncologia/status/1267231279642222592,CettroOncologia,"O resultado de eficácia da toxicidade e taxa de resposta da associação de lenvantinib a eribulina no tratamento de pacientes com lipossarcoma e leiomiosarcoma avançado são promissores.

#ASCO2020 #ASCO20 #CETTROASCO20 #ASCO20PSMA",2020-05-31
1267230982782017538,https://twitter.com/YishanChuang/status/1267230982782017538,YishanChuang,Incredible data presented at ASCO this year #ASCO20. Thank you @DrRoyHerbstYale for the great presentation and @dave6408 for the thoughtful discussion! https://t.co/nsDpagXH6D,2020-05-31
1267230891300003840,https://twitter.com/gselvaggiMD/status/1267230891300003840,gselvaggiMD,Brilliant breakdown of #alk #nsclc patients into Bad-Alk vs good-Alk by Ross Camidge! The way to go for next 1L series of studies... at @BMLIcancerCME Alk symposium #ASCO20 https://t.co/lngBJaqwF8,2020-05-31
1267230828536479751,https://twitter.com/jesusanampa/status/1267230828536479751,jesusanampa,"Me towards the end of #ASCO15  to  #ASCO19 - my brain wanted a break.

But in #ASCO20 ; the same thing happened, however, nobody was around to notice it - less embarrassed

One more benefit of virtual #ASCO20
https://t.co/p0zZywOuYa",2020-05-31
1267230822966452226,https://twitter.com/PortalOnconews/status/1267230822966452226,PortalOnconews,"Estudos que marcaram o panorama dos tumores colorretais no #ASCO20 são tema da análise dos oncologistas Roberto de Almeida Gil, @AlexandrePallad e Gustavo Sanches - https://t.co/kNbTloaDNP @ASCO @oncoclinicas @hospitaldeamor @Inca_rj #ONCONEWS #COLORRETAL #GI #ONCONEWSnoASCO20 https://t.co/PbXRKWkfYq",2020-05-31
1267229655440011265,https://twitter.com/DrChowdharyMD/status/1267229655440011265,DrChowdharyMD,"Seems like ADAURA results are practice changing based on comments

(whether agree or not w/ PFS endpoint)

Q: Is it too soon to run optimal Osimertinib duration trial?

Maybe 2 v 3 years?

cc @DevikaDasMD @NarjustDumaMD @JackWestMD @n8pennell @CharuAggarwalMD 

#ASCO20 #lcsm https://t.co/dv0jWXvNeh",2020-05-31
1267229417387982848,https://twitter.com/CancerDotNet/status/1267229417387982848,CancerDotNet,"Do you know that #advocates have a big impact on #cancerresearch? 🔬Understand why the advocate's role in #research is so important. 
https://t.co/u3jWnJbr1k #advocacy #advocate #patientadvocate #research #clinicaltrials #ASCO20 https://t.co/UWkdA5k3V6",2020-05-31
1267229281291243521,https://twitter.com/tmprowell/status/1267229281291243521,tmprowell,"#ASCO20

Hey what are you doing back here? The Virtual Scientific Program is finished. We’ve all gone home. 

Oh! You were looking for the tweet that said text ASCO to 41444 b/c it takes 30 secs to donate $5 to @ConquerCancerFd &amp; you’ll feel good to check it off your list. 👍 https://t.co/ohunkDEuNV",2020-05-31
1267228852218220546,https://twitter.com/sarahkrug1/status/1267228852218220546,sarahkrug1,Time Capsule Idea: Imagine if we had a layman's summary that accompanied every @asco abstract/session that was open access to all patients #asco20 https://t.co/NqIGj6LnDr,2020-05-31
1267228639646617602,https://twitter.com/inas_md/status/1267228639646617602,inas_md,"#ASCO20
Love this all-women panel and will be following their future accomplishments!💪 https://t.co/XxBPwAKcOa",2020-05-31
1267228283965505537,https://twitter.com/CarmenCalfa/status/1267228283965505537,CarmenCalfa,"Challenge accepted. Can the #orangemasks be purchased for $$ towards the 1mil goal? it would be great to have a photo collage with, hopefully, thousands of participants @ConquerCancerFd @ASCO #ASCO20 https://t.co/MZGyp1Jq2f",2020-05-31
1267228218962194434,https://twitter.com/Adriana42169771/status/1267228218962194434,Adriana42169771,"#asco2020 About pancreatic cancer, abstract 4638  answered something that I already found interesting to improve patients' quality of life. Reduce treatment intensity in patients with stable disease or partial remission. I like FOLFIRINOX, but it is not easy.",2020-05-31
1267228178071924737,https://twitter.com/AMarshallMD/status/1267228178071924737,AMarshallMD,"Our program, @MayoHemeOnc fellowship, stands against racism, discrimination, and race-based violence. We stand for tolerance, inclusion, and community. #MedTwitter @CaThompsonMD @OncoThor @hfuentesbayne @MayoClinic @HemOncWomenDocs @VincentRK @DavidSteensma @ASCO @ASH_hematology",2020-05-31
1267227922491990017,https://twitter.com/GBOT_Alerta/status/1267227922491990017,GBOT_Alerta,"O estudo DESTINY Lung-001 avaliou o uso do ADC trastuzumabe-deruxtecan em 42 pacientes com CPCNP e mutação de HER2. TRO-61,9% DCR-90,5% SLP mediana-14 meses. Toxicidade considerável, contudo. @ClaudioVladmir #ASCO20 #GBOT_Alerta https://t.co/bTIyCwBmmR",2020-05-31
1267227867613745153,https://twitter.com/MDAndersonNews/status/1267227867613745153,MDAndersonNews,"“If this hadn’t been available when I was diagnosed, I’m not sure I’d still be here today,” says Brian Odle, who participated in a clinical trial investigating the #immunotherapy drug magrolimab: https://t.co/WV0pliZZWj #ASCO20 #endcancer",2020-05-31
1267227725363806209,https://twitter.com/TiansterZhang/status/1267227725363806209,TiansterZhang,"A note on the @ASCO #ASCO20 GU kidney/bladder poster discussion. The all-women discussant panel highlights an emerging gender balance in the #GUoncology field. The honor was ours. The glory goes to the patients who moved the field forward. 
@shilpaonc @kalasri3 @katy_beckermann https://t.co/z9AkaeGSxt",2020-05-31
1267227605100527617,https://twitter.com/KayCurtin1/status/1267227605100527617,KayCurtin1,The evidence is clear 64% of patients treated with adjuvant pembro had not relapsed after 3 yrs vs 44% patients on placebo arm @ProfJohnCrown @hseNCCP @INFO_NCPE @melsup1 #ASCO20 #melsm https://t.co/R47z40UFxF,2020-05-31
1267227503577444352,https://twitter.com/agrothey/status/1267227503577444352,agrothey,"I have to say, what a GREAT year for GI ONC @ #ASCO20 - amazing, practice changing data all around. KN177, IDEA, rectal cancer w/ TNT as SOC, ctDNA rapidly emerging as SOC - and that’s just CRC. Thank you to everyone who helped move things forward! #OncoAlert #ASCOTotalHealth",2020-05-31
1267227451882643456,https://twitter.com/ShoMidha/status/1267227451882643456,ShoMidha,"Hard to believe another month has gone by, but that means another @HOJournalClub! In case you couldn't catch #ASCO20 plenary, should be an exciting discussion with @JackWestMD on #ADAURA &amp; #SELECT and the role of TKIs in adjuvant therapy #NSCLC 

Right up your alley @ajf324MD 😉 https://t.co/e5za2E8Ikf",2020-05-31
1267227418445692932,https://twitter.com/brian_rini/status/1267227418445692932,brian_rini,"Now that you have seen the data, hear from the presenting authors for several #ASCO20 GU abstracts. On Apple https://t.co/50LRa1WKS9, Spotify https://t.co/Gbdz1QDznv znc Google podcasts https://t.co/GEAS8gzZGv https://t.co/Pvv4FaTrgH",2020-05-31
1267226951674183683,https://twitter.com/GBOT_Alerta/status/1267226951674183683,GBOT_Alerta,"SCLC: braço Durva+Tremelimumabe+QT estudo CASPIAN foi negativo para SG (HR: 0,82) comparado a QT. Braço Durva+QT mantém benefício SG - HR:0,75 (0,62-0,91). Sem mudança de conduta! @cbaldotto #ASCO20 #GBOT_Alerta https://t.co/45udjV6QEX",2020-05-31
1267226811211091968,https://twitter.com/CettroOncologia/status/1267226811211091968,CettroOncologia,"Uso de imunoterapia após quimioterapia para pacientes com câncer de bexiga mostra nítido beneficio

#ASCO2020 #ASCO20 #CETTROASCO20 #ASCO20PSMA",2020-05-31
1267226365817913347,https://twitter.com/TargetedOnc/status/1267226365817913347,TargetedOnc,"FROM #ASCO20: Patients with ALK-positive non–small cell lung cancer showed clinically meaningful improvement in overall survival when receiving alectinib, according to updated data from the pivotal phase 3 ALEX trial.
https://t.co/zm4rROu98D #lcsm #lungcancer",2020-05-31
1267226198234419200,https://twitter.com/WilliamDale_MD/status/1267226198234419200,WilliamDale_MD,"#ASCO20 #GeriOnc Important to repeat: age and frailty are correlated, but are not the same. Even for younger people. You have to measure something if you want to act on it. @myCARG https://t.co/R7ACzZYzyE",2020-05-31
1267226197743804416,https://twitter.com/OncoGerard/status/1267226197743804416,OncoGerard,Avelumab shows promising efficacy as a manteinance for bladder cancer after platinum 1st line treatment by prolonging OS by 7 months vs BSC. Seen at #ASCO20 https://t.co/2jR04XY9Oe,2020-05-31
1267225849062883329,https://twitter.com/MDedgeHemOnc/status/1267225849062883329,MDedgeHemOnc,"#ASCO20: TRAIN-2, a randomized phase 3 trial suggests anthracyclines adds toxicity with no improved survival in patients with HER2-positive breast #cancer. https://t.co/gY7L8a7wYh  #ASCO2020 #medtwitter #Oncoalert #oncology @ASCO https://t.co/fHwY5BKzwa",2020-05-31
1267225725972733953,https://twitter.com/FernandoOnco/status/1267225725972733953,FernandoOnco,#ASCO20 looking this post https://t.co/nL3rIr2CPJ @hoperugo @PTarantinoMD @OncoAlert https://t.co/mz5RmLsGFi,2020-05-31
1267225626638864386,https://twitter.com/myCARG/status/1267225626638864386,myCARG,"Highlighting #GeriOnc abstracts from #ASCO20 during the ASCO CARG mtg. 

1/ @OncElias discussed his abstract on post-op #delirium in older patients following cancer related and other high-risk surgeries: https://t.co/TePGMaulCs",2020-05-31
1267225623598071808,https://twitter.com/urotoday/status/1267225623598071808,urotoday,"Phase II neoadjuvant Gemcitabine and Pembro for locally advanced #UrothelialCancer: Interim results from the cisplatin-ineligible cohort of GU14-188 presented by Hristos Kaimakliotis, MD @IUMedSchool. #ASCO20 coverage by @TheRealJasonZhu @LevineCancer &gt; https://t.co/VA4BwDL2fN https://t.co/Nv9o0r4yaj",2020-05-31
1267225618216882176,https://twitter.com/YaleCancer/status/1267225618216882176,YaleCancer,".@DrRoyHerbstYale presents in a poster presentation at #ASCO20 immune profiling and clinical outcomes in patients treated with ramucirumab and pembrolizumab in a phase I study. #lcsm @SmilowCancer @YaleMed @YNHH
https://t.co/zNi7uingrD https://t.co/TbHSW9I2xe",2020-05-31
1267225489309081601,https://twitter.com/OncoGerard/status/1267225489309081601,OncoGerard,"RAPIDO trial is another of the key players at #ASCO20: Are we in front of a new SOC for locally advanced rectal cancer? The Oral’s Stay Home Messages look like clear enough, https://t.co/XdFPhxnnXF",2020-05-31
1267225362985074689,https://twitter.com/MHExecutive/status/1267225362985074689,MHExecutive,"From an innovative model of delivering hospital-level care to collecting patient-reported outcomes remotely, researchers of ASCO presented findings that looked to a future of cancer treatment. #ASCO20
https://t.co/aNT1vjYeS4",2020-05-31
1267224956481331200,https://twitter.com/NicoleKuderer/status/1267224956481331200,NicoleKuderer,"🌟@asco 🌟: Inspiring patient scientist @davidfsjgennaum advice:
""Laugh hard, search relentlessly, fight shoulder to shoulder, unite &amp; communicate clearly” to #conquercancer &amp; #RareDisease #chasingmycure. Me: Still working on that communication part... @gary_lyman @doublewhammy https://t.co/N1T7AaDLfA",2020-05-31
1267224872691867656,https://twitter.com/OncLive/status/1267224872691867656,OncLive,"Following at least 3 yrs of follow-up, patients w/ advanced NSCLC and tumor PD-L1 expression ≥ 1% or &lt; 1% experienced durable &amp; long-term efficacy benefits from frontline treatment with nivolumab plus ipilimumab versus chemotherapy. @RamalingamMD #ASCO20 https://t.co/ZFaaklDsP9",2020-05-31
1267224545125117958,https://twitter.com/JonMarronMD/status/1267224545125117958,JonMarronMD,"Agreed- a million thx &amp; congrats to @ASCO staff/leadership including @ASCOPres @BurrisSkip &amp; @MLJohnsonMD2 for an incredible #ASCO20 Virtual Scientific Program under less-than-incredible circumstances

Looking forward to the Virtual Education Program led by @tmprowell in August!! https://t.co/EgrLTWq3cz",2020-05-31
1267224512191500290,https://twitter.com/g_mountzios/status/1267224512191500290,g_mountzios,"ASCO 2005 was ""AVASCO""
ASCO 2012 was ""IMMUNASCO""
#ASCO2020 will be ""UPFRONTASCO"" because everything moves upfront!
⭕️In UC, avelumab moves from 2nd to maint
⭕️In CRC MSI, pembro moves from 2nd to 1st
⭕️In NSCLC, osi moves from 1st to adjuvant
NOT sure  this is the way to go...🤔",2020-05-31
1267224388627247104,https://twitter.com/OncologyBio/status/1267224388627247104,OncologyBio,Ainda tem mais. Em breve as discussões sobre câncer de rim com @SoaresAndrey e @adrigons #ASCO20 https://t.co/pDI7vFT6W7,2020-05-31
1267224094468190210,https://twitter.com/GBOT_Alerta/status/1267224094468190210,GBOT_Alerta,"Selpercatinibe (LOXO292)  promoveu taxa de resposta intracraniana de  82% em 22 pacientes com CPCNP com fusão de RET e metástase cerebral mensurável no estudo LIBRETTO-001. Duração de resposta-9,4 meses @ClaudioVladmir #ASCO20 #GBOT_Alerta https://t.co/KfXGVNrmlr",2020-05-31
1267224018815508480,https://twitter.com/alalbuquerque/status/1267224018815508480,alalbuquerque,Excellent discussion of changes and perspectives in the scenario of Urothelial carcinoma. Congrats @igorpmorbeck @DrAndreFay @DiogoAssed @OncologyBio #asco20 #DialogoRoche https://t.co/TlFeNsp3bB,2020-05-31
1267223403859021824,https://twitter.com/aliepea/status/1267223403859021824,aliepea,"Abstract 2/2 at virtual #ASCO2020: estimates the indirect economic impact of premature cancer mortality in Brazil at US$6 billion in 2016 (0.2% of GDP). Regional patterns highlight need for regional policies, esp for lifestyle &amp; infection-related cancers - https://t.co/3JAzpTNfWb",2020-05-31
1267223157318078467,https://twitter.com/DrMarkham/status/1267223157318078467,DrMarkham,"Congratulations to @ASCOPres @BurrisSkip @MLJohnsonMD2 &amp; all of the @ASCO staff &amp; volunteers for making this #ASCO20 Virtual Scientific Session a wonderful event. One for the history books, for sure. 1/2",2020-05-31
1267223094055206912,https://twitter.com/WilliamDale_MD/status/1267223094055206912,WilliamDale_MD,"#ASCO20 is not quite over for the #GeriOnc crew. We are having virtual posters, celebrations of Hy Muss, and @andrewchap361 .  Nearly 70 people on a Sunday evening!  @myCARG @rochgerionc @HKlepinMD",2020-05-31
1267222812550299649,https://twitter.com/aruthak/status/1267222812550299649,aruthak,This weekend my feed was... #SpaceX #GeorgeFloyd #USRIOTS #ASCO2020 #COVID19 How can we be so far at the cutting edge of technology but lack basic human deceny??? We need to do some soul searching...,2020-05-31
1267222589866303488,https://twitter.com/aliepea/status/1267222589866303488,aliepea,"Abstract 1/2 at virtual #ASCO2020: ""Disparities in cancer premature mortality in Brazil: Predictions up to 2030 and #SustainableDevelopmentGoals"" shows disparities in cancer rates across regions and Brazil unlikely to meet #SDGs - https://t.co/iHusuFh73P",2020-05-31
1267222574087331846,https://twitter.com/drcbsteer/status/1267222574087331846,drcbsteer,"In Memoriam: Healthcare Workers Who Have Died of COVID-19 (updated May 28)
#COVID19 #ASCO20 @Medscape 

https://t.co/i88d69gI46 via @medscape",2020-05-31
1267222508622827520,https://twitter.com/ovarcome/status/1267222508622827520,ovarcome,"Getting the full picture of genetic testing results requires that patients have access to Genetic Counselors who can evaluate individual risk. #Ovarcome @ASCO  @YaleMed 
https://t.co/KEoS7z6ZLo",2020-05-31
1267222279504703488,https://twitter.com/eduhor82/status/1267222279504703488,eduhor82,"#TRAIN2 TRIAL: Her2 EII-III #breastcancer
💥No benefit and more toxicity in Anthracyclines arm
#bcsm #ASCO20 https://t.co/1aNJEkyAOf",2020-05-31
1267222180292628481,https://twitter.com/tmprowell/status/1267222180292628481,tmprowell,"#ASCO20. Imagine plentiful #SARSCoV2 vaccine➡️herd immunity. What aspects of virtual mtgs are worth retaining for lrg scientific confs going forward, even if we all can &amp; will gather in person? #ASCO21 #ASCO22 #COVID19 #pandemic

 (#ASCO45 @ASCO time capsule...just for kicks)",2020-05-31
1267222017285259277,https://twitter.com/GBOT_Alerta/status/1267222017285259277,GBOT_Alerta,"A coorte CPCNP metastático com fusão do gene RET do estudo de fase I/II ARROW, pralsetinibe (BLU-667) demonstrou alta TRO (65% na população avaliável - N=116). Taxa de resposta intracraniana 56%. Duração mediana de resposta-não alcançada. @ClaudioVladmir #ASCO20 #GBOT_Alerta https://t.co/uVS1ybnLa6",2020-05-31
1267221962163716098,https://twitter.com/eduhor82/status/1267221962163716098,eduhor82,"#TRAIN2 TRIAL Her2 EII-III #breastcancer
💥No benefit and more toxicity in Anthracyclines arm
#bcsm #ASCO2020 https://t.co/Jrw20jZhWe",2020-05-31
1267221829929893894,https://twitter.com/urotoday/status/1267221829929893894,urotoday,"Looking back on #COVID19 in order to move forward. #ASCO20 presentation by Giuseppe Curigliano, MD @IEOufficiale. Written coverage by @GoldbergHanan @UpstateNews on UroToday &gt; https://t.co/ddW37pde3D @ASCO @LaStatale @COVID19nCCC https://t.co/7GqfFjsqG0",2020-05-31
1267221822967353346,https://twitter.com/ASCO_pubs/status/1267221822967353346,ASCO_pubs,"Locoregional Treatment of Intact Primary Tumor Does Not Improve Survival, HRQoL in Metastatic #BreastCancer https://t.co/6n0wWmCRg0 #ASCODailyNews #bcsm #ASCO20",2020-05-31
1267221819607576578,https://twitter.com/syinvesting/status/1267221819607576578,syinvesting,"#ASCO20 Comparison of new BCMA-targeting data from JNJ-4528, bb2121, JCARH125 &amp; teclistamab.

$JNJ $LEGN $BMY $BMYRT $BLUE $GMAB #CellTherapy

@evaluatevantage article from @JacobPlieth: https://t.co/st8IQNbO6A https://t.co/PrpZT2y4jO",2020-05-31
1267221373304426502,https://twitter.com/Mrsprofessiona1/status/1267221373304426502,Mrsprofessiona1,Another great meeting! #ASCO20,2020-05-31
1267220649568862213,https://twitter.com/semodough/status/1267220649568862213,semodough,"GS Next week $REGN $MRK hosting #ASCO20 events. For REGN focus will be on Libtayo &amp;company’s bispecific platform, while for MRK incremental Keytruda data (TNBC, HCC&amp;MSI-high), but more of debate is around evolving competitive landscape in front-line lung given Roche’s TIGIT data.",2020-05-31
1267220623601827840,https://twitter.com/psico_onco/status/1267220623601827840,psico_onco,"#ASCO2020 Un oncologo italiano nella gallery nel video emozionale condiviso dal Presidente
 dell' @ASCO...
🇮🇹 🙏 https://t.co/DHqvVZekym",2020-05-31
1267220572540469254,https://twitter.com/cure_magazine/status/1267220572540469254,cure_magazine,"New findings suggest that patients with thoracic cancer who receive chemotherapy three months after a COVID-19 diagnosis may have an increased risk of death compared to similar patients who underwent different treatment. #ASCO2020
https://t.co/0u1ooAWJDf",2020-05-31
1267220148697681920,https://twitter.com/n8pennell/status/1267220148697681920,n8pennell,We are handicapped by our inability to truly detect MRD. Can't wait for the ctDNA studies to help us detect who really needs more treatment and who is cured! Eventually this discussion will look really dumb once we have better testing #ASCO20 #LCSM https://t.co/An9jl0Zj6h,2020-05-31
1267220056548806657,https://twitter.com/GBOT_Alerta/status/1267220056548806657,GBOT_Alerta,"Estudo ADAURA: análise interina mostrou significativa melhora na SLD quando comparado com placebo. Na população  do estudo do estágio II e III,  osimertinibe melhorou a SLD em 83% vs placebo. @SamiraMascaren2 #ASCO20 #GBOT_Alerta https://t.co/DcXQ6y9v9Z",2020-05-31
1267219820216373249,https://twitter.com/PestanaRC/status/1267219820216373249,PestanaRC,"Para os interessados, a equipe do Hospital Israelita Albert Einstein está realizando uma cobertura extensa dos trabalhos apresentados de forma oral na #ASCO2020 , com videos e podcasts

Ainda haverá upload de material durante toda a semana 

https://t.co/XGDGZUeXs6",2020-05-31
1267219131851563010,https://twitter.com/janicefarias_/status/1267219131851563010,janicefarias_,"❗️ TERAVOLT: congratulations to the team involved! 

Malignidade torácica e COVID-19
🚨mortalidade de 35,5%
🚨hospitalização 78.3%

High Risk: age, comorbidity, PS
❌steroids prior to COVID increases the risk

@CettroOncologia  #asco20 #CETTROASCO20 https://t.co/yPdiSxMTrC",2020-05-31
1267218690434641931,https://twitter.com/n8pennell/status/1267218690434641931,n8pennell,"Unbelievable job, under unprecedented challenges, by all the @ASCO leadership! I won't wish for another virtual ASCO AM but this one was truly great #ASCO2020 https://t.co/jnfteLRBRP",2020-05-31
1267218228155219968,https://twitter.com/BrasilOncologia/status/1267218228155219968,BrasilOncologia,"Acompanhe agora a melhor e mais completa cobertura do que acontece na #ASCO20 com Dr. Rodrigo Munhoz, Dr. Fabio Schutz, Dr. Fernando Santini e Dr. Alessandro Leal. Assista ao webinar ao vivo: https://t.co/z2AuocobB6 https://t.co/MCWK3HL7Sp",2020-05-31
1267218077269340161,https://twitter.com/GBOT_Alerta/status/1267218077269340161,GBOT_Alerta,Estudo ADAURA na Plenária! #ASCO20 #GBOT_Alerta https://t.co/IXo2ROlXeh,2020-05-31
1267218064325652485,https://twitter.com/urotoday/status/1267218064325652485,urotoday,Ensuring #cancer research progress during a global #pandemic. #ASCO20 presentation by @NCIDirector @theNCI. Written coverage by @GoldbergHanan @UpstateNews on UroToday &gt; https://t.co/0llOanQ2VU #COVID19 @ASCO #NCCAPS https://t.co/XNY9JQxD48,2020-05-31
1267218057627402241,https://twitter.com/OncEd/status/1267218057627402241,OncEd,"Dr. Bjorn Henning Gronberg provides an #ASCO20 update from the phase II trial for standard-dose vs. high-dose twice-daily thoracic radiotherapy in limited disease small-cell lung cancer: https://t.co/r1tsA0Idvj  
#SCLC #LCSM https://t.co/dv0t5inRWy",2020-05-31
1267218056071254017,https://twitter.com/OncotypeIQ/status/1267218056071254017,OncotypeIQ,#ASCO20 view an economic evaluation of the #Oncotype DX® test for HR+ early-stage #breastcancer from the Brazilian societal perspective in our on-demand posters cc: @ASCO https://t.co/V5umFgZRTZ  #Oncology #chemo,2020-05-31
1267217959820369921,https://twitter.com/tanyawildes/status/1267217959820369921,tanyawildes,"Almost as good as an in-person #asco20 dinner: ⁦@myCARG⁩ virtual dinner with ⁦@rochgerionc⁩, ⁦@WilliamDale_MD⁩ and ⁦@HKlepinMD⁩ https://t.co/hBfWqJwk4F",2020-05-31
1267217567195824131,https://twitter.com/katcrios/status/1267217567195824131,katcrios,👏🏼R&amp;D is heavily subsidized by tax dollars/breaks. The least companies can do is properly build out financing models to provide equitable access to drugs LMICs helped bring to market. Profitability+access to medication don't need to compete w/ each other. #ASCO20 #clinicaltrials https://t.co/rYGYBFVT3e,2020-05-31
1267217514402103297,https://twitter.com/ChristinaUwins/status/1267217514402103297,ChristinaUwins,"💜#goASCO20 💜  Gynaecological Oncology research
@ASCO #ASCO20 https://t.co/2PGUrsvCgq",2020-05-31
1267217503933079555,https://twitter.com/GBOT_Alerta/status/1267217503933079555,GBOT_Alerta,"KEYNOTE- 604: Pembrolizumabe combinado a QT demonstrou maior SLP (HR 0.75 [95% CI 0.61-0.91], P = 0.0023) em CPPC. SG não alcançou significância, mas tendência a benefício. #asco2020 #GBOT_Alerta https://t.co/g6veTLBMSh",2020-05-31
1267217403416580100,https://twitter.com/ChristinaUwins/status/1267217403416580100,ChristinaUwins,"💜#goASCO20 💜  Gynaecological Oncology research
@ASCO #ASCO20 https://t.co/w4JE6NZJIg",2020-05-31
1267217330129510403,https://twitter.com/ChristinaUwins/status/1267217330129510403,ChristinaUwins,"💜#goASCO20 💜  Gynaecological Oncology research
@ASCO #ASCO20 https://t.co/Fv5F2PwDmD",2020-05-31
1267217286391386114,https://twitter.com/DrJessDeLaune/status/1267217286391386114,DrJessDeLaune,"How was your #ASCO20 Sunday?
1️⃣@onepeloton PR
2️⃣#SweetWaterWetlandsPark w/my boys
3️⃣@ASCO plenary w/my little girl
4️⃣GU highlights w/@DrChoueiri 
5️⃣Made pork chops masala for dinner https://t.co/WpAfCdkiJp",2020-05-31
1267217253487034369,https://twitter.com/ChristinaUwins/status/1267217253487034369,ChristinaUwins,"💜#goASCO20 💜  Gynaecological Oncology research
@ASCO #ASCO20 https://t.co/H9l2xEMrxi",2020-05-31
1267216742591291392,https://twitter.com/myCARG/status/1267216742591291392,myCARG,The annual ASCO CARG get together is a tradition we’re happy to continue in any form ❤️ over 50 individuals virtually meeting up and celebrating the success of #gerionc at #ASCO20 https://t.co/wyvlXRZNWl,2020-05-31
1267216649016365057,https://twitter.com/GenomeGrl/status/1267216649016365057,GenomeGrl,So enjoyed viewing the data as well as @dave6408’s commentary. These compelling results will change molecular testing and treatment in early-stage #lungcancer. #ASCO2020 #lcsm https://t.co/lHm1xQANRb,2020-05-31
1267216511644688385,https://twitter.com/tsemiglazovaMD/status/1267216511644688385,tsemiglazovaMD,"#ADAURA #osimertinib vs placebo (3 years or progression in stage IB-IIIA resected EGFR+ LC). 45% of patients did not receive ad. CHT). Efficacy by stage IIIA&gt;II&gt;IB. Most patients were Asian, female &amp; non-smokers. DFS: 83% in stage II-IIIA; 79% in IB-IIIA. #ASCO20 #OncoAlert https://t.co/o0nRSW3UXM",2020-05-31
1267216049340104707,https://twitter.com/inas_md/status/1267216049340104707,inas_md,"#ASCO20
Feeling excited and inspired by all the great science @ASCO 
Missing catching up with friends and colleagues in person but very grateful nonetheless for the online community and format this year❤️ https://t.co/RuyVYFlT4x",2020-05-31
1267215818749771776,https://twitter.com/ElizSMcKenna/status/1267215818749771776,ElizSMcKenna,With NSCLC data preceding the phase 2 DESTINY data mentioned during today’s #lungcancer highlight session at #ASCO20 https://t.co/qLy6P7zK6S,2020-05-31
1267215570434502659,https://twitter.com/MoffittNews/status/1267215570434502659,MoffittNews,#ASCO20 Virtual Scientific Program: @abarata3105 (@Moffittnews) shares new data on neurotoxicity associated with CAR T therapy. View the full abstract here: https://t.co/INVN4DBru1 https://t.co/G2FoS5PDSU,2020-05-31
1267215324946018305,https://twitter.com/tompowles1/status/1267215324946018305,tompowles1,Discussion about how this might change practice in bladder cancer #ASCO2020 https://t.co/fPyE5zYjDU,2020-05-31
1267215278187982848,https://twitter.com/pashtoonkasi/status/1267215278187982848,pashtoonkasi,More discussions about our talk/poster 👆🏼@OncLearnNetwork https://t.co/GZDFMXM02B #ASCO20 #ctDNA #LiquidBiopsies #ctDNAInsights 🩸🧬,2020-05-31
1267215024520663043,https://twitter.com/Medscape/status/1267215024520663043,Medscape,"Some women with gestational trophoblastic tumors respond to immunotherapy when they are resistant to single chemotherapy, say results from TROPHIMMUN phase 2 trial. https://t.co/2lED0ENgFC #ASCO20",2020-05-31
1267215021907619840,https://twitter.com/OncoLucus/status/1267215021907619840,OncoLucus,Javelin100: a new SOC in advanced urothelial carcinoma. #bladdercancer #ASCO20 https://t.co/hotuyarspy,2020-05-31
1267214474873839616,https://twitter.com/TotalHealthConf/status/1267214474873839616,TotalHealthConf,"#ASCO20 may be over, but your education continues with ASCO Direct Highlights. Dive deeper into the research and strategies presented this weekend. Register for your city or a weekend that works for you: https://t.co/xmvtenyJ9M https://t.co/HH3kFfIXrK",2020-05-31
1267214420167593984,https://twitter.com/CancerResrch/status/1267214420167593984,CancerResrch,"This abstract at #ASCO20 demonstrates the utility of real-world data in interpreting non-randomized trials - https://t.co/hlB6dqvihC. For more info on RWE and its utility as an endpoint, visit https://t.co/OkqbM5hhJE",2020-05-31
1267214394817228800,https://twitter.com/mpdrc/status/1267214394817228800,mpdrc,Great summary by ⁦@DrDimpyShah⁩ of key ⁦@COVID19nCCC⁩  Results from #ASCO2020 and ⁦@TheLancet⁩. Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19) - ecancer. ⁦@UTHealthSAMDA⁩  https://t.co/bWAjr7g7ua,2020-05-31
1267214379050811392,https://twitter.com/OncologyTimes/status/1267214379050811392,OncologyTimes,Missed #ASCO20 highlights from Friday and Saturday? Here are some highlight sessions you might want to review on demand: https://t.co/g70A8uxlse #cancer #research https://t.co/4cqrk3pVyA,2020-05-31
1267214311014854656,https://twitter.com/urotoday/status/1267214311014854656,urotoday,"Neoadjuvant chemotherapy alone or in combination with Nivolumab ± Linrodostat Mesylate, followed by adjuvant postsurgical Nivolumab ± Linrodostat, in cisplatin-eligible #MIBC. Presented by @sonpavde @DanaFarber #ASCO20. Coverage by @zklaassen_md &gt; https://t.co/Bzl9yLazWa https://t.co/OPWtL6RzvX",2020-05-31
1267213987218849794,https://twitter.com/tsemiglazovaMD/status/1267213987218849794,tsemiglazovaMD,"#ECOG_ACRIN2108 NO differences between 2 treatment groups in regard to OS among HER2+ (HR 1.05, 95% CI 0.49, 2.24) or ER+HER2- subtype (HR 0.94, 95% CI 0.59, 1.51). In 20 women with the triple-negative BC, survival was worse HR 3.50, 95% CI [1.16, 10.57] #ASCO20 #OncoAlert #BC https://t.co/uElQvNgswt",2020-05-31
1267213723900317697,https://twitter.com/OBRtweets/status/1267213723900317697,OBRtweets,Yale Cancer Center Study Shows Profound Benefit with Targeted Therapy for Patients with Early Stage NSCLC #ASCO20 https://t.co/SaOmXmhtiU,2020-05-31
1267213618099224584,https://twitter.com/eduhor82/status/1267213618099224584,eduhor82,"#HERO trial:practice changing❗❗ in a subset of pts
Take home messages
#ASCO20 #pcsm https://t.co/CDSIQEJ2fT https://t.co/AETDalGtZ6",2020-05-31
1267213451811831813,https://twitter.com/SusanGKomen/status/1267213451811831813,SusanGKomen,"Komen scholar alum Dr. Julia White discussed clinical implications for locoregional therapy (LRT) in patients dx with de novo #MBC at #ASCO20. LRT does not improve survival, but can provide palliative care &amp; prevent tumor progression in some individuals #breastcancer",2020-05-31
1267213441078562819,https://twitter.com/cpgYALE/status/1267213441078562819,cpgYALE,thanks for addressing this important issue - so important to hear yours and @ASCO voice on this during #ASCO2020 #ASCO20 https://t.co/AtW25dd3N5,2020-05-31
1267213266452955144,https://twitter.com/brianreid/status/1267213266452955144,brianreid,This feels like a good time to amplify some important #ASCO20 tweets on diversity and disparities:,2020-05-31
1267213219380310016,https://twitter.com/tmprowell/status/1267213219380310016,tmprowell,"I will not text any of you until Tuesday morning, I promise. xoxo @tonsterps @DannyGrayson913 @lindsrowan. (And Katie Kiewlicz &amp; Sonia Dermer need to set up Twitter accts if they don't have them!  But not today! Today you rest!)
#ASCO20
@MLJohnsonMD2 @BurrisSkip @ASCOPres @asco https://t.co/QGNUKSV9u0",2020-05-31
1267212845172830214,https://twitter.com/ryangentzler/status/1267212845172830214,ryangentzler,Congrats to @MLJohnsonMD2 for putting together a spectacular scientific program for #ASCO20 despite the challenges of converting to a virtual meeting late in the year! Will be an ASCO to remember!!,2020-05-31
1267212785890492416,https://twitter.com/eduhor82/status/1267212785890492416,eduhor82,"#HERO trial:
Take home messages
#ASCO20 #Relugolix https://t.co/CDSIQEJ2fT https://t.co/L9gPmYUF3O",2020-05-31
1267212743834325000,https://twitter.com/NatashaDhawanMD/status/1267212743834325000,NatashaDhawanMD,"Wow!! We heard (read) what #LCSM experts have said on the topic, can’t wait to chat with trainees about it!

Great replacement for the trainee lounge at #ASCO20.

#HOJournalClub
@ASCO https://t.co/aUDew3a12b",2020-05-31
1267212700762816512,https://twitter.com/xCassandraxRae/status/1267212700762816512,xCassandraxRae,Learn more about how we are redesigning the clinical trial experience for patients during #COVID19. #ASCO20 #ScienceWillWin #PFEColleague https://t.co/LlS6q5EQdp,2020-05-31
1267212611315269633,https://twitter.com/TheWonkologist/status/1267212611315269633,TheWonkologist,"Important work by Kiran Clair &amp;co, finding NH-black patients less likely to receive @NCCN-concordant cancer care. Disparities are about care received, not biology! Good choice for merit award, @ASCO @ConquerCancerFd #ASCO20 cc: @peterbachmd 

https://t.co/6N11ZNJUCX https://t.co/RuZalURYtj",2020-05-31
1267212513311105026,https://twitter.com/SyedMAhmedMDPhD/status/1267212513311105026,SyedMAhmedMDPhD,"Randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer (E2108).
#ASCO20 #bcsm https://t.co/0tAR2j9q8I",2020-05-31
1267212188458024961,https://twitter.com/OncKIP/status/1267212188458024961,OncKIP,"As #ASCO20 live sessions draw to a close, continue your online professional development! Our free, #CME-accredited education is designed with experts to keep healthcare professionals up to date with #oncology research. Register for a free account to start learning today!",2020-05-31
1267212070459670535,https://twitter.com/FernandoOnco/status/1267212070459670535,FernandoOnco,#ASCO20: great debates and certainly more questions than answers. Congratulations @ASCO @ASCOPres @OncoAlert . See you in next virtual meeting https://t.co/JAAWHp37Mq,2020-05-31
1267211808990998528,https://twitter.com/SuannaBruinooge/status/1267211808990998528,SuannaBruinooge,Thanks @BurrisSkip for your leadership and recognition of the painful coincident events of #ASCO20 https://t.co/kAF9yaEmVW,2020-05-31
1267211752837730304,https://twitter.com/SarahCannonDocs/status/1267211752837730304,SarahCannonDocs,"As #ASCO20 draws to a close and we reflect on the incredible research presented, we cannot help but be reminded of @BurisSkip’s words from his Presidential Address: Unite &amp; Conquer. Thank you to the teams everywhere #FightingCancerTogether https://t.co/OZNSmAyuvi",2020-05-31
1267211725998153729,https://twitter.com/GeorgeSledge51/status/1267211725998153729,GeorgeSledge51,"Really great, thoughtful Higlights sessions by Drs. Erika Hamilton and Angela DeMichele. If you don’t have time to watch all the breast sessions these are well worth watching. #ASCO20 #bcsm",2020-05-31
1267211604455829504,https://twitter.com/RandySweisMD/status/1267211604455829504,RandySweisMD,Excellent thread on BEPx1 bs RPLND #ASCO20 https://t.co/KRd2Ma7e4e,2020-05-31
1267211525745410048,https://twitter.com/StrataOncology/status/1267211525745410048,StrataOncology,We are excited to showcase research demonstrating our commitment to enabling broad patient access to molecular profiling through system-wide implementation of a CGP test with industry-low tumor tissue requirements. #ASCO20  https://t.co/iAsULUhlsZ https://t.co/W2rWipYqyE,2020-05-31
1267211464005345282,https://twitter.com/ChristinaUwins/status/1267211464005345282,ChristinaUwins,"💜#goASCO20 💜  Gynaecological Oncology Presentation
@ASCO #ASCO20 https://t.co/Ck7xkSH7pB",2020-05-31
1267211384154132487,https://twitter.com/EdEsplin/status/1267211384154132487,EdEsplin,"9.6% of #germline mutations missed by #tumor-only testing in #prostatecancer #patients, ~98% of germline mutations were clinically actionable, inc. #precisiontherapy #clinicaltrials, study @Invitae #ASCO2020 #oncoalert #https://meetinglibrary.asco.org/record/188741/abstract",2020-05-31
1267211254965338112,https://twitter.com/MDedgeHemOnc/status/1267211254965338112,MDedgeHemOnc,"Patients with TNBC receiving 1 year of capecitabine treatment improved DFS, but not OS, according to a phase 3 trial shared at the #ASCO20 virtual scientific program. https://t.co/zsMcg5cHtU #ASCO2020 #cancer #oncoalert #medtwitter https://t.co/oaP7EPVTbp",2020-05-31
1267210715485671426,https://twitter.com/Tony_Calles/status/1267210715485671426,Tony_Calles,"Pues ya habéis visto cómo pasamos los fines de semana los oncólogos para mantenernos actualizados. Esta vez ha sido #ASCO20 Virtual. Es lo que tiene querer lo mejor para nuestros pacientes. Eso sí, esta vez sin el jet-lag del viaje y sin ir del aeropuerto a pasar consulta 😅",2020-05-31
1267210509612453891,https://twitter.com/urotoday/status/1267210509612453891,urotoday,"Association of molecular subtypes with pathologic response interface to studying of coexpression extrapolation #COXEN with neoadjuvant chemotherapy for localized #MIBC. Presented by Seth Lerner, MD, FACS @bcmhouston. #ASCO20 coverage by @GoldbergHanan &gt;  https://t.co/sradi7oJKd https://t.co/67fernDYS4",2020-05-31
1267210195064758272,https://twitter.com/MLJohnsonMD2/status/1267210195064758272,MLJohnsonMD2,"Special “elbow bump” of thanks and gratitude to the #ASCO20 wizards! @tonsterps @dannygrayson913
@lindsrowan, Katie and Sonia. Missed seeing you IRL ! Looking forward to part 2 #MedEd in August @tmprowell @ASCO @SarahCannonDocs https://t.co/rs3XL0cCTW",2020-05-31
1267210169424977927,https://twitter.com/NicoleRossiOnco/status/1267210169424977927,NicoleRossiOnco,#ASCO20 https://t.co/7UoLbvElfR,2020-05-31
1267210130220896256,https://twitter.com/SBRInvestor/status/1267210130220896256,SBRInvestor,"#asco20 #ASCO2020 NOT MUCH WAS DISCUSSED REGARDING PARPi and COVID-19!?
 ""Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for ARDS?"" https://t.co/KVLkjjHbb8",2020-05-31
1267209858085982209,https://twitter.com/HOJournalClub/status/1267209858085982209,HOJournalClub,"You caught the #ASCO20 plenary, now join us this Thurs, 6/4 9pm ET, for a special #HOJournalClub discussion w/ the incomparable @JackWestMD! All fellows, trainees, learners welcome! #ADAURA #LCSM #NSCLC #OncMedEd @DocLHenry @DevikaDasMD @DrMMurphy 
https://t.co/bBezkC2SXm https://t.co/BPFeh4xK0q",2020-05-31
1267209743006867459,https://twitter.com/fredhutch/status/1267209743006867459,fredhutch,"The 2020 @ASCO presentations are live now for registered attendees. Featuring work from Drs. @ShankaranVeena &amp; Scott Ramsey, Dr. Eric Chow, @PGrivasMDPhD, Dr. Heather Greenlee, @gary_lyman, Drs. Nancy Davidson, @LauraGrahamMD &amp; more @SeattleCCA #ASCO2020 
https://t.co/SjSnR8nWKd",2020-05-31
1267209675520593921,https://twitter.com/caseofdees/status/1267209675520593921,caseofdees,"Als je vanaf diagnose op afstand uitgezaaide borstkanker hebt, zorgt operatie en bestraling NIET voor langer leven en ook niet voor betere kwaliteit van leven. #asco20 #bcsm https://t.co/dbfmbkzjNR",2020-05-31
1267209439607762950,https://twitter.com/AAFretland/status/1267209439607762950,AAFretland,Really enjoying #ASCO2020. Jet lag somehow seems lighter this year. Great highlight session on upper GI by ⁦@mnoel3232⁩ ⁦@ASCO⁩ ⁦@DagensMedisin⁩ https://t.co/CDsL37kiXy,2020-05-31
1267209338692624384,https://twitter.com/MTCOSB/status/1267209338692624384,MTCOSB,LBA2、Ⅳ期乳癌手術するしない問題、グゥの音も出ないカーブ。#ASCO20 https://t.co/7jXDsdYIkp,2020-05-31
1267209288826540032,https://twitter.com/marklewismd/status/1267209288826540032,marklewismd,"Been thinking a lot about the patient-physician role since @DavidFajgenbaum spoke #asco20 

Obviously not all of us need (or should!) experience malignancy to be empathetic doctors

But I do think we need a bicameral mind that appreciates both the science &amp; humanism of oncology https://t.co/xmz8jG6Oag",2020-05-31
1267209255960141825,https://twitter.com/OncLive/status/1267209255960141825,OncLive,Belantamab mafodotin in combination with bortezomib and dexamethasone demonstrated a high rate of clinical benefit and an acceptable safety profile in patients with relapsed or refractory multiple myeloma. @AjayNookaMD @EmoryUniversity @ASCO #mmsm https://t.co/kCLizRIMSO,2020-05-31
1267209238880927745,https://twitter.com/PRIME_cme/status/1267209238880927745,PRIME_cme,Read PRIME’s abstract on Triple-Negative Breast Cancer at the #ASCO20 meeting: https://t.co/38I90VgU93 #oncology #cancer #TNBC #breastcancer,2020-05-31
1267208856276434946,https://twitter.com/chadinabhan/status/1267208856276434946,chadinabhan,"I really really am trying to stay positive as we finish virtual #ASCO20 but impossible with the riots all over Chicago and its suburbs...
Looks like coordinated efforts across various towns to destroy businesses and cause damage.
2 blocks away from my house, this is happening.",2020-05-31
1267208531947773958,https://twitter.com/CelsoMello15/status/1267208531947773958,CelsoMello15,Impressive results of Nivo and Nivo/Ipi + RdT for UPS. Have we found a better way to cure these patients or it is just another active combination for local control? What do u think?  #ASCO2020 @tomassoule @pires_veridiana @herbloong @JTrentMDPhD @SelnetH2020 https://t.co/NbPMjMNRCl,2020-05-31
1267208048050876416,https://twitter.com/PortalOnconews/status/1267208048050876416,PortalOnconews,"Os oncologistas @angelica_onco e Elias Abdo, coautor do estudo SOLO2, selecionado para apresentação oral no #ASCO20, discutem os avanços no tratamento sistêmico em oncoginecologia que devem impactar a prática clínica - https://t.co/vE9CqLMJWm @asco #ONCONEWS @GBTG_EVA https://t.co/TfBnV80vJ6",2020-05-31
1267207526925271041,https://twitter.com/tmprowell/status/1267207526925271041,tmprowell,"#ASCO20 
We'd ask @tonsterps, @DannyGrayson913, @lindsrowan, Katie Kiewlicz, &amp; Sonia Dermer to send a group pic of all of @ASCO leadership &amp; staff who make Annual Mtgs happen, but seems like @MLJohnsonMD2, @BurrisSkip, &amp; I should maybe not ask for help w/ anything for 1 day. 😃 https://t.co/FdPgZJJPMC",2020-05-31
1267207310914523136,https://twitter.com/jsparano/status/1267207310914523136,jsparano,"Having spent my first ASCO weekend in 30 years at home for #asco20, I'm confident that the 2 people most looking forward to an in-person meeting are both named Lori, one of whom is the next ASCO President - the other is my wife. Congratulations Lori Pierce as you take the gavel.",2020-05-31
1267207254392082432,https://twitter.com/_SMason/status/1267207254392082432,_SMason,"Easily one of the most exciting plenaries I’ve seen in recent years. Great discussion via chat, too. My hat is off to the committee for their selections. #ASCO20",2020-05-31
1267207204039524352,https://twitter.com/RossFH/status/1267207204039524352,RossFH,"In phase II trial of patients (n=15) w/ treatment-resistant GTN, avelumab #immunotherapy led to hCG normalization in &gt;50%; no recurrences observed w/ &gt;2y follow-up. @asco #ASCO20 #goASCO20 #gyncsm https://t.co/ySB0nHcwZ5",2020-05-31
1267207187337752576,https://twitter.com/DaniTernyila/status/1267207187337752576,DaniTernyila,Be sure to share your thoughts in our poll for #ASCO20! I'd love to hear your thoughts on the most impactful abstracts this year. https://t.co/Uk75lcJu7c,2020-05-31
1267206999734919173,https://twitter.com/KidneyCancer/status/1267206999734919173,KidneyCancer,"Thank you @ASCO for an inspired #ASCO20 program! 

Special thanks/congrats to our friends and colleagues with featured #kidneycancer research, we're grateful for your dedication to advancing science and improving lives!

#WeCan #UnstoppableTogether",2020-05-31
1267206752908357634,https://twitter.com/MTCOSB/status/1267206752908357634,MTCOSB,ADAURA試験(術後オシメルチニブ)、これは感涙のカーブですのぅ... #ASCO20 https://t.co/nY5hgdchz7,2020-05-31
1267206739813978115,https://twitter.com/urotoday/status/1267206739813978115,urotoday,"Morbidity associated with #cancer screening and treatment: A #Urologist perspective presented by Timur Mitin, MD, PhD @OHSUKnight. #ASCO20 written coverage by @GoldbergHanan @UpstateNews on UroToday &gt; https://t.co/qVJA3cXMA8 @ASCO https://t.co/87BXCC4HLZ",2020-05-31
1267206730901053445,https://twitter.com/ConquerCancerFd/status/1267206730901053445,ConquerCancerFd,"We ap-peel to your hearts and minds https://t.co/QpJOIwpkPM 
#ASCO20 🍊🧡 https://t.co/GkNObZmOGU",2020-05-31
1267206639859503105,https://twitter.com/BrasilOncologia/status/1267206639859503105,BrasilOncologia,"Estudo da @ASCO apresenta análise clínico-patológica de 104 pacientes com #mutações POLE que receberam ICI. Taxa de benefício clínico foi de 53,8%, sendo 4,3% resposta radiológica completa, 26,9% resposta parcial e 22,6% doença estável. Saiba mais: https://t.co/ZHWha9bxx4 https://t.co/BVfafhAZ5v",2020-05-31
1267206217081876480,https://twitter.com/GeorgeSledge51/status/1267206217081876480,GeorgeSledge51,"My thoughts on Khan plenary LRT results: while there are still times when LRT makes sense in pts with de novo Stage 4 disease, it should not be offered in hopes of improving OS. Nice job, Seema! #ASCO20 #bcsm",2020-05-31
1267205381417324544,https://twitter.com/ZoomRx/status/1267205381417324544,ZoomRx,"From potentially practice-changing data (Tagrisso, Keytruda, and Bavencio among many others) to new targets in immunotherapy, there is much to consider looking forward as the first ever virtual #ASCO wraps up. #ASCO20",2020-05-31
1267205324857126914,https://twitter.com/YG_TAO/status/1267205324857126914,YG_TAO,"Really impressive! I wonder whether one of ICIs (as Durvalumab in pacific) instead could obtain similar result if EGFR wt for Stage II-IIIa, any ongoing  trial? #asco20 https://t.co/pDnKCDwVc2",2020-05-31
1267205302534823937,https://twitter.com/GeorgeSledge51/status/1267205302534823937,GeorgeSledge51,Khan EA LRT plenary results: 256 randomized. Well balanced. OS was identical between the 2 arms. PFS identical. Local-regional progression higher in no LRT arm (10.2 vs 25.6). No QOL improvement with LRT. #ASCO20 #bcsm.,2020-05-31
1267205176542322694,https://twitter.com/PignotG/status/1267205176542322694,PignotG,Maintenance avelumab after first line chemotherapy : a new standard ! And what about second line after IO maintenance ? Perhaps time for enfortumab vedotin or anti-FGFR therapies.@ASCO https://t.co/Bd50aYW1x6,2020-05-31
1267205158234140672,https://twitter.com/TurnaRay/status/1267205158234140672,TurnaRay,Germline Results From Tumor-Normal Sequencing Guides Precision Therapy in Advanced Cancer Patients #asco20 @sloan_kettering @UMich https://t.co/avpmyqroRZ,2020-05-31
1267205057818345478,https://twitter.com/SatyenGohil/status/1267205057818345478,SatyenGohil,Excellent slides of important #ASCO2020 for haematologist https://t.co/Szq3Yq6Adj,2020-05-31
1267204907511304197,https://twitter.com/AshleySumrallMD/status/1267204907511304197,AshleySumrallMD,"Almost an even split, but the “yes” votes inched past. Thoughts? #asco20 https://t.co/J0B2sUkQDK",2020-05-31
1267204719182843907,https://twitter.com/pacylex/status/1267204719182843907,pacylex,Pacylex had two abstracts accepted for presentation as posters at the American Association for Cancer Research (AACR) Annual Meeting 2020 https://t.co/CHZOyGEglJ #ASCO2020 #ASCO20 #cancer #AML #BIO20 #BIO2020 #AACR https://t.co/otbYKPErob,2020-05-31
1267204564933054466,https://twitter.com/kaushalpar/status/1267204564933054466,kaushalpar,"Thank you @ASCO for organizing #ASCO20 and thank you #lcsm gurus for thought provoking insights. Now, on to space force bingeing! https://t.co/6WxohpRXgx",2020-05-31
1267204050078007298,https://twitter.com/RodriguezGIMD/status/1267204050078007298,RodriguezGIMD,"Thanks to  @ASCO staff, @CliffordHudis @MLJohnsonMD2 @ASCOPres and all presenters for making #ASCO20 a reality during #COVID19 pandemic",2020-05-31
1267203968729518080,https://twitter.com/Poggio_Fra/status/1267203968729518080,Poggio_Fra,Results of Bylieve at @ASCO: Another piece in the puzzle of #hormonereceptor+ #Her2- and #PIK3CA mutation progressing after #cdk 4/6i plus #AI @OncoAlert #ASCO2020 https://t.co/WYGQ625yy7,2020-05-31
1267203852597694464,https://twitter.com/VukovicPetra/status/1267203852597694464,VukovicPetra,"#ASCO20 Excellent discussion from prof. Overman on practice-changing results of #Keynote 177, raised questions  &amp; next steps #Oncoalert https://t.co/M1c0a2FzdI",2020-05-31
1267203660942962689,https://twitter.com/n8pennell/status/1267203660942962689,n8pennell,My take home this afternoon is that the majority of #LCSM on Twitter is aghast at the cost of targeted drugs and just about fed up. #ASCO2020 https://t.co/vyiPYuAz26,2020-05-31
1267203537563455488,https://twitter.com/IBCResearch/status/1267203537563455488,IBCResearch,"Virtual #ASCO20 has ended, now to catch-up on the abstracts &amp; presentations awaiting review. Grateful for the access, esp for #patientadvocates who often can’t attend due to cost. Miss IRL hugs, wine &amp; conversations. TY @ASCO &amp; all involved, well done!",2020-05-31
1267203526566055942,https://twitter.com/VivekSubbiah/status/1267203526566055942,VivekSubbiah,🥁 For the @asco #ASCO20 virtual meeting once again 2nd yr in a row the celebrity picture in a picture of @DrChoueiri wins the prize🏅. #InThisTogether #thistooshallpass #COVID19 #endcancer @ConquerCancerFd #hope 💫 https://t.co/riFiNFsFZL,2020-05-31
1267203136877326336,https://twitter.com/GeorgeSledge51/status/1267203136877326336,GeorgeSledge51,Plenary Session Dr. Seema Khan EA2108 randomized Phase 3 trial of localregional treatment in the setting of MBC. Patients got 4-8 mo of systemic therapy and if not progressing randomized to LRT or not. Primary endpoint was OS. COI: I am senior author. #ASCO20 #bcsm,2020-05-31
1267202954928537603,https://twitter.com/urotoday/status/1267202954928537603,urotoday,#TRANSFORMER: Bipolar androgen therapy vs Enzalutamide for castration-resistant metastatic #ProstateCancer. Presented by @denmesa @hopkinskimmel. #ASCO20 written coverage by @aloktewar @DanaFarber on UroToday &gt; https://t.co/JvB1UCxnd9 @ASCO #mCRPC https://t.co/7RvuU1rrzd,2020-05-31
1267202623020560384,https://twitter.com/AnaVManana/status/1267202623020560384,AnaVManana,"💯 we’ve seen the effects of #racism and #bias in medicine for years. Biggest example in #hemeonc: #SickleCell disease. Newest example: #ASCO20 abstract from Dr. Enzinger @DanaFarber showing #racialdisparities in #opioid access among pts with #cancer 

https://t.co/2WrNvNnY8L https://t.co/SCqGfv25o8 https://t.co/iXPk0JQXhf",2020-05-31
1267202459337818114,https://twitter.com/MarkJeffery4/status/1267202459337818114,MarkJeffery4,I could get used to virtual #ASCO20 if it means watching from bed w a cup of tea! https://t.co/IdWmP7rGsH,2020-05-31
1267202315116838912,https://twitter.com/_SEOM/status/1267202315116838912,_SEOM,"📡#ASCO20 | La Dra. Regina Gironés (@girogiro42), coordinadora de la Sección SEOM de Oncogeriatría, analiza las novedades sobre el paciente anciano con #cáncer.

🎞️Sus vídeo-píldoras ya están disponibles en nuestra plataforma de formación #OncoNexion. 

🔗https://t.co/wCdmkxtv0q https://t.co/i0p8H5MA85",2020-05-31
1267202285509193735,https://twitter.com/TargetedOnc/status/1267202285509193735,TargetedOnc,"ASCO POLL: Now that #ASCO20 has come to an end, in which cancer types do you think we saw the most impactful data? Share what abstracts you found most exciting in the comments below! Looking forward to sharing our annual review this week!
#LScm #BCsm #HemOnc #GICancers #GUCancers",2020-05-31
1267202237228613632,https://twitter.com/LynneWagnerPhD/status/1267202237228613632,LynneWagnerPhD,Agreed! Fortunate EA leadership and colleagues value QOL endpoints and are fun collaborators @eaonc @VincentRK @myelomaMD @awolff @jsparano @GeorgeSledge51 @fischmd @mtmdphd #ASCO20 Also NCI support is key @NCISymptomMgmt @NCICTEP_ClinRes @NCIprevention @NCICareDelivRes https://t.co/7gXlw56J3Y,2020-05-31
1267202081825476616,https://twitter.com/Tarek_Assi1986/status/1267202081825476616,Tarek_Assi1986,More than 40% did not receive adj. chemo. Who were these pts? HR for subgroup analysis were similar for those who received chemo vs no chemo (0.18 vs. 0.23)..Does this mean that chemo can be omitted even in high risk patients with osimertinib? #ASCO20 #ADAURA  #lungcancer #EGFR,2020-05-31
1267202053727817730,https://twitter.com/TMSchmidtMD/status/1267202053727817730,TMSchmidtMD,"Excellent summary of ENDURANCE trial 👇. Kudos to @myelomaMD, @eaonc for asking and answering this important question and to @ASCO for inclusion in #PlenarySession. Underscores vital importance of well-designed Ph3 cooperative #RCT. #mmsm #asco20 https://t.co/qZv5Qrt66q",2020-05-31
1267201825700265984,https://twitter.com/OncologyTimes/status/1267201825700265984,OncologyTimes,More from #ASCO20: Smoking Cessation Prior to #LungCancer Diagnosis Can Improve Survival https://t.co/l7fGtJtfcD #cancer #research via @UHN https://t.co/6W7Rl0tatV,2020-05-31
1267201795421622272,https://twitter.com/DrSGraff/status/1267201795421622272,DrSGraff,"As we flood the McCormick halls after plenary session #ASCO20, I want to congratulate @ASCOPres @BurrisSkip and Scientific Chair @MLJohnsonMD2 on an INSPIRED meeting. May we forever unite &amp; conquer. #ASCO20 👏🏻👏🏻👏🏻 https://t.co/REBirApzHQ",2020-05-31
1267201702563848207,https://twitter.com/WCMLymphoma/status/1267201702563848207,WCMLymphoma,".@JohnPLeonardMD describes #research underway to find more effective treatment strategies for people newly diagnosed with primary central nervous system #lymphoma, via #ASCO20. https://t.co/oA1ctrCS3Y (CC @ALLIANCE_org) https://t.co/cO7We5QZdf",2020-05-31
1267201578680926208,https://twitter.com/LGM_Biostats/status/1267201578680926208,LGM_Biostats,"#ASCO18 Throwback: Inspired by research presented in the plenary, attendees rush to #ConquerCancer donor lounge to fund more. #ASCO20: Different Meeting. Same Mission. Support @ASCOPres $1M challenge. TEXT ASCO to 41444 or visit https://t.co/3cJJG4Rpbl. #COVID19",2020-05-31
1267201167907524609,https://twitter.com/IBCResearch/status/1267201167907524609,IBCResearch,Appreciate the way you condense all the slides into a concise take home message...thank you @GeorgeSledge51! #ASCO20 https://t.co/bYaSDDlAaT,2020-05-31
1267200988626157570,https://twitter.com/ShrutiPatelMD/status/1267200988626157570,ShrutiPatelMD,"Incredible work from @YaleCancer on the use of osimertinib in IB-IIIA resected EGFR+ lung cancer at #ASCO20 #ADAURA 

As use of osimertinib increases, it is important to remember the associated cardiotoxicity! 

https://t.co/gq4ekfkpBl

@NarjustDumaMD @mayocvonc @ICOSociety",2020-05-31
1267200862838980610,https://twitter.com/HannahT_85/status/1267200862838980610,HannahT_85,This👇. Welcomed leadership @asco 🙏 https://t.co/0rLZ6v1sGz,2020-05-31
1267200761500364800,https://twitter.com/GeorgeSledge51/status/1267200761500364800,GeorgeSledge51,"Temel Phase 3 results: on process measures (EHR documentation) there were significant differences. On actual patient benefit measures, no diff in QOL, anxiety, depression, &amp; prognostic awareness. While EOL documentation is important this is disappointing outcome. #ASCO20 #bcsm",2020-05-31
1267200641576796160,https://twitter.com/marklewismd/status/1267200641576796160,marklewismd,"Last year after #asco19, @chadinabhan &amp; I envisioned greater patient inclusivity at this meeting

Obviously we couldn’t have anticipated #asco20 going virtual, which I think confounded the “feel” of the conference, but with n=76 here’s what advocates said this year 👇🏻

Thoughts? https://t.co/X0vlfEUmr9",2020-05-31
1267200640217989121,https://twitter.com/LanaBijelicMD/status/1267200640217989121,LanaBijelicMD,Very impactful data on tx of MSI-H mCRC presented at @ASCO 20. Pembro becomes standard for first line.Important implications for #surgical #oncologists treating #colorectalcancer metastases. @SocSurgOnc  @ESSOnews https://t.co/AV3GHBS3UX,2020-05-31
1267200428380430344,https://twitter.com/Medscape/status/1267200428380430344,Medscape,"Impartiality of medical society leadership called into question. 
https://t.co/HiOqtLsQJj #ASCO20",2020-05-31
1267200348566978565,https://twitter.com/AshleySumrallMD/status/1267200348566978565,AshleySumrallMD,That’s a wrap for #asco20 (until @ASCO ed session Aug 8-10). Thx @ASCO @sarah_c_hopkins @AmandaBinDC @ASCOPres @cancerassassin1 @ShaalanBeg for including me in featured voices. Until August.... 👋🏻 https://t.co/9HTANXHwPy,2020-05-31
1267200216035405825,https://twitter.com/santioncologia/status/1267200216035405825,santioncologia,"700 pacientes que no habían progresado después de al menos cuatro ciclos de quimioterapia de primera línea basada en platino. La terapia de mantenimiento con avelumab mejoró la sobrevida global en 7,1 meses en comparación con solo recibir la mejor atención de apoyo
@ASCO https://t.co/HCZ0mvuHVv",2020-05-31
1267200189993025538,https://twitter.com/ARosen380/status/1267200189993025538,ARosen380,"As this years #Virtual @ASCO comes to an end, I am grateful to have had access to so many leaders in the oncology field! However, I am still holding on to the memories of my 1st work related abstract at #GI20 #patientadvocate #healthdisparities #crcsm #ASCO20 #cancer #researcher https://t.co/nFw9lSbDdL",2020-05-31
1267200179234627586,https://twitter.com/MDAndersonNews/status/1267200179234627586,MDAndersonNews,"#Targetedtherapy studies led by our @skopetz and Dr. Arlene Siefker-Radtke indicate improved outcomes for colorectal cancer and bladder cancer patients with specific gene mutations.

Learn about the findings, presented at #ASCO20: https://t.co/W1iGyz0myZ #endcancer",2020-05-31
1267200175820476424,https://twitter.com/TJH0828/status/1267200175820476424,TJH0828,Avelumab Maintenance Therapy Improves Survival in Advanced Urothelial Cancer with commentary from @ERPlimackMD @ASCO https://t.co/ZhXh8UAV6C,2020-05-31
1267200066571419648,https://twitter.com/tlnaka/status/1267200066571419648,tlnaka,"#ASCO2020 - I wish someone would do a study on effects of long term immunotherapy use- stage IV nsc lung ca Dx 4/2013- mets to brain and adrenals, started opdivo 9/2015 NED 3/2016- still on therapy 1x per month",2020-05-31
1267199778062061574,https://twitter.com/ivanpantic1980/status/1267199778062061574,ivanpantic1980,"Ensuring practice changing before data are mature is a practice we must start changing #ASCO20 
PS: I have done it too.",2020-05-31
1267199673732825098,https://twitter.com/LAMcAlarnenMD/status/1267199673732825098,LAMcAlarnenMD,This is amazing! Take home messages from #ASCO2020 #SGOatASCO https://t.co/7x2MvQllOS,2020-05-31
1267199559584944129,https://twitter.com/n8pennell/status/1267199559584944129,n8pennell,"Would it make any difference to do it that way versus primary DFS and key secondary OS? You get the same timing of results, I bet the main change would be larger sample size but likely still would have been stopped at interim analysis #ASCO20 #LCSM https://t.co/DX7s9FYrv8",2020-05-31
1267199326230646787,https://twitter.com/AshleySumrallMD/status/1267199326230646787,AshleySumrallMD,"Non-clinical take-home points from #asco20: 
🔶 GIVE to @ConquerCancerFd https://t.co/3IHreBhuH0
🔶 BE an advocate https://t.co/aBifAQVNGE
🔶 LEAD a trainee to join #SoMe @ASCO @HOJournalClub 
🔶 EDUCATE yourself on how cancer issues affect POC
🔶 ATTEND @ASCO Ed session Aug 8-10 https://t.co/36BXS6CDuz",2020-05-31
1267199286284034051,https://twitter.com/RosarVidal/status/1267199286284034051,RosarVidal,Amazing results! Happy to see these #ASCO20 New standard of care in dMMR / MSI-H mCRC. Step by step. https://t.co/lzdqagfNbS,2020-05-31
1267199222907990016,https://twitter.com/GeorgeSledge51/status/1267199222907990016,GeorgeSledge51,"Temel Phase 3 trial of combined oncologist/ palliative care intervention vs standard care. Endpoints were EOL and MOLST form documentation as well as QOL, anxiety &amp; depression and prognostic awareness. Intervention = monthly visits X 6. #ASCO20 #bcsm",2020-05-31
1267199221859565570,https://twitter.com/urotoday/status/1267199221859565570,urotoday,"The IP1-PROSTAGRAM study: population-based #ProstateCancer screening using a prospective, blinded, paired screen-positive comparison of #PSA and fast #MRI. Presented by @eldredevans @imperialcollege. #ASCO20 coverage by @WallisCJD @VanderbiltU &gt; https://t.co/i5Jiq5ldyX @ASCO https://t.co/xjd8JvlTv0",2020-05-31
1267199175403462658,https://twitter.com/ConquerCancerFd/status/1267199175403462658,ConquerCancerFd,Many thanks to @EisaiUS for being a Silver Level supporter of the #ConquerCancer Bundle at #ASCO20 https://t.co/awdNooRDml,2020-05-31
1267199170416455681,https://twitter.com/JAMANetwork/status/1267199170416455681,JAMANetwork,"We're interested in reviewing your #ASCO20 research for publication in @JAMA_current, @JAMAOnc, or our other Network journals. Watch how to prepare and submit your manuscripts 
 https://t.co/5oIlErH1ll",2020-05-31
1267199170357727233,https://twitter.com/syinvesting/status/1267199170357727233,syinvesting,"#ASCO20 Here's a look at Boehringer's first-in-human Phase 1 clinical trial of its pan-KRAS inhibitor (BI 1701963). @Boehringer

3 patients have been treated as of 02/11/20. Primary completion data is stated as Feb '21.

Trial link: https://t.co/8aWoWahkFn

$AMGN $MRTX $JNJ $LLY https://t.co/dVNrXIOaUB",2020-05-31
1267199130578964480,https://twitter.com/ShannonWestin/status/1267199130578964480,ShannonWestin,I am honored to lead this international study with Drs. Moore &amp; Vergote - we will determine the role of #immunotherapy and #PARPi in advanced/recurrent #endometrialcancer Many thanks to @GOG for my Scholar Investigator Award which supports this work! #ASCO20 #SGOatASCO #gyncsm https://t.co/9sJNol7L0M,2020-05-31
1267199106205863937,https://twitter.com/Dr_Ivanoncologo/status/1267199106205863937,Dr_Ivanoncologo,El mensaje para llevar a casa del #ASCO20 #strongertogether #Oncoalert https://t.co/LQu1VveTf7,2020-05-31
1267199083204182020,https://twitter.com/cbtadvisors/status/1267199083204182020,cbtadvisors,More good news from $MRK re Keytruda. Excellent Ph3 data in patients with high mutation burden. #ASCO20 #oncology https://t.co/N8xiL1E0Xz,2020-05-31
1267198918296772615,https://twitter.com/DrLaurenNye/status/1267198918296772615,DrLaurenNye,"Thank you for acknowledging racism is related to health + medicine and therefore, it is our job to acknowledge, address and act as physicians and oncologist. #BlackLivesMatters #ASCO20 we can’t be silent. Shout out to our black colleagues, you matter, we stand by you. https://t.co/nt071Q8z8d",2020-05-31
1267198793587589124,https://twitter.com/eduhor82/status/1267198793587589124,eduhor82,"#KEYNOTE177: Practice changing in dMMR mCRC
#Pembrolizumab vs ChemoT
#ASCO20 #crcsm https://t.co/JZPq1DGo6E https://t.co/RB7eVfAydV",2020-05-31
1267198513445834758,https://twitter.com/wyv_123/status/1267198513445834758,wyv_123,$TRIL #ASCO20 #CD47 https://t.co/TolsakGIR3,2020-05-31
1267198385645223936,https://twitter.com/marklewismd/status/1267198385645223936,marklewismd,"Mad props to @tmprowell, who couldn’t care less about Twitter clout but effortlessly crushes it anyway. 

She is part of the behind-the-scenes connective tissue of the @asco meeting (&amp; called her shot on @DavidFajgenbaum years ago — talk about a can’t-lose bet! 👏)

#asco20 https://t.co/KetdRGiC69",2020-05-31
1267198318452539394,https://twitter.com/TempusLabs/status/1267198318452539394,TempusLabs,"This summer, we're launching two new precision medicine-driven oncology tests; Tempus|HRD, which identifies a patient’s homologous recombination deficiency (HRD) status, and Tempus|TO, which predicts the tissue of origin (TO) for tumors: https://t.co/tCuLTboQIL. #ASCO20",2020-05-31
1267198229315301377,https://twitter.com/tmprowell/status/1267198229315301377,tmprowell,"As part 1 of the @ASCO Virtual Annual Mtg comes to a close, if you missed any content, you can find it all on the #ASCO20 Annual Mtg website https://t.co/HKrxKFUw3u where a pic is worth 1000 words. 😊

Can't wait to see everyone back 8/8-8/10 for #ASCO20 Virtual Ed Program.🤜🤛 https://t.co/8p4INMCxIN",2020-05-31
1267198170255298568,https://twitter.com/Anon_Knee_Mouse/status/1267198170255298568,Anon_Knee_Mouse,#ASCO2020 #breastcancer  #Asco https://t.co/9obAoAk3d5,2020-05-31
1267197935655190534,https://twitter.com/Jorge_GarciaRod/status/1267197935655190534,Jorge_GarciaRod,Prostate cancer highlights #ASCO20 https://t.co/jTuV7dzZoD,2020-05-31
1267197911823237120,https://twitter.com/radioligand/status/1267197911823237120,radioligand,"Thank you for a fascinating highlights session to #ASCO20. Lots of important considerations for all rapidly evolving therapeutics, including #radioligandtherapy. @ASCO",2020-05-31
1267197777425072136,https://twitter.com/pharmaphorum/status/1267197777425072136,pharmaphorum,"And that’s a wrap for our live coverage from ASCO, this year sponsored by @SyneosHealth.

We’ll have more on the subject next week and then in the forthcoming Deep Dive: Oncology issue of our digital magazine.

https://t.co/yQ3bqeUiNJ #pharma #biotech #ASCO20",2020-05-31
1267197687616745472,https://twitter.com/fischmd/status/1267197687616745472,fischmd,"Nice shoutout for @eaonc and the exquisite value of @theNCI sponsored #clinicaltrials
#ASCO20 https://t.co/UI5JVuDQ92",2020-05-31
1267197679165231104,https://twitter.com/OncologyBio/status/1267197679165231104,OncologyBio,PSMA como agente terranostico demonstrou eficácia quando combinado com lutecio em comparação a cabazitaxel em pacientes com mCRPC após falha de docetaxel e a maioria dos pacientes a abi ou enza. Ainda não uma mudança de prática mas uma opção sólida a quem pode pagar #ASCO20 https://t.co/njJ3Dq8HzZ,2020-05-31
1267197635196342273,https://twitter.com/Dr_Ivanoncologo/status/1267197635196342273,Dr_Ivanoncologo,"BLU-667 en cánceres pancreáticos y de CCA,
parece prometedor
#ASCO20 #ASCO2020 #Cáncer #cancercare #OncoAlert https://t.co/YtBJ9YEcoM",2020-05-31
1267197598802165760,https://twitter.com/thomcalandra/status/1267197598802165760,thomcalandra,#ASCO20 Yet more peer-reviewed conclusions from IMV and Dr. Dorigo in his DPX-Survivac treatment of last-resort ovarian cancer; Nova Scotia &amp; Québec @imv_inc https://t.co/3SUEylRF7I,2020-05-31
1267196936991506436,https://twitter.com/Dr_Ivanoncologo/status/1267196936991506436,Dr_Ivanoncologo,"#ASCO20 Nueva actualización.
 #RET ADN en #cholangiocarcinoma.
#RareDisease #RareADN #oncoalert https://t.co/PnJLvFtAyW",2020-05-31
1267196874693328896,https://twitter.com/moyhararit/status/1267196874693328896,moyhararit,"Results from ADAURA trial data cut-off from plenary session are impressive, truly practice changing for EGFR mutated early stage NSCLC. #ASCO2020 #lungcancer https://t.co/iAVONfeg6M",2020-05-31
1267196824244420614,https://twitter.com/OncoAlert/status/1267196824244420614,OncoAlert,"Thank you so much @ASCO for an Amazing #ASCO20 ‼️Although we would have loved to be there in person, y'all delivered under these pressing times. 
We thank ALL our colleagues for making @OncoAlert  7⃣0⃣%of the top influencers this time. 
We Are ALL #OncoAlert 🌐
@weoncologists https://t.co/LldKLVWVid",2020-05-31
1267196810239586305,https://twitter.com/milosicevic/status/1267196810239586305,milosicevic,Virtual #ASCO20 also brought more memes https://t.co/G8GD7GcRCf,2020-05-31
1267196788320210945,https://twitter.com/OncologyBio/status/1267196788320210945,OncologyBio,Os estudos avaliando o papel dos novos antiandrogenos nos pacientes com nmCRPC demonstrou ganho de sobrevida global com o tratamento mais precoce. O perfil de toxicidade é importante para definir a escolha? #ASCO20 https://t.co/ZQcwf10cKU,2020-05-31
1267196552705183755,https://twitter.com/_B_I_O_T_E_C_H_/status/1267196552705183755,_B_I_O_T_E_C_H_,"JEFF #ASCO2020: Updates on $IMMU, $TGTX #ASCO20 May 31, 2020 IMMU. 1) Interim data from Ph2 cisplantin (cont) https://t.co/WeVIBsDeRe",2020-05-31
1267196401844473856,https://twitter.com/CleClinicMD/status/1267196401844473856,CleClinicMD,New research reveals the promise of taking an algorithmic approach to differentiating true glioblastoma progression from pseudoprogression on MRI: #ASCO20 https://t.co/YlUGo8r7h4,2020-05-31
1267196272030683136,https://twitter.com/OncologyBio/status/1267196272030683136,OncologyBio,"Excelente resultado de avelumab como terapia de manutenção nos pacientes sem progressão após quimioterapia com platina. Infelizmente aproximadamente 15% dos pacientes ainda precisam de uma terapia efetiva, e neste caso são os de pior prognóstico #ASCO20 https://t.co/bc9rkWXeLK",2020-05-31
1267196153331765248,https://twitter.com/AshleySumrallMD/status/1267196153331765248,AshleySumrallMD,"It only takes 30 seconds to ask your lawmakers to support our patients and providers through the #COVID19 crisis.  While you are there, send them notes to support  #HR913 &amp; #HR3107 #ASCOactnetwork #ASCOACT #ASCO20 https://t.co/9ssFHP3Obm https://t.co/gYV1q1bgjU",2020-05-31
1267196095266009090,https://twitter.com/GlobalOncPod/status/1267196095266009090,GlobalOncPod,"Out-of-pocket payment for HER-2 directed therapy identified as a barrier to access in #Armenia 

https://t.co/IeMAVTfQod

From Dr Gevory Tamamyan et al 

But do #biosimilars ⬇️ cost?

Was it @Oncology_bg who suggested an alternative term #pricesimilar?

#GlobalOncology #ASCO20",2020-05-31
1267196012814233601,https://twitter.com/MichelleStric/status/1267196012814233601,MichelleStric,#ASCO20 may be a little different this year but no less important. I'm proud to work for a company that is dedicated to understanding the biology of #cancer to better help patients in need. #pfizerproud https://t.co/ZyypzK2pmE,2020-05-31
1267195901879164928,https://twitter.com/MDedgeHemOnc/status/1267195901879164928,MDedgeHemOnc,Did you hear at #ASCO20? Oral relugolix works to a T against advanced #prostatecancer. https://t.co/wqYwWUafwJ https://t.co/YdsUzyJ5qW,2020-05-31
1267195898641162240,https://twitter.com/MedscapeOnc/status/1267195898641162240,MedscapeOnc,"80% reduction in the risk of disease recurrence or death in certain patients with NSCLC. 
https://t.co/qbq3thXaUJ #ASCO20",2020-05-31
1267195836942839810,https://twitter.com/WallStChameleon/status/1267195836942839810,WallStChameleon,"$MRK Keytruda phase 3 study shows double the progression time (16.5 v 8.2 months) for untreated colon cancer w/MSI-H and dMMR mutations (both hinder (DNA repair) vs standard chemotherapy regiment. Another win for Keytruda #asco2020
C: StatNews ASCO In 30 Seconds newsletter May 31",2020-05-31
1267195776402436097,https://twitter.com/manjuggm/status/1267195776402436097,manjuggm,"Isn't this so cool? Now we need similar studies in CRC..
Pseudoprogression versus real progression?
Dr.Eng @CathyEngMD mentioned true pseudoprogression I add vs false pseudoprogression? 🤪😜
#ASCO20 @TotalHealthConf #CRCSM https://t.co/H4weHGLBef",2020-05-31
1267195661776302084,https://twitter.com/FJCarmonas/status/1267195661776302084,FJCarmonas,"Plasma sequencing captures larger number of actionable alterations than tissue genotyping &amp; accelerates enrolment of patients with GI #Cancer in clinical trials without compromising treatment efficacy―data on GI-SCREEN &amp; GOZILA discussed at #ASCO20 by Dr Chandra.

#liquidbiopsy https://t.co/Vl4KPfXimB",2020-05-31
1267195555752665090,https://twitter.com/TotalHealthConf/status/1267195555752665090,TotalHealthConf,What do you enjoy most about #ASCO20? #ASCOTotalHealth,2020-05-31
1267195536978870272,https://twitter.com/CharuAggarwalMD/status/1267195536978870272,CharuAggarwalMD,Thank you @jillfeldman4 for sharing your story. So important to hear this. @EGFRResisters @ASCO #ASCO20 https://t.co/zfuh1bydEU,2020-05-31
1267195534038663168,https://twitter.com/dcmadoff/status/1267195534038663168,dcmadoff,Poster at #ASCO2020 on newly proposed response criteria for #intratumoral #immunotherapy in solid #tumors: itRECIST!  #irad #cancer @ASCO @RSNA @SIRspecialists @YaleRadiology @Yale_IR @YaleMed @YaleCancer @Merck @upmc @GustaveRoussy @ICR_London @ColumbiaMed https://t.co/7ZrD8UJ0GY,2020-05-31
1267195464597639168,https://twitter.com/stage4kelly/status/1267195464597639168,stage4kelly,"besides missing the IRL connections, I didn't get in the thousands of daily steps, so Gryffindor the dog and I are off for a walk. Thanks #ASCO20 and ""see"" you at the educational program in August! 
(PS Dr @tmprowell you better catch up on your rest before then!)",2020-05-31
1267195440015032326,https://twitter.com/krknrm/status/1267195440015032326,krknrm,"Fab Dev Therapy Highlights by @MunTheLoon - a fantastic wrap-up to #ASCO20. Thanks to all the #tweeps for a wonderful job to keep up with multiple tracks, &amp; @ASCO organizers for a superb meeting. Stay in touch if you would like to discuss your clinical work with @NatureCancer! https://t.co/Zwnb8BEb6S",2020-05-31
1267195411867066368,https://twitter.com/urotoday/status/1267195411867066368,urotoday,"PROREPAIR-A: Clinical and molecular characterization study of #prostatecancer patients with and without previously known #germline BRCA1/2 mutations. Presented by Rebeca Lozano, MD @CNIO_Cancer. #ASCO20 coverage by @aloktewar @DanaFarber on UroToday &gt; https://t.co/ih4omNEOrq https://t.co/agUT8KB5n0",2020-05-31
1267195398998949888,https://twitter.com/ConquerCancerFd/status/1267195398998949888,ConquerCancerFd,Special thanks to @bmsnews for supporting #ASCO20 Virtual https://t.co/qa1t8Fglcn,2020-05-31
1267195259810914309,https://twitter.com/OncologyBio/status/1267195259810914309,OncologyBio,"Os dados de sobrevida global na população de bom prognóstico não tem o mesmo impacto que no risco intermediário/alto, porém ainda não mudam a prática clínica. Porém existe um espaço para avaliar monoterapia nestes casos #ASCO20 https://t.co/blsG4Zxa0h",2020-05-31
1267195211551252482,https://twitter.com/HSaterMD/status/1267195211551252482,HSaterMD,#ASCO20 Thanks @DrGattiMays @thenasheffect for a great challenge! I call on @gulleyj1 @Dr_RaviMadan @FatimaKarzai @ScotNiglio @apolo_andrea @ZakhariaYousef @SamahNd to spread the candle light🕯started by @ASCOPres @ConquerCancerFd to reach $1M ⏳ via https://t.co/f6qqesGW70 🌍 https://t.co/YUyQhoOXcp,2020-05-31
1267195178646994944,https://twitter.com/AshleySumrallMD/status/1267195178646994944,AshleySumrallMD,Grabbed a few #ascoispy moments! Thx @VivekSubbiah for the challenge! #asco20 https://t.co/KJt95iiLWw,2020-05-31
1267195022979538946,https://twitter.com/YaleCancer/status/1267195022979538946,YaleCancer,"In a poster presentation at #ASCO20, Dr. Rozalyn Rodwin reports on neuropathy in survivors of childhood central nervous system tumors in the @StJude Lifetime cohort. #pediatriccancer @SmilowCancer @YaleMed @YNHH https://t.co/nk1HCpXjTZ https://t.co/Nh5JoENtHo",2020-05-31
1267194857765961733,https://twitter.com/Genmab/status/1267194857765961733,Genmab,#ASCO2020 https://t.co/4fFTq8w3UA,2020-05-31
1267194748990705664,https://twitter.com/stage4kelly/status/1267194748990705664,stage4kelly,"thank you @ASCO @ASCOPres @MLJohnsonMD2 and everyone involved in #ASCO20. While I missed the IRL hugs, laughs, and wine, the content &amp; delivery were incredible and it's a #SilverLining to be able to easily watch missed sessions/info (in sweats!) in this #VirtualConference format.",2020-05-31
1267194564009504769,https://twitter.com/sarahkrug1/status/1267194564009504769,sarahkrug1,"Although I missed the IRL interactions, many thanks to the presenters, @ASCO staff, @CliffordHudis @ASCOPres  who gave us the opportunity to engage virtually #asco20 
The online chat function + tweet chats  allowed for deeper dives, debate, great discussions &amp; new friends! https://t.co/VnReQISu6v",2020-05-31
1267194550763892740,https://twitter.com/Marzia_Del_Re/status/1267194550763892740,Marzia_Del_Re,The only thing I am definitely not missing from being at the #ASCO20 in person... is the #airco 🥶!!!!! 💨❄️🤣,2020-05-31
1267194351375069194,https://twitter.com/YaleCancer/status/1267194351375069194,YaleCancer,"In a poster presentation at #ASCO20, @MarioSznol presents results of #Immunotherapy Phase II trial of Voyager-VI in combination with cemiplimab in patients with #NSCLC, #melanoma, HCC or endometrial carcinoma. @SmilowCancer @YaleMed @YNHH #OncoAlert 
https://t.co/pJXI15hvPz https://t.co/rbcHRYwe5T",2020-05-31
1267194343686901767,https://twitter.com/OncologyBio/status/1267194343686901767,OncologyBio,A profundida de resposta acima de 80% mostrou ser tão importante para sobrevida global quanto as respostas completas #ASCO20 https://t.co/0mWoDcZDGZ,2020-05-31
1267194230910353414,https://twitter.com/drlw2309/status/1267194230910353414,drlw2309,"Don’t know what to make of this trial, as I’ve never seen pembro used for mCRC in any line - #NHS. Sceptical about validity of control arm or crossover. It’s being hailed at #ASCO20 as the new SoC. Would like to know subsequent therapies received along with OS data. https://t.co/IOSv8KhGju",2020-05-31
1267194087771451399,https://twitter.com/sarah_c_hopkins/status/1267194087771451399,sarah_c_hopkins,"Wish we could film in-person again this year, but IG Live will do! 5 mins until @MKnoll_MD hosts a discussion on @ASCO’s IG! #ASCO20 https://t.co/7vgqRv8Bn0 https://t.co/XPvGzV9fwP",2020-05-31
1267193897626882049,https://twitter.com/IlariaAttiliMD/status/1267193897626882049,IlariaAttiliMD,Waiting for OS... and confounding effect of unblinding on it🔀 #LCSM #ASCO20 https://t.co/jdtke114hW,2020-05-31
1267193881176805376,https://twitter.com/arjazieh/status/1267193881176805376,arjazieh,"Outstanding Plenary Session #ASCO20 
High quality studies and excellent presenters and discussants. 
Practice changing findings. Although missing in person @ASCO meeting in Chicago, it was wise decision to hold virtually to share such data on time with the oncology community.",2020-05-31
1267193863548145667,https://twitter.com/OncologyBio/status/1267193863548145667,OncologyBio,"Após 30 anos uma estratégia mostrou-se superior ao tratamento padrão com ganho de sobrevida na 1L do carcinoma urotelial. Avelumab como terapia de manutenção aumentou significativamente a sobrevida global, independente da expressão de PD-L1 e da elegibilidade a cisplatina #ASCO20 https://t.co/a0SKXu37Ja",2020-05-31
1267193811383603201,https://twitter.com/montsecarrere/status/1267193811383603201,montsecarrere,Targeting EGFR in early stage NSCLC #ASCO20 https://t.co/WqdmmIQjD7,2020-05-31
1267193734158000130,https://twitter.com/ThisIsSeanB/status/1267193734158000130,ThisIsSeanB,"This!
Large improvement in DFS with no improvement in OS means no benefit. 
Either we help patients live longer (OS) or we help them live better (QoL). Those are the outcomes that matter
#ASCO20 https://t.co/UE0Vjo3pbm",2020-05-31
1267193625126989824,https://twitter.com/GeorgeSledge51/status/1267193625126989824,GeorgeSledge51,PARSIFAL randomized Phase 2 of palbociclib + either AI or fulvestrant. Quick take: overlapping PFS and OS curves. Since is is a randomized Phase 2 can’t rule out a small advantage for either combo but boy those curves look similar. #ASCO20 #bcsm,2020-05-31
1267193602477867009,https://twitter.com/PoorviDesaiMD/status/1267193602477867009,PoorviDesaiMD,"Thank you @MoffittNews @MoffittResearch for this feature about my presentation on #anaplasticlargecelllymphoma at #ASCO20!

Abstract in link&amp; virtual poster here:
https://t.co/UdNYkuB0gF 

#ALCL #PCALCL #BIAALCL #Immunohistochemistry #tissuemicroarray @ASCO @ConquerCancerFd https://t.co/cEArABDH6B",2020-05-31
1267193375876354049,https://twitter.com/GhosnMd/status/1267193375876354049,GhosnMd,Despite the COVID 19 situation we enjoyed the ASCO20 Virtual meeting #ASCO #asco20 excellent scientific meeting and excellent web support by#ASCO leadership for better medicine for better care of our patients #ASCOTogether in Beirut,2020-05-31
1267193136297783297,https://twitter.com/OncotypeIQ/status/1267193136297783297,OncotypeIQ,"#ASCO20 explore the COVID-19 Consortium guidance for #breastcancer treatment and how a low-risk Recurrence Score® result from a core biopsy may be used to treat patients with Stage 1 or 2 disease, including N+ (1-3), with endocrine therapy alone https://t.co/V5umFgZRTZ #oncology https://t.co/sp5kvhJvGq",2020-05-31
1267193076826681345,https://twitter.com/karenluMD/status/1267193076826681345,karenluMD,Happy to accept the challenge from @drdonsdizon and @ShannonWestin !!! Grateful for what @ConquerCancerFd @ASCO  does for young investigators!! Tagging my buddies committed to Prevention/Genetics @evilarsan @gynoncology @loconte https://t.co/7CPfD1IO9j,2020-05-31
1267193046954913793,https://twitter.com/GOncologia/status/1267193046954913793,GOncologia,"What a great plenary session !
@ASCO #ASCO2020",2020-05-31
1267192893405528066,https://twitter.com/OncologyTimes/status/1267192893405528066,OncologyTimes,Don't miss these new abstracts on Chronic Lymphocytic #Leukemia from #ASCO20 https://t.co/0USWqp3C8I #cancer #bloodcancer #leusm #medtwitter #CLL https://t.co/xDBaYrGFdG,2020-05-31
1267192889622355968,https://twitter.com/OncLive/status/1267192889622355968,OncLive,Alectinib Continues to Maintain Significant OS Benefit in ALK+ NSCLC @peters_solange @CHUVLausanne @ASCO #ASCO20 #lcsm https://t.co/1aJCroNTgn,2020-05-31
1267192878708580352,https://twitter.com/marklewismd/status/1267192878708580352,marklewismd,"It’s been a blast, #ASCO20.

Since I don’t need to fly home now, I am going to simulate the passengers who won’t share the armrest on the plane with my Frenchie who won’t share the sunbed. https://t.co/fNLbTiJUAV",2020-05-31
1267192549392949252,https://twitter.com/Tucker_MatthewD/status/1267192549392949252,Tucker_MatthewD,This reduction in risk of MACE is serious. We need more studies like HERO investigating ways to make therapy more tolerable. Great discussion from @DrDaveWise! #ASCO20 See full study at https://t.co/wtbKeFHmE4 @Daniel_J_George https://t.co/DYn99xTXMd,2020-05-31
1267192455864221698,https://twitter.com/SusanGKomen/status/1267192455864221698,SusanGKomen,New findings presented at #ASCO20 show no survival or quality of life benefit from local surgery/radiation tx for newly dx #metastatic #breastcancer patients. Read more: https://t.co/MmKyaERmm3,2020-05-31
1267192428953366528,https://twitter.com/LinMateo/status/1267192428953366528,LinMateo,Our new #ASCO2020 abstract highlights how we are using H&amp;E whole-slide images to predict molecular alterations such as #MSI status for #colorectal #cancer patients #immunotherapy #io #digitalpathology #machinelearning #precisionpathology #ai https://t.co/ZomgaHf3qq,2020-05-31
1267192296199483392,https://twitter.com/GeorgeSledge51/status/1267192296199483392,GeorgeSledge51,"BYLieve study of alpelisib + fulvestrant in PIK3CA-mutant ER-pos MBC with prior AI+CDK4/6i. Quick take: results similar to SOLAR-1, and interesting data suggesting antihistamines reduce alpelisib rash. #ASCO20 #bcsm",2020-05-31
1267192289723637761,https://twitter.com/UCCancerCenter/status/1267192289723637761,UCCancerCenter,"As #ASCO20 wraps up, @UCCancerCenter would like to thank and congratulate all of our wonderful #oncologists and #oncology healthcare professionals who work every day to advance cancer research and improve patient care. #AnswerCancer. Stay tuned for highlights! https://t.co/0O9twTo64M",2020-05-31
1267192166029373440,https://twitter.com/OncoAlert/status/1267192166029373440,OncoAlert,"Wow y'all, 
Just WOW!5⃣0⃣0⃣in less than3⃣Days‼️
Just to clarify, we have NO🚫followers
 We have colleagues who are part of our global #OncoAlert family &amp; do their best in keeping ALL colleagues updated.  Thank y'all so much for the support during #ASCO20 
Best,
@weoncologists https://t.co/SFBwhX6OeB",2020-05-31
1267192083351298049,https://twitter.com/OncologyBio/status/1267192083351298049,OncologyBio,Apesar de muito atrativo o tratamento com monoterapia em 1L no câncer renal reduzindo toxicidade e custos o mesmo ainda não deve ser a prática clínica. Biomarcadores devem trazer os pacientes ideias para esta estratégia #ASCO20 https://t.co/nS1KbwD2hs,2020-05-31
1267192073859461120,https://twitter.com/stage4kelly/status/1267192073859461120,stage4kelly,"whether it's cancer, or #COVID19, or life in general POC get the short end of the stick. This is wrong. It is unethical. As physicians and advocates - as human beings - we must use our privilege to change this, to stand up and speak out. #BlackLivesMatter #ASCO20 https://t.co/Q4btCCvqQi",2020-05-31
1267192051730452482,https://twitter.com/NoopurRajeMD/status/1267192051730452482,NoopurRajeMD,The ENDURANCE trial @ASCO presented by @myelomaMD. I think the slide below speaks to the data directly... only standard risk patients included and &gt; 30% of patients more than 70 years. KRD may be better in younger transplant eligible patients and those with high risk disease. https://t.co/zBBsvGbdn9,2020-05-31
1267191882741764097,https://twitter.com/jayistobe/status/1267191882741764097,jayistobe,"#ASCO20 is different this year, but we remain committed to cancer research. Our data highlights our approach to developing transformative medicines and advanced diagnostics, harnessing real-world data and analytics to accelerate #cancer research. https://t.co/AiXGmLQE6p",2020-05-31
1267191828996112384,https://twitter.com/cdanicas/status/1267191828996112384,cdanicas,Yes the question is what about the combination of #Relugolix + NHT? in mPC? Can we achieve similar results as LHRHa? #ASCO2020 https://t.co/3Urm506flW,2020-05-31
1267191827087503360,https://twitter.com/jamienholloway/status/1267191827087503360,jamienholloway,"And that's a wrap for the live edition of #ASCO20! (Though I'll be catching up for a while, I'm sure!) Thanks to the crew at @ASCO &amp; all those who have generated so much discussion on twitter!",2020-05-31
1267191781457825792,https://twitter.com/DianaRoettger/status/1267191781457825792,DianaRoettger,"Amazing to see the encouraging research in #GBM at #ASCO2020 

Congratulations to Medicenna Therapeutics Corp. for presenting impressive Phase 2b trial results of MDNA55 in recurrent GBM.

""Currently there are no approved therapies for rGBM that can exten…https://t.co/do8DCqd0sI",2020-05-31
1267191660590571522,https://twitter.com/ExelixisInc/status/1267191660590571522,ExelixisInc,"After a successful #ASCO20 weekend, we thank @ASCO organizers for an excellent virtual meeting. https://t.co/GGU7tMomM3",2020-05-31
1267191653321904128,https://twitter.com/aspenbio/status/1267191653321904128,aspenbio,Here's Why Adaptimmune Therapeutics Is Rocketing Higher Today |@Adaptimmune @ASCO #oncology #cancer https://t.co/pTIwpmWBXf,2020-05-31
1267191644287352841,https://twitter.com/urotoday/status/1267191644287352841,urotoday,"Assessment and management of #cardiovascular risk factors among #US #veterans with #ProstateCancer-initiating androgen deprivation therapy. Presented by Lova Sun, MD @Penn. #ASCO20 coverage by @GoldbergHanan @UpstateNews on UroToday &gt; https://t.co/uuLvasXGLI @ASCO https://t.co/cyI0C3FvPw",2020-05-31
1267191624112787462,https://twitter.com/ConquerCancerFd/status/1267191624112787462,ConquerCancerFd,We're grateful to @HelsinnGroup for being a Gold Level supporter of the #ConquerCancer Bundle at #ASCO20 https://t.co/bPldl88nld,2020-05-31
1267191620341919744,https://twitter.com/NexusOncology/status/1267191620341919744,NexusOncology,"That's a wrap on #ASCO20. Great discussions. Remarkable presentations. Thank you @ASCO for the opportunity to participate, we're already looking forward to next year.",2020-05-31
1267191620220284928,https://twitter.com/AmgenOncology/status/1267191620220284928,AmgenOncology,Check in for the poster discussion on our #KRASG12C in mixed advanced solid tumors.  Join the #ASCO20 Developmental Therapeutics Session today at 4pm ET to learn more. https://t.co/1OUo4XSjoC,2020-05-31
1267191618983153667,https://twitter.com/sema4/status/1267191618983153667,sema4,Leveraging real-world data can help assess critical barriers to the multidisciplinary treatment of muscle-invasive bladder cancer. Read our #ASCO20 abstract here: https://t.co/r2a2s382kQ #RWD https://t.co/YOwjXzFvRe,2020-05-31
1267191569737748484,https://twitter.com/VivekSubbiah/status/1267191569737748484,VivekSubbiah,"Brain mets in RET+ #NSCLC are hard to treat. Presenting the 🥁""Intracranial activity of selpercatinib (LOXO-292)/ RETEVMO in RET + non-small cell #lungcancer #LCSM LIBRETTO-001 trial @ASCO #ASCO20 @alexdrilon @DHymanMD @https://meetinglibrary.asco.org/record/186081/abstract https://t.co/oltpBfB6Eg",2020-05-31
1267191522275065862,https://twitter.com/tmprowell/status/1267191522275065862,tmprowell,"The credit for #ASCO20 Virtual Scientific Program belongs to Scientific Program Committee Chair @MLJohnsonMD2, @ASCOPres @BurrisSkip, &amp; @ASCOstaff.  Grateful to Dr. Johnson &amp; all for blazing the trail before the #ASCO20 Virtual Education Program 8/8-8/10! 😅 https://t.co/aqudukG3q6",2020-05-31
1267191484375347202,https://twitter.com/OncologyBio/status/1267191484375347202,OncologyBio,Com mais de uma opção ativa no tratamento de primeira linha do câncer renal conhecer os desejos e preocupações dos pacientes e cuidadores é fundamental. A decisão compartilhada também se faz muito importante #ASCO20 https://t.co/Hlr44TqblQ,2020-05-31
1267191420248453120,https://twitter.com/PritiHegde/status/1267191420248453120,PritiHegde,Congratulations to @DrRoyHerbstYale  and the ADAURA team. That was a Mic drop moment when Roy shared the DFS KM curve. Targeted therapies officially enter early NSCLC! @ASCO @AstraZeneca https://t.co/5uHDHHIq2M,2020-05-31
1267191352288256003,https://twitter.com/maryam_lustberg/status/1267191352288256003,maryam_lustberg,Special thank you to you @coffeemommy and all the advocates who participated in #ASCO20 and helped us learn and understand diverse patient perspectives #PatientAdvocacy #PatientsFirst #OncoAlert https://t.co/yQlLu4kykf,2020-05-31
1267191240644272129,https://twitter.com/heatherahannon/status/1267191240644272129,heatherahannon,#ASCO20 has been wonderful! Most impressed how organized information was and easy to access!  When you think about the sheer # of attendees it’s pretty amazing 👏👏👏 @ASCO  🙏 and now I must make sure the 🐕 are not bothering newborn sparrows on our deck.  See you 2021!,2020-05-31
1267191238857555970,https://twitter.com/RodriguezGIMD/status/1267191238857555970,RodriguezGIMD,In all tumors! profiling should be done! #ASCO20 https://t.co/KpBsTuYqQm,2020-05-31
1267191180170846209,https://twitter.com/DrN_CancerPCP/status/1267191180170846209,DrN_CancerPCP,"Abstract #10551 #ASCO20 

Lung cancer as a subsequent neoplasm: A report from the Childhood Cancer Survivor Study (CCSS).

Increased risk of lung cancer especially among those with high dose radiation. Still tough clinical decision whether to refer for screening... 

#survonc https://t.co/vTkU24sucN",2020-05-31
1267191002533638146,https://twitter.com/SBRInvestor/status/1267191002533638146,SBRInvestor,$clvs @clovisoncology #ASCO20 #ASCO2020 #OncoAlert #PARPi #ovariancancer #Lynparza #Rubraca #parpinhibitors #ONCONEWSnoASCO20 #MedscapeEdu #oncmeded https://t.co/gZFXAnBeAr https://t.co/UU8Lre0Z2P,2020-05-31
1267190883595796480,https://twitter.com/tmprowell/status/1267190883595796480,tmprowell,"#ASCO20 The struggle is real. We are all BBC guy in 2020. At least it's not live while tens of thousands of people are watching you @StephenVLiu. 

#ASCO20 #Quarantine https://t.co/2BAfooufBV https://t.co/AlXGrH1d4v",2020-05-31
1267190857049858049,https://twitter.com/Dr_Ivanoncologo/status/1267190857049858049,Dr_Ivanoncologo,Síganme para enterarse de lo más nuevo que esta sucediendo durante el congreso anual virtual de ASCO 2020. #DrIvánRGonzález #Oncólogo #Oncology #Cáncer #ASCO20 #FollowMe #Sígueme https://t.co/H2uGam6tnQ,2020-05-31
1267190762321698819,https://twitter.com/RodriguezGIMD/status/1267190762321698819,RodriguezGIMD,"Thanks to  @ASCO staff, @CliffordHudis @tmprowell @ASCOPres and all presenters for making #ASCO20 a reality during #COVID19 pandemic https://t.co/ziLxRbFci4",2020-05-31
1267190587339481088,https://twitter.com/AshleySumrallMD/status/1267190587339481088,AshleySumrallMD,Show us your orange &amp; donate before #asco20 ends. 🧡 Every $ counts!@ConquerCancerFd @ASCO https://t.co/FMTLT6efZ6 https://t.co/oBgdTUJ8A8,2020-05-31
1267190503889567745,https://twitter.com/MDedgeHemOnc/status/1267190503889567745,MDedgeHemOnc,3 PHOEBE Trial: Pyrotinib + capecitabine extends PFS in HER2+ metastatic breast cancer. #ASCO20 https://t.co/ZCohN0T4mW #breastcancer #ASCO2020 #medtwitter https://t.co/DYoovaVhII,2020-05-31
1267190459081900032,https://twitter.com/DrSGraff/status/1267190459081900032,DrSGraff,"As #ASCO20 comes to a close and America continues to struggle with #GeorgeFloyd allow this: 

Blacks are 25% more likely to die of cancer. #BlackLivesMatter 

https://t.co/sXuRJGGtM2",2020-05-31
1267190081309343744,https://twitter.com/TBJulianMD/status/1267190081309343744,TBJulianMD,Dr. Wolmark’s remarks reinforce the changes which Dr. Fisher brought forward by the use of science and clinical trials. A true visionary. @NSABPFoundation @NCICancerTrials @NRGonc @BCRFcure #ASCO2020 https://t.co/J4lgPu8pNN,2020-05-31
1267189993581264897,https://twitter.com/DrGattiMays/status/1267189993581264897,DrGattiMays,Calling @theredmanMD @HSaterMD @slipkowitz to donate to a great cause and help @ASCOPres get the $1M goal during #ASCO20 Donate to @ConquerCancerFd via https://t.co/iL6xQOh6VQ pass it forward 🧬🧫🦠🩺,2020-05-31
1267189892343369730,https://twitter.com/AshleySumrallMD/status/1267189892343369730,AshleySumrallMD,Celebrate the close of #ASCO20 by giving to @ConquerCancerFd ! https://t.co/VvGR47BS57,2020-05-31
1267189774340591616,https://twitter.com/coffeemommy/status/1267189774340591616,coffeemommy,"Whether you're a clinician, researcher, or something else entirely, your @ASCO efforts on our behalf make you an advocate for cancer patients. And, as #ASCO20 closes, I would like to thank each &amp; every one of you for doing what you do, for us, every single day. 💗 #grateful #QoL https://t.co/NeqXllswiz",2020-05-31
1267189686927319041,https://twitter.com/Cancer_talks/status/1267189686927319041,Cancer_talks,"ADAURA study DFS curves are impressive with a hard to ignore HR

1. Yes I will offer Osi to the small subset of #EGFR resectable NSCLC- maybe skip chemo for Ib

2. I want more outcomes- sure longer OS, also clinical and molecular characteristics of progression...

#asco20 #lcsm",2020-05-31
1267189669013401606,https://twitter.com/MSDiazC/status/1267189669013401606,MSDiazC,"Los resultados del Keynote 177, con mayor SLP y menor toxicidad en 1ª línea de CCRm MMRd/MSI-H. Buenas noticias...#ASCO2020 @gedefo_sefh https://t.co/jABvBV6mO0",2020-05-31
1267189531033337858,https://twitter.com/SilasInman/status/1267189531033337858,SilasInman,"In-person Visits Are Invaluable, but Telehealth Is Here to Stay https://t.co/l4hNAyNYGu #ASCO20",2020-05-31
1267189185334689792,https://twitter.com/weoncologists/status/1267189185334689792,weoncologists,"Dear Colleagues at #ASCO20
As we near the end of this great virtual meeting, I would like to introduce the newest member to your @OncoAlert 🚨network. An Honor to Have @raalbany in the #oncoalert family!! https://t.co/SMuO0XbJUl",2020-05-31
1267189119865806853,https://twitter.com/LGG1/status/1267189119865806853,LGG1,"#ASCO20 As we reach the end of our scheduled broadcasts, I want to say what a joy it has been for ASCO staff to support all of you in this new delivery of science. Please continue to give us feedback on how we can improve - and we'll see you Aug 8-10 for the Education Program!",2020-05-31
1267189106477617159,https://twitter.com/AJacomeMD/status/1267189106477617159,AJacomeMD,#ASCO20 atendees waiting for simultaneous publications after plenary session... https://t.co/XYn0bPV5Jb,2020-05-31
1267188875761500160,https://twitter.com/ReeseFCRC/status/1267188875761500160,ReeseFCRC,"This is great news for #colorectalcancer patients with MSI-H tumors! #ASCO20 @FightCRC 

https://t.co/GxEdW3oTZH https://t.co/xWG8C20RFl",2020-05-31
1267188831037657093,https://twitter.com/Arohatgi/status/1267188831037657093,Arohatgi,On my mind while listening to #ASCO2020 this weekend. Physicians and scientists need to do their part https://t.co/VmnWnj0jTu,2020-05-31
1267188781066543104,https://twitter.com/neerajaiims/status/1267188781066543104,neerajaiims,#ASCO20 Very thoughtful perspective by David Wise @NYUTischSchool cancer center on the HERO trial--&gt; Relugolix is a change of SOC for a subset of pts with advanced #ProstateCancer with significant history of cardiovascular disease. Pros and cons of GnRH agonist vs antagonists. https://t.co/Ef28qh2I8i https://t.co/OclTUlHQCE,2020-05-31
1267188757255593984,https://twitter.com/inas_md/status/1267188757255593984,inas_md,"#ASCO20 
Excellent data by @AnnaLeeMDMPH et al on the cancer mortality benefit under ACA.
Again and again, studies highlight the significant ethnic and gender disparities that persist. https://t.co/sq52zvy8qZ",2020-05-31
1267188747205931008,https://twitter.com/DianaNrco/status/1267188747205931008,DianaNrco,"You see, I’m not the kind of person who goes wow in the Plenary session but I just went wow in the care delivery highlights session seeing evidence that cancer mortality decreased after the Medicaid expansion with ACA - that is what change looks like #ASCO20",2020-05-31
1267188637004898308,https://twitter.com/TiansterZhang/status/1267188637004898308,TiansterZhang,"Highlights from @DrChoueiri for #kidneycancer:
☞ Follow up of pembro-axitinib for 1st line met tx held PFS HR 0.71, OS HR higher 0.68, more CRs 8.8%
☞ #HCRN trial (along w/ #FRACTION &amp; #OMNIVORE) showed ipi in refractory setting not better than upfront
#kcsm @ASCO #ASCO20 https://t.co/BinLBdbHoz",2020-05-31
1267188556012744704,https://twitter.com/jamienholloway/status/1267188556012744704,jamienholloway,This thread straight from the presenter— definitely worth a read if you missed the talk. #asco20 https://t.co/JDS449f0Ej,2020-05-31
1267188441676042242,https://twitter.com/fireflyann/status/1267188441676042242,fireflyann,"still more to learn... as I hit the wall

#ASCO20 #CRCSM https://t.co/0ElYCcqVUH",2020-05-31
1267188254232776705,https://twitter.com/jasonlukemd/status/1267188254232776705,jasonlukemd,"As #ASCO20 virtual live meeting wraps plz consider supporting @ConquerCancerFd. Tx for great effort @ASCO staff &amp; @ASCOPres! So many of us benefited from CCF grants early in our careers. Plz consider paying things forward for the next gen w a donation now!
https://t.co/ruS0Moiqcw",2020-05-31
1267188035143098368,https://twitter.com/jrgralow/status/1267188035143098368,jrgralow,.@ASCO Releases Resource-Stratified Guideline on the Treatment of Late-Stage Colorectal Cancer https://t.co/hwjrQ6aHIp,2020-05-31
1267188032303706114,https://twitter.com/LUNGevity/status/1267188032303706114,LUNGevity,Fantastic prez by @AnnaLeeMDMPH @sloan_kettering showing clear mortality benefit in patients w/ cancer within states w/ or w/out Medicaid expansion following the Affordable Care Act. First national-scale analysis of ACA proves equal access to care = Better outcomes #ASCO20 #LCSM https://t.co/nTR1K6pNHi,2020-05-31
1267187989144383490,https://twitter.com/sarahkrug1/status/1267187989144383490,sarahkrug1,"Great to see #patient preferences in action. As experts  living w/their disease, what matters most to them is key, as well as how they weigh benefits and risks. #asco20 https://t.co/BPzoi302jp",2020-05-31
1267187986837286913,https://twitter.com/JasonYeRadOnc/status/1267187986837286913,JasonYeRadOnc,"Surgery doesn't benefit all women w/ de novo stage IV #breastcancer, but may be helpful if symptomatic or progressing despite systemic therapy.
https://t.co/NfyokpQW5w
Excellent discussion by @Dr_Julia_White on the study and  the potential role of #sbrt in oligometastasis
#ASCO20",2020-05-31
1267187887231172609,https://twitter.com/VJOncology/status/1267187887231172609,VJOncology,"What an amazing experience #ASCO20 was! With so much scientific content being aired we don’t blame you for needing a recap! @VJOncology 👉https://t.co/ys1d8pDAKO👈 has all you need to refresh your knowledge 💻👩‍⚕️📊

@ASCO #LCsm #BCsm #PCsm #scmsm #HNCsm #BTsm #CRCsm https://t.co/GZ07hqxcEz",2020-05-31
1267187881002532864,https://twitter.com/gdurm/status/1267187881002532864,gdurm,There are some advantages to virtual #ASCO2020 https://t.co/Yw0TtnLcXS,2020-05-31
1267187876019740675,https://twitter.com/VivekSubbiah/status/1267187876019740675,VivekSubbiah,On popular demand presenting the talk from Clinical Science Symposium @ASCO --&gt; Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors @ASCO #ASCO20 @MLJohnsonMD2 @curijoey @rdoebele @JustinGainor   https://t.co/F1IsuchX2f https://t.co/XvPtqaWW2S,2020-05-31
1267187868121907204,https://twitter.com/urotoday/status/1267187868121907204,urotoday,Single-agent PD-1 inhibitor #biomarkers in untreated and previously treated advanced #RCC: What can biomarkers teach us to advance clinical care? Presented by @katy_beckermann @VanderbiltU. #ASCO20 coverage by @WallisCJD @VUMChealth on UroToday &gt; https://t.co/TbRHpaHxux @ASCO https://t.co/966yPG9aNJ,2020-05-31
1267187845518618624,https://twitter.com/DrAbhiPal/status/1267187845518618624,DrAbhiPal,"#Informedconsent #asco20 #asco2020 Abs 7/7–communication training improved clinical team's ability for #shareddecisionmaking. Key factors – determining patient's decision style preference, risk tolerance and goals @BelindaKiely @shalsubra @MartinStockler 

https://t.co/VS3egKIVzK",2020-05-31
1267187815915425793,https://twitter.com/CharuAggarwalMD/status/1267187815915425793,CharuAggarwalMD,"#ADAURA #ASCO20 
Advocates: what do you think? 

@EGFRResisters @jillfeldman4 @ivybelkins https://t.co/qPN5RLX7qX",2020-05-31
1267187743995682820,https://twitter.com/KidneyCancer/status/1267187743995682820,KidneyCancer,"Thanks for summarizing those GU highlights @DrChoueiri! Especially #RCC studies Keynote-426 and HCRN. As @ERPlimackMD mentioned, looks like nivolumab alone is not sufficient in first line, it needs help from ipilimumab. #ASCO20 #kidneycancer #CancerResearch https://t.co/LLxm8d9O26",2020-05-31
1267187735225401345,https://twitter.com/Kenrickng1/status/1267187735225401345,Kenrickng1,"Phase III #HERO trial: Relugolix, new oral GnRH antagonist vs Leuprolide in #mHSPC. Practice-changing for pts with CV problems and injection site issues with degarelix. Benefits: oral, and 54% reduction in major CV events. @NICEComms @ProstateUK #prostateca #ASCO20 https://t.co/syKPZtD47R",2020-05-31
1267187730183786504,https://twitter.com/chadinabhan/status/1267187730183786504,chadinabhan,"I missed it #ASCO20
Anything you want to summarize? https://t.co/3dZcTMWvdt",2020-05-31
1267187366558666754,https://twitter.com/atperez_md/status/1267187366558666754,atperez_md,Congratulations @BurrisSkip @ASCOPres and @ASCO for a great meeting under very difficult circumstances. The oncology community always comes together! Unite and Conquer!,2020-05-31
1267187364243427329,https://twitter.com/n8pennell/status/1267187364243427329,n8pennell,"Resectable EGFR mut+ pts eligible for adjuvant osi is a relatively small #, and remember all who recur take it for potentially years at that time anyway. So yes think this is sustainable, although it would work much better if the drug was cheaper, no argument there. #ASCO20 #LCSM https://t.co/4N49ruASUt",2020-05-31
1267187249877221377,https://twitter.com/DrYukselUrun/status/1267187249877221377,DrYukselUrun,"Avelumab Maintenance Therapy Improves Survival in Advanced Urothelial #Cancer  @ERPlimackMD 

#ASCO20 @ASCO @OncoAlert 
https://t.co/l6eQRm8LLu https://t.co/dwtZx1WS90",2020-05-31
1267187238489788416,https://twitter.com/DrN_CancerPCP/status/1267187238489788416,DrN_CancerPCP,"Abstract #11023 #ASCO20 

Oncology fellows’ survivorship clinic: An opportunity for education and multidisciplinary care delivery.

Small numbers, but so important. Perhaps an opportunity for #hemeonc #medonc fellowships to collaborate on larger trial? 

#survonc https://t.co/EbgG1a6oe2",2020-05-31
1267187090363686914,https://twitter.com/Medscape/status/1267187090363686914,Medscape,"#ASCO20: When added to standard chemo, a generic PPI demonstrated a higher-than-expected rate of pathologic complete response in TNBC.  https://t.co/ZprS3KqS4k",2020-05-31
1267187084823011335,https://twitter.com/tobyeyre82/status/1267187084823011335,tobyeyre82,"Further refinement of risk grp &amp; stratification in #PTLD

Trappe et al

Post R-mono x 4 CR+PR with ≤2 IPI RFs at diagnosis (low-risk) continue with 4 x 3-wkly R

Low risk 2y OS 100%
Outstanding #PTLD investigators who create helpful prospective data for community #lymsm #ASCO20 https://t.co/Q8YZUNjkiB",2020-05-31
1267187035837796352,https://twitter.com/JTrentMDPhD/status/1267187035837796352,JTrentMDPhD,"Cabazitaxel in pts w advanced dediff #liposarcoma
-Met 1º endpoint w 54% PF rate at 12 weeks
- 2 pts (5.3%) w PR &amp; 23 SD (60.5%)
-PR+SD in 25 pts (65.8%)
-mPFS=7.4 mos (95%CI 2.8-10.3)
-Consider ph3 or combo w other agents: eribulin, ICIs, CDK4i @Robertasanfili #ASCO20 #sarcoma",2020-05-31
1267186995798867972,https://twitter.com/coloncanada/status/1267186995798867972,coloncanada,Good news indeed and let’s work together to give patients access to immunotherapy in Canada. #ASCO20 #cometogether #CRC #standardofcare #patientsfirst #pCODR #INESSS #CRC #CRCSM #KEYNOTE177 https://t.co/dcEoww6Oj9,2020-05-31
1267186929080184835,https://twitter.com/OncoAlert/status/1267186929080184835,OncoAlert,"Dear Colleagues at #ASCO20
Catch our Awesome @OncoAlert 🚨Colleague 
@marklewismd 👨‍⚕️as he takes us on his picks of his top GI #cancer abstracts at @ASCO 2020.  

✅Click the link below to our YouTube channel to access
https://t.co/br9bnOzFwA

Best,
@weoncologists https://t.co/TL259tlDsm",2020-05-31
1267186901624123392,https://twitter.com/stage4kelly/status/1267186901624123392,stage4kelly,"While a #NurseNavigator based intervention led to better outcomes, cost was prohibitive. How about using trained peer navigators? #ASCO20 @oncoalert https://t.co/LpPA7Eg8Da",2020-05-31
1267186765401636865,https://twitter.com/heatherahannon/status/1267186765401636865,heatherahannon,My bedroom is like a sports bar for #oncologists making it easier to engage in multiple learning topics. #multitasking a silver lining of a virtual meeting @ASCO #ASCO20 although not getting as much exercise with this strategy 🏃‍♀️ from session to session https://t.co/fMDgH2sllb,2020-05-31
1267186758443241474,https://twitter.com/milton_lombana/status/1267186758443241474,milton_lombana,"Apesar de preguntas por resolver, #ASCO20, #ADAURA, #javelinbladder100, #KEYNOTE177, todos practice chaging",2020-05-31
1267186727791312897,https://twitter.com/GrupoGetne/status/1267186727791312897,GrupoGetne,"Este año traemos pocas novedades desde #ASCO20 para los socios de @GrupoGetne y los pacientes de @aecat_es y @Netespana. Nada nuevo en #TNE y la certeza de que queda mucho trabajo por hacer en el ámbito de la inmunoterapia en #Tiroides.

La revancha en #ESMO20!!! https://t.co/jmG7cfHBky",2020-05-31
1267186621750882312,https://twitter.com/TiansterZhang/status/1267186621750882312,TiansterZhang,"What a great day to see increasing OS for #BladderCancer! 
Main highlights from @DrChoueiri:
☞ Switch maint avelumab is practice changing, add avelumab after chemo for metastatic dz
☞ Adjuvant atezo not beneficial;  we need biomarkers of micro dz to ID pts

#blcsm @ASCO #asco20 https://t.co/rv7pVfkmow",2020-05-31
1267186613592915973,https://twitter.com/Mirjam_BVN/status/1267186613592915973,Mirjam_BVN,Uitgezaaide @borstkanker #ASCO2020 https://t.co/7m4G0K8E6o,2020-05-31
1267186587097579520,https://twitter.com/DrAbhiPal/status/1267186587097579520,DrAbhiPal,"#Informedconsent #asco20 #asco2020 Abs 6/7 – online decision aid (breast sx) about tradeoffs (cost, AEs of radiation) improved decisional conflict. Arm 3 involved administering the DA to a family member @TataMemorial @NickZdenkowski @SDM_ULAVAL

https://t.co/iLZFfvYkWr",2020-05-31
1267186564871917571,https://twitter.com/chadinabhan/status/1267186564871917571,chadinabhan,Yes me too #ASCO20 https://t.co/OJ6aYWWxna,2020-05-31
1267186472274276353,https://twitter.com/LeandroJonatad1/status/1267186472274276353,LeandroJonatad1,Amazing slide by @dave6408 for explaining adjuvant therapy on #ADAURA discussion in the plenary at  #ASCO20. https://t.co/0bT4mM5oV6,2020-05-31
1267186402141384707,https://twitter.com/maryam_lustberg/status/1267186402141384707,maryam_lustberg,#survonc #ASCO20. Cc @DrLeslieAppiah @oncofertility @FertilityNP https://t.co/ZcJCwsK8zF,2020-05-31
1267186249946857473,https://twitter.com/jdsoumerai/status/1267186249946857473,jdsoumerai,"Great collection of #ASCO20 #lymphoma and #CLL abstracts, thanks @lymphomahub https://t.co/uvYy8BNiUz",2020-05-31
1267186212349100037,https://twitter.com/SoaresAndrey/status/1267186212349100037,SoaresAndrey,"Amazing survey by @RCCadvocate @crisbergerot @PavlosMsaouel @EJonasch @TiansterZhang @Daniel_J_George @MichaelStaehler looking at what are the patient’s desire, expectations and fears about mRCC treatment #ASCO20 @OncologyBio @kcCURE @IKCCorg https://t.co/eGkeLRS2VX",2020-05-31
1267186152299208706,https://twitter.com/pharmaphorum/status/1267186152299208706,pharmaphorum,AZ's Tagrisso wows virtual ASCO https://t.co/YQA3I0eMkm #pharma #ASCO20,2020-05-31
1267185951962550283,https://twitter.com/coloncanada/status/1267185951962550283,coloncanada,Take home points Keynote-177 A new standard of care and we will have to work hard together to get it reimbursed in Canada for mCRC patients. #pCODR #INESSS #ASCO20 #CRC https://t.co/8jsQ0B2syR,2020-05-31
1267185928839270403,https://twitter.com/n8pennell/status/1267185928839270403,n8pennell,"I'm sorry but multiple straw men. Not treating everyone, most compelling in stage 2/3 which is where I think it makes sense. Tx is 3 years. Most of these pts relapse and get TKI anyway so it is early versus late for a chance at longer OS (we'll learn about in a few years) #ASCO20 https://t.co/xlnEwbWoNs",2020-05-31
1267185848677695490,https://twitter.com/drkomanduri/status/1267185848677695490,drkomanduri,"I’m so privileged to have been a part of that fellowship leadership team with Bob Wolff, Ki and Karen Hahn. It’s like planting a tree one day and years later enjoying the fruit!  What an amazing and talented group of trainees—it’s great to see them blossom into leaders. #ASCO20 https://t.co/SHYf54WoHt",2020-05-31
1267185845490135046,https://twitter.com/ronaldsiadoj/status/1267185845490135046,ronaldsiadoj,Relugolix...... oral treatment for prostate cancer with fewer cardiovascular adverse events #ASCO20 medicamento oral para tratar el cancer de prostata con menos eventos adversos cardiovasculares.....#herotrial https://t.co/bKr9618xe1,2020-05-31
1267185844340682753,https://twitter.com/hemedoc/status/1267185844340682753,hemedoc,Great work on diversity in Hem-Onc by one of our awesome fellows @anavmanana. #ASCO20 https://t.co/o7FJy2e43L,2020-05-31
1267185762568744969,https://twitter.com/ZieglerColleen/status/1267185762568744969,ZieglerColleen,NGS of cell-free plasma DNA is useful not only for the detection of ALK fusions and resistance mutations but also for assessing prognosis and monitoring the dynamic changes of genomic alterations in ALK+ NSCLC treated with ALK TKI.#ASCO20 @alk_fusion #LCSM https://t.co/r0bWi8DcPq,2020-05-31
1267185747481821185,https://twitter.com/BenjaminBesseMD/status/1267185747481821185,BenjaminBesseMD,"Adjuvant EGFR TKI
— ADAURA —
HR 0.17 for DFS will impact OS? Events delayed after 3yrs of osi?
Remember OPTIMAL (erlo in advanced NSCLC): HR 0.16 for PFS &amp; HR 1.19 for OS, with longer FU and 69% cross over to TKI.
Adjuvant treatment must CURE, not only delay recurrence.
#ASCO20 https://t.co/iWM7bCRMLS",2020-05-31
1267185746705739776,https://twitter.com/ChilesResearch/status/1267185746705739776,ChilesResearch,Just a reminder that you can find all our abstracts from this weekend's #ASCO20 ⏩https://t.co/sShhg6XmsU #finishcancer,2020-05-31
1267185685414457345,https://twitter.com/ShannonWestin/status/1267185685414457345,ShannonWestin,Absolutely practice-changing study demonstrating that patients can receive #genetic testing and counseling from home!!! Especially in times of social distancing - this is awesome! #ASCO20 #SGOatASCO #gyncsm https://t.co/dlkaaIn6fJ,2020-05-31
1267185633623040000,https://twitter.com/stage4kelly/status/1267185633623040000,stage4kelly,"grateful that with this #VirtualConference format I don't have to choose between care delivery &amp; regulatory policy highlights or developmental therapeutics highlights, just which to watch in real time and which later. #ASCO20 @OncoAlert",2020-05-31
1267185551863676936,https://twitter.com/LeCancerFr/status/1267185551863676936,LeCancerFr,Focus plénière : L'étude JAVELIN modifie la prise en charge des patients métastatiques - https://t.co/QpSO7B4tpk #asco20 #urologie https://t.co/jnV3dmdzvV,2020-05-31
1267185383042887680,https://twitter.com/heatherahannon/status/1267185383042887680,heatherahannon,#Nursenavigation being discussed #ASCO20 ❤️👏👏,2020-05-31
1267185352424542208,https://twitter.com/CancerNetwrk/status/1267185352424542208,CancerNetwrk,"A phase III study presented at @ASCO showed encouraging efficacy data suggesting savolitinib could be used to treat patients with MET-driven papillary renal cell carcinoma.
https://t.co/NPFP8FrRTI https://t.co/xuQ1Zr8zY5",2020-05-31
1267185337664585728,https://twitter.com/urotoday/status/1267185337664585728,urotoday,#ASCO20 Discussant: Novel immunotherapy-based therapy in metastatic #urothelialcancers and rare #genitourinary malignancies. Presentation by @kalasri3 @UofT. Written coverage by @zklaassen_md @GACancerCenter on UroToday &gt; https://t.co/iLrRyahJeP @ASCO https://t.co/FgHbul1BBh,2020-05-31
1267185282438385668,https://twitter.com/ShannonWestin/status/1267185282438385668,ShannonWestin,Another success from our @MDAndersonNews fellows - Dr. Sims received an #ASCO20 @ConquerCancerFd Merit Award for his work that highlights the importance of the microbiome in #cervicalcancer survival #SGOatASCO #gyncsm https://t.co/S3uSBlArnD,2020-05-31
1267185203048402946,https://twitter.com/marklewismd/status/1267185203048402946,marklewismd,"My Scottish gran used to insulate me from insults by saying “everyone’s a critic”

What she meant is that anyone can find fault if they look closely enough, as none of us are perfect

So while there might have been some tech glitches let’s applaud @asco for the #asco20 meeting! https://t.co/6RS0B5lHG9",2020-05-31
1267185167132745732,https://twitter.com/NovartisCancer/status/1267185167132745732,NovartisCancer,“Who do you want to be at the next moment?” Transitions help you recover better and show up better. Thanks @TIGNUM for the tips. #ASCO20 https://t.co/BAq2orhemK,2020-05-31
1267185130910568451,https://twitter.com/JasonYeRadOnc/status/1267185130910568451,JasonYeRadOnc,Exciting times for #sbrt for #lungcancer at #ASCO20 ! This study in EGFR+ patients reaffirms our knowledge that radiation therapy benefits stage IV oligometastatic lung cancer! #radonc https://t.co/pkICNyR6kH,2020-05-31
1267185108626411527,https://twitter.com/JTrentMDPhD/status/1267185108626411527,JTrentMDPhD,Ditto.  There are some great #ASCO20 #sarcoma summary tweets out there. https://t.co/vF5FVwE33u,2020-05-31
1267184919475871746,https://twitter.com/ShannonWestin/status/1267184919475871746,ShannonWestin,So proud of our @MDAndersonNews fellows - Dr. Nitecki received an #ASCO20 @ConquerCancerFd Merit Award for her important work assessing incidence of MDS in women with #ovariancancer receiving #PARPi - very relevant given the reported rate of MDS in SOLO2 #gyncsm #SGOatASCO https://t.co/uGPPvAM8n6,2020-05-31
1267184891315265536,https://twitter.com/mercade_monica/status/1267184891315265536,mercade_monica,Interesting highlights form ASCO! Here we go! #ASCO20 https://t.co/HgcnEfdw2S,2020-05-31
1267184573429022731,https://twitter.com/crisbergerot/status/1267184573429022731,crisbergerot,"New discovery... @ASCO #ASCO20

This #TwitterJail allows me to follow a restricted number of followers 😱🤬 https://t.co/ayd7FnUfOn",2020-05-31
1267184436698910724,https://twitter.com/ndenduluri1/status/1267184436698910724,ndenduluri1,Agree - the #antihistamines are important and #bloodsugar #lifestyle more important than ever #ASCO20 https://t.co/0gPi1XLkIj,2020-05-31
1267184340351451143,https://twitter.com/SGO_org/status/1267184340351451143,SGO_org,Giving the findings in SOLO2 - these types of analyses are relevant for women receiving #PARPi for #ovariancancer #ASCO20 #gyncsm #SGOatASCO https://t.co/Bwz6zS4p7i,2020-05-31
1267184269622947842,https://twitter.com/janicefarias_/status/1267184269622947842,janicefarias_,"❗️ADAURA trial: osimertinib adjuvant. 
Ganho muito significativo de SLD! HR 0.17

🔥Questions:
Were metastatic patients (no pet ct or cranial resonance)??
Impact on OS?
Better quality of life in relapse ?
#CETTROASCO20 @CettroOncologia  #lungcancer #asco20 https://t.co/GF69zA1Jx4",2020-05-31
1267184220641865728,https://twitter.com/MM_Hub/status/1267184220641865728,MM_Hub,"CONGRESS | #ASCO20 | @Nbahlis, @Ucalgary, outlined the LYNX trial study design. LYNX is a multicenter, randomized, phase II study, evaluating the safety and efficacy of SC daratumumab in patients with multiple #myeloma who have been previously treated with IV daratumumab. #mmsm https://t.co/eGF4mhUVYs",2020-05-31
1267184216246288385,https://twitter.com/LeCancerFr/status/1267184216246288385,LeCancerFr,Focus plénière : L'étude JAVELIN modifie la prise en charge des patients métastatiques - https://t.co/QpSO7B4tpk #asco20 #urologie https://t.co/UE9m83i5Zc,2020-05-31
1267184184159764481,https://twitter.com/TargetedOnc/status/1267184184159764481,TargetedOnc,"Check out what Dr. Awad had to say about the characterization of patients with non–small cell lung cancer who have MET exon 14 skipping alterations and potential acquired resistance mechanisms.
https://t.co/JbbaZb22AE #lcsm #ASCO20",2020-05-31
1267184142384578562,https://twitter.com/urotoday/status/1267184142384578562,urotoday,"#ProstateCancer relative survival by stage and race/ethnicity, #UnitedStates, 2001 to 2015. Presented by David Siegel, MD, MPH @CDCgov. #ASCO20 written coverage by @GoldbergHanan @UpstateNews on UroToday &gt; https://t.co/udbnUz8xDs @ASCO https://t.co/gPlXw2LDpB",2020-05-31
1267184089540460549,https://twitter.com/ASCO/status/1267184089540460549,ASCO,Using data from #CancerLinQ @JPaicePhD et al examine annual trends in #opioid rx for pts w mNSCLC 2010 to 2017 (Abstract 2076) #lcsm #hpm #ASCO20 https://t.co/tA5KB7P7ax https://t.co/hWhvo5URqi,2020-05-31
1267184088861093888,https://twitter.com/JanssenGlobal/status/1267184088861093888,JanssenGlobal,"That’s a wrap for #ASCO20. We were honored to share some of our latest research as we advance science and treatments for patients. At #Janssen Oncology, our goal is the elimination of cancer. For key #news and data presentations, visit: https://t.co/brGKKOobxi https://t.co/cYOrrH2uye",2020-05-31
1267184077960105985,https://twitter.com/ConquerCancerFd/status/1267184077960105985,ConquerCancerFd,We greatly appreciate @DaiichiSankyo for being the Technology Sponsor at #ASCO20 https://t.co/Z36WCP6SRw,2020-05-31
1267184073098711040,https://twitter.com/DrAbhiPal/status/1267184073098711040,DrAbhiPal,"#Informedconsent #asco20 #asco2020 Posters 5/7–communication courses for oncology training.  Trainees who are not taught communication skills rate themselves much higher than examiner. Unconscious incompetence? @MOGA_ORG @FayUCCancerCr @FallowfieldLJ 

https://t.co/y9WHeZ1DxI https://t.co/GsrTPSQc6E",2020-05-31
1267184052857188352,https://twitter.com/SGO_org/status/1267184052857188352,SGO_org,The microbiome is relevant to survival in #cervicalcancer - novel findings from #ASCO20 #SGOatASCO #gyncsm https://t.co/iWC5eEvdBh,2020-05-31
1267183959114428416,https://twitter.com/Lymphoma_Doc/status/1267183959114428416,Lymphoma_Doc,"The @ConquerCancerFd is one of the best ways to fight cancer. The grants to early career doctors help their good ideas become tomorrow's treatments. My ASCO YIA and ASCO CDA were critical. 
I strongly encourage you to join me &amp; donate $ you saved by not traveling to #ASCO20. https://t.co/O168ACh503",2020-05-31
1267183904798228480,https://twitter.com/marinagarassino/status/1267183904798228480,marinagarassino,"Clearly practice changing trial 0.17 no doubts, but very curious to see the final OS effect in 2023. Maturity is 33% and TKIs do not have a curative intent until now. What will happen when most of patients will finish 3 yrs? #ADAURA #ASCO20 #osimertinib https://t.co/xftuM2Ow1U",2020-05-31
1267183879032619010,https://twitter.com/ASCO/status/1267183879032619010,ASCO,"As #ASCO20 Virtual Scientific Program winds down, join @MKnoll_MD on our IG Live (ascocancer) at 4:45 PM ET for a Science Summary! https://t.co/VgUMxuFCCl",2020-05-31
1267183729933459457,https://twitter.com/MarcoLDavila/status/1267183729933459457,MarcoLDavila,Looking forward to developmental therapeutics talk starting now #ASCO20,2020-05-31
1267183726997331968,https://twitter.com/marklewismd/status/1267183726997331968,marklewismd,"Ok as a GI oncologist I know I should be grateful for KEYNOTE-177 at #ASCO20 but I gotta admit: still salty about PRODIGE-24 getting less love than it deserved at #ASCO18

I may forgive, but I never forget ...
#pancsm https://t.co/9ssQVX0UUy",2020-05-31
1267183718915080193,https://twitter.com/DrLauraPorter/status/1267183718915080193,DrLauraPorter,"#ASCO2020 @ccalliance get your biomarkers tested and get a copy of the results. It is very important for mCRC, MSI testing for all stages https://t.co/K3xXdI8bVV",2020-05-31
1267183707674292224,https://twitter.com/MattSmeltzer/status/1267183707674292224,MattSmeltzer,"Great presentation of striking ADAURA results from @DrRoyHerbstYale and thoughtful discussion by @dave6408  

We need to increase molecular testing in #lungcancer ! @IASLC @ASCO #ASCO20 #lcsm",2020-05-31
1267183678746177539,https://twitter.com/_B_I_O_T_E_C_H_/status/1267183678746177539,_B_I_O_T_E_C_H_,"JMP $ALLO Virtually Live From #ASCO20: Platform #Validated – Raising Target to $53 (previously was $37)
Comparable response rates to autologous counterparts de-risks the
platform.
Low rates of GvHD, CRS and NT further showcase the potential of the
#allogeneic product #ASCO2020",2020-05-31
1267183613742927872,https://twitter.com/HemOncToday/status/1267183613742927872,HemOncToday,"Jeremy Lyle Warner, MD @VUMC_Cancer during @ASCO #ASCO20 - Progressing malignancy linked to higher mortality among patients with cancer and #COVID19 https://t.co/mQFOA0LjdO Perspectives from Lee Greenberger, PhD @LLSusa &amp; Martin J. Edelman, MD @FoxChaseCancer https://t.co/LjD75hB4R0",2020-05-31
1267183368464146433,https://twitter.com/GervasoLorenzo/status/1267183368464146433,GervasoLorenzo,"Outstanding LBA4 dissertation by @michael_overman!! 
Curve crossing explationation 👏🏻 👏🏻 Key-177 will be practice changing but 29% of pts progressing to pembro still arises some concerns #ASCO2020",2020-05-31
1267183347064848384,https://twitter.com/renata_bonadio/status/1267183347064848384,renata_bonadio,"I agree that OS is the most important endpoint, but… If you were a patient, would you prefer to: 1) wait and have only 28% probability of being disease-free at 3y, or; 2) take an oral drug and have 80% probability of being disease-free?

Adjuvant Osimertinib #ASCO20 #OncoAlert https://t.co/A4Y4mXV5F9",2020-05-31
1267183212251549697,https://twitter.com/EmilyVenanzi/status/1267183212251549697,EmilyVenanzi,Radiation or surgery in conjunction with brigatinib has been safe for 17 patients so far in the BRIGHTSTAR trial. @MDAndersonNews @YYElamin @alk_fusion @ALKLungCancer #lcsm #ASCO20 https://t.co/r0OyMbjych,2020-05-31
1267183165485056000,https://twitter.com/CancerTherAdvsr/status/1267183165485056000,CancerTherAdvsr,KRd fails to improve outcomes compared with VRd in newly diagnosed multiple myeloma. https://t.co/deENeql6Jk #cancer #ASCO20,2020-05-31
1267183117892272129,https://twitter.com/YaleCancer/status/1267183117892272129,YaleCancer,"At #ASCO20 in a poster presentation, @TaraSanftMD reports findings for delivery of #cancersurvivorship education to community health care professionals. @SmilowCancer @YaleMed @YNHH
https://t.co/ECThDrtusw https://t.co/7wtjmAOx23",2020-05-31
1267183084400672768,https://twitter.com/maryam_lustberg/status/1267183084400672768,maryam_lustberg,#ASCO20  #mbc #bcsm Helpful discussion including reference to ongoing work to address #tox issues many patients experience on #alpelisib. Studies for dietary  and drug management of #hyperglycemia are getting underway cc @Neil_Iyengar @sardesai_sagar @Novartis https://t.co/9z9KXJDCBS,2020-05-31
1267183063844470791,https://twitter.com/ZieglerColleen/status/1267183063844470791,ZieglerColleen,Brightstar: Brigatinib with LCT is safe and feasible in patients with ALK-rearranged advanced NSCLC irrespective of number of metastatic sites. Brigatinib and LCT may be an effective therapeutic strategy in this subset of NSCLC patients. #ASCO20 @alk_fusion #LCSM https://t.co/7U65FTrJuV,2020-05-31
1267183063735373826,https://twitter.com/_B_I_O_T_E_C_H_/status/1267183063735373826,_B_I_O_T_E_C_H_,"JEFF: $KPTI #ASCO20 Post-Ph.III BOSTON Conf Call Takeaways -- Data Support Early-Line, Combo Use (cont) https://t.co/KmcNJZRYzv",2020-05-31
1267182947687268352,https://twitter.com/montypal/status/1267182947687268352,montypal,"Great #ASCO20 discussion by @DrChoueiri on ImVigor 010 during GU highlights. Agree that @apolo_andrea @ALLIANCE_org trial includes higher risk pts. Would also consider PROOF302 which tests FGFR3i in a selected population! Seeing ADAURA in lung, eager to explore targeted approach. https://t.co/pN0UBHdYr4",2020-05-31
1267182812278386689,https://twitter.com/radioligand/status/1267182812278386689,radioligand,Getting ready to login to the highlights sessions on Developmental Therapeutics. #ASCO20 @ASCO,2020-05-31
1267182812215545857,https://twitter.com/DrAbhiPal/status/1267182812215545857,DrAbhiPal,"#Informedconsent #asco20 #asco2020 Poster 4/7–participant scores are higher on 72 hour post consenting educational testing markers when consented using eConsent (digitised consent) versus paper, high acceptance @staplehedge @JuliaLaiKwon @sloan_kettering 

https://t.co/nfK08aVpbs https://t.co/RQgUSD87BA",2020-05-31
1267182730745348096,https://twitter.com/EmilyVenanzi/status/1267182730745348096,EmilyVenanzi,"Phase I and expansion trial in China of a new ALK TKI, TQ-B3139.  Shows efficacy both first- and subsequent-line.  Some side effects, esp GI. Phase 3 first-line trial in progress. @alk_fusion @ALKLungCancer #lcsm #ASCO20 https://t.co/AYp5wLfF4g",2020-05-31
1267182567129825286,https://twitter.com/yzafar/status/1267182567129825286,yzafar,"Really important point by @ADesaiMD. It is not sustainable. To be clear, the question should NOT be “Is the gain is survival worth the price?”

Key questions are “Why is it priced so high, to start? &amp; “If it’s all R&amp;D, where’s price transparency?”  #ASCO20 https://t.co/DuGy8cTLPC",2020-05-31
1267182536423288833,https://twitter.com/VivekSubbiah/status/1267182536423288833,VivekSubbiah,Amazing discussion by the GU king 👑 @DrChoueiri ! @marklewismd There are Clevelanders who can win. @ASCO #ASCO20 @AmandaBinDC @montypal trying to find the picture in a picture photo. https://t.co/1y25C4ie43,2020-05-31
1267182489992409088,https://twitter.com/UroDocAsh/status/1267182489992409088,UroDocAsh,"As #ASCO20 comes to a close; given all that is happening in the world; I humbly remind myself and my friends/colleagues of this:

@BladderCancerUS @EurUrolOncol @AmerUrological @ASCO https://t.co/oThyqSZLXI",2020-05-31
1267182486972444679,https://twitter.com/OncoAlert/status/1267182486972444679,OncoAlert,"Dear Colleagues,
A great pleasure to present our amazing @OncoAlert 🚨colleague @JTrentMDPhD 👨‍⚕️of @SylvesterCancer  discussing #immunotherapy in #sarcomas at #ASCO20 
Best,
@weoncologists https://t.co/tv7vJlb78i",2020-05-31
1267182419993661441,https://twitter.com/EmilyVenanzi/status/1267182419993661441,EmilyVenanzi,"ATLAS trial - new trial in Korea of immunotherapy (atezolizumab, anti-PDL1) plus chemotherapy for ALK and EGFR patients who have exhausted their TKI options.  Results expected late 2022. @alk_fusion @ALKLungCancer #lcsm #ASCO20 https://t.co/ChhFjVQ6jw",2020-05-31
1267182208378384384,https://twitter.com/Lymphoma_Doc/status/1267182208378384384,Lymphoma_Doc,"Excellent presentation by @DrSarahRuth on our Venetoclax + REPOCH trial. Toxicities similar to chemo alone, very impressive response rates. Randomized trial forthcoming. 
#ASCO20 #lymsm
https://t.co/YkYtZ0ky9N https://t.co/39UznMhiID",2020-05-31
1267182159992741889,https://twitter.com/stage4kelly/status/1267182159992741889,stage4kelly,Wish I had planned better and ordered a Wi-Fi booster before #ASCO20 started so I could have sat here to learn! But it’s back to the kitchen table in 10 min for the next virtual session. #VitaminDBreak @OncoAlert https://t.co/li3UOhAb51,2020-05-31
1267182124341374976,https://twitter.com/EmilyVenanzi/status/1267182124341374976,EmilyVenanzi,Lorlatinib in 2nd or subsequent line treatment for ALK+ and ROS1+ NSCLC in France @nicogirardcurie @alk_fusion @ALKLungCancer #lcsm #ASCO20 https://t.co/3LQFMdsy3G,2020-05-31
1267182095933206530,https://twitter.com/ClarkeLow/status/1267182095933206530,ClarkeLow,"It’s my son’s book, but it seems at my level. I am going to start studying tonight so that I can understand all of ⁦@marklewismd⁩  obscure Greek mythology references. #asco20 https://t.co/4ps7GH1fRX",2020-05-31
1267182061074464768,https://twitter.com/karenluMD/status/1267182061074464768,karenluMD,Shoutout to our fellow Dr. Roni Nitecki! @ConquerCancerFd Merit Award for study on MDS and Parpi #ASCO20. Stay tuned as this story unfolds! @RauhHainMD @aaronshafer99 @Frumovitz @michaelaonstad #oncsurgery @MDAndersonNews https://t.co/05eTkAuoDP,2020-05-31
1267182054149689345,https://twitter.com/Felipegaliza/status/1267182054149689345,Felipegaliza,There is no doubt that Molecular imaging and theranostics are great improvements in Prostate cancer management in the last few years. #ASCO20 is just confirming the importance of PSMA on precision medicine. Hopefully this is just the beginning. #PSMA @SNM_MI @officialEANM https://t.co/pbIUIxJM3w,2020-05-31
1267182036437082112,https://twitter.com/diegoadiazg/status/1267182036437082112,diegoadiazg,"#ADAURA Great discussion by @dave6408 👏🏻 
Also, there is an urgent need to improve global access to novel therapies such as osimertinib. #ASCO20 #lcsm https://t.co/ntvIgnXlGe",2020-05-31
1267182000026329089,https://twitter.com/DrN_CancerPCP/status/1267182000026329089,DrN_CancerPCP,"Abstract #10528 #ASCO20 
Assisted reproductive technology outcomes in childhood cancer survivors: A report from the Childhood Cancer Survivor Study. 

IVF live births rates similar to siblings, but pelvic radiation ⬇️ chance of live birth, not alkylators. 
#survonc @CancerSurvSM https://t.co/vxYQk4J4LG",2020-05-31
1267181973711155201,https://twitter.com/PGrivasMDPhD/status/1267181973711155201,PGrivasMDPhD,Wonderful discussion by master @DrChoueiri @ASCO #ASCO20 highlights covering #bladdercancer &amp; RCC abstracts! Exciting data @ERPlimackMD @MLJohnsonMD2 @VivekSubbiah @TiansterZhang @OncoBellmunt @DrRanaMcKay @ALLIANCE_org @apolo_andrea @DanaFarber @OncoAlert @montypal @neerajaiims https://t.co/9e2nIvwRJp,2020-05-31
1267181915842453504,https://twitter.com/Dr_Ivanoncologo/status/1267181915842453504,Dr_Ivanoncologo,"#JustNow en sesión plenaria, #pembrolizumab tiene resultados significativos vs #chemotherapy en pacientes con MSI-H mCRC.
#ASCO20 #Oncoalert https://t.co/sWADXAeaYn",2020-05-31
1267181901078581250,https://twitter.com/ADesaiMD/status/1267181901078581250,ADesaiMD,"As a #trainee, you will rarely see a well explained #ASCO session then @DrChoueiri's #ASCO20 overview of #RCC/#Bladder #cancer discussing the scope of #treatment for #GU cancers! https://t.co/E22baQLNPr",2020-05-31
1267181722426380289,https://twitter.com/dr_aschmidt/status/1267181722426380289,dr_aschmidt,A concise review of GU highlights from #ASCO20 https://t.co/lKjVXpTBsu,2020-05-31
1267181595183714306,https://twitter.com/kaushalpar/status/1267181595183714306,kaushalpar,"Given the recent no. of approvals by FDA, it is v likely that osi will get approved, pending OS data. How likely are you to prescribe it? @JackWestMD @Jbauml @AMansfieldMD @PatelOncology @StephenVLiu @ipreeshagul @n8pennell @HosseinBorghaei #ASCO20",2020-05-31
1267181586816143362,https://twitter.com/Kenrickng1/status/1267181586816143362,Kenrickng1,"Very impressive but interestingly PDL1+ve population defined TPS&gt;25% (accounting for 51% of total population) by Ventana SP263. HR 0.87 in PDL1-ve population, is treatment intensification worth the SE in this population? Anxiously anticipating full paper @tompowles1 #ASCO20 https://t.co/0P5N07X9f5",2020-05-31
1267181567081881606,https://twitter.com/VJOncology/status/1267181567081881606,VJOncology,"Hear all about developmental therapeutics during the next session at #ASCO20! @VJOncology had a great chat w/ @MLJohnsonMD2 of @SarahCannonDocs 🎬👩‍⚕️

Check all the updates at 👉https://t.co/883ZhnpQsm👈

@ASCO #Oncology #oncoalert #CTsm #LCsm #BCsm #PCsm #HNCsm #BTsm #CRCsm https://t.co/sjDX9dOVX3",2020-05-31
1267181560190599180,https://twitter.com/MoffittNews/status/1267181560190599180,MoffittNews,"Dr. Hatem Solliman, @Moffittnews, presents at @ASCO Virtual Scientific Program on the use of neoadjuvant chemotherapy in breast cancer patients. View abstract: https://t.co/ytVsgI9jzN #ASCO20 #BCSM https://t.co/vZeC220vQA",2020-05-31
1267181554104700933,https://twitter.com/DrAbhiPal/status/1267181554104700933,DrAbhiPal,"#Informedconsent #asco20 #asco2020 Poster 3/7 – great intervention in #precisiononcology decision making for testing for pts @viveksubbiah – 600 pt RCT, web-based module increased knowledge of genetics.  Interactions with education level and literacy. 

https://t.co/7mmkpT35LS https://t.co/JVPMXSx3g2",2020-05-31
1267181538321588227,https://twitter.com/weoncologists/status/1267181538321588227,weoncologists,"Dear @OncoAlert 🚨colleagues,
We just wanted to wish you a Happy #NoTobaccoDay 🚭and asking you to tell anyone who has ears that 1⃣5⃣% of the global deaths are attributed to smoking🚬
We Oncologists must take a stand against the number one killer in the world‼️#ASCO20 https://t.co/GhXXkMLM5B",2020-05-31
1267181505626935298,https://twitter.com/StephenVLiu/status/1267181505626935298,StephenVLiu,"#ASCO20 With the #ADAURA presentation on the books, did the full presentation change your mind? What will you do Monday with regard to adjuvant osimertinib (assume approved and available) after complete resection for stage II/III #EGFR+ #NSCLC? #OncoAlert #LCSM",2020-05-31
1267181491106316289,https://twitter.com/ERPlimackMD/status/1267181491106316289,ERPlimackMD,"Consistent finding across metastatic #kidneycancer studies highlighted by @DrChoueiri - low ORR with strategy of nivo front line reserving ipi for progression.  Seems ipi must be given up front to achieve greatest benefit, toxicity notwithstanding. We can't start slow.  #ASCO20 https://t.co/ONsS9GPywX",2020-05-31
1267181335774474241,https://twitter.com/IvyLorena_Md/status/1267181335774474241,IvyLorena_Md,"Here, my feeling towards #oncology after the plenary session at #ASCO20 @ASCO 

#ADAURA #JAVELIN #keynote177 #ENDURANCE https://t.co/l31F3xhPgg",2020-05-31
1267181322767867904,https://twitter.com/MyriamChalabi/status/1267181322767867904,MyriamChalabi,"#ASCO20 Frontline pembrolizumab in MSI mCRC should become standard of care following impressive #keynote177 data. How do we select, and what should we do, with non-responders? Ipilimumab? Upfront nivo/ipi?",2020-05-31
1267181197236539399,https://twitter.com/sarahkrug1/status/1267181197236539399,sarahkrug1,"As a #raredisease advocate, diagnostics is another weak link. We need board certified ""diagnosticians"" whose primary role is to aggregate medical records from specialists and piece together the puzzle (esp. for #patients who go undiagnosed for years) ! #ASCO20 https://t.co/RR6mYRxZrW",2020-05-31
1267181178265702403,https://twitter.com/EmilyVenanzi/status/1267181178265702403,EmilyVenanzi,Liquid biopsy monitoring before and during ALK TKI treatment - correlations with prognosis @alk_fusion @ALKLungCancer #lcsm #ASCO20 https://t.co/zchlTOW5KU,2020-05-31
1267181069364682754,https://twitter.com/fireflyann/status/1267181069364682754,fireflyann,#ASCO20 #CRCSM https://t.co/bJNr1oCgu9,2020-05-31
1267180934685696000,https://twitter.com/ranjanpathk/status/1267180934685696000,ranjanpathk,"Impressive and provocative but with median f/u period&lt;duration of adjuvant therapy, unclear if osimertinib is simply delaying the inevitable. Would be interesting to see what happens after 3 yrs. #ASCO20 #lcsm @ASCO",2020-05-31
1267180921372975106,https://twitter.com/heatherahannon/status/1267180921372975106,heatherahannon,"#ADAURA #OS #DFS debate might continue, but one thing we can all agree on- #DrSpigel review of the trial was outstanding! @SarahCannonDocs #ASCO20",2020-05-31
1267180886237143041,https://twitter.com/DrYukselUrun/status/1267180886237143041,DrYukselUrun,"Phenomenal overview of RCC/bladder studies 
from master @DrChoueiri 
@OncoAlert #ASCO20 @ASCO @DanaFarber @montypal @neerajaiims @PGrivasMDPhD @tompowles1 @apolo_andrea @ERPlimackMD @drenriquegrande @cdanicas @brian_rini @MattGalsky https://t.co/wRF2y85i02",2020-05-31
1267180821003337732,https://twitter.com/camillayamada/status/1267180821003337732,camillayamada,Metastatic 1o. line urothelial cancer: all information in one slide! Excellent! #ASCO20 @MOCBrasil @bporgbr https://t.co/ibFKFtdpzQ,2020-05-31
1267180819371745282,https://twitter.com/EmilyVenanzi/status/1267180819371745282,EmilyVenanzi,Lorlatinib effective in most patients with CNS-only progression. @IbiayiMD @alk_fusion @ALKLungCancer #lcsm #ASCO20 https://t.co/4vkGTMqccR,2020-05-31
1267180677042180096,https://twitter.com/BrasilOncologia/status/1267180677042180096,BrasilOncologia,"Os resultados finais do estudo LMS-02 foram apresentados durante a #ASCO20 e demonstraram mediana de SLP geral de 10,1 meses e mediana SG de 34,4 meses. Saiba mais: https://t.co/XeaIFc1Di2 https://t.co/RZe3xrkFjZ",2020-05-31
1267180610386345984,https://twitter.com/karenluMD/status/1267180610386345984,karenluMD,Congrats to our fellow Dr. Travis Sims on his @ConquerCancerFd Merit Award for #ASCO20 study showing diverse gut microbiome is independent predictor of survival in cervix cancer pts. @AnnKloppMD @aaronshafer99 @Frumovitz @maonstad #oncsurgery @MDAndersonNews https://t.co/w3OoLqwWz3,2020-05-31
1267180599393095682,https://twitter.com/NickMarcouxMD/status/1267180599393095682,NickMarcouxMD,"Almost pains me to say this, but I’ll wait a bit before jumping on the #ADAURA train. Amazing results, but we should at least see what happens after 3 yr median f/u. Still one of the most important studies ever in EGFR IMO #EGFR #lcsm #ASCO20",2020-05-31
1267180553452900354,https://twitter.com/ipreeshagul/status/1267180553452900354,ipreeshagul,"Wonderful plenary presentation by @DrRoyHerbstYale with discussion @dave6408. DFS breakdown by stage - clearly greatest benefit in stage III pts, but DFS is not a surrogate for OS. Anxiously awaiting the paper with further details. #LCSM #ASCO2020 #ADAURA #OncoAlert https://t.co/Tb1VQrfYwA",2020-05-31
1267180316139151361,https://twitter.com/VJOncology/status/1267180316139151361,VJOncology,"Care delivery and regulatory policy is next on the #ASCO20 program! Kelly Morgan of @sloan_kettering gave us an engaging talk on the #BRCA founder outreach study 📊👩‍⚕️🎥

Watch the interview here 👉https://t.co/2pwh7ctKWt👈

@ASCO #Oncology #oncoalert #CTsm #genetics https://t.co/dkmj5vc1KL",2020-05-31
1267180311894515713,https://twitter.com/urotoday/status/1267180311894515713,urotoday,"Association of gene expression with clinical outcomes in patients with renal cell carcinoma #RCC treated with Pembrolizumab in #KEYNOTE427. Presented by David F. McDermott, MD @BIDMChealth. #ASCO20 coverage by @TheRealJasonZhu @LevineCancer &gt; https://t.co/DBSvh1ORAx @ASCO https://t.co/R7vDarnh6m",2020-05-31
1267180295779946496,https://twitter.com/DrAbhiPal/status/1267180295779946496,DrAbhiPal,"#Informedconsent #asco20 #asco2020 Poster 2/7– consent starts from understanding of simple medical terms.  This poster a reminder to not assume patients understand words such as palliative or curative.  Educational videos helped significantly @staplehedge

https://t.co/CJ6BMjdzrH https://t.co/LGgOs2GUSj",2020-05-31
1267180251098071040,https://twitter.com/seydagunduz_md/status/1267180251098071040,seydagunduz_md,impressive results... Practice changing data  #osimertinib  #ADAURA trial #ASCO20 https://t.co/JjlBRLNaUn,2020-05-31
1267180240041893889,https://twitter.com/ManuelDomine/status/1267180240041893889,ManuelDomine,"Nuestro Servicio de Oncologia  está  muy orgulloso de haber presentado 16 comunicaciones y  participado en 7 ensayos clínicos pivotales, incluido el ensayo ADAURA en la sesión  plenaria del Congreso Americano de Oncologia #ASCO2020 virtual.@Hospital_FJD @DocenciaFJD @UAM_Madrid",2020-05-31
1267180161864208390,https://twitter.com/Lymphoma_Doc/status/1267180161864208390,Lymphoma_Doc,"Dr. Strati from @MDAndersonNews shows steroid treatment for axi-cel #CARTcell toxicity is associated with inferior outcomes. Is this due to the steroids or due to why steroids needed, the chicken or the egg? https://t.co/jjMT5NbnhZ
#ASCO20 #lymsm https://t.co/wvVyGGSADr",2020-05-31
1267180055031099392,https://twitter.com/UroDocAsh/status/1267180055031099392,UroDocAsh,"Important questions raised by JAVELIN100 highlighted @DrChoueiri @PGrivasMDPhD @tompowles1 #ASCO20 

Comparisons with Pembro maintenance inevitable? @MattGalsky @MountSinaiNYC https://t.co/xRwF5qhJny",2020-05-31
1267180028799979520,https://twitter.com/milosicevic/status/1267180028799979520,milosicevic,Proposed resilience curriculum as part of medical oncology training at #ASCO20 ♻️ https://t.co/Rf02XW7Lwg,2020-05-31
1267179954120404993,https://twitter.com/EmilyVenanzi/status/1267179954120404993,EmilyVenanzi,"Brigatinib can be effective after progression on alectinib and other next-generation ALK TKIs @seto_md @alk_fusion @ALKLungCancer #lcsm #ASCO20
￼ https://t.co/HdLIzlWjwT",2020-05-31
1267179823505473539,https://twitter.com/katcrios/status/1267179823505473539,katcrios,"Technology exists in #CancerLinQ + other solutions to harness real-world data from EHRs across many practice settings to help understand uptake+emerging patterns on new treatment options, i.e osimertinib, but how - or will - this data help inform clinical practice? #lcsm #ASCO20",2020-05-31
1267179758670041088,https://twitter.com/clarissamathias/status/1267179758670041088,clarissamathias,"Quer saber as principais novidades apresentadas no #ASCO2020 sobre tumores torácicos? Assista às análises de Dr. Vladmir Lima, Dr. Gilberto de Castro Júnior, Dra. Carolina Kawamura, Dr. Luiz Araújo e Dr. Guilherme… https://t.co/tp3Sc4fUsM",2020-05-31
1267179741922168834,https://twitter.com/JTrentMDPhD/status/1267179741922168834,JTrentMDPhD,Patrick Leavey @UTSWNews presenting #sarcoma highlights @ASCO #ASCO20.  Dose dense chemotherapy for Ewing #sarcoma is superior. https://t.co/wqGXOsfaKM,2020-05-31
1267179738612760577,https://twitter.com/DrSGraff/status/1267179738612760577,DrSGraff,#ASCO20 #MedTwitter https://t.co/08uTw0jm3L,2020-05-31
1267179694526529538,https://twitter.com/sophia_kamran/status/1267179694526529538,sophia_kamran,"My twitter feed is 2 much right now, oscillating b/t euphoria from advances presented at #ASCO2020 &amp; sadness surrounding #blacklivesmatter/the state of things. Take care of yourselves friends. ""If we lose love and self-respect for each other, this is how we finally die""-m.angelou",2020-05-31
1267179614910271491,https://twitter.com/ScheryllAlken/status/1267179614910271491,ScheryllAlken,It's so important when we tweet about new evidence that it's accessible.... acronyms are everywhere in medicine! This is brilliant 👇 #ASCO20 https://t.co/jK12ox1lw3,2020-05-31
1267179604244082689,https://twitter.com/jsoriamd/status/1267179604244082689,jsoriamd,Promising data with a PROTAC Androgen receptor protein degrader in prostate cancer. This is a new approach to follow #ASCO20 https://t.co/oCgyde0spa,2020-05-31
1267179557804802051,https://twitter.com/juampmarlar/status/1267179557804802051,juampmarlar,"#ASCO20 RESULTADOS actualizados de SOBREVIDA GLOBAL del estudio PROSPER, en hombres con Cáncer de Prostata resistente a la castración no metastásico.

#cancer #prostate #genitourinary https://t.co/Cl5GP84Dd8",2020-05-31
1267179520714571776,https://twitter.com/Connect_CMC/status/1267179520714571776,Connect_CMC,#ASCO2020 Amazing plenary session ends with ADAURA trial in EGFR mutation positive NSCLC presented by @DrRoyHerbstYale and discussed by @dave6048 Dr Spigel asks would we take osimertinib ourselves seeing the data as they currently stand? His answer is yes #beatcancer #ASCO20 https://t.co/1wiQb4Buws,2020-05-31
1267179415856971777,https://twitter.com/PortalOnconews/status/1267179415856971777,PortalOnconews,"Em que cenários é possível realizar o de-escalonamento do tto do câncer de cabeça e pescoço? Os médicos @alinelauda, Luiz Paulo Kowalski e @Marta_GustavoN discutem o tema, presente em alguns estudos da sessão oral de câncer de cabeça e pescoço no #ASCO20 - ://tinyurl.com/ybwyme88 https://t.co/DJQ5dRd3PI",2020-05-31
1267179398777778177,https://twitter.com/teekayowo/status/1267179398777778177,teekayowo,Excellent plenary with great presentations and discussions!. #ASCO20 @ASCO @ASCOPres @MLJohnsonMD2 https://t.co/hXb8rMbK3o,2020-05-31
1267179272042618882,https://twitter.com/DrShubhamPant/status/1267179272042618882,DrShubhamPant,TIP #ASCO2020 Novel way to target the (mostly) Undruggable #KRAS. SOS Inhibitor as monotherapy and combination with trametinib in Kras mutated tumors. Trial open now @MDAndersonNews and other centers. #endcancer @PanCAN @letswinpc @curecc @skopetz @Aiims1742 https://t.co/mTIIADjuKF,2020-05-31
1267179255064072194,https://twitter.com/tmprowell/status/1267179255064072194,tmprowell,#ASCO20 #ADAURA trial of adjuvant osimertinib vs placebo in Stg IB-3A #EGFR non-squamous #NSCLC presented by Dr. @DrRoyHerbstYale met primary endpt of DFS. OS data not mature (5% events). #lcsm https://t.co/h2Lhi9CXQx,2020-05-31
1267179206322118662,https://twitter.com/EmilyVenanzi/status/1267179206322118662,EmilyVenanzi,"Excellent 5 year OS results for 1st line alectinib in ALEX trial from @peters_solange.  62.5% 5-year survival, 34.9% still on alectinib! @alk_fusion @ALKLungCancer #lcsm #ASCO20 https://t.co/22XhGTrATJ",2020-05-31
1267179042320547843,https://twitter.com/PCF_Science/status/1267179042320547843,PCF_Science,#PCFfunded Young Investigator Dr. @DrDaveWise @nyulangone is the discussant for #ProstateCancer highlights at #ASCO20 Virtual Meeting today.  Broadcasting live now! @PCFnews @nyuniversity @ASCO,2020-05-31
1267179037438414848,https://twitter.com/DrAbhiPal/status/1267179037438414848,DrAbhiPal,"#Informedconsent #asco20 #asco2020 Poster 1/7–consent starts from an assumption of health literacy and numeracy.  This poster a great reminder that we cannot assume patients are confident with medical forms or understand statistics @hagsie @FayUCCancerCr 

https://t.co/dmZZE8auVB https://t.co/Jw1R2Zx0v9",2020-05-31
1267178963081719808,https://twitter.com/fireflyann/status/1267178963081719808,fireflyann,"super important slide from the Keynote 177 presentation.

Intriguing/puzzling... so many directions still to explore.
Grateful that researchers collect/preserve tissue for analysis for treatment stratification.

#ASCO20 #CRCSM https://t.co/RA3fVW9Plj",2020-05-31
1267178953288146945,https://twitter.com/SGO_org/status/1267178953288146945,SGO_org,Very nice way to review the #bestofASCO for #gyncsm- thanks @drdonsdizon #ASCO20 #SGOatASCO https://t.co/9suDHhJedA,2020-05-31
1267178943326621696,https://twitter.com/StephenVLiu/status/1267178943326621696,StephenVLiu,#ASCO20 Discussion of #ADAURA provided by @dave6408 of @SarahCannonDocs reminding us why we give adjuvant therapy after surgery for NSCLC. Are we curing or are we controlling/delaying? We view toxicity (physical and financial) differently in these two situations. #OncoAlert https://t.co/tSPvznDLir,2020-05-31
1267178841572810759,https://twitter.com/VivekSubbiah/status/1267178841572810759,VivekSubbiah,LIVE NOW  --&gt; @ASCO #ASCO20 from the MEGA STAR &amp; George Clooney of Oncology the one &amp; only @DrChoueiri ! @neerajaiims @montypal @PGrivasMDPhD @TiansterZhang https://t.co/yDiX7m144j https://t.co/gQ3tRSS9L4,2020-05-31
1267178650354561025,https://twitter.com/lungcancerpall/status/1267178650354561025,lungcancerpall,Why were we not given the numbers of patients who received CTX in the different stage groups? This would have been easy! #ADAURA #ASCO20 https://t.co/Cq3AlGSuck,2020-05-31
1267178557639254016,https://twitter.com/MrsKEnriquez/status/1267178557639254016,MrsKEnriquez,This is amazing! @RobinNYC - hope you see how many Cancer Docs (#ASCO20) were riding with you this morning! https://t.co/dqQkEjRJ1F,2020-05-31
1267178502811500545,https://twitter.com/ivanpantic1980/status/1267178502811500545,ivanpantic1980,This #ASCO20 plenary session seems more like a planetary session,2020-05-31
1267178499804037121,https://twitter.com/cavemom11/status/1267178499804037121,cavemom11,"I donated! Just think of all the resources saved with a virtual ASCO (coffee and late night cocktails, not to mention the new outfits that I would have “needed”!) Make a donation for a good cause today! @ASCOPres @ConquerCancerFd #ASCO20 https://t.co/yECAx9xSBZ",2020-05-31
1267178499745312768,https://twitter.com/nbh_48/status/1267178499745312768,nbh_48,"After 2 big cancer conferences in US under COVID-19 outbreak, SNS communication among participants is getting popular and important to develop our knowledge and experiences. It may be a great opportunity. #aacr20 #ASCO20",2020-05-31
1267178498566885376,https://twitter.com/ShuchiGulati/status/1267178498566885376,ShuchiGulati,On now the highlights of GU studies with @DrChoueiri at @ASCO #ASCO20 🧐 https://t.co/vktG4OqC0d,2020-05-31
1267178497862238209,https://twitter.com/CarlosHTonco/status/1267178497862238209,CarlosHTonco,ADAURA wins? For sure OS is the gold standard but with this such impressive DFS adj OSI is really practice changing!!! #ASCO20 https://t.co/GyjjG0e02G,2020-05-31
1267178462864965634,https://twitter.com/drcoronacruz/status/1267178462864965634,drcoronacruz,"Reducción del 79% en el riesgo de recurrencia con osimertinib adyuvante en CP completamente resecado:
- Mejoró el pronóstico de pacientes desde etapa IB, el mayor efecto en IIIA
- Incluyó pacientes con y sin QT adyuvante, ambos grupos se benefician
#ASCO20 #ADAURA
#LCSM https://t.co/DF6KgAGJ29",2020-05-31
1267178412969508866,https://twitter.com/CettroOncologia/status/1267178412969508866,CettroOncologia,"Parar de fumar melhora a sobrevida global dos pacientes, mesmo entre aqueles que pararam há menos de 2 anos. 

@janicefarias_ 
#ASCO2020 #ASCO20 #CETTROASCO20 #ASCO20PSMA",2020-05-31
1267178386675417089,https://twitter.com/LynneWagnerPhD/status/1267178386675417089,LynneWagnerPhD,"#ADAURA trial: great point by Discussant David Spigel @dave6408. GI tox and paronychia require careful management given oral agent to be taken for 3 years, for this important advance to be sustainable for patients #ASCO20 #lcsm #OncoDerm",2020-05-31
1267178143506247680,https://twitter.com/EvanHallMD/status/1267178143506247680,EvanHallMD,"I don't treat lung cancer anymore, but noted results of #ADAURA trial presented by @DrRoyHerbstYale at #ASCO20.  Very provocative split in DFS with 3 yrs of adj osimertinib vs pbo in early stage EGFR-mut lung ca.  Need to see long-term OS data to see if this is truly curing pts.",2020-05-31
1267178042419527681,https://twitter.com/sarahkrug1/status/1267178042419527681,sarahkrug1,"There are &gt;7,000 types of #raredisease and only 5% with approved treatments. With advances in genetic tech &amp; research on the rise, we need more liaisons between the world of big data and frustrated families that bounce around through the healthcare system w/o answers. #ASCO20 https://t.co/FCHBOcO7YZ",2020-05-31
1267178026586046464,https://twitter.com/n8pennell/status/1267178026586046464,n8pennell,"Interesting to see 3 year DFS in control arm only 41% across stages, which matched RADIANT. In SELECT (https://t.co/gXtl7GHxuZ), 5 year DFS was 56% in the single arm TKI treated group even after only 2 years of TKI, very similar stage breakdown #ASCO20 #LCSM https://t.co/tx5meom7aH",2020-05-31
1267177980222210054,https://twitter.com/Lymphoma_Doc/status/1267177980222210054,Lymphoma_Doc,"Interesting data on AUTO3, a CD19 and CD22 bicistronic #CART-cell, presented at #ASCO20. Very low CRS and preliminary impressive efficacy. More patients and longer follow up needed, but the cell therapy momentum continues to build. #lymsm https://t.co/l86udEQC7V https://t.co/KO0FTklhIc",2020-05-31
1267177972525600768,https://twitter.com/Pranyvida/status/1267177972525600768,Pranyvida,At #ASCO20 Learning what is New in Oncology https://t.co/D3B5FPshrn,2020-05-31
1267177929315885056,https://twitter.com/OncoGerard/status/1267177929315885056,OncoGerard,This looks like a definitive game changer in MSI-H mCRC: Pembro improves PFS &amp; ORR in 1stL. Wellcoming a new SOC! #ASCO20 https://t.co/PqrvlTt0K6,2020-05-31
1267177908088569856,https://twitter.com/LeeJonesMBA/status/1267177908088569856,LeeJonesMBA,"Very interesting study of all worldwide randomized clinical trials 2014-2017. Trials were dominated by high income countries and even positive trials had questionable ""substantial clinical benefit."" #ASCO20 https://t.co/PXdoOFd00k",2020-05-31
1267177898303123457,https://twitter.com/ClarkeLow/status/1267177898303123457,ClarkeLow,I am hopeful that we learn from the GI community and use circulating tumor DNA to better predict who needs adjuvant tx and who is being overtreated. #LCSM #ASCO20,2020-05-31
1267177887645523973,https://twitter.com/esinghimd/status/1267177887645523973,esinghimd,"Results of the #ADAURA trial evaluating adjuvant osimertinib in early stage EGFR + NSCLC. ⚠️Can’t deny the very impressive DFS improvement, but OS impact remains unclear. And I would like more info on the no adjuvant chemo patients #lcsm #ASCO20 https://t.co/10jcrLJBz8",2020-05-31
1267177857958191109,https://twitter.com/jamienholloway/status/1267177857958191109,jamienholloway,"David Spigel on the ADAURA trial, starting with important background on impact of adjvant therapy. Benefit depends on stage:  #ASCO20 #LCSM https://t.co/XSfCaLuv0V",2020-05-31
1267177810549968897,https://twitter.com/Agendia/status/1267177810549968897,Agendia,Read what we discovered here: https://t.co/LADXpTAjAQ #ASCO20 #breastcancer https://t.co/0vZhPOuZcB,2020-05-31
1267177790354403328,https://twitter.com/urotoday/status/1267177790354403328,urotoday,#ASCO20 Discussant: Rare variant histologies in Renal Cell Carcinoma: Making the unclear be more clear. Presentation by @montypal @cityofhope. Written coverage by @zklaassen_md @GACancerCenter on UroToday &gt; https://t.co/1cJwSHfBiq @ASCO @NazliDizman #RCC https://t.co/O4i900PqvR,2020-05-31
1267177779214184448,https://twitter.com/DrAbhiPal/status/1267177779214184448,DrAbhiPal,"#burnout #asco20 #ASCO2020 Poster 2/2 – structured resiliency education within medical oncology training – monthly, 1 hour sessions for 7 months. Mindfulness, art, setting boundaries, reflective writing @BethanRichards3 @FayUCCancerCr @MOGA_ORG 
https://t.co/ttMnhNmJsk https://t.co/Zu3cFZuTYu",2020-05-31
1267177765826113536,https://twitter.com/RamiNassabein/status/1267177765826113536,RamiNassabein,Coffee break #ASCO20,2020-05-31
1267177636943495168,https://twitter.com/sergio_crispino/status/1267177636943495168,sergio_crispino,NSCLC : test all pts for EGFRm #ASCO2020 plenary session https://t.co/Naisq0XVUW,2020-05-31
1267177598771097600,https://twitter.com/Sonampuri/status/1267177598771097600,Sonampuri,ADAURA trial .. is adjuvant osimertinib the standard of care .. the big question #ASCO20 #LCMS https://t.co/mDOlmosaEQ,2020-05-31
1267177543586766848,https://twitter.com/prat_aleix/status/1267177543586766848,prat_aleix,amazing results! anti-PD1 monotherapy standard of care for this group of patients with advanced colorectal cancer. Still 30% progress. Additional biomarkers needed. I see a strong interation with KRAS/NRAS mutational status #ASCO20 @OncoAlert https://t.co/9v0pov1AHU,2020-05-31
1267177531666464770,https://twitter.com/ivanpantic1980/status/1267177531666464770,ivanpantic1980,Does anyone have ADAURA post progression treatment data? #ASCO20 Just a non-lung oncologist naïve question.,2020-05-31
1267177531238645760,https://twitter.com/bmassutis/status/1267177531238645760,bmassutis,ADAURA trial: Osimertinib postop in resected EGFRmut NSCLC. Huge difference in DFS but limited diff in OS. Only 55% received chemotherapy (nowadays standard of care) #ASCO2020 #LCSM ⁦@OncoAlert⁩ https://t.co/IUCqHTRFca,2020-05-31
1267177475131523079,https://twitter.com/JenniferCKing/status/1267177475131523079,JenniferCKing,"#ADAURA plenary discussion conclusions at #ASCO20 - Dr. Spigel @dave6408 says if he had to choose, he would choose to take osimertinib. #lcsm https://t.co/blvHp00NFh",2020-05-31
1267177466629468161,https://twitter.com/marklewismd/status/1267177466629468161,marklewismd,"Phew, what a plenary!

If you have the chance, take a page from my dog’s book and rest your eyes for a minute after hours of #ASCO20 screen time https://t.co/61IiBfdNB5",2020-05-31
1267177393569095680,https://twitter.com/EmilyVenanzi/status/1267177393569095680,EmilyVenanzi,"Analysis of ALTA-1L brigatinib trial data shows similar response but better PFS for ALK variant 1 vs. variant 3.  TP53 mut also —&gt; worse outcomes.  Possible “higher risk” ALK+ group. @alk_fusion @ALKLungCancer #lcsm #ASCO20
￼ https://t.co/UjnwGlo2Q4",2020-05-31
1267177390331121664,https://twitter.com/EnriqueSoto8/status/1267177390331121664,EnriqueSoto8,"Ok #asco20 Plenary Session is over, so I can go back to vacuuming, doing the dishes and buying my online groceries! @asco https://t.co/pBJ7N6QTW4",2020-05-31
1267177390196903937,https://twitter.com/OncoGerard/status/1267177390196903937,OncoGerard,If someon thought that targeted therapy was done in NSCLC: much more &amp; much better to come. This year adyuvant Osimertinib in EGFR+ patients looks like best at #ASCO20 https://t.co/R8tk9Bx3SL,2020-05-31
1267177298438078472,https://twitter.com/TiansterZhang/status/1267177298438078472,TiansterZhang,"Highlights from @DrChoueiri are underway! 2 bladder and 2 kidney cancer abstracts to discuss
@ASCO #ASCO20 https://t.co/o2gFKDVbSO",2020-05-31
1267177283627999233,https://twitter.com/IvyLorena_Md/status/1267177283627999233,IvyLorena_Md,"Discussion by Dr. @michael_overman 
Keynote 177. “These results should change clinical practice” 
My heart is pounding. More options for the patients 👏🏻 #ASCO20 https://t.co/rOSmzazKM5",2020-05-31
1267177261586882560,https://twitter.com/mtmdphd/status/1267177261586882560,mtmdphd,EGFR should be testing in NSCLC of ANY STAGE - @dave6408 #ASCO20 #lcsm #PrecisionMedicine #oncopath cc @antonyruggeri @mullane_michael,2020-05-31
1267177211951529984,https://twitter.com/ERPlimackMD/status/1267177211951529984,ERPlimackMD,Dr. Spigel @dave6408 asks the key questions relevant to all adjuvant cancer #clinicaltrials  #ASCO20 https://t.co/wzOEcmfvba,2020-05-31
1267177195790905344,https://twitter.com/yzafar/status/1267177195790905344,yzafar,Congrats to @ASCO @BurrisSkip @MLJohnsonMD2 for putting together an outstanding virtual plenary session! #ASCO20 https://t.co/GlNamV9XCN,2020-05-31
1267177174076919810,https://twitter.com/Kenrickng1/status/1267177174076919810,Kenrickng1,"ADAURA Pros: Very impressive HR, relatively few SEs. Qualms: No HRQOL measures considering 3y treatment, some Stage III patients without adj cis/vin, no OS data, loss of excellent ORR and hence symptom relief afforded by osi if/when relapse, and very financially toxic! #ASCO20 https://t.co/YgZAVGOjMU",2020-05-31
1267177137473290242,https://twitter.com/CCAlliance/status/1267177137473290242,CCAlliance,Hot off the #ASCO20 presses- Pembrolizumab should be considered standard of care for MSI high metastatic colorectal cancer. @DrLauraPorter @MDAndersonNews,2020-05-31
1267177006107631619,https://twitter.com/ManuelDomine/status/1267177006107631619,ManuelDomine,ADAURA TRIAL. It has been an honor to be the first center that recruited more patients in Spain in this study that has changed clinical practice as adjuvant treatment in stage IB-IIIA EGFR + patients. @Hospital_FJD @DocenciaFJD @gecp_org @OncoAlert  #LCSM #ASCO20 https://t.co/5T4pwrjdO7,2020-05-31
1267176994334216192,https://twitter.com/jsoriamd/status/1267176994334216192,jsoriamd,In a superb discussion of ADAURA ⁦@dave6408⁩ shared that osimertinib had clear benefit even in patients who were treated with adj CT in the placebo arm  #ASCO20 But is this cure or delaying relapse? Anyhow for a family member he will choose Osimertinib in the adj setting https://t.co/B17rxlKq7V,2020-05-31
1267176982183280642,https://twitter.com/NatRevClinOncol/status/1267176982183280642,NatRevClinOncol,"#ASCO20 If you are enjoying the discussion of ADAURA, you might want to read more about osimertinib in NSCLC in a recent News and Views https://t.co/421ozDscK0",2020-05-31
1267176981981835264,https://twitter.com/marklewismd/status/1267176981981835264,marklewismd,"Dr. Spigel echoes the question we all hear in clinic (but should be asking ourselves unprompted): ""doctor, would you use this new therapy if it was YOU?""

Cancer need not be forced upon us in order to summon empathy in our decision-making

#ASCO20",2020-05-31
1267176964831485956,https://twitter.com/APassaroMD/status/1267176964831485956,APassaroMD,"#ASCO20 #LCSM
Discussing ADAURA results by @dave6408 
Open questions improving the understanding of EGFR-positive disease https://t.co/kvqM5chuqY",2020-05-31
1267176963896233984,https://twitter.com/COlazagasti/status/1267176963896233984,COlazagasti,The question with osimertinib in early stage remains: are we curing or delaying the disease? #ASCO20 https://t.co/Xrjqljgn96,2020-05-31
1267176905779920898,https://twitter.com/LeciaSequist/status/1267176905779920898,LeciaSequist,"Totally agree with @dave6408 - if it were me in the patient’s shoes, I would take adjuvant osi for early stage EGFR cancer at this time. We need OS and there are many unanswered questions, but ADAURA data is meaningful @EGFRResisters #ASCO20 #LCSM https://t.co/Lz0ANOy5ro",2020-05-31
1267176862486274048,https://twitter.com/manjuggm/status/1267176862486274048,manjuggm,"Great slide on MMR testing from Dr. Overman's talk..
Stealing for the CRC101 group in @COLONTOWN1 
#ASCO20 #ASCOTotalHealth #CRCSM #MMRtesting

And yes..let's make sure all patient tumors get tested for MMR status! https://t.co/CAZkjWeXFl",2020-05-31
1267176831687499778,https://twitter.com/ASCOPost/status/1267176831687499778,ASCOPost,Data From TAPUR Study Cohorts on Olaparib for BRCA-Mutated Advanced Prostate and Pancreatic Cancers https://t.co/MBpYz1xQxM #pcsm #pancsm #oncology #cancer #ASCO20,2020-05-31
1267176805162782720,https://twitter.com/rsm2800/status/1267176805162782720,rsm2800,"Spigel (LBA5-ADAURA trial):  ""I would choose osimertinib"" (if it were me - Dr. Spigel)) #ASCO20 #lcsm",2020-05-31
1267176779468464130,https://twitter.com/FunchainMD/status/1267176779468464130,FunchainMD,"Sensible comments applicable to any solid cancer by @dave6408 while discussing adjuvant osi #plenary data

When considering adjuvant benefit look at absolute OS benefit (over HR/relative benefit), pictured here is NSCLC from @ASCO guidelines paper (Kris JCO 2017)

#ASCO20 https://t.co/UXAGKiJ9DP",2020-05-31
1267176754109722625,https://twitter.com/KatyPiddock/status/1267176754109722625,KatyPiddock,"That moment when you think a study sounds good...and then you see what @VPrasadMDMPH has to say about it…🤦‍♀️😂 

More learning required.

Time to get back to the real @Plenary_Session 

And #Malignant of course 

#ASCO20 #MedEd #ClinicalTrials https://t.co/11vhVUE8hl",2020-05-31
1267176752691818496,https://twitter.com/ClarkeLow/status/1267176752691818496,ClarkeLow,"Good summary of big questions and going back to the patient: what would I do if I were the patient? Nice discussion by @dave6408 
#LCSM #asco20 https://t.co/VjZFqgWcWU",2020-05-31
1267176730160234496,https://twitter.com/Latinamd/status/1267176730160234496,Latinamd,A map of technology divide? #ASCO20 @Twitter user locations. https://t.co/D7i3CEhvjh,2020-05-31
1267176688036851713,https://twitter.com/Run_itt/status/1267176688036851713,Run_itt,#Keynote177 great commentary by @michael_overman. Important to find out those #colorectalcancer patients with #MSI-high /#dMMR who do not respond to #pembro beyond #KRAS-mut. #immunotherapy #newSOC #PrecisionMedicine #ASCO20,2020-05-31
1267176628272205824,https://twitter.com/rsm2800/status/1267176628272205824,rsm2800,Spigel (LBA5-ADAURA trial): Look at this earlier gefinitib adjuvant study; could this foreshadow what we will see with ADAURA? #ASCO20 #lcsm https://t.co/4CT1J0fW5Y,2020-05-31
1267176608282087424,https://twitter.com/VivekSubbiah/status/1267176608282087424,VivekSubbiah,So much going on in these uncertain times of #COVID19. Unreal that the @ASCO #ASCO20 is a virtual meeting. Thanks to @DrRoyHerbstYale for the amazing plenary &amp; Dr. @dave6408 for the discussion on #ADAURA. Positive news elevates all of us #InThisTogether @ASCOPres @ConquerCancerFd https://t.co/UBh08emcOP,2020-05-31
1267176606382141441,https://twitter.com/SusieSunMD/status/1267176606382141441,SusieSunMD,Important results from #ASCO20. Thanks @puneetsinghmd for the awesome summary. https://t.co/SMs5ry4mOL,2020-05-31
1267176600057057280,https://twitter.com/tmortiz/status/1267176600057057280,tmortiz,Does adjuvant chemotherapy do anything for EGFR mutant patients? #ASCO20 #LCSM https://t.co/xsG2peyfGD,2020-05-31
1267176576325574656,https://twitter.com/marklewismd/status/1267176576325574656,marklewismd,"My final thoughts on this #ASCO20 plenary: it was practice-changing for many of us &amp; across several tumor types

I remember my first tentative ipi infusion to a melanoma patient in 2011

Now IO is SOC in histologies from lung to GU &amp; GI! 

What a decade!

https://t.co/UKEZrwE9Ep",2020-05-31
1267176542058229765,https://twitter.com/urotoday/status/1267176542058229765,urotoday,Evaluation of predictive #biomarkers for Nivolumab in patients with metastatic clear cell renal cell carcinoma #RCC from #CheckMate025. Presentation by @miriamficial @BrighamWomens. #ASCO20 coverage by @TheRealJasonZhu @LevineCancer &gt; https://t.co/p8KFoYg8mv @ASCO https://t.co/Xr1xreOJ4K,2020-05-31
1267176540430893065,https://twitter.com/aspenbio/status/1267176540430893065,aspenbio,Early survival data boost Ziopharm's 'controlled IL-12' immunotherapy for glioblastoma |@Ziopharm @ASCO #ASCO #Ziopharm https://t.co/Vhr7oO6Vwy,2020-05-31
1267176533673811968,https://twitter.com/lymphomahub/status/1267176533673811968,lymphomahub,"#ASCO20 Annual meeting is almost over, and we hope you enjoyed as much as us! Find below the highlighted abstracts and stay tuned for new articles covering TOP presentations about #lymphoma and #CLL. 🔜 #EHA25Virtual https://t.co/G5qQ3FAojG",2020-05-31
1267176524765151233,https://twitter.com/ASCO_pubs/status/1267176524765151233,ASCO_pubs,Avelumab Maintenance Therapy Improves Survival in Advanced Urothelial Cancer https://t.co/yUiQ24yyMy #ASCODailyNews #ASCO20 #LBA @ERPlimackMD,2020-05-31
1267176522525421572,https://twitter.com/JAMANetwork/status/1267176522525421572,JAMANetwork,"New @JAMAOnc papers presented at #ASCO20 free online, including results from the SAVOIR study of Savolitinib Vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma, part of the Genitourinary Cancer—Kidney and Bladder Oral Abstract Session
https://t.co/WTnXNkC9zv https://t.co/wwafAJBGgl",2020-05-31
1267176521426337792,https://twitter.com/DrAbhiPal/status/1267176521426337792,DrAbhiPal,"#burnout #asco20 #ASCO2020 Poster 1/2 – great QI project at @KimmelCancerCtr on reflection rounds to improve wellness for trainees - now up to fostering empathy for colleagues, palliative care chaplain at the round, regular monitoring @erica_nakajima  https://t.co/0wtsOwuiyb https://t.co/vafbWkVIQg",2020-05-31
1267176501390249984,https://twitter.com/DevikaDasMD/status/1267176501390249984,DevikaDasMD,Great questions ! I want demographic break down as well in terms of racial representation 🙏🏽🛑#lcsm #ASCO20 https://t.co/rI8mbtjh9P,2020-05-31
1267176368246099968,https://twitter.com/nbh_48/status/1267176368246099968,nbh_48,I feel like AACR was more approachable to participants than ASCO....But I'm not sure if such a feeling came from my expertise/developmental stage. #aacr20 #ASCO20,2020-05-31
1267176254043828229,https://twitter.com/Tony_Calles/status/1267176254043828229,Tony_Calles,"🚨 Plenary Session. #ADAURA 
💊 Osimertinib vs placebo in stage IB-IIIA completely resected EGFR+ lung cancer. 

🗣 And the info everyone is waiting for. 
👉 Overall survival data. Preliminary and inmature. HR 0.4 but wide confident interval. 

#ASCO20 #LCSM @OncoAlert https://t.co/TAAOYGOaz1",2020-05-31
1267176250336051202,https://twitter.com/Marzia_Del_Re/status/1267176250336051202,Marzia_Del_Re,Great results from the #ADAURA study! 🙌🏻🤩 But how will you treat patients at the disease #recurrence after #adjuvant #osimertinib? #ADAURA #ASCO20 @OncoAlert https://t.co/u6sz89ErsH,2020-05-31
1267176128072101889,https://twitter.com/JTrentMDPhD/status/1267176128072101889,JTrentMDPhD,Here we go #sarcoma! #ASCO20 Highlights https://t.co/uVuph2jG14,2020-05-31
1267176075198713859,https://twitter.com/FernandoOnco/status/1267176075198713859,FernandoOnco,Is osimertinib in the adjuvant treatment of lung cancer as imatinib for GIST? The scores are lacking for a better selection of which patients will really have benefit. #ASCO20 @OncoAlert @GlopesMd https://t.co/yud8VAHQTH,2020-05-31
1267176049051414530,https://twitter.com/szusmani/status/1267176049051414530,szusmani,Different therapies rendered; continuous PI/IMiD therapy in S1211 phase II vs. fixed duration induction following by IMiD maintenance in the E1A11 Phase III. #mmsm #ASCO20 https://t.co/4qfJDDmhZs,2020-05-31
1267175905438371840,https://twitter.com/rsm2800/status/1267175905438371840,rsm2800,Spigel (LBA5-ADAURA trial): Impact on DFS greater for IIIA than for IB (not surprising) #ASCO20 #lcsm https://t.co/QSNqTAA22N,2020-05-31
1267175877957300229,https://twitter.com/bmassutis/status/1267175877957300229,bmassutis,"ADAURA Trial: Osimertinib adjuvant postop treatment after surgery of EGFRmut NSCLC: impressive DFS improvement but not clear impact on survival, early stop and duration therapy for 3 years #ASCO2020 #LCSM ⁦@OncoAlert⁩ https://t.co/8BM45wgFOa",2020-05-31
1267175877470814208,https://twitter.com/DrZ_84/status/1267175877470814208,DrZ_84,"Great results and great presentation by @DrRoyHerbstYale of practice changing treatment for adjuvant NSCLC. 

#ADAURA 
#ASCO2020 
#OncoAlert https://t.co/mjvqdTogNq",2020-05-31
1267175785242165248,https://twitter.com/dhovekamp42/status/1267175785242165248,dhovekamp42,ICYMI $AFMD #Amphivena Presents Data from First-in-Human Study of #AMV564 in #Solid Tumor Patients at the #ASCO2020 including a 1st #CR https://t.co/JCZ0hYXyjF,2020-05-31
1267175766825017344,https://twitter.com/DrSteveMartin/status/1267175766825017344,DrSteveMartin,"One downside of virtual #ASCO20 i had to recognize. While one could peacefully nap through the less relevant talks in the cavernous halls of McCormick, at home both my wife and my son woke me up saying that i told them i had an important conference to watch... https://t.co/KTcHKIXido",2020-05-31
1267175753801555968,https://twitter.com/ClarkeLow/status/1267175753801555968,ClarkeLow,"True. But the ""clear"" endpoint of PFS doesn't necessarily mean it was the best endpoint.
#LCSM #ASCO20 https://t.co/nOyVCon1AK",2020-05-31
1267175599921078272,https://twitter.com/jesusanampa/status/1267175599921078272,jesusanampa,"Feelings summary after #ASCO20 plenary session:
🔸Avelumab 😀 in advanced Urothelial Cancer
🔸Carfilzomib😢 in newly dx. Myeloma
🔸Pembrolizumab 😀 in advanced Colorectal Cancer
🔸Osimertinib 😀 in early NSCLC
🔸Surgery 😢 in metastatic Breast Cancer
@ASCO
#oncoalert https://t.co/H0JtLtVECE",2020-05-31
1267175578647638019,https://twitter.com/DrSGraff/status/1267175578647638019,DrSGraff,"🥰 I say things, quarantine hair edition. Thanks @OncoAlert! 
#bcsm #ASCO20 https://t.co/5PQ1C7GI0P",2020-05-31
1267175524222279681,https://twitter.com/MDedgeHemOnc/status/1267175524222279681,MDedgeHemOnc,#ASCO20: PPI + chemo improves breast tumor response rates in phase 2 trial. https://t.co/h6XTyUDfer #ASCO2020 @ASCO #Oncoalert #cancer https://t.co/Q26hGZm3sK,2020-05-31
1267175498343280641,https://twitter.com/marklewismd/status/1267175498343280641,marklewismd,"""Simple"" is not an insult, but a compliment, when it comes to trial design!
#ASCO20
#lcsm https://t.co/dVwAwmazEf",2020-05-31
1267175418798489600,https://twitter.com/BurrisSkip/status/1267175418798489600,BurrisSkip,"The fact that there is a known driver mutation, EGFR, somewhat reminiscent of Her2+ breast cancer, and that there is very effective metastatic therapy, again much like Her2+ breast cancer, it seems impractical to wait on OS data for these lung cancer patients. #ASCO20",2020-05-31
1267175357616197637,https://twitter.com/LUNGevity/status/1267175357616197637,LUNGevity,"As targeted therapies move to earlier-stage disease as adjuvant tx after surgery, are we equipped to ensure early-stage patients receive biomarker testing after surgery? @ros1cancer @ALKLungCancer @alk_fusion @EGFRResisters @METCrusaders @NTRKers @kRasKickers #ASCO20 #LCSM",2020-05-31
1267175349995081731,https://twitter.com/HamidEmamekhoo/status/1267175349995081731,HamidEmamekhoo,"Fantastic discussion by @ERPlimackMD!  New standard of care in treatment of metastatic #bladdercancer. 
#ASCO20 @BladderCancerUS https://t.co/0yRDrPfQWf",2020-05-31
1267175332211232776,https://twitter.com/aparna1024/status/1267175332211232776,aparna1024,Check out HR! Amazing 1L msi Chemo free option for #crcsm #crc lets think re 30% of tumors that are primary progessors/falling off quickly. Who are they? anyone catch somatic vs germline breakdown? missed this (blaming catching plenary on phone/on bike ride with kids!) #ASCO20 https://t.co/RYRf2oCDmo,2020-05-31
1267175305707425794,https://twitter.com/tmprowell/status/1267175305707425794,tmprowell,"#ASCO20

So, on Monday, in which tumor types will we NOT be doing profiling? This is a serious Q. Don't just like the tweet, pls comment. This is an important takeaway from the @ASCO Annual Mtg for general oncologists seeing pts w/ all tumor types &amp; for ppl w/ cancer.",2020-05-31
1267175281145643008,https://twitter.com/JTrentMDPhD/status/1267175281145643008,JTrentMDPhD,#WomenInSTEM #WomenInMedicine #WomenInSarcoma #ASCO20 #sarcoma @VaiaFlorou @srothschild @NeetaSomaiah1 @Melissa8Burgess @OncoAlert https://t.co/oeSWXo93mC,2020-05-31
1267175268298473473,https://twitter.com/Dr_Ivanoncologo/status/1267175268298473473,Dr_Ivanoncologo,"#JustNow En sesión plenaria con el Dr. S. Kumar, exponiendo que KRd no mejora la PFS vs VRd, por lo que este debe seguir siendo el estándar de tratamiento inicial para el Mieloma múltiple. #ASCO20 #Oncoalert https://t.co/75MIbnotVZ",2020-05-31
1267175161872220160,https://twitter.com/CharuAggarwalMD/status/1267175161872220160,CharuAggarwalMD,"Benefit seen across age, sex, race, smoking status and receipt of adjuvant chemo. #ADAURA #ASCO20 #LCSM https://t.co/tkwjvDz7go",2020-05-31
1267175137096368129,https://twitter.com/OncLive/status/1267175137096368129,OncLive,Tepotinib Displays Durable Clinical Benefit in METex14-Altered NSCLC @LeXiuning @MDAndersonNews @ASCO #ASCO20 #lcsm https://t.co/PoqCSv6w26,2020-05-31
1267175111435497473,https://twitter.com/JustinGainor/status/1267175111435497473,JustinGainor,Congratulations @DrRoyHerbstYale and the rest of the ADAURA investigators. Very impressive data! Love it when a HR looks more like a p value!! #ASCO2020 @EGFRResisters https://t.co/hO2H7tGgun,2020-05-31
1267174915951583233,https://twitter.com/s_brond/status/1267174915951583233,s_brond,Excited to see trend of molecular testing and immuno/targeted tx moving toward both 1st line and earlier stage settings. Inspiring to think about all the people these survival curves represent. #KEYNOTE177 #ADAURA #ASCO20 #plenary,2020-05-31
1267174835194662913,https://twitter.com/Lymphoma_Doc/status/1267174835194662913,Lymphoma_Doc,"What if patient with DLBCL relapses after #CART-cell? A second CAR T-cell can help, but usually with shorter benefit. Clinical trials are a better option. 
#ASCO2020 #lymsm 
https://t.co/IAZBiBOvdm https://t.co/KwdUrSZ4rb",2020-05-31
1267174797152260097,https://twitter.com/Esanzgarcia/status/1267174797152260097,Esanzgarcia,"BRAF, MSI and HER2 are finding its place in mCRC. Finally precision medicine is succesful in mCRC. Hopefully we may see in the future years results with the undruggable KRAS #asco20",2020-05-31
1267174766030598147,https://twitter.com/saramatarmd/status/1267174766030598147,saramatarmd,Impressive results from @DrRoyHerbstYale #ADUARA #ASCO20 #LCSM https://t.co/DX2fdDDvbb,2020-05-31
1267174735173095426,https://twitter.com/Tony_Calles/status/1267174735173095426,Tony_Calles,"🚨 Plenary Session. #ADAURA 
💊 Osimertinib vs placebo in stage IB-IIIA completely resected EGFR+ lung cancer. 

Side effects as expected. 
However, no QoL info presented today. 

#ASCO20 #LCSM @OncoAlert https://t.co/pbDs0vpn9v",2020-05-31
1267174692236005390,https://twitter.com/CettroOncologia/status/1267174692236005390,CettroOncologia,"Estudo indica que não há benefício em se operar Câncer de mama metastático: https://t.co/WPXM76Yyhm

@drjoaonunes 
#ASCO2020 #ASCO20 #CETTROASCO20 #ASCO20PSMA",2020-05-31
1267174538128867335,https://twitter.com/rsm2800/status/1267174538128867335,rsm2800,"Spigel (LBA5-ADAURA trial):  Good reminder that adjuvant therapy does 1 of 3 things: eliminate micromets, suppress micromets for awhile, or nothing good because there were no micromets #ASCO20 #lcsm",2020-05-31
1267174488392773632,https://twitter.com/NormandBlais/status/1267174488392773632,NormandBlais,💥ADAURA questions: 1 - patterns of relapse (radiologic ou clinical? Brain??). 2 - Availability of osi at relapse in placebo group. 3 - high risk of relapse in placebo group although 50% received adjuvant chemo. Impressive results overall!! @ASCO #LCSM #ASCO20,2020-05-31
1267174451566841859,https://twitter.com/krknrm/status/1267174451566841859,krknrm,Exciting plenary by @DrRoyHerbstYale showing the impressive DFS curves from ADAURA study -- osimertinib post-surgery vs placebo in NSCLC Ib -II- IIIa w or w/o Adj chemo #ASCO20 https://t.co/llOQlPDaDb,2020-05-31
1267174316761919488,https://twitter.com/JenniferCKing/status/1267174316761919488,JenniferCKing,At #ASCO20 @DrRoyHerbstYale concludes ADAURA trial is practice changing! Here are some of the key data to consider (side effects and stages). #lcsm https://t.co/UleIWmlEjk,2020-05-31
1267174259887136769,https://twitter.com/Medidata/status/1267174259887136769,Medidata,"Last chance: Join Bryant Fields @ASCO as he discusses the role of #RWD &amp; #ML. Get a better understanding of oncology therapies, incl synthetic controls, endpoint mapping &amp; identification of omics-based responders. Registrants view presentation here https://t.co/6ReMeNAcoi
#ASCO20 https://t.co/0pNKIZOvng",2020-05-31
1267174165238501376,https://twitter.com/Tony_Calles/status/1267174165238501376,Tony_Calles,"🚨 Plenary Session. #ADAURA 
💊 Osimertinib vs placebo in stage IB-IIIA completely resected EGFR+ lung cancer. 

Efficacy by stage, as expected IIIA&gt;II&gt;IB. Outstanding HR.
Without mandatory PET and brain MRI at screening, how accurate is this staging? 

#ASCO20 #LCSM @OncoAlert https://t.co/c7ztOHG4cZ",2020-05-31
1267174150361284613,https://twitter.com/DrLauraPorter/status/1267174150361284613,DrLauraPorter,"#ASCO2020 @ccalliance “60% of patients with stage III CRC are low risk and should receive 3 months of CAPOX. The other 40% are high risk the majority risk-benefit assessment suggests 3 months of CAPOX . For those unwilling to lose even 1% to 2% of efficacy, 6 months of therapy""",2020-05-31
1267174115309486088,https://twitter.com/jsoriamd/status/1267174115309486088,jsoriamd,"Osimerinib efficacy in ADAURA trial is impressive. Not only HR is very impressive in the primary endoint population, we also see efficacy across all stages, PFS curves remain very well separated &amp; OS curves are promising. How many pats in the PBO arm received CT ? #ASCO20 https://t.co/gAEZV71CJP",2020-05-31
1267174085873655808,https://twitter.com/ClarkeLow/status/1267174085873655808,ClarkeLow,"I suspect that ADAURA is accomplishing the middle, but await longer-term data. I think we need a vigorous discussion re: benefits, value, cost of middle goal of adjuvant tx identified by @dave6408 
#LCSM #asco20 https://t.co/VXXUr5z7rW",2020-05-31
1267174067645419521,https://twitter.com/ahmadalhader/status/1267174067645419521,ahmadalhader,"Imo this unplanned interim analysis was done too early to be presented at ASCO’s plenary, hard to know if Osimertinib as adjuvant therapy vs observation improves overall survival for now. Can’t ignore the impressive HR, but will need to wait for OS data. Thoughts?

#ASCO20 https://t.co/u1ADkYq98u",2020-05-31
1267174024402006016,https://twitter.com/marklewismd/status/1267174024402006016,marklewismd,"Dr Spiegel breaks down the 3 paths of adjuvant therapy at #ASCO20

I've always thought of it as the trolley problem myself:
https://t.co/OcRCH4ankl https://t.co/bdOSUxsa3O",2020-05-31
1267174004256698368,https://twitter.com/pascualine27/status/1267174004256698368,pascualine27,Fund new cancer research. Text ASCO to 41444 to donate or visit https://t.co/YfXee2daE5 #ASCO20 #SundayVibes #ConquerCancer #CureCancer,2020-05-31
1267173898296188930,https://twitter.com/inas_md/status/1267173898296188930,inas_md,"#ASCO20 
Fantastic plenary sessions as always! https://t.co/eAQanbsuPe",2020-05-31
1267173810937176070,https://twitter.com/PatrickCMa1/status/1267173810937176070,PatrickCMa1,All eyes are on Discussion of ADAURA by Dr. David Spigel now. #ASCO2020 #LCSM https://t.co/IQCzJElmN3,2020-05-31
1267173799541211136,https://twitter.com/pashtoonkasi/status/1267173799541211136,pashtoonkasi,👇🏼This! 🙌👏👍🏼#ASCO20 https://t.co/ZSw17xr6ht,2020-05-31
1267173797477711873,https://twitter.com/APassaroMD/status/1267173797477711873,APassaroMD,"#ASCO20 #LCSM
ADAURA discussion by @dave6408 https://t.co/hTEzxhnYNH",2020-05-31
1267173711376986112,https://twitter.com/yzafar/status/1267173711376986112,yzafar,"Thanks to @VPrasadMDMPH for answering my ?:

""Crossover is desirable:
Situations in which the experimental drug has ALREADY proven benefit in a later line of therapy or is standard of care in
the latter line"" 

https://t.co/h7jNS5J4dt #ASCO20 https://t.co/EghFnSPIjT",2020-05-31
1267173657727643648,https://twitter.com/jesusanampa/status/1267173657727643648,jesusanampa,"ADAURA phase III trial: Osimertinib in early NSCLC
Most patients were Asian, female, &amp; non-smokers
🔸83% improvement in DFS in stage II-IIIA
🔸79% improvement in DFS in stage IB-IIIA
🔸DFS improved regardless of use of adjuvant chemo
🔥Practice changing

#ASCO20 #OncoAlert https://t.co/W4yl841Ds3",2020-05-31
1267173656561627138,https://twitter.com/manjuggm/status/1267173656561627138,manjuggm,"Great talk by Dr. Overman on Keynote 177.
New SOC for 1 line MSI-H mCRC!!!
Was surprised to hear about KRAS WT/MUT difference in response, (did I hear that right?) curious to know what sp KRAS mut. Happy to know that BRAF status didn't matter.
#ASCO20 @TotalHealthConf #CRCSM https://t.co/NYyHz9TscE",2020-05-31
1267173635812253696,https://twitter.com/MarkPerla5/status/1267173635812253696,MarkPerla5,Learn more about how we are redesigning the clinical trial experience for patients during #COVID19. #ASCO20 #ScienceWillWin #PFEColleague https://t.co/84GLbtaSAj,2020-05-31
1267173591478665216,https://twitter.com/SilasInman/status/1267173591478665216,SilasInman,"Really nice DFS with adjuvant osimertinib in stage II-IIIa EGFR+ NSCLC! Trending toward OS (5% data maturity; HR, 0.40). ADAURA likely to change practice https://t.co/qo7TgE7iGC #ASCO20 #LCSM",2020-05-31
1267173578396635136,https://twitter.com/kgapo/status/1267173578396635136,kgapo,"News from #ASCO2020 for #HeadandNeck cancer 
@amanda_psyrri @g_mountzios https://t.co/UNzph6bXyj",2020-05-31
1267173493583441920,https://twitter.com/KatsuakiMaehara/status/1267173493583441920,KatsuakiMaehara,"The results are astounding and overwhelming！

A new standard of care for EGFR mut+ postoperative adjuvant chemotherapy has been created.

At 3 years, DFS rates in the osi arm fell by 20% and this point cannot be taken lightly.

 @DrRoyHerbstYale
 @ASCO
#ASCO20
#OncoAlert
#LCSM https://t.co/WnJ7bcuUS4",2020-05-31
1267173460721176576,https://twitter.com/LeciaSequist/status/1267173460721176576,LeciaSequist,"Not a huge surprise, but seems like adjuvant osi in ADAURA was easier to tolerate that adjuvant erlotinib in SELECT. Grade 3 AE rates were only seen in 1-2% of patients. Even all grade diarrhea did not meet 50%. #ASCO20 #LCSM @EGFRResisters https://t.co/3eGDkVSBUW",2020-05-31
1267173364503896067,https://twitter.com/jamienholloway/status/1267173364503896067,jamienholloway,ADAURA: Adjuvant osimertinib in early stage NSCLC @drroyherbstyale. Unmet need to prevent recurrence after surgery in early stage NSCLC #LCSM #ASCO20 https://t.co/TCv2d0TBLN,2020-05-31
1267173322716053504,https://twitter.com/CarmeloPozzo/status/1267173322716053504,CarmeloPozzo,Impressive and practice changing results of Keynote 177 with pembro front-line in MSI mCRC. Someone has to explain why RASmt do not benefit form upfront CPI  #ASCO20 @Oncoinfo_it #ASCO2020 #ASCO20VR #Asco https://t.co/GBnqaFOe9H,2020-05-31
1267173301123788803,https://twitter.com/LUNGevity/status/1267173301123788803,LUNGevity,"Provocative ADAURA trial data w/ osimertinib in adjuvant setting fr EGFRm St IB, II, III disease shows clear benefit of osi irrespective of stage, use of adjuvant chemo, &amp; type of EGFR mutation. New SOC for EGFR adjuvant tx? @DrRoyHerbstYale @YaleMed #ASCO20 #LCSM https://t.co/EuaSPoZJU8",2020-05-31
1267173251131858945,https://twitter.com/FJCarmonas/status/1267173251131858945,FJCarmonas,"Unplanned interim analysis of ADAURA trial on adjuvant osimertibib in EGFRm #lungcancer presented by @DrRoyHerbstYale ... wow! 

#ASCO20 https://t.co/IbZM3pe0yw",2020-05-31
1267173221943537664,https://twitter.com/acmoorephd/status/1267173221943537664,acmoorephd,Conclusions from the ADAURA study for osimertinib in the adjuvant setting for early stage EGFR #NSCLC @DrRoyHerbstYale #ASCO20 #lcsm https://t.co/60yRWW8K9g,2020-05-31
1267173219880108032,https://twitter.com/APassaroMD/status/1267173219880108032,APassaroMD,"#ASCO20 #LCSM
Conclusion by @DrRoyHerbstYale on Adjuvant Osimertinib in ADAURA trial 
A new standard of care? https://t.co/QNhhVUTooH",2020-05-31
1267173148513972230,https://twitter.com/Cortellis/status/1267173148513972230,Cortellis,Today @DrRoyHerbstYale presents that adjuvant osimertinib provides an effective new treatment strategy for stage IB/II/IIIA EGFR mutation-positive NSCLC patients. #ASCO20,2020-05-31
1267173131740950528,https://twitter.com/n8pennell/status/1267173131740950528,n8pennell,"ADAURA OS curve was shown (didn't get the pic in time), very immature but almost no deaths in osi arm, HR 0.4 so far. Looks a lot like the early FLAURA OS curve we saw 2 years before maturity but again much to early to be statistically significant. #ASCO20 #LCSM",2020-05-31
1267173084554903552,https://twitter.com/DrRoyHerbstYale/status/1267173084554903552,DrRoyHerbstYale,"Presenting the ADAURA data now @ASCO @ASCOPost at the plenary session. #ASCO20  The primary endpoint was met with DFS HR=0.17!  Thank you to all the coinvestigators, study team &amp; patients for participating in this practice changing study! @AstraZeneca @YaleCancer @Yale @LungMAP https://t.co/vpO2SVyLeq",2020-05-31
1267173039252230144,https://twitter.com/mabelonc/status/1267173039252230144,mabelonc,Unprecedented HR 0.12 in a phase 3 oncology trial = history in the making #asco20 #Notallbad in #year20,2020-05-31
1267173028082794496,https://twitter.com/VPrasadMDMPH/status/1267173028082794496,VPrasadMDMPH,"Q1 - unanswered
Q2 - answered
Q3 - unanswered
Q4 - sorta answered

#asco20 #asco2020 https://t.co/Yz1mmVKsLr",2020-05-31
1267173005827821568,https://twitter.com/marklewismd/status/1267173005827821568,marklewismd,"I have it on ""good authority"" that we don't need to be worried about the QT interval anymore, #ASCO20 🤦‍♂️

#hydroxychloroquine",2020-05-31
1267172940749119488,https://twitter.com/Tony_Calles/status/1267172940749119488,Tony_Calles,"🚨 Plenary Session. #ADAURA 
💊 Osimertinib vs placebo in stage IB-IIIA completely resected EGFR+ lung cancer. 

Trial design and patient characteristics. 

😳 45% of patients did not receive adjuvant chemotherapy!!! No granular data by stage. 

#ASCO20 #LCSM @OncoAlert https://t.co/s5vxZwo6GI",2020-05-31
1267172870783930375,https://twitter.com/APassaroMD/status/1267172870783930375,APassaroMD,"#ASCO20 #LCSM
ADAURA plenary 
Are you sure that waiting for the OS is not needed? https://t.co/j3P12SZLYZ",2020-05-31
1267172813695311874,https://twitter.com/ARosen380/status/1267172813695311874,ARosen380,Great disssion by @michael_overman  of @MDAndersonNews discussing keynote 177. Key takeaways:  ALL CRC patients should be tested for MMR/MSI and these results should change clinical practice! #ASCO20 #cancer #crcsm @ASCO @OncoAlert @FightCRC https://t.co/QzNJVmhNsL,2020-05-31
1267172780094742536,https://twitter.com/VivekSubbiah/status/1267172780094742536,VivekSubbiah,#ADAURA DFS vs OS fight begins @ASCO #ASCO20 @marklewismd @StephenVLiu @chadinabhan https://t.co/lI3P0hpNvz https://t.co/jxl4CeuxzO,2020-05-31
1267172779956281344,https://twitter.com/Run_itt/status/1267172779956281344,Run_itt,Great news for #colorectalcancer patients #MSI-high/#dMMR. A real breakthrough with #pembro as first line therapy in #keynote177 Impressive response and much longer duration with less toxicity than chemo. #ASCO20 #immunotherapy #precisionmedicine @CCAlliance https://t.co/rRsTr5vCYm,2020-05-31
1267172764638642179,https://twitter.com/Dr_Ivanoncologo/status/1267172764638642179,Dr_Ivanoncologo,"#JustNow Excelente sesión plenaria de la Dra. Seema A. Khan, sobre los resultados obtenidos del estudio fase III E2108. #ASCO20 #Oncoalert https://t.co/CeTsQw8dKi",2020-05-31
1267172764546486273,https://twitter.com/VJOncology/status/1267172764546486273,VJOncology,"Coming up next on the #ASCO20 program: #GenitourinaryCancers highlights! Neal Shore and @DrRanaMcKay gave us a great run-down of the HERO &amp; OMNIVORE studies

Don’t miss their interviews👉https://t.co/EyygDws7dE👈

@ASCO #Oncology #CTsm #KCsm #TSCsm #PCsm #BCLsm #UroOnc #UroSoMe https://t.co/dULV671WvF",2020-05-31
1267172762843525122,https://twitter.com/urotoday/status/1267172762843525122,urotoday,Perioperative novel systemic #immunotherapy-based approaches in urinary cancers. #ASCO20 presentation by @shilpaonc @CleClinicMD. Written coverage by @WallisCJD @VUMChealth on UroToday &gt; https://t.co/70UUTaPrUF @ASCO https://t.co/W9xLxmdruW,2020-05-31
1267172605024321537,https://twitter.com/VPrasadMDMPH/status/1267172605024321537,VPrasadMDMPH,"What really matters  👇

Placebo arm has to get osi at relapse (not gefitinib or god forbid chemo)
#asco20 https://t.co/nQ0E1Etlc9",2020-05-31
1267172547008827399,https://twitter.com/LeciaSequist/status/1267172547008827399,LeciaSequist,Congrats @DrRoyHerbstYale @TommyJohn00 and the whole ADAURA team. What impressive results! DFS HR 0.12 in stage IIIA cancers - practice changing! @EGFRResisters #LCSM #ASCO20 https://t.co/JI6uYLjpas,2020-05-31
1267172530395262977,https://twitter.com/OncLive/status/1267172530395262977,OncLive,Robust Data and Multivariate Analyses Support Cabazitaxel as a Standard of Care in mCRPC @UCLouvain_be @ClinUnivStLuc @ASCO #ASCO20 #pcsm https://t.co/E33di1HhQu,2020-05-31
1267172509532794881,https://twitter.com/tmprowell/status/1267172509532794881,tmprowell,"#ASCO20

The hazard ratios in 2020 look like the p-values from the start of my career.

#ScienceIsAwesome #oncology #drugdevelopment #ClinicalTrials",2020-05-31
1267172395066032130,https://twitter.com/drlw2309/status/1267172395066032130,drlw2309,"A beautiful trial, showing that locoregional treatment (surgery and radiotherapy to the primary breast tumour) is unnecessary in metastatic breast cancer. Do it for symptom control only; it won’t help patients live longer #ASCO20 https://t.co/HqS0CbpO1D",2020-05-31
1267172278095228931,https://twitter.com/APassaroMD/status/1267172278095228931,APassaroMD,"#ASCO20 #LCSM
ADAURA subgroups in the overall population.
What about Exon 21? https://t.co/7MDOJy7R6h",2020-05-31
1267172259929772036,https://twitter.com/Lin_ling_88/status/1267172259929772036,Lin_ling_88,"$MRKR will hold a press conference on Monday, hosted by Dr.Smaglo, PI, &amp; Ceo Hoang, to discuss the interim results of its #panc_cancer trial (#TACTOS) as presented at #ASCO20

▪️Monday, June 1st at 8:00 am EST 877-407-8913 (domestic) or 201-689-8201 (international)

▪️Key data: https://t.co/eGZeOUFppq",2020-05-31
1267172254347075586,https://twitter.com/flatironhealth/status/1267172254347075586,flatironhealth,"Leveraging #machinelearning to help infer metastatic status from unstructured EHR data in an effort to rapidly identify patients for clinical trials. Presenting at #ASCO20: 

https://t.co/YsUMpbzGbq 

#realworlddata @hjameshamrick https://t.co/ka4HCJengt",2020-05-31
1267172043906301953,https://twitter.com/DrLauraPorter/status/1267172043906301953,DrLauraPorter,#ASCO2020 @CCAlliance Good news for MSI-H mCRC.  ALL CRC patients need to have microsatellite testing done. @ng_kimmie @CathyEngMD @agrothey https://t.co/v8ODGbcHrt,2020-05-31
1267171970929643520,https://twitter.com/UroDocAsh/status/1267171970929643520,UroDocAsh,Moving the needle in a truly meaningful way for #bladdercancer; congratulations @tompowles1 @PGrivasMDPhD @OncoBellmunt @cnsternberg @kalasri3 #ASCO20 @neerajaiims https://t.co/XVSXgzq8AJ,2020-05-31
1267171959965655048,https://twitter.com/RandiMHernandez/status/1267171959965655048,RandiMHernandez,ADAURA #ASCO20 83% reduction in risk of death/progression. Osimertinib plus placebo in EGFR-positive NSCLC https://t.co/dmWLNeT88W,2020-05-31
1267171953451950082,https://twitter.com/JeffHirstPhD/status/1267171953451950082,JeffHirstPhD,Continued development of TKIs over the past 20 years for the treatment of EGFRmut lung cancer has led to outstanding response to osimertinib #ASCO2020 https://t.co/Dl4nOzap8c,2020-05-31
1267171886095568896,https://twitter.com/Dr_ZiMingZhao/status/1267171886095568896,Dr_ZiMingZhao,#ASCO20  impressive results reported by Yale colleague @DrRoyHerbstYale https://t.co/3ssZHLLxLp,2020-05-31
1267171747163447296,https://twitter.com/SeattleCCA/status/1267171747163447296,SeattleCCA,"#ASCO20: Dr. @mshadman's poster ""Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials."" Read on our SCCA at @ASCO page: https://t.co/Q9gooDX4ma https://t.co/Re9GHm9HNZ",2020-05-31
1267171717870485504,https://twitter.com/heatherahannon/status/1267171717870485504,heatherahannon,Here we go ... #DFS #OS  👀#ASCO20 https://t.co/4lbtOXPAV4,2020-05-31
1267171669220745217,https://twitter.com/CMicheri/status/1267171669220745217,CMicheri,"#ECOG-ACRIN (E2108) 🧐 Fase3. EIV de novo. Tto. sistemico por 4-8 meses, luego Random a tratamiento LocoRegional de la mama o no
256 pacientes / Obj: OS a 3y and PFS. 🗒
* Sin diferencias en OS (p=0.63)
* Sin diferencias en PFS (p=0.40) #ASCO20 #aaoc @aaoncoclinica @gaicoinforma https://t.co/NZn9Pa1OhJ",2020-05-31
1267171588463566850,https://twitter.com/Dr_Ivanoncologo/status/1267171588463566850,Dr_Ivanoncologo,"#JustNow En sesión plenaria, el estudio #JAVELIN100 marca el inicio de dos cambios en el paradigma del tratamiento del #cáncer urotelial avanzado. #ASCO20 #Oncoalert https://t.co/YaGXsKRgTm",2020-05-31
1267171585942794246,https://twitter.com/DrChoueiri/status/1267171585942794246,DrChoueiri,"Don't forget to tune-in in less than 30 minutes for the GU Cancers Highlight session #ASCO20 @ASCO!

You will only be seeing the data, suit, and tie... 
No slippers in sight!
@montypal @ERPlimackMD @tompowles1 @TiansterZhang @NarjustDumaMD @VivekSubbiah https://t.co/vaTcB7MK0f",2020-05-31
1267171567819251713,https://twitter.com/rsm2800/status/1267171567819251713,rsm2800,.@DrRoyHerbstYale (LBA5-ADAURA trial): The winner for today's most impressive HR (=0.17). And 3yr DFS for osimertinib was 80% vs 20% for placebo #ASCO20 #lcsm https://t.co/11d5kBDZSf,2020-05-31
1267171516069957634,https://twitter.com/LeciaSequist/status/1267171516069957634,LeciaSequist,ADAURA adjuvant osimertinib: You can do cartwheels in between these curves! Early and clear separation. This is a big advance for EGFR patients. #ASCO20 #LCSM @EGFRResisters https://t.co/qsxZ1P8HPV,2020-05-31
1267171505596706816,https://twitter.com/VJOncology/status/1267171505596706816,VJOncology,"The plenary session at #ASCO20 was truly fascinating! 👩‍⚕‍🎥
Stay tuned for the interviews with @DrRoyHerbstYale, @tompowles1 and @MLJohnsonMD2👉https://t.co/RxPDf3FmyP👈

@ASCO #Oncology #oncoalert #CTsm #LungCancer #LCsm #NSCLC #SLCL #Mesothelioma @VJOncology https://t.co/zU5nkAie7q",2020-05-31
1267171501750525953,https://twitter.com/pharmaphorum/status/1267171501750525953,pharmaphorum,Cost analysis of Velcade vs Kyprolis hands an advantage to Takeda when the two proteasome inhibitors are compared https://t.co/YQA3I0eMkm #pharma #ASCO20,2020-05-31
1267171497220636677,https://twitter.com/inas_md/status/1267171497220636677,inas_md,"#ASCO20 
#LCSM
Look at those curves! https://t.co/DzHXrtPB9Z",2020-05-31
1267171474928001024,https://twitter.com/sergio_crispino/status/1267171474928001024,sergio_crispino,"CRC, Test all pts for  MSI/MMR: practice changing #ASCO2020 https://t.co/ASazZgo4SY",2020-05-31
1267171458041569281,https://twitter.com/PatrickCMa1/status/1267171458041569281,PatrickCMa1,ADAURA study - Are you surprised that it does not stratify pts with vs without adjuvant chemotherapy use? #ASCO2020 #lcsm @JackWestMD @HosseinBorghaei @DrSteveMartin @VamsiVelcheti @n8pennell @StephenVLiu @CharuAggarwalMD,2020-05-31
1267171437896482816,https://twitter.com/TashakoriM/status/1267171437896482816,TashakoriM,#RareDisease #ASCO20 https://t.co/twI3AgdtUH,2020-05-31
1267171408758611971,https://twitter.com/krknrm/status/1267171408758611971,krknrm,"Loved the presentation + discussion of the exciting  KEYNOTE-177 @michael_overman and Thierry Andre - would love to see these frontline results in non-CRC tumors as well as other settings (adj, neoadj), and whether this PFS translates into equally impressive OS too!

#ASCO20 https://t.co/Fy0xPP998x",2020-05-31
1267171368015147014,https://twitter.com/DevikaDasMD/status/1267171368015147014,DevikaDasMD,Watching closely... #LCSM #ASCO20 https://t.co/aLkp3UaEaL,2020-05-31
1267171352085172225,https://twitter.com/JenniferCKing/status/1267171352085172225,JenniferCKing,Impressive DFS curve from ADAURA - osimertinib after surgery #ASCO20 #LCSM https://t.co/38Pf6f5dnf,2020-05-31
1267171322561519616,https://twitter.com/IBCResearch/status/1267171322561519616,IBCResearch,"Helpful having additional input on E2108, particularly framework, pros/cons providing perspective &amp; context to the data. While one might have ideas about potential benefit or harm, pts are typically most interested in QOL &amp; OS and these are clearly shown. #ASCO20 #BCSM. https://t.co/qzGkJDxR6z",2020-05-31
1267171310196666388,https://twitter.com/barrosonco/status/1267171310196666388,barrosonco,"#ASCO20 @ConquerCancerFd @ASCO 
A small contribution for a great cause! https://t.co/g5m5cul5ao",2020-05-31
1267171278676545536,https://twitter.com/HamidEmamekhoo/status/1267171278676545536,HamidEmamekhoo,"Selecting the best regimen for 1st line #mRCC remains challenging. Ipi/Nivo vs Pmbro/Axi? I like the PFS tail in Ipi/Nivo KM curves at 42 mon. 
Which outcomes do you consider? How do you counsel your patients? @kcCURE #ASCO20 #kidneycancer https://t.co/JGiq0LHSE1",2020-05-31
1267171274033266688,https://twitter.com/Dr_Ivanoncologo/status/1267171274033266688,Dr_Ivanoncologo,"#Cáncer | #Pembrolizumab VS #quimio en MSI-H metastásico SLP 16.5 a 8.2 meses #ASCO2020

￼ https://t.co/CjFR5ueMPA",2020-05-31
1267171265070194689,https://twitter.com/LeciaSequist/status/1267171265070194689,LeciaSequist,"For those who worried that DFS may be altered in ADAURA because of frequent monitoring, this monitoring schedule seems on par with SOC #LCSM #ASCO20 @EGFRResisters https://t.co/csxxCI8nDu",2020-05-31
1267171222007296000,https://twitter.com/duemed/status/1267171222007296000,duemed,LBA5 #ASCO20 Presidential Session ADAURA trial results by @DrRoyHerbstYale https://t.co/sm7uLnwPw6,2020-05-31
1267171189501374464,https://twitter.com/aakonc/status/1267171189501374464,aakonc,Really terrific commentary on #LBA4 by @michael_overman. Excellent explanation of curves crossing and agree this is practice-changing! What a relief to not subject pts to months of 1L chemo! #ASCO20,2020-05-31
1267171090293538816,https://twitter.com/APassaroMD/status/1267171090293538816,APassaroMD,"#ASCO20 #LCSM
ADAURA baseline characteristics in overall study population (stage Ib - IIIa) @DrRoyHerbstYale https://t.co/oGO7lC8kM6",2020-05-31
1267171040641331200,https://twitter.com/AmandaBinDC/status/1267171040641331200,AmandaBinDC,"#ASCORoomRaters @ASCOPres @BurrisSkip authentic, genuine, books &amp; good lighting. United #ASCO20 virtually. @ConquerCancerFd supporter. All around nice guy! 10/10 https://t.co/bLYe2VUTbH",2020-05-31
1267170965449924608,https://twitter.com/arkhaki/status/1267170965449924608,arkhaki,Nuanced understanding of crossover  very important for #ASCO20 #plenary today as an issue that was relevant for both Javelin 100 (LBA 1) and keynote 177 (LBA 4) https://t.co/v93l7zBxzq,2020-05-31
1267170961763127296,https://twitter.com/VPrasadMDMPH/status/1267170961763127296,VPrasadMDMPH,"45% no adjuvant chemo!  
Uh oh, that is super high . 

Q2
#asco20 #asco2020 https://t.co/Yz1mmVKsLr",2020-05-31
1267170918662647809,https://twitter.com/Jorge_GarciaRod/status/1267170918662647809,Jorge_GarciaRod,Abstract  5506. CTC as a prognostic marker of PSA response and progression in mCSPC. #ASCO20 https://t.co/WQxj8OJMIN,2020-05-31
1267170894734151682,https://twitter.com/tmprowell/status/1267170894734151682,tmprowell,"#ASCO20 I'm not #biostats, BUT
I'm playing one on TV here: it's not valid to conclude posthoc from a neg superiority RCT that ""the two txs are the same."" For starters, that is a non-inferiority Q your trial prob isn't even adequately powered to answer. @LGM_Biostats @gonen_mithat",2020-05-31
1267170859250118656,https://twitter.com/GillSharlene/status/1267170859250118656,GillSharlene,#ASCO20 #CRCSM #plenary 🙏 for an insightful discussion @michael_overman on the implications of KN177 👍 Practice changing for dMMR mCRC? Yes! More questions? For sure! Good news for our patients? Absolutely! @coloncanada https://t.co/JEa2fbA0Bf,2020-05-31
1267170830208978944,https://twitter.com/agrothey/status/1267170830208978944,agrothey,"We can celebrate a new SOC for first line MSI-H mCRC! Pembro has the best data. Congrats to the investigators. Now let’s make it even better and raise the tail further, CURE more pts! #OncoAlert #ASCO20 #ASCOTotalHealth",2020-05-31
1267170775049605120,https://twitter.com/gkkaradeniz/status/1267170775049605120,gkkaradeniz,ECOG-ACRIN Research Group- Systemic Rx vs Systemic Rx+Local therapy in stage IV breast cancer #ASCO2020 @eaonc https://t.co/Jj87F6G1la,2020-05-31
1267170736743108612,https://twitter.com/MedscapeOnc/status/1267170736743108612,MedscapeOnc,#ASCO20: Improval rate seen in HER2+ breast #cancer patients with brain metastases when given combo drug with tucatinib. https://t.co/PHT7stZcS5 https://t.co/eFnxHixJo6,2020-05-31
1267170736202027008,https://twitter.com/Medscape/status/1267170736202027008,Medscape,#ASCO20: Improval rate seen in HER2+ breast #cancer patients with brain metastases when given combo drug with tucatinib. https://t.co/q2vB0qshbG https://t.co/ob4a6ZZo2I,2020-05-31
1267170564961157121,https://twitter.com/GrupoGTG/status/1267170564961157121,GrupoGTG,"Andre et al, ph 3 KEYNOTE-177 trial: 

Pembro significantly increased PFS (median 16.5 mo vs 8.2 mo, HR 0.60; 2-y PFS 48% vs 19%) and ORR (44% vs 33%) compared to chemotherapy as first-line therapy for pts with MSI-H/dMMR mCRC, with fewer treatment-related AEs.

#ASCO20 https://t.co/kJcvvH5Q9t",2020-05-31
1267170553066029060,https://twitter.com/arjunlakshmanMD/status/1267170553066029060,arjunlakshmanMD,Comparable PFS for VRd vs KRd induction in standard and intermediate risk MM in ECOG-ACRIN ENDURANCE trial presented by @myelomamd at #ASCO20 plenary. KRd associated with higher cardiopulmonary and renal toxicity. VRd continues to be the standard induction approach in NDMM #mmsm https://t.co/1xPG0VjYsZ,2020-05-31
1267170548049514496,https://twitter.com/PatelOncology/status/1267170548049514496,PatelOncology,I am watching a video of a video of a video while tweeting with the people in the video @asco #plenarythings https://t.co/28NzQNfVcF,2020-05-31
1267170505532084225,https://twitter.com/TiansterZhang/status/1267170505532084225,TiansterZhang,"More in the theme of molecularly targeting tumors @ASCO #ASCO20 - Pembro improved PFS &amp; ORR over standard chemotherapy. Beware the first 6 months where the KM curves crossed, but responders  to pembrohave durable responses.
@OncoAlert https://t.co/DqztOWj1ob",2020-05-31
1267170444462952448,https://twitter.com/byilmaz2020/status/1267170444462952448,byilmaz2020,"Please join me for Poster session: Evidence of intratumoral localization, activation &amp; immunomodulatory effect of CX-072, a probody therapeutic targeting PDL1, in a PhI/II trial. 
@ANaingMD. Virtual #ASCO20 Fri, May 29-Sun, May 31. https://t.co/z3Ey8fMJOL
https://t.co/1bJmeovIs8",2020-05-31
1267170425903165440,https://twitter.com/SBOC_Oncologia/status/1267170425903165440,SBOC_Oncologia,"Assista às análises de Dr. Vladmir Lima, Dr. Gilberto de Castro Júnior, Dra. Carolina Kawamura, Dr. Luiz Araújo e Dr. Guilherme Geib, em dois vídeos exclusivos para os associados SBOC, em https://t.co/TFbMleFyNv. #ASCOvirtual #SBOCnaASCO #ASCO2020 https://t.co/06lyLZj3b9",2020-05-31
1267170395351900161,https://twitter.com/sema4/status/1267170395351900161,sema4,Is there a better way to personalize #MultipleMyeloma treatments? Learn how Sema4 uses #modeling to help predict benefits of MM therapy options in this #ASCO20 abstract https://t.co/OXTtSXzY9m #mmsm https://t.co/Cvh6EpvWdN,2020-05-31
1267170287872696320,https://twitter.com/coffeemommy/status/1267170287872696320,coffeemommy,"My FAVORITE #ASCO20 slides are those including, ""These results should change clinical practice."" 
Slide Translation: We need to test all patients for microsatellite instability (MSI) &amp; MSI-high patients should receive Pembro as 1st line treatment. #crcsm #Boom #OncoAlert https://t.co/26d6az5n8t",2020-05-31
1267170249348186115,https://twitter.com/cornellGUcancer/status/1267170249348186115,cornellGUcancer,Dr. Cora Sternberg (@cnsternberg) details findings from the JAVELIN study of avelumab #immunotherapy as maintenance treatment for advanced #urothelialcarcinoma patients. This high-impact research was presented as part of the #ASCO20 plenary session. https://t.co/w3BFjaLJ3m #blcsm https://t.co/rGJJR8KVZn,2020-05-31
1267170235649531905,https://twitter.com/Tony_Calles/status/1267170235649531905,Tony_Calles,EGFR mutations. A successful history in lung cancer. #ASCO20 #LCSM https://t.co/XAguQuv3SB,2020-05-31
1267170233032327168,https://twitter.com/CancerDotNet/status/1267170233032327168,CancerDotNet,"How do doctors and researchers ensure the safety of patients in #clinicaltrials? 

Read about #patientsafety and finding more information about participating in clinical trials ➡️ https://t.co/F3BAifPfUw

#cancerresearch #research #ASCO20",2020-05-31
1267170194683822089,https://twitter.com/Connect_CMC/status/1267170194683822089,Connect_CMC,#ASCO2020 More practice-changing data being presented during the @ASCO plenary - this time in MSI-H colorectal cancer #ASCO20 #beatcancer https://t.co/LF6nYo7Qfv,2020-05-31
1267170134168346626,https://twitter.com/TGeorgeMD/status/1267170134168346626,TGeorgeMD,"Agree, but would add we should test ALL cancer patients for MMR/MSI! 😉 #ASCO20 https://t.co/scfC3XAW1w",2020-05-31
1267170130540277762,https://twitter.com/FatimaKarzai/status/1267170130540277762,FatimaKarzai,"As we learn and aim to help our patients thanks to the important data presented at #ASCO20, it is also important to acknowledge the hurt and anger sweeping through the streets in Chicago and all across the country. We owe it to everyone we treat.",2020-05-31
1267170107207241728,https://twitter.com/LeoNissolaMD/status/1267170107207241728,LeoNissolaMD,TMB has been looked at in so many ways and yet not associated with OS.  Shouldn't we look for a biomarker elsewhere? #ASCO2020 https://t.co/g1qkO3cZnQ,2020-05-31
1267170044338941952,https://twitter.com/VivekSubbiah/status/1267170044338941952,VivekSubbiah,#ADAURA #ADAURA finally ...DFS vs OS debate begins. Lets see what the discussant says --&gt; @ASCO #ASCO20 @marklewismd @StephenVLiu @JackWestMD @JackWestMD @CharuAggarwalMD @LeciaSequist @DrRoyHerbstYale @drgandara @chadinabhan https://t.co/kn2TAyQhQu,2020-05-31
1267169981638291457,https://twitter.com/CancerDotNet/status/1267169981638291457,CancerDotNet,"¿Cómo aseguran los médicos y los investigadores la seguridad de los pacientes en los #ensayosclínicos? 

Leer sobre la #seguridaddelpaciente y obtener más información sobre la participación en los ensayos clínicos. ➡️  https://t.co/lA2MqQORxC

#investigacióndelcáncer #ASCO20",2020-05-31
1267169970406010883,https://twitter.com/APassaroMD/status/1267169970406010883,APassaroMD,"#ASCO20 #LCSM @DrRoyHerbstYale 
@EGFRResisters 
From 1997 to 2020.... the history of EGFR TKIs in lung cancer https://t.co/I0VadLTq7f",2020-05-31
1267169961753169925,https://twitter.com/EnriqueSoto8/status/1267169961753169925,EnriqueSoto8,"For all ADAURA-related issues  and concerns, just refer to @JackWestMD TL #ASCO20 https://t.co/36Yv3Mhiry",2020-05-31
1267169942111207429,https://twitter.com/StephenVLiu/status/1267169942111207429,StephenVLiu,#ASCO20 Highly anticipated plenary presentation of #ADAURA by @DrRoyHerbstYale: 3y of adjuvant osimertinib after resection of #EGFR+ NSCLC #OncoAlert #LCSM https://t.co/gtla2IOsUT,2020-05-31
1267169868157157378,https://twitter.com/nuenojpn/status/1267169868157157378,nuenojpn,クイーン・メディカル・センターは、太平洋諸島の島民は炎症性乳がんの発生率が高いことを示しており、一般的な米国人口の2-4％と比較して9％であることを示している（アブストラクトe19083）。＃asco20,2020-05-31
1267169741204074498,https://twitter.com/ryanhuey/status/1267169741204074498,ryanhuey,KEYNOTE-177 puts MSI-H mCRC where NSCLC was 2-3 years ago. YES to IO but combination with chemo and/or sequencing questions remain unanswered. Crossing of curves important for a subset who shouldn't get IO alone up front. #ASCO20,2020-05-31
1267169711621578753,https://twitter.com/nuenojpn/status/1267169711621578753,nuenojpn,ECOG-ACRIN e2108. de novo転移性乳癌では手術でOSが改善しなかった。de novo stage IV IBCの場合はどうなのでしょうか？緩和手術の理由はOSではなくQOLの改善であり、この研究では取り上げられていません。腫瘍が巨大化している人の緩和手術のために、私の診療が変わるとは思えません。#asco20,2020-05-31
1267169618038329344,https://twitter.com/nuenojpn/status/1267169618038329344,nuenojpn,IM（免疫調節）分子サブタイプは、早期TNBCにおけるネオアジュバント療法を含む免疫療法を予測。新たに開発されたTNBC-IMサブタイプを検出する27遺伝子アルゴリズムは、PD-L1 IHCと比較して、ネオアジュバント免疫療法におけるpCRのより信頼性の高い予測値を示した(Abstract 3117)　#asco20,2020-05-31
1267169561876586498,https://twitter.com/DianaNrco/status/1267169561876586498,DianaNrco,"So far, good results from KEYNOTE-177 but I find it confusing to hear about practice change when no OS results have been presented - please help me see what is the point that I am missing here #ASCO20",2020-05-31
1267169552133246977,https://twitter.com/rsm2800/status/1267169552133246977,rsm2800,Herbst (LBA5): https://t.co/llqHwVLdtE study (ADAURA) #ASCO20 #lcsm,2020-05-31
1267169535112732672,https://twitter.com/JonMarronMD/status/1267169535112732672,JonMarronMD,"Kudos to @eaonc ECOG ACRIN research team here for examining 1)tumor-specific factors, 2)survival (OS=1° outcome), *AND* 3)pt-defined HRQOL. Too often we only see 1st of those 3

The combo helps identify which therapies are TRULY meaningful &amp; effective for patients 👏👏👏

#ASCO20 https://t.co/lM220xseHq",2020-05-31
1267169532029874182,https://twitter.com/inas_md/status/1267169532029874182,inas_md,"#ASCO20 
The much awaited ADAURA trial plenary session!
@DrRoyHerbstYale https://t.co/SpRckaLIgr",2020-05-31
1267169482134507520,https://twitter.com/Dr_Ivanoncologo/status/1267169482134507520,Dr_Ivanoncologo,#JustNow #ASCO2020 Sesión plenaria sobre #BCS para carcinoma urotelial avanzado con #avelumab en estudio #JAVELIN #oncoalert https://t.co/FTez9cBMUO,2020-05-31
1267169475406761989,https://twitter.com/ahmadalhader/status/1267169475406761989,ahmadalhader,"Now the presentation with the most controversy in the plenary session

#ASCO20 https://t.co/keTcgS81yA",2020-05-31
1267169453021646849,https://twitter.com/KatsuakiMaehara/status/1267169453021646849,KatsuakiMaehara,"Fantastic analysis and discussion point 
by Michael J Overman, MD ！

The initial decline in dosing has been similar in lung cancer and has improved with the use of combined chemotherapy.

@ASCO
#ASCO20
#OncoAlert https://t.co/UPl6bg2kb4",2020-05-31
1267169420385947650,https://twitter.com/mdmanishshah/status/1267169420385947650,mdmanishshah,"Congratulations to KEY177 investigators, and to 
@michael_overman for an excellent overview and providing important context!  This is practice changing!  
#ASCO20 
@ASCO  @MDAndersonNews  @luisdiaznyc https://t.co/EPaiGXB7PV",2020-05-31
1267169413977047041,https://twitter.com/nuenojpn/status/1267169413977047041,nuenojpn,PDL1陽性TNBCでのペンブロリズマブは3種類の化学療法で有効（KEYNOTE-533 1st line PDL1+ TNBCに対する選択肢が増えた。しかし、FDAがネオアジュバント設定でKEYNOTE-522レジメンを承認してしまえば、3-5年後からはあまり意味がなくなる。#ASCO20,2020-05-31
1267169409958850560,https://twitter.com/LeciaSequist/status/1267169409958850560,LeciaSequist,Here we go!!! 🤩 @EGFRResisters #ASCO20 #LCSM https://t.co/cK223eo4wN,2020-05-31
1267169364819746816,https://twitter.com/jsoriamd/status/1267169364819746816,jsoriamd,Keynote 177 trial shows superiority of pem over CT in MSI CRC in term of PFS. But note that the curves do cross over!. May be combining CT with pembro would be the ideal approach in MSI CRC. Remember MSI but KRASmut CRC may not benefit from IO #ASCO20 https://t.co/xXLQ4W9HdC,2020-05-31
1267169331038715904,https://twitter.com/marklewismd/status/1267169331038715904,marklewismd,"Am I a bad person for rubbing my hands as a non-thoracic oncologist waiting to watch my lung cancer colleagues discuss the meaning of osimertinib in ADAURA?
#lcsm
#ASCO20 https://t.co/MJ4clVxAFf",2020-05-31
1267169317369626626,https://twitter.com/Tony_Calles/status/1267169317369626626,Tony_Calles,ADAURA. C’mon! #ASCO20 #LCSM @DrRoyHerbstYale,2020-05-31
1267169288789454848,https://twitter.com/VPrasadMDMPH/status/1267169288789454848,VPrasadMDMPH,"Lets see how many qs are answered

#asco20 #asco2020 . 

My bet is 1/4 https://t.co/Yz1mmVKsLr",2020-05-31
1267169284817633282,https://twitter.com/DevikaDasMD/status/1267169284817633282,DevikaDasMD,About time ! #lcsm #ASCO20 ADAURA https://t.co/WMhoGnY7pI,2020-05-31
1267169268623454208,https://twitter.com/ShuchiGulati/status/1267169268623454208,ShuchiGulati,Relevant point as several plenary session @ASCO #ASCO20 talk about cross overs! 🧐 https://t.co/JG3qxMDLEf,2020-05-31
1267169256447315968,https://twitter.com/NarjustDumaMD/status/1267169256447315968,NarjustDumaMD,"Here we go!

ADAURA Trial Presentation!

#ASCO20",2020-05-31
1267169217431961601,https://twitter.com/rsm2800/status/1267169217431961601,rsm2800,Overman (LBA4): Test all CRC pts for MMR/MSI! #ASCO20 https://t.co/ZJxuQdIc8D,2020-05-31
1267169206749011971,https://twitter.com/nuenojpn/status/1267169206749011971,nuenojpn,初期のTNBCに対するカペシタビンの補助療法は、何もしない場合に比べて有効であるが、標準的な化学療法に比べては効果がない。しかし、標準的な化学療法とは比較にならない。AC-TやTCが服用できない場合はメトロノミックカペシタビンが適しているかもしれない(SYSCCU-001)。特に高齢者には #asco20,2020-05-31
1267169193331511301,https://twitter.com/Jbauml/status/1267169193331511301,Jbauml,"OK here we go!  ADAURA presentation is starting now, from @DrRoyHerbstYale #LCSM #ASCO20",2020-05-31
1267169186419269632,https://twitter.com/AmgenMexico/status/1267169186419269632,AmgenMexico,"En #ASCO20, se darán a conocer los resultados del estudio de Fase 1 de una de nuestras moléculas BiTE®, que beneficia a los pacientes con #LeucemiaMieloideAguda. 
#OncoAmgen",2020-05-31
1267169159261159424,https://twitter.com/ERPlimackMD/status/1267169159261159424,ERPlimackMD,".@michael_overman : Interpretation of crossing curves depends on time scale. Yes!  Which part of scale is most important? I'd argue all of it. We love to see long term survivors, but for those who don't ride the tail, extra months still matter. #ASCO20 https://t.co/o0UylxqOzP",2020-05-31
1267169148016132098,https://twitter.com/jamienholloway/status/1267169148016132098,jamienholloway,Discussing KEYNOTE-177: Michael Overman. PFS curves cross at 6 months-- interesting. Benefit depends on time. Which do patients care about? He argues (I would agree) most care about the later timepoints #ASCO20 https://t.co/03dHXUmR1m,2020-05-31
1267169139543683073,https://twitter.com/nuenojpn/status/1267169139543683073,nuenojpn,MONALEESA（ML）第III相進行乳癌のプールされたctDNA解析では、PFSの改善につながる可能性のある複数の遺伝子変化が示された。FRS2、PRKCA、MDM2、ERBB2、AKT1、BRCA1/2。ESR1の負の効果はなかった。なぜなのか？CHD4、ATM、CDKN2はネガティブインパクト。アブストラクト1009 #asco20,2020-05-31
1267169068974518273,https://twitter.com/nuenojpn/status/1267169068974518273,nuenojpn,ネオアジュバント内分泌療法、がんの増殖を抑える効果が特に高いレジメンはない（alternate）。効果があれば、進行する確率は2％以下。低Ki67 HR+腫瘍に対してネオアジュバント内分泌療法を行うのは、より安心して施行できる？#asco20,2020-05-31
1267169032513499136,https://twitter.com/urotoday/status/1267169032513499136,urotoday,Phase II trial of Atezolizumab in #BCG-unresponsive non-muscle invasive #BladderCancer SWOG S1605. Presented by @pcvblack @VanProstateCtr. #ASCO20 coverage by @WallisCJD @VUMChealth on UroToday &gt; https://t.co/5o9diBowBe @SimaPorten @koshkin85 @kellystratton @tbivala1 @SWOG #NMIBC https://t.co/fBNHxTCG9D,2020-05-31
1267169011185352704,https://twitter.com/LevineCancer/status/1267169011185352704,LevineCancer,"“There's been a real focus at Levine Cancer Institute on looking at studies and research efforts that will highlight rare cancers. We feel that every patient who's diagnosed needs to have an opportunity, not only for drugs, but clinical trials and research.” @EdKimMDLCI #ASCO20",2020-05-31
1267169003140677634,https://twitter.com/nuenojpn/status/1267169003140677634,nuenojpn,フルベストラントはHR+ HER2- MBC（PARFIL）でパルボシクリブと併用してもAIより優れていない。ということで、1stラインはAI＋CDK4/6阻害剤 #ASCO20,2020-05-31
1267168996199206917,https://twitter.com/ASCOPres/status/1267168996199206917,ASCOPres,#ASCO20 really is united! Phenomenal participation &amp; engagement ➡️ over 3.1 million page views and counting! We will share final numbers shortly after the meeting. 👏,2020-05-31
1267168994462781441,https://twitter.com/Elsevier_Med/status/1267168994462781441,Elsevier_Med,"Take 30% off all oncology books including the JUST PUBLISHED Proton Therapy, 1st Edition! Use code ASCO30 at checkout. @ASCO https://t.co/7RYdS8Schd https://t.co/VeDa2rmvRE",2020-05-31
1267168992189440001,https://twitter.com/ConquerCancerFd/status/1267168992189440001,ConquerCancerFd,"Meet @lillian_siu, a 2020 #WomenWhoConquerCancer Mentorship Award recipient https://t.co/wvEXMJwurp #ASCO20",2020-05-31
1267168975399424001,https://twitter.com/DanaFarberNews/status/1267168975399424001,DanaFarberNews,"Promising clinical activity in women with recurrent uterine serous #carcinoma given adavosertib monotherapy. Joyce Liu, MD, MPH, presents findings of a phase II trial of the Wee1 inhibitor at #ASCO20

👉 Abstract link: https://t.co/R34kZZUlKt https://t.co/BSZv4bOsc6",2020-05-31
1267168974900473856,https://twitter.com/AmgenOncology/status/1267168974900473856,AmgenOncology,We’ve launched our new #CodeBreaK website with information on clinical trials for certain cancers that contain the #KRASG12C mutation. Visit: https://t.co/UWDkYTWmwo #ASCO20 https://t.co/twyGY5GyDi,2020-05-31
1267168973457469440,https://twitter.com/AstellasUS/status/1267168973457469440,AstellasUS,"As we wrap up #ASCO20, we want to extend our thanks to the #oncologists and #oncology healthcare professionals who work every day to make important advances in cancer and #cancerresearch. https://t.co/4hNG7ddI6K",2020-05-31
1267168971628912647,https://twitter.com/Mrsprofessiona1/status/1267168971628912647,Mrsprofessiona1,"Where you receive your tx for #Burkittlymphoma should NOT matter; however, it does according to this RWE study compromised of 30 academic &amp; community centers in the US.#ASCO20 #disparties @OncologyNursing https://t.co/TXk63Aqxl8",2020-05-31
1267168926250815488,https://twitter.com/Tarek_Assi1986/status/1267168926250815488,Tarek_Assi1986,High progressive rate in pembrolizumab subgroup..how to select those hyper-progressors? #ASCO20 #ASCO #ASCO2020 #cancer #keynote177 https://t.co/xlLKft1UWo,2020-05-31
1267168893577150465,https://twitter.com/nuenojpn/status/1267168893577150465,nuenojpn,HR+ MBCに対するCDK 4/6阻害薬やmTOR阻害薬に失敗した後のXelodaの選択は、後ろ向き試験に基づいて合理的である（抄録141）#asco20,2020-05-31
1267168798055870464,https://twitter.com/JackWestMD/status/1267168798055870464,JackWestMD,"Agree w/this sentiment. TMB has had more than its day in court. If it were that useful, we wouldn't be having this debate abt it during #ASCO20, after yrs of study. 

The biomarker(s) we need should convince us all with far less effort. And we need to prioritize what to focus on. https://t.co/66bdE5e4GZ",2020-05-31
1267168785514938369,https://twitter.com/VPrasadMDMPH/status/1267168785514938369,VPrasadMDMPH,"Crossover is the most misunderstood endpoint
IF a drug already has benefit in latter line, and you want to move up, you NEED X over and you NEED an OS benefit or a HrQoL benefit across time (long time)👇

#asco20 #asco2020
Explained here

https://t.co/SMfCztTwmd",2020-05-31
1267168746260627458,https://twitter.com/nuenojpn/status/1267168746260627458,nuenojpn,CDK 4/6耐性HR+ HER2- PIK3CA変異MBC、フルベストラント、アルペリシブは第II相試験に基づく妥当な腫瘍反応率を示す。SOLAR-1試験結果を補完するものである。#asco20,2020-05-31
1267168714849423360,https://twitter.com/inas_md/status/1267168714849423360,inas_md,"#ASCO20 
Excellent discussion points! https://t.co/pV6dd3fVVR",2020-05-31
1267168704657100800,https://twitter.com/JustinGainor/status/1267168704657100800,JustinGainor,"After the plenary, join me, Ross Camidge, Shirish Gadgeel and Richard Gralla for a CME session on ""Optimizing Outcomes in ALK-Positive NSCLC"" (4:30 pm). We promise that you won't have to brave the ASCO shuttle service during rush-hour in Chicago for this one! #ASCO2020 #ALK https://t.co/PYtFUe8sAK",2020-05-31
1267168696411226114,https://twitter.com/yzafar/status/1267168696411226114,yzafar,Critical point by Dr. Overman: How do we treat symptomatic MSI-H patients w/ #coloncancer at risk for disease-related complications? #ASCO20 https://t.co/gXG0lcIOXo,2020-05-31
1267168689171902464,https://twitter.com/HTawbi_MD/status/1267168689171902464,HTawbi_MD,"Long term updates for Pembro and BRAF/MEKi in adjuvant- mostly showing that even with safe effective adjuvant therapy, still close to 50% of stage III melanoma recur, highlights need for our proposed @SWOG study of triplet (BRAF/MEKi + Anti-PD-1) for high risk melanoma #ASCO20",2020-05-31
1267168652366880774,https://twitter.com/rsm2800/status/1267168652366880774,rsm2800,"Overman (LBA4):  Interesting ? raised, should poor performance pts received chemo +/- Pembrolizumab first to control disease #ASCO20",2020-05-31
1267168611967344640,https://twitter.com/nuenojpn/status/1267168611967344640,nuenojpn,ベースラインのESR1変異はHR+ HER2- MBC（PADA1）でCDK4/6阻害薬＋AIの予後不良。ESR1の前もってのチェックと後からのチェックが必要？液体生検による縦断的モニタリングの時期? #asco20,2020-05-31
1267168535320633347,https://twitter.com/nuenojpn/status/1267168535320633347,nuenojpn,THPは標準治療のままである（KAITLIN試験）。 T-DM＋ペルツズマブとトラスツズマブ＋ペルツズマブを比較しても有効性がHER2陽性初期乳がんでは認められませんでした。毒性プロファイルが大きく異なる。T-DM1は心臓に問題のある人だけに投与するのか？　　#ASCO20,2020-05-31
1267168491481690112,https://twitter.com/ninashah33/status/1267168491481690112,ninashah33,I'm super proud to be a part of the Waun-Ki Hong @MDAndersonNews lineage.  He would be so proud that  TWO of his fellows are plenary discussants this year @michael_overman @ERPlimackMD #ASCO20 https://t.co/TmqEc61xfS,2020-05-31
1267168393645510657,https://twitter.com/oncology_bg/status/1267168393645510657,oncology_bg,Have any of the #plenaries at #ASCO20 been published simultaneously in journals?,2020-05-31
1267168374305501184,https://twitter.com/YishanChuang/status/1267168374305501184,YishanChuang,Ellie and I are both excited to hear the ADAUDA plenary presentation #ASCO20!! https://t.co/sBPTm8HW4u,2020-05-31
1267168337789964290,https://twitter.com/OncLive/status/1267168337789964290,OncLive,"TONIGHT AT 7 PM EST: Join us live for our last virtual On Location for #ASCO20! In this segment, @ginacolumbusonc will speak with @ASCOPres @ASCO @SarahCannonDocs! Register now to access this exclusive interview: https://t.co/Pf4peGT1rv! https://t.co/T22V1MMBJT",2020-05-31
1267168230348599297,https://twitter.com/rsm2800/status/1267168230348599297,rsm2800,Overman (LBA4): Robust decrease in toxicity with pembro vs. chemo #ASCO20 https://t.co/E872QMzvex,2020-05-31
1267168222584995841,https://twitter.com/nuenojpn/status/1267168222584995841,nuenojpn,HER2+脳転移に対するトラスツズマブとカペシタビンを併用したツカチニブの生存効果は印象的である（HER2CLIMB）。これを最初の1st lineで与える必要があるのか？ #ASCO20,2020-05-31
1267168222543056903,https://twitter.com/LurieCancer/status/1267168222543056903,LurieCancer,"Make sure you attend Seema Khan’s, MD, plenary session at #ASCO20: A Randomized Phase III Trial of #SystemicTherapy Plus Early #LocalTherapy Versus Systemic Therapy Alone in Women With De Novo Stage IV Breast Cancer. Full text will be posted here: https://t.co/4FslLM79Hp. https://t.co/HdUPJ8Onyq",2020-05-31
1267168021367238657,https://twitter.com/ChilesResearch/status/1267168021367238657,ChilesResearch,"Congrats to our own Matthew Taylor MD for his contributions to this study presented at #ASCO20. View full abstract and on-demand video &gt;&gt; https://t.co/Xmk4OdUkNG 

#FinishCancer #Pralsetinib https://t.co/ZoVDK4y3JI",2020-05-31
1267167992648839168,https://twitter.com/NazliDizman/status/1267167992648839168,NazliDizman,"👏👏Outstanding discussion by @montypal @ASCO #ASCO20 highlighting the importance of collaborative efforts &amp; making clinical trials for #rarecancers pts available in multiple centers!

""We've got to band together with patients, advocates, and industry to get these studies done"" https://t.co/OJX88NxGdw https://t.co/D0prbiiMOk",2020-05-31
1267167983488708608,https://twitter.com/ARosen380/status/1267167983488708608,ARosen380,Pembrolizumab should be the new standard-of-care as first-line therapy in patients with MSI-H mCRC @ASCO @OncoAlert @FightCRC @CCAlliance #ASCO20 #crcsm #plenary #colorectal #Cancer https://t.co/Zg5hZlH4dD,2020-05-31
1267167970217857030,https://twitter.com/SKamath_MD/status/1267167970217857030,SKamath_MD,"Impressive data for 1st-line pembrolizumab metastatic #colorectalcancer. New standard of care. The early progressors are concerning though, maybe RAS-mutated? 

If only more than 5-8% have MSI-H tumors...#ASCO20 https://t.co/h2QalCbqPb",2020-05-31
1267167837669466115,https://twitter.com/fmassari79/status/1267167837669466115,fmassari79,"What a fantastic news from #ASCO20 !! This is an important hope for #bladdercancer patients. 
#ASCO2020 https://t.co/1DmsuQNqXO",2020-05-31
1267167809072771079,https://twitter.com/ConquerCancerFd/status/1267167809072771079,ConquerCancerFd,#ASCO20 - Water you waiting for? Donate now at https://t.co/QpJOIwpkPM 🌊🧡 #WeCan https://t.co/yXSjqcOAjC,2020-05-31
1267167697416056832,https://twitter.com/Dr_Ivanoncologo/status/1267167697416056832,Dr_Ivanoncologo,#Cáncer | RET fusions are oncogenic drivers in multiple tumor types #ASCO20 https://t.co/evMiW4x2cp,2020-05-31
1267167669003878405,https://twitter.com/StephenVLiu/status/1267167669003878405,StephenVLiu,#ASCO20 Watching KEYNOTE-177 plenary of pembrolizumab vs chemotherapy in #MSI-H metastatic CRC with mPFS 16.5m vs 8.2m. Crossing curves noted - will we see benefit to chemo-IO in this setting? #OncoAlert https://t.co/FnbCfd3w7D,2020-05-31
1267167634207969286,https://twitter.com/HTawbi_MD/status/1267167634207969286,HTawbi_MD,"New promising combo for mucosal melanoma (axitinib+Anti-PD1~50% ORR), TIL impressive in PD-1 refractory melanoma, and safe possibly effective IT nivo for LMD- all great news in MOST UNMET NEEDS as expertly discussed by Ryan Sullivan, must watch #ASCO20 https://t.co/LeOTP1VF5p",2020-05-31
1267167333522563073,https://twitter.com/rsm2800/status/1267167333522563073,rsm2800,Overman (LBA4):  PFS curves cross. What do patients care about more? Likely it's the longer term freedom from progression #ASCO20 https://t.co/lt1b5lZeIo,2020-05-31
1267167314530586624,https://twitter.com/sleotin/status/1267167314530586624,sleotin,Thanks for sharing Stacey. I feel that the problem of #cancerdisparities was under discussed at #ASCO20. It is bigger than a palliative care problem and should be given more attention. We need to tackle this issue at a higher level and unite and conquer to drive change. https://t.co/veU45ekeEG,2020-05-31
1267167254308950024,https://twitter.com/DrScottTagawa/status/1267167254308950024,DrScottTagawa,Exactly a question in my mind listening @tompowles1 presentation and @ERPlimackMD excellent discussion #ASCO20 https://t.co/svzwqzjdTj,2020-05-31
1267167228174184448,https://twitter.com/ryanhuey/status/1267167228174184448,ryanhuey,.@michael_overman raising the right questions re: crossing of curves #ASCO20 https://t.co/j576Jdd7Fh https://t.co/58otHVG0P4,2020-05-31
1267167179063078913,https://twitter.com/ChristinaUwins/status/1267167179063078913,ChristinaUwins,"💜#goASCO20 💜  Gynaecological Oncology Presentation
@ASCO #ASCO20 https://t.co/u4ejOXQ4Us",2020-05-31
1267167178836459520,https://twitter.com/marklewismd/status/1267167178836459520,marklewismd,".@michael_overman breaks down the meaning of the crossing curves in KEYNOTE-177: at what timepoint should  we place the most weight? (He conjectures that most patients are looking at the 'long game')

#crcsm
#ASCO20 https://t.co/YNjRR5VrHY",2020-05-31
1267167167751041040,https://twitter.com/giconnectInfo/status/1267167167751041040,giconnectInfo,#ASCO20: thanks Andre T. et al. For presenting these great PFS results with #pembrolizumab in MSI-H or dMMR #CRCSM patients: great evidence to become new standard of care in those patients in 1L settings...OS still to be defined! https://t.co/W8xXsOpjpq,2020-05-31
1267167154572591104,https://twitter.com/IBCResearch/status/1267167154572591104,IBCResearch,"Good to see background &amp; specifics of E2108. Lots of discussion in pt community questioning role of surgery in stage IV. More trials are needed to help inform decisions in both de novo stage IV &amp; recurrent disease, taking into account pt desires as well. #ASCO20 #BCSM https://t.co/kyv9FP38pc",2020-05-31
1267167064688558088,https://twitter.com/VivekSubbiah/status/1267167064688558088,VivekSubbiah,Pembrolizumab emerges as front-line therapy for MSI-H mCRC #colorectal cancer @ASCO #ASCO20 https://t.co/HYlvJ1BNlX,2020-05-31
1267167042907537409,https://twitter.com/MHExecutive/status/1267167042907537409,MHExecutive,"Women who get a genetic testing for hereditary breast &amp; ovarian cancer are often advised to talk to a genetic counselor before &amp; after they take the test, even if the result is negative for a mutation that would indicate a greater risk. #ASCO20
https://t.co/iR6nHYcwF4",2020-05-31
1267167021021777922,https://twitter.com/ChristinaUwins/status/1267167021021777922,ChristinaUwins,"💜#goASCO20 💜  Gynaecological Oncology Presentation
@ASCO #ASCO20 https://t.co/gic7ncKzDU",2020-05-31
1267166798086057985,https://twitter.com/ChristinaUwins/status/1267166798086057985,ChristinaUwins,"💜#goASCO20 💜  Gynaecological Oncology Presentation
@ASCO #ASCO20 https://t.co/LGdqADszKT",2020-05-31
1267166710651592708,https://twitter.com/DFBC_PedCare/status/1267166710651592708,DFBC_PedCare,"Research led by Hannah Olsen of @DFBC_PedCare titled, ""Trends in conditional survival and predictors of late death in neuroblastoma,"" is being presented this weekend as part of #ASCO20. https://t.co/pfu9tpxNGx Cc: @ASCO https://t.co/xXi6RVoEmx",2020-05-31
1267166688136458240,https://twitter.com/WilliamDale_MD/status/1267166688136458240,WilliamDale_MD,Great thread combinig #geriatrics with #SupportiveCare for older adults with cancer #ASCO20 https://t.co/sOpz4TVUjV,2020-05-31
1267166647309070336,https://twitter.com/ramyathota1/status/1267166647309070336,ramyathota1,So many ways to test for MMR and MSi testing- IHC/PCR/NGS @michael_overman  @ASCO #crcsm #ASCO20VR https://t.co/ARE1qozo2F,2020-05-31
1267166631958122499,https://twitter.com/barrosonco/status/1267166631958122499,barrosonco,#ASCO20 #MedTwitter https://t.co/h0FRqr3LRJ,2020-05-31
1267166545299603457,https://twitter.com/ChristinaUwins/status/1267166545299603457,ChristinaUwins,"💜#goASCO20 💜  Gynaecological Oncology Presentation
@ASCO #ASCO20 https://t.co/6WoMiQssZg",2020-05-31
1267166491281182721,https://twitter.com/KaterinaSaveli1/status/1267166491281182721,KaterinaSaveli1,"Wow, what a great exciting results from Keynote-177! Great to see new standard of care for first line mCRC patients! @ASCO #ASCO20",2020-05-31
1267166470171230216,https://twitter.com/urotoday/status/1267166470171230216,urotoday,#JAVELIN Bladder 100 #Results! Maintenance Avelumab + best supportive case vs BSC alone after platinum-based first-line chemotherapy in adv #UrothelialCarcinoma. Presented by @tompowles1 @QMBCI #ASCO20 coverage by @aloktewar @DanaFarber on UroToday &gt; https://t.co/TXJm0fjqHc @ASCO https://t.co/yIfBvCzmU2,2020-05-31
1267166432418320385,https://twitter.com/yzafar/status/1267166432418320385,yzafar,"Thoughts on PFS results from KEYNOTE-177:

1) The curves cross at ~6mo. As we know, checkpoint-i take longer to get to response

2) Data does not suggest that MSI-H is prognostic. Control arm PFS 8mo, not better than seen in other trials.

3) 16.5 mo - WOW

#ASCO20 #crcsm https://t.co/gIwnC0qGk5",2020-05-31
1267166400046665729,https://twitter.com/DrMirallas/status/1267166400046665729,DrMirallas,"📢 Great news for MSI #CCR ‼️
Keynote-177 brings hope with a median PFS of 16.5 months in the #Pembrolizumab vs #CT ✅ @ASCO
⚠️ Pembrolizumab becomes the new standard of care for #MSI colorectal M1 cancer ⚠️
@OncoAlert #ASCO20 #ASCO2020 https://t.co/TlkUe3yePh",2020-05-31
1267166378269777920,https://twitter.com/medhavigupta09/status/1267166378269777920,medhavigupta09,"Phase III KEYNOTE-177 study, Plenary #ASCO20 #CRCSM 
1:1 Pembro vs. SOC chemo (+/- biologic) as 1st-line Rx in MSI-H/dMMR mCRC 

⬆️PFS 16.5 mo vs 8.2 mo, HR 0.6
⬆️ORR 44% vs. 33%
⬇️Gr 3-5 TRAEs
✳️Practice changing for front-line mCRC MSI-High pts https://t.co/csKi356bHD",2020-05-31
1267166324016455680,https://twitter.com/teamoncology/status/1267166324016455680,teamoncology,"I totally agree with you. The reason for the surgery is not for the OS. For example, inflammatory breast cancer, 30% will present with met. It is a major QOL issue if we just let the primary sit on the chest wall. #ASCO20 https://t.co/AieVyI9o5Q",2020-05-31
1267166285395361793,https://twitter.com/FJCarmonas/status/1267166285395361793,FJCarmonas,"Results on presented by Dr Thierry Andre support a new treatment standard with pembrolizumab on MSI-high metastatic #colorectalcancer patients in first line. Impressive effects on PFS and durable clinical responses.

@ldiaz1 #ASCO20 #Immunotherapy https://t.co/vwsdt5ljJa",2020-05-31
1267166257977143298,https://twitter.com/saramatarmd/status/1267166257977143298,saramatarmd,How likely is Keynote-177 to change your practice for MSI-H Met. #colorectalcancer ? #ASCO20,2020-05-31
1267166249055813632,https://twitter.com/CliffordHudis/status/1267166249055813632,CliffordHudis,Absolutely! Where else would they be going? #ASCO20 @ConquerCancerFd @ASCOPres $1M Challenge TEXT ASCO to 41444 or visit https://t.co/90D94FK22r. https://t.co/Ul0B581jKF,2020-05-31
1267166213022666757,https://twitter.com/inas_md/status/1267166213022666757,inas_md,"#ASCO20 
Impressive data! #crcsm https://t.co/BsSkrro1uT",2020-05-31
1267166137852268546,https://twitter.com/SBRInvestor/status/1267166137852268546,SBRInvestor,ANOTHER ABSTRACT REPORTED SIMILAR MDS/AML percentage. Alternative PARPi should be considered ! @clovisoncology #ASCO20 #ASCO2020 #Lynparza #Rubraca #ovariancancer #ONCONEWSnoASCO20 #oncology #onctwitter #OncoAlert #oncmeded #MedEd #PARPi #parpinhibitors https://t.co/er3Me4VvEH https://t.co/mDekcTIBht,2020-05-31
1267166126389280769,https://twitter.com/HTawbi_MD/status/1267166126389280769,HTawbi_MD,"Several interesting studies looking at various doses, schedules in melanoma to anti-CTLA4+anti-PD1- goal minimize toxicity&amp; retain efficacy- 2nd line study lower ORR than initial report but still valuable option. Great Discussion by Doug Johnson! #ASCO20 
https://t.co/rP8MuxQvAl",2020-05-31
1267166122350202881,https://twitter.com/IvyLorena_Md/status/1267166122350202881,IvyLorena_Md,"Wow! 🔥🔥🔥 Pembro vs. chemotherapy in patients with MSI-H mCRC, my favorite one from the plenary session #ASCO20 

Let’s see the discussion by Dr. Overman https://t.co/Rq1P1RI990",2020-05-31
1267166108655783937,https://twitter.com/elena_elez/status/1267166108655783937,elena_elez,A change of paradigm in mCRC @VHIO @vallhebron #ASCO20 https://t.co/QjVvfdVanN,2020-05-31
1267166090175471617,https://twitter.com/marklewismd/status/1267166090175471617,marklewismd,".@michael_overman of @MDAndersonNews explains the mechanism of mismatch repair deficiency

I am pinning this slide for future explanations to patients of how MSI-H/dMMR yields new therapeutic opportunities

#crcsm
#ASCO20 https://t.co/6YcNpbFy4b",2020-05-31
1267166056340172800,https://twitter.com/DrYukselUrun/status/1267166056340172800,DrYukselUrun,"Impressive KM curves in KN trial!

@OncoAlert #ASCO20 @ASCO https://t.co/LlBQ7WG3lW",2020-05-31
1267166044818374667,https://twitter.com/Transplant_Doc/status/1267166044818374667,Transplant_Doc,An insightful summary of the ENDURANCE trial for NDMM by @BerdejaJesus that included a slide on lower cost of VRd at #ASCO20 #myeloma #mmsm https://t.co/4njfpWTVfM,2020-05-31
1267166031166033922,https://twitter.com/ChristinaUwins/status/1267166031166033922,ChristinaUwins,"💜#goASCO20 💜 promote Gynaecological Oncology Presentation
@ASCO #ASCO20 https://t.co/YtH39kryds",2020-05-31
1267165947741298689,https://twitter.com/maryam_lustberg/status/1267165947741298689,maryam_lustberg,#ASCO20 Doing what we do - but Better- Quality Improvement Highlights       Stewart Fleishman MD https://t.co/GoBEH8Oosz,2020-05-31
1267165926736252929,https://twitter.com/davisa20/status/1267165926736252929,davisa20,"3:55 pm on Sunday of the @ASCO Annual Meeting is one of my favorite moments of each year.  The excitement, enthusiasm and controlled chaos of 40,000+ gathered to conquer cancer never fails to inspire.  This year lets keep that energy going and donate to @ConquerCancerFd. #ASCO20 https://t.co/ENj63isT7n",2020-05-31
1267165922906836996,https://twitter.com/rsm2800/status/1267165922906836996,rsm2800,"Overman (LBA4):  MMR and MSI testing (for this study, PCR and IHC used) #ASCO20 https://t.co/WiMwBZVEIN",2020-05-31
1267165866682179584,https://twitter.com/OncLive/status/1267165866682179584,OncLive,Cabozantinib Plus Atezolizumab Shows Promise in mCRPC @neerajaiims @huntsmancancer @ASCO #ASCO20 #pcsm https://t.co/Y09mWwyfnt,2020-05-31
1267165755709276161,https://twitter.com/Prof_Nick_James/status/1267165755709276161,Prof_Nick_James,It’s the weekend. The sun is shining. Your family needs to see you. Go outside with them and stream whatever you need in work time. #ASCO2020 https://t.co/f8RERAwhxH,2020-05-31
1267165755327512578,https://twitter.com/teamoncology/status/1267165755327512578,teamoncology,Performing a palliative surgery to de novo inflammatory metastatic breast cancer is a complex topic. Those who have uncontrolled IBC is a major QOL issue. #ASCO20 #bcsm,2020-05-31
1267165691498704897,https://twitter.com/Tarek_Assi1986/status/1267165691498704897,Tarek_Assi1986,Pembrolizumab should be the new standard of care in the first line setting of MSI-H colorectal cancer in comparison to standard chemotherapy #ASCO20 #ASCO2020 https://t.co/qK2ff39pLt,2020-05-31
1267165683340713984,https://twitter.com/E_de_Azambuja/status/1267165683340713984,E_de_Azambuja,This survey will indeed help us understanding multidisciplinary tumor boards worldwide... it takes less than 10 min and you can make a difference for #breastcancer #patients #bcsm @MarianaBrandao0 @asofiacferreira @RitaSaudeConde @weoncologists @JulesBordet @OncoAlert #ASCO20 https://t.co/QCaDuPfnT3,2020-05-31
1267165655477841920,https://twitter.com/ninashah33/status/1267165655477841920,ninashah33,ENDURANCE ASSURANCE: VRD is still SOC per these results.  I guess my main question is what’s worse: cardiopulm AEs or neuropathy? This is why QOL analyses  so important!!! Also we need RW dosing data: I use weekly dosing for V &amp; K Congrats @myelomaMD &amp; @BerdejaJesus #mmsm #ASCO20 https://t.co/mLhogjrvyg,2020-05-31
1267165651623383040,https://twitter.com/ligia_traldi/status/1267165651623383040,ligia_traldi,Wow. #ASCO20 https://t.co/Rjayj95EvM,2020-05-31
1267165619968933889,https://twitter.com/ChristinaUwins/status/1267165619968933889,ChristinaUwins,"💜#goASCO20 💜 promote Gynaecological Oncology Presentation
@ASCO #ASCO20 https://t.co/jmbuJWzsN5",2020-05-31
1267165528352686080,https://twitter.com/ramyathota1/status/1267165528352686080,ramyathota1,"KN177 practice changing study, new standard of care for first line MSI -H mCRC. Improved PFS, OS, ORR and fewer side effects @ASCO #asco20 #crcsm https://t.co/BWyYB2GDtf",2020-05-31
1267165527279120385,https://twitter.com/ryanhuey/status/1267165527279120385,ryanhuey,KEYNOTE-177 - Overall Survival is... waiting... still waiting... still... #ASCO20 https://t.co/tyMyAJemFm,2020-05-31
1267165484501344258,https://twitter.com/ChristinaUwins/status/1267165484501344258,ChristinaUwins,"💜#goASCO20 💜 promote Gynaecological Oncology Presentation
@ASCO #ASCO20 https://t.co/wz3XEcnCO3",2020-05-31
1267165415433744385,https://twitter.com/ChristinaUwins/status/1267165415433744385,ChristinaUwins,"💜#goASCO20 💜 promote Gynaecological Oncology Presentation
@ASCO #ASCO20 https://t.co/h2y7GeNydt",2020-05-31
1267165407770804224,https://twitter.com/ahmadalhader/status/1267165407770804224,ahmadalhader,"KN-177 studying 1st line pembro vs chemo in MSI-H colorectal ca, showing impressive results, very convincing PFS benefit with a plateau. The disturbing part are the events in the first 4 months or so (primary resistance to anti-PD1)

Pembro should be the new 1st line SOC

#ASCO20 https://t.co/lngd2zaGyy",2020-05-31
1267165405694623745,https://twitter.com/NimaSharifiMD/status/1267165405694623745,NimaSharifiMD,Pembrolizumab vs chemo for MSI+ metastatic colorectal cancer. Wow! Just look at those KM curves! #ASCO20 https://t.co/Tgevfzxv8O,2020-05-31
1267165386518208512,https://twitter.com/CarlosHTonco/status/1267165386518208512,CarlosHTonco,It’s time for IO in first line colon treatment! #ASCO20 https://t.co/YxBTnjOnGw,2020-05-31
1267165383519338498,https://twitter.com/jamienholloway/status/1267165383519338498,jamienholloway,KEYNOTE-177: chemo v. Pembro for MSI-h/dMMR CRC. Phase 3 data. PFS 16.5 mos in pembro v. 8.2 mos w/chemo-- HR 0.60. Meets primary endpoint #1 #ASCO20 https://t.co/BvlzPbxpJm,2020-05-31
1267165381724078082,https://twitter.com/DrEstfan/status/1267165381724078082,DrEstfan,"KEYNOTE-177 1st line pembro vs chemo in MSI-H #CRCSM. 
Two words: Damn!
Okay that’s one word but, Damn!
Now we need a drug that converts all mCRC To MSI-H. 
Impressive DFS, DOR, and will await final OS results (crossover did occur). Any role for combo? #ASCO20 #CleClinicCancer https://t.co/cuYTbdBLMt",2020-05-31
1267165363495743488,https://twitter.com/KidneyCancer/status/1267165363495743488,KidneyCancer,"Between the #ASCO20 Plenary and #GUcancer sessions, visit the KCA's virtual exhibit and connect with us to learn more about our dedicated research symposiums, grant program, and resources for people impacted by #kidneycancer. https://t.co/834MJ1PTIR",2020-05-31
1267165333783117826,https://twitter.com/marklewismd/status/1267165333783117826,marklewismd,"The new SOC for 1st-line management of MSI-H mCRC has arrived

#crcsm
#ASCO20 https://t.co/7HNAyW0obH",2020-05-31
1267165317350002690,https://twitter.com/rsm2800/status/1267165317350002690,rsm2800,"Andre (LBA4):  ""Pembro should be new 1st line Rx for MSI-H metastatic colorectal cancer patients"" (but remember that's only ~5 of all mCRC pts) #ASCO20",2020-05-31
1267165288300150789,https://twitter.com/ChristinaUwins/status/1267165288300150789,ChristinaUwins,"💜#goASCO20 💜 promote Gynaecological Oncology Presentation
@ASCO #ASCO20 https://t.co/1Lk42DdJV0",2020-05-31
1267165268830117889,https://twitter.com/KatsuakiMaehara/status/1267165268830117889,KatsuakiMaehara,"It's an impressive result.

Congratulations KN-177 trial members！

Well deserved all of you.

@ASCO
#ASCO20
#OncoAlert https://t.co/xCWZ9mZjXG",2020-05-31
1267165227679993857,https://twitter.com/SilasInman/status/1267165227679993857,SilasInman,Nice PFS and safety data for frontline pembrolizumab versus chemo for MSI-high or MMR deficient CRC. New standard of care https://t.co/hRDDDz8ByU #ASCO20,2020-05-31
1267165225096282113,https://twitter.com/UCCancerCenter/status/1267165225096282113,UCCancerCenter,Highlights in genitourinary cancer #ASCO20: @UCCancerCenter expert Dr. @WalterStadler5 and colleagues optimize #nivolumab + #ipilimumab treatment for advanced renal cell carcinoma. Presented by Dr. McKay: https://t.co/BjA6CDeMiS https://t.co/8Z5J11szeF,2020-05-31
1267165215571017728,https://twitter.com/urotoday/status/1267165215571017728,urotoday,A phase Ib trial of neoadjuvant/adjuvant Durvalumab +/- Tremelimumab in locally advanced renal cell carcinoma. Presented by @MosheOrnsteinMD @ClevelandClinic. #ASCO20 written coverage by @TheRealJasonZhu @LevineCancer on UroToday &gt; https://t.co/mY75d2npEF @ASCO https://t.co/VelnyfNAHK,2020-05-31
1267165206528000000,https://twitter.com/MikeCusnir/status/1267165206528000000,MikeCusnir,Amazing data in #crc presented during #asco20. Also 11% complete response and 83% patients keeping response at 2 yrs. I’m concerned that only 59% of the patients were able to crossover to immunotherapy. Agree that pembrolizumab is the new standard of care for front line colon ca https://t.co/pVU4uiggnQ,2020-05-31
1267165192896614406,https://twitter.com/OncologistTom/status/1267165192896614406,OncologistTom,"KEYNOTE-177✅: No doubt, #Pembrolizumab SOC in patients with MSI-H mCRC #ASCO20 #asco https://t.co/wuQx74tzax",2020-05-31
1267165156653568002,https://twitter.com/CathyEngMD/status/1267165156653568002,CathyEngMD,"Pembro 1st line MSI-H for met #colrectal #cancer. RR= 44% vs 33%, median duration of response NR, superior PFS. 36% crossover to Pembro. OS pending. #newSOC.  @OncoAlert @Merck @VUMC_Cancer #ASCO2020 #plenarysession @ASCO @FightCRC @CCAlliance @COLONTOWN1 #Immunotherapy #crcsm https://t.co/3KmQDsdWk0",2020-05-31
1267165146511785985,https://twitter.com/rschilsky/status/1267165146511785985,rschilsky,"#ASCO18 Throwback: Inspired by research presented in the plenary, attendees rush to #ConquerCancer donor lounge to fund more. #ASCO20: Different Meeting. Same Mission. Support @ASCOPres $1M challenge. TEXT ASCO to 41444 or visit https://t.co/uQZILF36O2. #COVID19",2020-05-31
1267165127046057986,https://twitter.com/vini_carrera/status/1267165127046057986,vini_carrera,"Would you consider choosing therapy on nmCRPC  based on toxicity profile? Data presented at #ASCO20 showed OS benefit in PROSPER, SPARTAN and ARAMIS.                  What is your preference? @fsabino_onco @DiogoAssed @FabioSchutz78 @SoaresAndrey @igorpmorbeck @asasse",2020-05-31
1267165106779103233,https://twitter.com/ryanhuey/status/1267165106779103233,ryanhuey,KEYNOTE-177: Only 59% of patients in chemo arm received subsequent immunotherapy. Which seems problematic. #ASCO20,2020-05-31
1267165066308325379,https://twitter.com/VivekSubbiah/status/1267165066308325379,VivekSubbiah,Pembrolizumab VS  chemo in #MSI-H metastatic  PFS 16.5 to 8.2 months @ASCO #ASCO20 https://t.co/x5hYUhn8Xh,2020-05-31
1267165064106311683,https://twitter.com/ChristinaUwins/status/1267165064106311683,ChristinaUwins,"💜#goASCO20 💜 promote Gynaecological Oncology Presentation
@ASCO #ASCO20 https://t.co/VE05dKyQA7",2020-05-31
1267164986650001409,https://twitter.com/Transplant_Doc/status/1267164986650001409,Transplant_Doc,Conclusions from an excellent presentation on ENDURANCE trial for NDMM at the plenary session of #ASCO20 by @myelomaMD #myeloma #mmsm @VincentRK @nsc_natalie @Myeloma_Doc @SagarLonialMD https://t.co/h28fmagzOn,2020-05-31
1267164967729614851,https://twitter.com/ChristinaUwins/status/1267164967729614851,ChristinaUwins,"💜#goASCO20 💜 promote Gynaecological Oncology Presentation
@ASCO #ASCO20 https://t.co/jAJQEBTdXL",2020-05-31
1267164902696693760,https://twitter.com/SurbhiSidanaMD/status/1267164902696693760,SurbhiSidanaMD,"1/ ENDURANCE trial #ASCO20 by @myelomaMD, discussion @BerdejaJesus 

RCT of KRD vs VRD in non-high risk NDMM, t(4;14) patients were allowed. 

Patients without intent for upfront ASCT. 

Plan for 36 weeks of induction before Len maintenance.

&gt; 1000 patients randomized  #mmsm",2020-05-31
1267164899429486594,https://twitter.com/ChristinaUwins/status/1267164899429486594,ChristinaUwins,"💜#goASCO20 💜 promote Gynaecological Oncology Presentation
@ASCO #ASCO20 https://t.co/0vI4xKfk0d",2020-05-31
1267164888457191426,https://twitter.com/DrSukeshiArora/status/1267164888457191426,DrSukeshiArora,Great to see flattening of the tail on survival curve and less toxicity! #crcsm #ASCO20 https://t.co/DLPX73FKzn,2020-05-31
1267164845750747139,https://twitter.com/womenofteal/status/1267164845750747139,womenofteal,"#6029 Survival differences by race after minimally invasive versus open radical hysterectomy for #cervicalcancer (CC) 
#ASCO20 #gyncsm #disparity
Black women w/ CC have worse survival than white women
Black women w/cervical cancer have less MIS surgery. 
1/2",2020-05-31
1267164829548187650,https://twitter.com/ChristinaUwins/status/1267164829548187650,ChristinaUwins,"💜#goASCO20 💜 promote Gynaecological Oncology Presentation
@ASCO #ASCO20 https://t.co/kuDjuTAkCH",2020-05-31
1267164816298455050,https://twitter.com/stage4kelly/status/1267164816298455050,stage4kelly,clarifying that in E2108 it's 40% of people with #denovo #MBC that are alive at 5 yrs. #bcsm #ASCO20 @OncoAlert https://t.co/MDsyGhk8Vm,2020-05-31
1267164803287654401,https://twitter.com/rsm2800/status/1267164803287654401,rsm2800,Andre (LBA4):  Note this study is still blinded for OS endpoint #ASCO20,2020-05-31
1267164759117443075,https://twitter.com/_B_I_O_T_E_C_H_/status/1267164759117443075,_B_I_O_T_E_C_H_,"$GILD Barclays #ASCO20 While Impressed by $ALLO Allogene’s Initial Readout, Our KOL Still Favors Gilead’s (cont) https://t.co/nARO7y7vHX",2020-05-31
1267164756118507522,https://twitter.com/ChristinaUwins/status/1267164756118507522,ChristinaUwins,"💜#goASCO20 💜 promote Gynaecological Oncology Presentation
@ASCO #ASCO20 https://t.co/3oPNAq8mcq",2020-05-31
1267164752037502983,https://twitter.com/HTawbi_MD/status/1267164752037502983,HTawbi_MD,"Ph3 atezo+cobi+vem (TRILOGY) with improvement in PFS and DOR over cobi+vem alone, an important knowledge gap is activity of triplet in 1st line for pts with unirradiated #BrainMets-  this study (TRICOTEL) will generate critical info and provide background to S2000 #asco20 @SWOG https://t.co/GRgLuGEeKj",2020-05-31
1267164704687915008,https://twitter.com/ChristinaUwins/status/1267164704687915008,ChristinaUwins,"💜#goASCO20 💜 promote Gynaecological Oncology Presentation
@ASCO #ASCO20 https://t.co/LzXTc1UiTq",2020-05-31
1267164480665989120,https://twitter.com/ChristinaUwins/status/1267164480665989120,ChristinaUwins,"💜#goASCO20 💜 promote Gynaecological Oncology Presentation
@ASCO #ASCO20 https://t.co/iQ7ftOO7mw",2020-05-31
1267164478086549505,https://twitter.com/ShoMidha/status/1267164478086549505,ShoMidha,"Not entirely surprising results from ENDURANCE by @myelomaMD of no diff in PFS/OS between VRd &amp; Krd in NDMM (excl high-risk phenotypes). Happy to see inclusion of &gt;10% black participants given ⬆️ risk, but why only 26-28% autoHSCT and higher rates of CV, pulm &amp; renal AE? #ASCO20 https://t.co/lxwsKSpwDP",2020-05-31
1267164459593859074,https://twitter.com/IMFmyeloma/status/1267164459593859074,IMFmyeloma,"Were it not for the coronavirus pandemic, thousands of cancer researchers would have been descending on Chicago this weekend for the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO). Instead, the meeting has moved online. #ASCO20 
https://t.co/NRotgz8jLg https://t.co/quCMEacSvP",2020-05-31
1267164456431366146,https://twitter.com/aakonc/status/1267164456431366146,aakonc,#ASCO20 LBA4 48% 2y PFS is super impressive. But worried about seeming lack of benefit for  RAS mutant MSI-H patients -  do these findings not apply to that subgroup? #crcsm,2020-05-31
1267164447514263553,https://twitter.com/TGeorgeMD/status/1267164447514263553,TGeorgeMD,That study is ongoing: FOLFOX+bev+/- Atezo.  COMMIT Trial. @NRGonc @SWOG #ASCO20 https://t.co/MHlLvt9j2B https://t.co/VM4eO0zD7C,2020-05-31
1267164317104984066,https://twitter.com/nycdoc29/status/1267164317104984066,nycdoc29,Value? Bortezomib is now generic and several hundred dollars less than Velcade and Kyprolis #mmsm #ASCO20 https://t.co/yZAx3jRJCG,2020-05-31
1267164311731859458,https://twitter.com/marklewismd/status/1267164311731859458,marklewismd,"Especially in the IO era, ORR may get exposed as an inadequate surrogate for PFS

See below from KEYNOTE-177

#crcsm
#ASCO20 https://t.co/KXy26ivqCp",2020-05-31
1267164191821041667,https://twitter.com/ChristinaUwins/status/1267164191821041667,ChristinaUwins,"💜#goASCO20 💜 promote Gynaecological Oncology Presentation
@ASCO #ASCO20 https://t.co/GJvYHSf37Z",2020-05-31
1267164145784426496,https://twitter.com/fcicca/status/1267164145784426496,fcicca,"#ASCOplenary on phase III clinical trial KEYNOTE: progression free survival of patients with advanced MSI colorectal cancer doubled with Pembrolizumab. Better patient stratification needed: for more on this, watch this space soon! @ASCO #asco2020 #immunotherapy #crc",2020-05-31
1267164125798584323,https://twitter.com/COlazagasti/status/1267164125798584323,COlazagasti,Look at those curves! Pembro vs chemo in MSI-H metastatic CRC #ASCO20 https://t.co/ZW2L5VmhN3,2020-05-31
1267164125521760261,https://twitter.com/ChristinaUwins/status/1267164125521760261,ChristinaUwins,"💜#goASCO20 💜 promote Gynaecological Oncology Presentation
@ASCO #ASCO20 https://t.co/Cgvmkjx1k1",2020-05-31
1267164075630505990,https://twitter.com/ChristinaUwins/status/1267164075630505990,ChristinaUwins,"💜#goASCO20 💜 promote Gynaecological Oncology Presentation
@ASCO #ASCO20 https://t.co/oBdSV8Loaz",2020-05-31
1267164073952763907,https://twitter.com/jillfeldman4/status/1267164073952763907,jillfeldman4,"Yes, All trials should include the 3rd ❌! OS is not the only meaningful endpoint to patients. #QOL matters. Solomon said in 12 yrs a slave, ""I don't want to survive, I want to LIVE!"" We need to work towards not trading QOL for LOL when dev new Rx #LCSM #BCSM #ASCO20 #OncoAlert https://t.co/MrpA4hNstm",2020-05-31
1267164070517649408,https://twitter.com/ryanhuey/status/1267164070517649408,ryanhuey,Pembro v chemo in MSI-H metastatic #crcsm PFS 16.5 to 8.2 months. Notable crossing of curves seen in other tumor types w/ IO v chemo. #ASCO20 https://t.co/I1OeqJkTYN,2020-05-31
1267164020437659660,https://twitter.com/renata_bonadio/status/1267164020437659660,renata_bonadio,"Our poster at #ASCO20.
Study of biomarkers in anal cancer treated with chemoradiation.
Congrats, Dr. Camila Venchiarutti!

@ICESP_ @paulohoff10 @BraghiroliIgnez @RachelRiechelm2 https://t.co/fKTEv9XIgC",2020-05-31
1267163976107986946,https://twitter.com/rsm2800/status/1267163976107986946,rsm2800,"Andre (LBA4):  PFS HR=0.6, p=0.0002. Benefit for Pembrolizumab seen in all subgroups except KRAS/NRAS mutant #ASCO20 https://t.co/SpiU63SSGB",2020-05-31
1267163963701317638,https://twitter.com/ChristinaUwins/status/1267163963701317638,ChristinaUwins,"💜#goASCO20 💜 promote Gynaecological Oncology Presentation
@ASCO #ASCO20 https://t.co/8AJY8X2sHK",2020-05-31
1267163887029420037,https://twitter.com/ChristinaUwins/status/1267163887029420037,ChristinaUwins,"💜#goASCO20 💜 promote Gynaecological Oncology Presentation
@ASCO #ASCO20 https://t.co/McoT6cK2Dj",2020-05-31
1267163751368855558,https://twitter.com/elena_elez/status/1267163751368855558,elena_elez,And here it is! @VHIO #ASCO20 @vallhebron https://t.co/sBPWdPfAXN,2020-05-31
1267163728690049026,https://twitter.com/VPrasadMDMPH/status/1267163728690049026,VPrasadMDMPH,"Does someone know why did not attempt pembro + FOLFOX (ala lung), might have helped this part of the curve?

is there a p1, i missed?

#asco20 #asco2020 https://t.co/ygP4SvUogY",2020-05-31
1267163583487623168,https://twitter.com/BenWestphalen/status/1267163583487623168,BenWestphalen,"LBA4 @ASCO #ASCO20 plenary session: 
Thierry Andre presents the results of KEYNOTE-177 (Pembro vs. CTX) in MSI/dMMR #crcsm : Doubling of PFS w. Prembro (1️⃣6️⃣.5️⃣ vs  8️⃣.5️⃣ months - HR 0.60). Median DOR was not reached (‼️) in the Pembro group (vs. 10.6 months). 
@OncoAlert 🚨 https://t.co/9G22kr7fvG",2020-05-31
1267163486229913600,https://twitter.com/dronkoloji/status/1267163486229913600,dronkoloji,Yeni normalde Onkoloji Kongresi #ASCO2020 https://t.co/oXrOpFvpGi,2020-05-31
1267163439522287619,https://twitter.com/ACCCBuzz/status/1267163439522287619,ACCCBuzz,90% of respondents to a survey published at #ASCO20 reported no formal #healthliteracy assessment at their programs. Learn more about barriers to optimal #NSCLC care: https://t.co/P8Z23KbNPT https://t.co/vIItAJ91pS,2020-05-31
1267163244684365828,https://twitter.com/PauloBergerot/status/1267163244684365828,PauloBergerot,"Outcomes of pts w mRCC treated with 1L IO who do not meet eligibility criteria for Clin trials
➡️ substantial number of pts
➡️ inferior outcomes
#ASCO20 @ASCO 
@ShaanDudani @NazliDizman @DrDanielHeng @montypal @ZiadBakouny @DrVaishampayan @DrChoueiri 
👉🏼https://t.co/k4pbbm78aC https://t.co/rWm26TlQSV",2020-05-31
1267163067391115267,https://twitter.com/sarahhalford7/status/1267163067391115267,sarahhalford7,Good news for treatment of Urothelial Cancer from #ASCO2020 Plenary! JAVELIN Bladder 100 trial - maintenance avelumab significantly increases overall survival in all patients - trial led by ⁦@tompowles1 ⁦@NHSBartsHealth⁩ ⁦@QMUL - new 1st line standard of care #ASCO20 https://t.co/Oznh4nnyG4,2020-05-31
1267163018355527688,https://twitter.com/pashtoonkasi/status/1267163018355527688,pashtoonkasi,#ASCO20 #HappeningNow #ASCOPlenary the hall is virtually overflowing. 👏 https://t.co/LgfCrynFFn https://t.co/L43sHff0o4,2020-05-31
1267162948998438912,https://twitter.com/yzafar/status/1267162948998438912,yzafar,Why is OS a primary endpoint in a cross-over trial? #ASCO20  #CRCSM https://t.co/0cQGvC15xK,2020-05-31
1267162944221204482,https://twitter.com/agrothey/status/1267162944221204482,agrothey,"KN177 indisputably: first line IO is SOC in MSI-H mCRC. PFS very impressive. Great news for pts! But 2.5x more PD as best response, brief crossing of PFS curves. Perhaps combo with chemo or CTLA-4 mAb even better? #OncoAlert #ASCO20 #ASCOTotalHealth @TotalHealthConf @west_cancer",2020-05-31
1267162861190643721,https://twitter.com/n8pennell/status/1267162861190643721,n8pennell,Rufus is anxiously awaiting ADAURA plenary presentation at #ASCO20 He made me promise to wake him #LCSM https://t.co/1BTvlO27G8,2020-05-31
1267162709340164096,https://twitter.com/BrasilOncologia/status/1267162709340164096,BrasilOncologia,"A partir das 19h, oncologistas abordam #mutações raras, novas drogas e novo potencial agnóstico, #biomarcadores e medicina de precisão, #melanoma, #sarcoma e câncer geniturinário no #webinar de hoje de cobertura da #ASCO20. Cadastre-se para participar: https://t.co/Aypowblvie https://t.co/tatyt9BBDq",2020-05-31
1267162695150731265,https://twitter.com/drjoaonunes/status/1267162695150731265,drjoaonunes,"Congratulation @Pittsil for study presentation at #asco20 . proud to have you as a mentor in my PhD course
https://t.co/YL5SpA4d52
@CettroOncologia",2020-05-31
1267162685965242370,https://twitter.com/MoffittNews/status/1267162685965242370,MoffittNews,#ASCO20 coverage: Dr. Damon Reed (@MoffittNews) on a new phase I/II clinical trial for Ewing Sarcoma patients treated with seclidemstat. View abstract: https://t.co/XkG5rLnZ1l https://t.co/nfuNs7odYR,2020-05-31
1267162537092620289,https://twitter.com/DalsassoEliza/status/1267162537092620289,DalsassoEliza,"#ASCO2020 #plenarysession 2 trabalhos muito interessantes: Javelin com um possível novo padrão para tto de Ca de bexiga metastatico com SG 21 meses para quem recebeu avalumabe de manutenção, sendo que 52% dos pctes do braço controle receberam IO na 2a linha https://t.co/lcpIZQhM2O",2020-05-31
1267162516079153152,https://twitter.com/Adriana42169771/status/1267162516079153152,Adriana42169771,"Advanced/metastatic biliary tumors remain treated with gem / cis in the first line and FOLFOX as a better option than FOLFIRI for the second line. Perhaps FGFR inhibitors can be used, but without benefit in anti-angiogenic or anti-MET. #ASCO2020",2020-05-31
1267162390661083136,https://twitter.com/inas_md/status/1267162390661083136,inas_md,"Love the memes =D 
#asco20 https://t.co/lowPTS7wj0",2020-05-31
1267162386743599105,https://twitter.com/rsm2800/status/1267162386743599105,rsm2800,Andre (LBA4):  Colorectal cancer is 2 different diseases #ASCO20 https://t.co/7zsmoe45j3,2020-05-31
1267162353201745920,https://twitter.com/Aydah_AlAwadhi/status/1267162353201745920,Aydah_AlAwadhi,Long-awaited data fron ECOG-ACRIN E2108 by Dr.Khan: no OS or improvrd QoL advantage with locoregional(LR) therapy for de novo mBC vs systemic Tx only! LR Tx to be considered for palliation and ?role in de novo oligometastaic disease (ongoing studies) #bcsm #asco20 https://t.co/PVogJjw6Bf,2020-05-31
1267162263162511360,https://twitter.com/Dr_Ivanoncologo/status/1267162263162511360,Dr_Ivanoncologo,#Cáncer | Se necesitan pruebas genómicas universales 🧬para ganar la guerra contra el cáncer #ASCO20 https://t.co/d7hGyHOjDI,2020-05-31
1267162262869102592,https://twitter.com/kevincmillerMD/status/1267162262869102592,kevincmillerMD,"Toxicity, OS and PFS from the E1A11 trial presented by @myelomaMD and @eaonc group. ~1/4 received transplant in the VRd and KRd arms (designed for delayed, not upfront ASCT). Non-hematologic toxicity was significantly greater with KRd. Overlapping PFS and OS. #mmsm #ASCO2020 https://t.co/KfJDaVqZfn",2020-05-31
1267162251070443521,https://twitter.com/elena_elez/status/1267162251070443521,elena_elez,Here we go!!! @VHIO #ASCO20 https://t.co/MvWz01PctW,2020-05-31
1267162211568570368,https://twitter.com/CliffordHudis/status/1267162211568570368,CliffordHudis,Of course this picture is how our servers are feeling at the moment! #asco20 https://t.co/4A79bFsltK,2020-05-31
1267162206401167366,https://twitter.com/FernandoOnco/status/1267162206401167366,FernandoOnco,Waiting @VPrasadMDMPH considerations about KN-177 #ASCO20 https://t.co/P5Z07MO3r5,2020-05-31
1267162205365157888,https://twitter.com/maryam_lustberg/status/1267162205365157888,maryam_lustberg,#survonc #ASCO20 cc @DrN_CancerPCP @subatomicdoc @rayychan @jjonestoronto @NicoleKuderer https://t.co/OdMXpcty2h,2020-05-31
1267162164994826241,https://twitter.com/marklewismd/status/1267162164994826241,marklewismd,"After ~15 years of an increasingly stale marriage to fluoropyrimidines and the ice queen oxaliplatin, GI oncologists have a wandering eye for the new hotness of IO in mCRC after KEYNOTE-177

#crcsm
#ASCO20 https://t.co/CAzDD5NIM3",2020-05-31
1267162154052079616,https://twitter.com/drsomedeb/status/1267162154052079616,drsomedeb,"KRD - NO better #OS or #PFS than VRD for #NDMM, more ≥ grade 3 cardio-pulmonary- renal toxicity, VRD remains SOC upfront w/wo #monoclonalAb?? Another great plenary session! @ASCO @myelomaMD @rajshekharucms @VincentRK @kyawzinthein86 https://t.co/yi9tiKNuDt",2020-05-31
1267162145168523268,https://twitter.com/nccnunes/status/1267162145168523268,nccnunes,#ASCO2020 https://t.co/ynK3wDL38a,2020-05-31
1267162054114320396,https://twitter.com/OncologyTimes/status/1267162054114320396,OncologyTimes,#ASCO20 Update: Pembrolizumab as Firstline Therapy for Advanced #ColorectalCancer With Mismatch Repair Deficiency https://t.co/7ZRCK2GbjK #cancer #medtwitter via @HopSaintAntoine https://t.co/kiaNn309nf,2020-05-31
1267162047877386245,https://twitter.com/rsm2800/status/1267162047877386245,rsm2800,Andre (LBA4): https://t.co/lW8YdsWNDq #ASCO20,2020-05-31
1267162026213879808,https://twitter.com/ryanhuey/status/1267162026213879808,ryanhuey,"KEYNOTE-177 study, here we go #ASCO20 https://t.co/dxVlDekfep",2020-05-31
1267162024422801411,https://twitter.com/ConquerCancerFd/status/1267162024422801411,ConquerCancerFd,"#ASCO18 Throwback: Inspired by research presented in the plenary, attendees rush to #ConquerCancer donor lounge to fund more. #ASCO20: Different Meeting. Same Mission. Support @ASCOPres $1M challenge. TEXT ASCO to 41444 or visit https://t.co/QpJOIwpkPM. #COVID19 https://t.co/vGbvwWGDLM",2020-05-31
1267162016730365952,https://twitter.com/stage4kelly/status/1267162016730365952,stage4kelly,we can always count on @drdonsdizon to deliver information with flair! #gyncsm #ASCO20 @OncoAlert https://t.co/aihXjtL1YX,2020-05-31
1267161948585590784,https://twitter.com/aakonc/status/1267161948585590784,aakonc,Ok here comes LBA4! #ASCO20,2020-05-31
1267161873641865221,https://twitter.com/drkamzaki/status/1267161873641865221,drkamzaki,"we close #BladderCancerAwarenessMonth with a positive study presented at #ASCO20 showing the longest overall survival benefit ever documented for an advanced urothelial cancer trial, thank you to @GSTTnhs patients who were involved @DebEnting @TOUR_KCL https://t.co/jxIjUIaidG",2020-05-31
1267161868487077888,https://twitter.com/pashtoonkasi/status/1267161868487077888,pashtoonkasi,"👏👏👏 🆕#HappeningNow #ASCO20 📺#ASCOPlenary 🔔🔔🔔👇🏼#Immunotherapy changing standard of care❗️#KEYNOTE177 MSI⬆️. Happy for our patients.☺️

#OncoAlert @ASCO @ASCO_pubs @ASCOPost #ASCOTotalHealth #ASCO2020 #CRCSM https://t.co/4qMF2VSNuH https://t.co/tVfXgAOAYW",2020-05-31
1267161851902734344,https://twitter.com/FernandoOnco/status/1267161851902734344,FernandoOnco,Waiting ADAURA 🤔 #ASCO20,2020-05-31
1267161847280566273,https://twitter.com/rsm2800/status/1267161847280566273,rsm2800,"Berdeja (LBA3):  Cost of VRd vs. KRd in ENDURANCE. Decision to use KRd may best be made on basis of pre-existing organ dysfunction (e.g., neuropathy)  #ASCO20 https://t.co/ME3AeUGAST",2020-05-31
1267161830163509248,https://twitter.com/RahulBanerjeeMD/status/1267161830163509248,RahulBanerjeeMD,"Excellent discussion of VRd versus KRd at #ASCO20 - PROs measuring QOL had already made an appearance, but really glad that @BerdejaJesus brought up the question of cost as well! Also a very relevant question for our patients and healthcare system. #mmsm https://t.co/8pn5C4yTFE",2020-05-31
1267161814506364929,https://twitter.com/jvdoyle/status/1267161814506364929,jvdoyle,Discussing financial toxicity #ASCO20 https://t.co/QCGu2n4cdP,2020-05-31
1267161769958662148,https://twitter.com/DianaNrco/status/1267161769958662148,DianaNrco,About to start short rows while following #ASCO20 and I’m not sure whether I should go all the way first in the first or last row of the series. RCT trying each approach in one half? https://t.co/haSHxxYRW8,2020-05-31
1267161749775691776,https://twitter.com/tmprowell/status/1267161749775691776,tmprowell,"#ASCO20 #mmsm #E1A11 
#ENDURANCE trial comparing KRd vs VRd in pts w/ newly diagnosed std/intermediate risk #multiplemyeloma who deferred immediate SCT: KRd not superior to VRd. https://t.co/G6yopVE2tv",2020-05-31
1267161719245340673,https://twitter.com/CarlosHTonco/status/1267161719245340673,CarlosHTonco,The 3rd one! MM. #ASCO2020 https://t.co/dnakEf4umk,2020-05-31
1267161718268059648,https://twitter.com/NagiSaghir/status/1267161718268059648,NagiSaghir,"Although we hoped for positive resuits, @ECOG E2108 by Dr Seema Khan at #asco20 is another negative study for surgery in patients w metastatic #breastcancer. Systemic therapy is improving survival and this is where the money is &amp; where efforts &amp; money should be invested @ASCO https://t.co/aaLoWTEdKG",2020-05-31
1267161709858500611,https://twitter.com/Jodischeck/status/1267161709858500611,Jodischeck,Watching the #ASCO20 plenary session from the beach.  Can’t do this at McCormick Center #chicago. #privacyscreenguard #yesimwatching #SocialDistancingatthebeach https://t.co/TmpNleSFTs,2020-05-31
1267161599300628480,https://twitter.com/crisonco/status/1267161599300628480,crisonco,"ECOG-#ACRIN 2108 Trial don't show benefit of overall #survival when #surgery of the primary de novo breast cancer was added to the sistemic treatment.
#ASCO2020 #breastcancer https://t.co/oFgxqjb3s1",2020-05-31
1267161589301555201,https://twitter.com/PatrickCMa1/status/1267161589301555201,PatrickCMa1,Much to be discussed in this ADAURA study.... Eager to see the Plenary data presentation and the eventual Discussion both on program and off program online. #ASCO2020 #LCSM https://t.co/SrkHycUJ0T,2020-05-31
1267161570125250561,https://twitter.com/womenofteal/status/1267161570125250561,womenofteal,"This poster peaked my interest - 
ctDNA from ascites as an alternative to tumor sampling for HRD (homologous recombination deficiency) testing in ovarian cancer (OC) #6066 
Copy number from Ascites  is possible to detect HRD. #ASCO20 #gyncsm 1/2 https://t.co/0f5bdwQ1IZ",2020-05-31
1267161442442231809,https://twitter.com/urotoday/status/1267161442442231809,urotoday,"Phase II study of Nivolumab and Ipilimumab for advanced rare #genitourinary cancers. Presentation by @BradMcG04 @DanaFarber. #ASCO20 written coverage by @zklaassen_md @GACancerCenter on UroToday &gt; https://t.co/AYSN1Z60vz @ASCO @harvardmed @sonpavde
@DrRanaMcKay @DrChoueiri https://t.co/ZER261ol5U",2020-05-31
1267161430526251010,https://twitter.com/PRIME_cme/status/1267161430526251010,PRIME_cme,#ASCO20 includes outcomes from PRIME’s study on Real-world Practice Patterns and Barriers to Quality Care in Acute Myeloid Leukemia (AML). Read More: https://t.co/8vQog4FTFF #AcuteMyeloidLeukemia #AML #cancercare,2020-05-31
1267161369188671488,https://twitter.com/SGO_org/status/1267161369188671488,SGO_org,"At #ASCO20 J. Liu presented @NRGonc research comparing olaparib and cediranib to platinum-based chemotherapy in recurrent #ovariancancer - there was no difference in progression free survival between the two arms #gyncsm #SGOatASCO
https://t.co/r6xOAAQ9OT",2020-05-31
1267161164988940294,https://twitter.com/rsm2800/status/1267161164988940294,rsm2800,"Sunshine and #ASCO20 plenary, quite a combo https://t.co/S3Vb53ZJJa",2020-05-31
1267161064963178499,https://twitter.com/Dr_Ivanoncologo/status/1267161064963178499,Dr_Ivanoncologo,#Cancer #ASCO2020 | Un resumen de los puntos importantes sobre #metástasis en #Cancerpulmon células no pequeñas. https://t.co/ZaMkiVGhkI,2020-05-31
1267161060383109121,https://twitter.com/PauloBergerot/status/1267161060383109121,PauloBergerot,"1st RCT w probiotic supplementation in mRCC pts receiving VEGF-TKIs
@NazliDizman @hsuperjo88 @montypal 
@cityofhope #ASCO20 @ASCO 
@OncoAlert 
👉🏼https://t.co/yGfpbCbtyh… https://t.co/LT6NAJznia",2020-05-31
1267160981530173440,https://twitter.com/PauloBergerot/status/1267160981530173440,PauloBergerot,"Genomic &amp; transcriptomic correlates of clin benefit IO &amp; TT in mRCC pts
Transcriptomic: MYC-targ agents &amp; epigenetic modifiers (KAT2A) could overcome IO resistance
@NickSalgia @NazliDizman @YungLyou @hsuperjo88 @montypal 
@cityofhope #ASCO20 @ASCO 
👉🏼https://t.co/nerl5obTpO… https://t.co/73I6nJRFll",2020-05-31
1267160865603756033,https://twitter.com/SondosZayedMD/status/1267160865603756033,SondosZayedMD,"The #DARS Phase III #RCT shows significantly improved MDADI, PSS-HN, and QoL scores favoring Dysphagia-Optimized IMRT to Standard IMRT. Could this be a new standard of care for CA of the oropharynx/hypopharynx?  
@ASCO #ASCO2020 https://t.co/kKKPOyUH9F",2020-05-31
1267160829071253504,https://twitter.com/fireflyann/status/1267160829071253504,fireflyann,"Getting ready for next presentation in Plenary Session #ASCO20 
Phase 3 KEYNOTE-177 study
 link to the abstract 
Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic #colorectalcancer 
#MSI #CRCSM #mCRC
https://t.co/bmn8s9db9Q https://t.co/qZJQQ2m3IO",2020-05-31
1267160772116983808,https://twitter.com/1stOncology/status/1267160772116983808,1stOncology,Breakdown of #ImmunoOncology Therapies Present at #ASCO20. Free whitepaper tool here https://t.co/9Y2gwOzLCQ #Cancerresearch #Precisionmedicine #Cancertreatment #Cancer #Bispecificantbodies #ImmuneCheckpointInhibitors #CancerVaccines #OncolyticVirotherapies #CARtherapies https://t.co/HB5uMd4Sxf,2020-05-31
1267160745134841856,https://twitter.com/DrLizBrem/status/1267160745134841856,DrLizBrem,Enjoying the plenary commentary by @BerdejaJesus. Agree that now the focus needs to shift to our high risk patients. #ASCO20 #myeloma #mmsm https://t.co/prLWZ9Tjlv,2020-05-31
1267160609335934976,https://twitter.com/maryam_lustberg/status/1267160609335934976,maryam_lustberg,#survonc #PRO #patientsfirst #ASCO20 https://t.co/FERrlNCfmY,2020-05-31
1267160416569954307,https://twitter.com/IBCResearch/status/1267160416569954307,IBCResearch,Good question @stage4kelly  We really need more studies in this area and adequately enroll #IBC &amp; #lobular patients as results for them may be different given tumor tissue growth pattern in those subtypes. #ASCO20 #BCSM https://t.co/OqYrRLOBqs,2020-05-31
1267160167352864779,https://twitter.com/MedscapeOnc/status/1267160167352864779,MedscapeOnc,Frontline pembrolizumab doubles PFS in patients with MSI-H/dMMR metastatic CRC in the KEYNOTE-177 study released at #ASCO20. https://t.co/REV2zCYSlv #ASCO2020 https://t.co/SoKu8BZFI1,2020-05-31
1267160080987951110,https://twitter.com/bdermanmd/status/1267160080987951110,bdermanmd,"For ENDURANCE: Rate of transplant was similar in each arm (~27-28%). But, 40% of KRd and 57% (!) of VRd did not complete induction! Yikes. Pts on VRd d/c'd due to AEs at almost 2x rate of KRd. Subgroup analysis suggests benefit for abnormal metaphase cytogenetics. #mmsm #asco20 https://t.co/sGzl7bak8l https://t.co/iIL8DSZyPb",2020-05-31
1267160005930823681,https://twitter.com/VivekSubbiah/status/1267160005930823681,VivekSubbiah,#ASCO20 @ASCO https://t.co/68SbbEPNVz,2020-05-31
1267159914415378433,https://twitter.com/MDedgeHemOnc/status/1267159914415378433,MDedgeHemOnc,First-line nivolumab plus platinum/etoposide proves effective in extensive-stage SCLC. https://t.co/PEESvHvmAB #ASCO20 #ASCO2020 #SCLC #lungcancer #onctwitter https://t.co/ACDQIBLYws,2020-05-31
1267159768822620165,https://twitter.com/RabiHannaMD/status/1267159768822620165,RabiHannaMD,"Targeted Tx Improves Outcomes in High-Risk Pediatric Cancers #ASCO2020  . 
8% of patients have a very high priority target; 14.8%, a high; 20.3%, moderate; 23.6%, intermediate; 4.4%, borderline; 2.5%, low; and 1%, very low; 15.4% had no actionable target. https://t.co/uMnDbKkhgD",2020-05-31
1267159673578426370,https://twitter.com/jamienholloway/status/1267159673578426370,jamienholloway,I missed the GYN session yesterday— was glad to see a quick summary of the highlights until I can watch the whole thing! Thanks @drdonsdizon! #asco20 https://t.co/AZFa1dijQS,2020-05-31
1267159501007998980,https://twitter.com/CarmonLior/status/1267159501007998980,CarmonLior,#Roche is using #ASCO2020 to revel promising phase II results targeting #TIGIT combined with #PDL1 in #NSCLC. An unclear point is a lack of efficacy in low PDL1 TPS (1-49%) pts. https://t.co/0s4bN2lvaq,2020-05-31
1267159405268697095,https://twitter.com/maryam_lustberg/status/1267159405268697095,maryam_lustberg,#survonc #ASCO20 great work by @kmustian @MJanelsins @iankleckner and group evaluating benefits of #yoga for #insomnia https://t.co/2CxKqRPerf,2020-05-31
1267159286980980736,https://twitter.com/drkamzaki/status/1267159286980980736,drkamzaki,"LBA1 discussion by @ERPlimackMD at #ASCO20 #plenarysession 

Phase III JAVELIN 100 showed maintenance avelumab after a response to platinum chemotherapy confers OS benefit as 1L Rx of advanced urothelial cancer #blcsm @OncoAlert https://t.co/9JbjtPuTpD",2020-05-31
1267159234980073472,https://twitter.com/MM_Hub/status/1267159234980073472,MM_Hub,"CONGRESS | #ASCO20 | In this plenary session, MM Hub SC member, @myelomaMD, @mayoclinic, discussed the results from the phase III ENDURANCE trial, evaluating KRd vs VRd for initial therapy of newly diagnosed multiple #myeloma. #mmsm https://t.co/tn41Htgfa0",2020-05-31
1267159186510667778,https://twitter.com/StephenVLiu/status/1267159186510667778,StephenVLiu,"#ASCO20 Abstract 9529: Increasingly relevant work by @n8pennell reviewing cost of NGS vs single gene testing. Better testing leads to better outcomes. And there are other ""costs"" to missing a driver in #NSCLC! #OncoMed #LCSM https://t.co/BDaaxaiEK3",2020-05-31
1267159083116724225,https://twitter.com/KatsuakiMaehara/status/1267159083116724225,KatsuakiMaehara,"This result is premature and should be observed 
in the long term.

At this point in time no change standard of care.

@ASCO
#ASCO20
#OncoAlert https://t.co/VwiB0bYx3Q",2020-05-31
1267159011176198152,https://twitter.com/coloncanada/status/1267159011176198152,coloncanada,"NIVO + low-dose IPI continued to show robust, durable clinical benefit and was well tolerated with no new safety signals identified with longer follow-up. NIVO + low-dose IPI may represent a new 1L for mCRC #ASCO20 #CRC #immunotherapy  https://t.co/F7NkVAHOsM",2020-05-31
1267159010882408448,https://twitter.com/stage4kelly/status/1267159010882408448,stage4kelly,and our friends and fellow #advocates in the #btsm #crcsm #melsm #mmsm #pcsm communities. Please add other cancer community hashtags! #ASCO20 @oncoalert https://t.co/tWVCHa4BnM,2020-05-31
1267158917617979393,https://twitter.com/cure_magazine/status/1267158917617979393,cure_magazine,"“The cancer care community urgently needs data on the effects of COVID-19, specifically in patients with cancer.” #ASCO2020 
https://t.co/JWWq2M9rIy",2020-05-31
1267158776936890374,https://twitter.com/BurrisSkip/status/1267158776936890374,BurrisSkip,"VRD vs KRD in Myeloma — simple but elegant clinical trial, providing volumes of data for often asked questions. Congrats to the authors and participants. #ASCO20 @ASCO @SarahCannonDocs",2020-05-31
1267158683420680194,https://twitter.com/rsm2800/status/1267158683420680194,rsm2800,Berdeja (LBA3): A brief history of myeloma Rx showing better responses over time #ASCO20 https://t.co/AJKLQrrN0w,2020-05-31
1267158618018807809,https://twitter.com/ADesaiMD/status/1267158618018807809,ADesaiMD,"I am very happy to see that so far TWO #negativetrials have been presented at #ASCO #PlenarySession @ASCO, and incorporation of #HRQoL for #patients! #LessIsMore @OncoAlert @oncology_bg @VPrasadMDMPH @EnriqueSoto8 @DevikaDasMD @THilalMD",2020-05-31
1267158523261132801,https://twitter.com/SanaAlSukhun/status/1267158523261132801,SanaAlSukhun,"Never say NEVER to locoregional therapy in #MBC #breastcancer, yes no OS  or QoL in #E2108, true for those who responded to STx &amp; randomized, still individuize esp. for those with discordant response in multiple foci?!pending data for those with oligomets #asco20 @ASCO_pubs https://t.co/8k6OYOONuP",2020-05-31
1267158513056391168,https://twitter.com/DrGPrakash/status/1267158513056391168,DrGPrakash,"VRd is here to stay for quite sometime. PN is more acceptable than cardio-renal SAEs seen more frequently with KRd.
#mmsm @myelomaMD @ASCO #ASCO2020 https://t.co/4Zqt87I68j",2020-05-31
1267158311348158472,https://twitter.com/Tarek_Assi1986/status/1267158311348158472,Tarek_Assi1986,VRD should remain the standard of care as the initial therapy of multiple myeloma (no superiority of KRD but more renal/cardiac toxicity)...#ASCO20 #ASCO2020 @ASCO #oncology #cancer #MultipleMyeloma https://t.co/JPSWrfTGnL,2020-05-31
1267158275201683457,https://twitter.com/NausheenAhmedMD/status/1267158275201683457,NausheenAhmedMD,Excellent presentation by @myelomaMD. VRD remains standard of care for NDMM #mmsm #ASCO20 https://t.co/c7Yw92u8xX,2020-05-31
1267158257103245313,https://twitter.com/duemed/status/1267158257103245313,duemed,"#ASCO20 #JAVELINbladder100

Anyone else is worried about that 30% of pts not receiving ANY subsequent therapy at progression?

It seems the initial decision conditions the global evolution of metastatic bladder cancer. https://t.co/PugItuphvz",2020-05-31
1267158200937254915,https://twitter.com/jacquealcalde1/status/1267158200937254915,jacquealcalde1,"Dr. White presented a great discussion, putting in context other facts that matter:  # QOL, real-world data in LMIC.  And concluded with an invitation to answer important questions. #ASCO20 https://t.co/mV2OdP36pB",2020-05-31
1267158136563040257,https://twitter.com/mlazqui/status/1267158136563040257,mlazqui,"Great results of #avelumab in #bladdercancer 
#javelinbladder #ASCO20 @tompowles1 https://t.co/825EMsrlfG",2020-05-31
1267157920665477120,https://twitter.com/EnriqueGallar12/status/1267157920665477120,EnriqueGallar12,Congrats @tompowles1 for presentation at Plenary session #ASCO20 Meeting at the computer! New SOC for met #urothelialcancer @Uromigos @sogug1 https://t.co/XZRWUkuEoq,2020-05-31
1267157908216741888,https://twitter.com/chadinabhan/status/1267157908216741888,chadinabhan,"Conclusions of @myelomaMD @VincentRK and coauthors #ASCO20 @ASCO 
Kudos to leading a difficult study &amp; looking forward to more data from this study. https://t.co/AOxQKtaJHw",2020-05-31
1267157900457398274,https://twitter.com/barrosonco/status/1267157900457398274,barrosonco,"#ASCO20 #SRS
Interim results of prospective pilot phase II trial of concurrent anti-PD-1 and stereotactic radiosurgery (SRS) for melanoma and NSCLC patients with brain metastases (NCT02858869). https://t.co/gezvha0Nqa",2020-05-31
1267157889346605056,https://twitter.com/AshleySumrallMD/status/1267157889346605056,AshleySumrallMD,Even my kids are excited about #asco20 😊 https://t.co/GMDWublJrg,2020-05-31
1267157716369358852,https://twitter.com/CarlosHTonco/status/1267157716369358852,CarlosHTonco,"The second one!! Breast surgery. #asco20. ADAURA will be the last, but not the least!! https://t.co/mqIaBC6zfw",2020-05-31
1267157681925763072,https://twitter.com/urotoday/status/1267157681925763072,urotoday,"#Erdafitinib in locally advanced or metastatic #UrothelialCarcinoma: Long-term outcomes in #BLC2001. #ASCO20 presentation by Arlene Siefker-Radtke, MD @MDAndersonNews. Written coverage by @TheRealJasonZhu @LevineCancer on UroToday &gt; https://t.co/yr0yYg6tBT @ASCO https://t.co/nXnwz7qeRV",2020-05-31
1267157555538788353,https://twitter.com/rsm2800/status/1267157555538788353,rsm2800,Carfilzomib is not having a good day #ASCO20,2020-05-31
1267157543320793089,https://twitter.com/drenriquegrande/status/1267157543320793089,drenriquegrande,Now it’s time for #ASCO20 GU Highlights by the master of masters @DrChoueiri!!!! A lot to discuss this year. Wonderful Congress for the GU community @PGrivasMDPhD @ERPlimackMD @montypal @cdanicas @SoaresAndrey @DrAndreFay @FabioSchutz78 @tompowles1 @MattGalsky @g_develasco,2020-05-31
1267157516141592583,https://twitter.com/tmprowell/status/1267157516141592583,tmprowell,"#ASCO20 #bcsm 
 
Agree. #E2108 reminds us that 1) OS is an important endpt 2) it's not the only important endpt 3) neg RCTs can be just as practice-changing as positive ones, &amp; that's why you're seeing it in the Plenary (same for ANNOUNCE trial in #sarcoma in #ASCO19 Plenary). https://t.co/0FTd3vCz2a",2020-05-31
1267157462681112576,https://twitter.com/ndenduluri1/status/1267157462681112576,ndenduluri1,You caught me @aakonc 😜@reshmajagsi @DrReshmaMahtani @ramyathota1 @DrPKSudi will you please ask your teams: text ASCO to 41444 or https://t.co/shmGKUp0kV and support @ConquerCancerFd #ASCO20 https://t.co/1VbRvemRb9 https://t.co/ymPlcLnjNk,2020-05-31
1267157395135795205,https://twitter.com/VPrasadMDMPH/status/1267157395135795205,VPrasadMDMPH,"VRd v KRd just another comprehensive cooperative group study that I am a fan of -- Qol, OS, PFS, measurement of all the things you might want

#asco20 #asco2020",2020-05-31
1267157279188623365,https://twitter.com/rsm2800/status/1267157279188623365,rsm2800,.@myelomaMD (LBA3): KRd has more non-heme toxicities than VRd except for neuropathy #ASCO20 https://t.co/FFhyUL6djw,2020-05-31
1267157183147520000,https://twitter.com/JaniceTNBCmets/status/1267157183147520000,JaniceTNBCmets,"Took a brief break from #ASCO20 to watch, live, an historic moment for #LaunchAmerica #NASA &amp; the people of the #UnitedStates. I’ve enjoyed watching the dragon 🐉 floating in &amp; out of the pictures. 😂Godspeed to all #astronauts who risk their lives for progress &amp; exploration.🇺🇸 https://t.co/msZAdzYUIF",2020-05-31
